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Abbreviations 
A 
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AKAPs A-kinase anchoring protein 
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AP Action potential 
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ATXII Sea anemone toxin II 
B 
βAR β-adrenergic receptor 
βARS βAR stimulation 
BVR Beat-to-beat variability of repolarization 
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C 
CaMKII Ca2+/Calmodulin kinase II 
cAMP 3’-5’ cyclic adenosine monophosphate 
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CICR Ca2+-induced Ca2+ release 
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DI Diastolic interval 
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F 
FRET  Fluorescence resonance energy transfer 
G 
Gi Inhibitory G-protein 
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H 
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I 
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PDE inhibitor 
ICab Background Ca2+ current 
ICaL L-type Ca
2+ current 
ICl(Ca) Ca
2+-dependent Cl- current 
If Pacemaker (“funny”) current 
IK1 Inward rectifying K
+ current 
IKp Plateau K
+ current 
IKr Rapidly-activating delayed-rectifier K
+ 
current 
IKs Slowly-activating delayed-rectifier K
+ 
current 
IKur Ultrarapidly-activating delayed rectifier K
+ 
current 
Ileak JSR Ca
2+ leak flux 
INa Fast Na
+ current 
INab Background Na
+ current 
INaCa Na
+-Ca2+ exchange current 
INaK Na
+-K+ pump current 
INaL Late / persistent Na
+ current 
Inh1  Inhibitor protein 1 
IP3 Inositol(1,4,5)-triphosphate 
IpCa Plasmalemmal Ca
2+ pump current 
IPS Induced pluripotent stem cell 
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2+ release flux 
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Iti Transient inward current 
ITo 4 AP-sensitive transient outward K
+ 
current 
Iup SR Ca
2+ uptake flux by SERCA2a 
I-V Current-voltage relationship 
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1.1 SUDDEN CARDIAC DEATH 
Despite significant advances in diagnostic modalities and treatment options, cardiovascular diseases 
still remain the most common cause of death and morbidity in the developed world. Based on an 
overall cardiovascular-disease-related death rate of 262.5 per 100,000 inhabitants (USA, 2006), it 
can be estimated that more than 2300 people die every day from cardiovascular diseases in the 
United States alone.1 In The Netherlands, 176.5 and 84.2 cardiovascular-disease-related deaths 
occurred per 100,000 inhabitants in 2007 among men and women, respectively,1 making it indeed 
the most common cause of death.2 The etiology of the diseases underlying these deaths is diverse. 
The incidence of sudden cardiac death remains difficult to assess and published numbers vary 
between 180,000 and 450,000 cases per year in the United States.3 However, even the lowest 
estimate indicates a sizable incidence. In the Maastricht area, the mean yearly incidence of sudden 
cardiac arrest in the general population (age group 20 to 75 years) was 1 in 1,000 and in 
approximately half of the cases sudden cardiac arrest was most likely the first manifestation of heart 
disease.4 The relatively high prevalence of sudden cardiac death and its high impact on society give 
rise to what Zipes and Rubart5 called “one of the most important—and vexing—questions in clinical 
cardiology today”: “Why did he die on Tuesday and not on Monday?”  
 
In general, the genesis of arrhythmias involves at least two components: a vulnerable substrate 
created by the disease and a trigger. For many diseases, and in particular for congenital conditions, it 
can be assumed that the substrate did not change significantly between Monday and Tuesday. As 
such, sudden cardiac death can be considered an “electrophysiological accident”.6 Therefore, part of 
the answer to the question concerning the origin and control of the proximate precipitator to 
sudden cardiac death5 may be found in a better understanding of the “accident”-specific triggers. 
Signaling pathways that relay external cues to the heart play a critical role herein. Of these 
pathways, the autonomic nervous system has been described as a major modulator of arrhythmic 
events in a wide variety of cardiovascular diseases, including atrial fibrillation7-9, heart failure10-12, 
myocardial infarction13, 14, long-QT syndrome15-17 and catecholaminergic polymorphic ventricular 
tachycardia.18-20  
 
In this thesis we present an integrative experimental and computational analysis of the signaling 
pathways involved in sympathetic stimulation of the heart and their effects on cardiac cellular 
electrophysiology in physiological and pathophysiological conditions. We focus on conditions in 
which there is a structurally normal heart. Such a primary electrophysiological abnormality accounts 
for approximately 3-5% of the sudden cardiac death cases6 and provides an important paradigm to 
further our understanding of arrhythmogenesis. However, the insights obtained from these studies 
also provide information that can be applied to the more common acquired conditions such as heart 
failure, myocardial ischaemia, or digitalis intoxication, in which sympathetic stimulation causes 
electrophysiological alterations that predispose the development of ventricular arrhythmias.21-24 In 
the remainder of this chapter, we present a brief introduction to cardiac electrophysiology and 
adrenergic signaling under normal conditions, as well as an overview of computational approaches 
in electrocardiology. 
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1.2 CARDIAC ELECTROPHYSIOLOGY AND ADRENERGIC SIGNALING 
The “raison d’être” of the human heart is to supply O2 and nutrient-rich blood to the body and pump 
CO2-rich blood to the lungs. A ‘normal’ heart does so by beating more than three billion times during 
an average person’s lifetime. However, calling the heart simply a pump would not do justice to the 
incredible complexity this organ has accrued during millions of years of evolution. The pumping 
function of the heart is orchestrated through a large number of electrical and biochemical pathways. 
Under normal conditions, each beat starts from an electrical signal initiated by spontaneously-
activating cells in the sinoatrial node. The electrical wave spreads across the atria and results in the 
pumping of blood from the atria to the ventricles. The electrical signal is delayed at the 
atrioventricular node to allow sufficient time for the ventricles to fill and then propagates through 
the rapid conduction system to facilitate synchronous activation of the ventricular muscle and 
pumping of blood to the lungs (from the right ventricle) and other organs (from the left ventricle). 
 
At the level of the single ventricular myocyte, depolarization of the membrane from its resting 
potential of approximately -80 mV results in rapid activation of voltage-gated Na+ channels (giving 
rise to the Na+ current: INa) to depolarize the membrane (Phase 0). At positive potentials the Na
+ 
channels rapidly inactivate, resulting in a peak membrane potential of approximately 30 mV. In some 
cell types, most prominently the epicardial myocytes, this rapid depolarization is followed by a fast 
partial repolarization (Phase 1) due to the activation of a transient outward K+ current (Ito) and a 
Ca2+-activated Cl- current (ICl(Ca)). During phases 0 and 1, L-type Ca
2+ channels are activated, giving rise 
to ICaL. The Ca
2+ brought into the cell via ICaL triggers release of Ca
2+ from the intracellular stores (the 
sarcoplasmic reticulum; SR) through ryanodine receptors (RyRs). The combined free subcellular Ca2+ 
can bind to the cell’s contractile machinery, thereby activating cell contraction. This process is 
termed excitation-contraction coupling (ECC) and provides the main link between electrical and 
mechanical properties of the cardiac myocyte.     During the plateau phase (Phase 2), there exists a 
delicate balance between depolarizing currents (ICaL, the late component of INa and Na
+-Ca2+ 
exchange current) and repolarizing currents. A concerted effort of multiple voltage-gated K+ 
channels (in particular the rapidly and slowly activating delayed rectifiers IKr and IKs), as well as the 
Na+-K+ pump (INaK), underlie the final repolarization phase (Phase 3). The resting membrane potential 
(Phase 4) is maintained mainly by the inward rectifier K+ current (IK1) and INaK and is, as such, close to 
the K+ reversal potential.  Meanwhile, Ca2+ is pumped back in to the SR by SERCA2a and out of the 
cell by the Na+-Ca2+ exchanger (and to a lesser extent the sarcolemmal Ca2+-ATPase) to maintain 
homeostasis and achieve cell relaxation. For a more complete overview of the molecular 
constituents of cardiac electrophysiology and ECC, the interested reader is referred to excellent 
reviews on this topic25-28. The time course of membrane depolarization and repolarization is called 
the cardiac action potential (AP) and AP duration (APD) is the most commonly used quantification. 
There exist significant differences in AP morphology between different species as well as between 
cells from different regions of the heart. 29-32 This thesis mostly concerns the canine (left) ventricular 
myocyte. A prototypical example of an AP and Ca2+ transient (CaT) from a canine epicardial myocyte, 
and the main underlying currents, are shown in Figure 1. 
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Figure 1. Prototypical epicardial action potential, Ca2+ transient and ionic currents. Numbers indicate 
the four phases of the action potential. Outward currents are shaded in light grey, inward currents in 
dark grey. Not to scale. 
 
Of pivotal importance in the operation of the heart is its connection to the autonomic nervous 
system which can tailor the cardiac performance through the activation of various signaling 
cascades. The autonomic nervous system is divided into two parts. Activation of the sympathetic 
nervous system results in a fight-or-flight response characterized by enhanced heart rate 
(chronotropy), force of contraction (inotropy), rate of relaxation (lusitropy) and conduction 
(dromotropy). These adaptations greatly increase cardiac output, allowing the body to respond 
swiftly and strongly to any potential threat. The sympathetic nervous system uses the 
neurotransmitter norepinephrine to activate signaling cascades via adrenergic receptors. In contrast, 
the parasympathetic nervous system balances the response to sympathetic stimulation and 
decreases cardiac output and rate. The parasympathetic nervous system controls the heart via 
muscarinic receptors and uses acetylcholine as its neurotransmitter.33 These two pathways show 
complex interactions.34 
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At the single myocyte level, the effects of sympathetic stimulation are largely mediated by the α-
adrenergic- and β-adrenergic receptor (βAR) signaling pathways (Figure 2). Both types are part of the 
large family of G-protein coupled receptors.21 When catecholamines are released from sympathetic 
nerves they bind to the βAR, resulting in activation of the receptor-bound stimulatory G-proteins 
(Gs). Activation of Gs is achieved by dissociation of the α and βγ subunits resulting from a GTP-GDP 
exchange on the Gsα subunit. Active Gsα can subsequently stimulate adenylyl cyclases to produce the 
ubiquitous second messenger 3’-5’- cyclic adenosine monophosphate (cAMP), which can be broken 
down by phosphodiesterases (PDEs). The “traditional” downstream element of cAMP is protein 
kinase A (PKA). Activation of PKA results in the phosphorylation of many intracellular proteins (PKA 
substrates). Stimulation of α-adrenergic receptors activates Gq-proteins and phospholipase C, 
generating inositol(1,4,5)-triphosphate and diacylglycerol. These molecules in turn mobilize 
intracellular Ca2+, leading to the activation of protein kinase C (PKC) and Ca2+/Calmodulin kinase II 
(CaMKII).35 
 
 
Figure 2. Schematic representation of the βAR signaling pathway. Ligand binding (1) causes 
dissociation of the Gsα subunit as a result of GDP-GTP exchange (2). Gsα activates adenylyl cyclases 
(AC) to produce cAMP from ATP (3). Phosphodiesterases degrade cAMP (4). cAMP activates PKA (5) 
which causes dissociation of the catalytic subunit that can subsequently phosphorylate intracellular 
proteins (6). The α-adrenergic receptor pathway is shown on the right. 
 
In the ventricular myocyte the PKA substrates include, among others, ICaL, IKs, INa, INaK, RyR, 
phospholamban (PLB) and Troponin I (TnI). Activation of PKA results in increased CaT amplitude and 
rate of decay, contributing to the inotropic and lusitropic effects of sympathetic stimulation. In 
sinoatrial node cells, there is evidence both for direct cAMP-dependent modulation of the 
hyperpolarization-activated (“funny”) current (If) and increased Ca
2+ handling via PKA underlying the 
increased chronotropy during sympathetic stimulation.36 PKA-dependent increases in Ca2+ handling 
Introduction 
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and ICaL in the atrioventricular node are also responsible for the increased dromotropic effects.
37 In 
addition to these effects of βAR stimulation via cAMP/PKA, recent reports have highlighted 
interactions with other signaling pathways, including the PKC and CaMKII pathways, leading to a 
complex ‘signalome’.38, 39 This interaction is established through the PKA-dependent changes in Ca2+ 
cycling and heart rate as well as through a PKA-independent pathway involving the exchange protein 
activated by cAMP (EPAC), Phospholipase C, and PKC.38 The CaMKII pathway has also been 
implicated in the adverse effects of long-term adrenergic stimulation in a variety of conditions.40, 41 
 
Because of its critical importance in the control of cardiac output and rate, the adrenergic signaling 
pathway is tightly controlled, both temporally and spatially. Several negative feedback loops exist to 
limit excessive cAMP levels. These temporal control mechanisms include desensitization (and 
subsequent internalization) of βAR due to phosphorylation by PKA- and G-protein-coupled receptor 
kinases, as well as stimulation of cAMP hydrolysis by the long isoforms of PDE3 and PDE4 after 
phosphorylation by PKA.21, 42 Moreover, in recent years it has become increasingly clear that cAMP 
signaling is highly localized. Localization is essential for different receptors that all affect cAMP to 
achieve a specific response. For example, it has been shown that stimulation of β1AR results in a 
cell-wide response, whereas β2AR stimulation results in localized elevation of cAMP.43 Localized 
signaling is achieved by macromolecular signaling complexes that are tethered to specific subcellular 
locations.44 One such complex is created by caveolin-3, which is involved in the formation of 
caveolae, small invaginations in the cell membrane. In addition, it acts as a scaffold protein that 
groups various channels and transporters as well as signaling molecules together.45  In addition, A-
kinase anchoring proteins bind to various PKA substrates and localize PKA, phosphatases and PDEs to 
the channel complex.46 These localized signaling domains, together with cAMP-limiting actions by 
PDEs and Gi-proteins, allow for local elevation of cAMP and specific responses to stimulation of 
different receptors.47 Although improved cAMP-imaging techniques have facilitated the analysis of 
localized signaling domains48, 49, it remains difficult to experimentally quantify the contributions of 
individual signaling components to the local and global effects of adrenergic stimulation.  
 
1.3 COMPUTATIONAL APPROACHES TO UNDERSTANDING CARDIAC 
ELECTROPHYSIOLOGY 
From the aforementioned description, it will be readily apparent that the heart is a complex, 
nonlinear system with numerous interacting components and a high degree of synthesis and 
integration. Since human intuition subsides in face of these complexities, it is virtually impossible to 
predict the effect of perturbations to this complex system by reasoning alone. Because of this, the 
field cardiac (electro)physiology has a rich history of computational approaches to promote the 
understanding of various mechanisms, including arrhythmogenesis. The interaction between 
experimental and computational cardiology started in the early 1960s and thanks to the advent of 
more powerful computing hardware, the field has grown ever since. Figure 3 illustrates this growth 
by showing the number of publications on computational electrocardiology since 1962. Recently, a 
USA National Institutes of Health / National Heart, Lung and Blood Institute workshop on sudden 
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cardiac death recommended to “establish multiscale integrative models, including molecular, 
cellular, organ-level, animal and computational, relevant to human electrophysiology and disease” 
and “enhance acceptance and use of such models to achieve improved mechanistic understanding 
of arrhythmogenesis as well as the effects and implications of new antiarrhythmia therapies.”50  
 
Figure 3. Number of articles published per 5 year period that satisfy the Pubmed query (cardiac OR 
heart OR ventricle OR ventricular OR atria) AND ("action potential" OR electrical OR 
electromechanical OR electrophysiological OR electrophysiology) AND (computational OR 
mathematical OR simulation) AND model (in title and/or abstract). 
 
A brief overview of important milestones and recent research efforts in computational 
electrocardiology is given below. 
 
The history of computational modeling of excitable cells based on underlying ionic mechanisms 
started with the seminal work by Hodgkin and Huxley (HH) on the conduction in the giant axon of 
the squid in 1952.51 Noble52 was among the first to adapt this work to the cardiac domain by 
adapting the HH equations to reproduce the long plateau of the action potential from the cardiac 
Purkinje fiber. Noble and coworkers subsequently expanded this model53 to include seminal 
experimental discoveries by the laboratories of Carmeliet,54 Coraboef,55 Trautwein,56 Weidmann57 
and others. This model was later adapted to the first model of a ventricular cell by Beeler and 
Reuter.58 In 1985, DiFrancesco and Noble59 created the first model that incorporated dynamic 
changes in intracellular ion concentrations as well as a formulation for Ca2+ release from the SR. 
These models are sometimes referred to as “dynamic” or “Phase 2” models. The DiFrancesco-Noble 
model and its subsequent extension with Ca2+ buffering by Hilgemann and Noble60 (for an atrial 
action potential) provided the starting point for many subsequent simulation studies on Ca2+ 
handling in cardiac cells.   
Introduction 
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The ventricular cell model by Beeler and Reuter was expanded in two seminal studies by Luo and 
Rudy61, 62 to include many new experimental data specific for the single ventricular myocyte that had 
accumulated as a result of improved experimental techniques. Their model provided a very 
complete overview of the guinea-pig ventricular action potential and remains extensively used to 
date. This class of models has subsequently been extended by many research groups to describe the 
cardiac cellular electrophysiology of a wide variety of species (including, recently, human specific) 
and cell types and represents the most common type of models in computational 
electrocardiology63-71 (see Winslow et al.72 or Chapter 8 for a more complete list). 
 
Several different research directions can be distinguished that have expanded on these initial results. 
One important direction focuses on a more detailed understanding of ion-channel function and the 
disturbances that occur as a result of various hereditary channelopathies. To describe these details, 
models that explicitly reflect a physical state (or aggregate of states) of ion channels were 
developed. In contrast to the HH formulations, these Markov models also made it possible to 
represent interdependencies between channel activation and inactivation, consistent with 
experimental observations.73 In the early 1990s the first Markov models were developed to study 
gating properties of ion channels.74, 75 However, it was not until the late 90s when the first studies 
integrated Markov model representations of ion channels into a computational model of the cardiac 
action potential. A prime example of such a study is that by Clancy and Rudy.76 Their models of the 
wild-type and ΔKPQ-mutant cardiac sodium channel illustrated how Markov models that represent 
individual channel states can provide mechanistic insight into the effects of genetic mutations that 
alter channel gating. This technique has since been applied to a wide variety of channels and 
diseases. Recently, Silva et al. added another level of physiological detail by proposing a model for IKs 
that combines molecular dynamics and electrostatics to determine a multidimensional, continuous 
energy landscape that can be used to determine channel transitions and single channel currents.77 
This approach provides a more mechanistic understanding of channel function than can be obtained 
with Markov models, where model topology has to be determined manually instead of being based 
on the physical channel structure. Incremental approaches that extend on Silva et al.77 can 
potentially enhance the understanding of genotype/phenotype relationships in various 
channelopathies. 
 
Markov models have also played an important role in so called “local control” models that include 
details of subcellular Ca2+ handling, particularly in the dyadic cleft. The dyadic cleft is a small region 
between the sarcolemmal invaginations called t-tubules and the opposing intracellular SR. This space 
is a microdomain for Ca2+ signaling where ECC is initiated via Ca2+-induced Ca2+ release (CICR).78 CICR 
is a highly localized process characterized by strong positive feedback. The Jafri-Rice-Winslow model 
was the first to include a more detailed description of CICR using Markov models for the L-type Ca2+ 
channel and RyR and a subcellular compartment representing the total cellular dyadic space.79 In the 
myocyte, the dyadic cleft is a large cluster of small microdomains. These volumes are so small that 
only a few L-type Ca2+ channels interact with a few dozen RyRs and under physiological conditions 
only a small number of Ca2+ ions are present in each domain. With such small numbers involved, 
models using deterministic ordinary differential equations based on continuum assumptions may 
Chapter 1 
| 19 
not be appropriate.80 Stochastic descriptions of CICR were first developed by Stern.81 He showed that 
common pool models are not able to reproduce both the high-gain and graded-release properties of 
CICR observed experimentally. Since then much work has been performed, particularly concerning 
the question what ends the positive feedback loop that controls CICR.82 In 2002, Greenstein and 
Winslow83 were the first to incorporate a stochastic local control model of CICR into a detailed 
model of the ventricular action potential. Stochastic simulations combined with the nonlinear 
dynamics of the ventricular action potential have recently been described to result in dynamic 
temporal repolarization patterns, including the generation of arrhythmogenic early 
afterdepolarizations84 and the induction of noise-induced chaos85. Since temporal variability of 
repolarization has been described as a marker for proarrhtyhmic risk86, future models incorporating 
local stochastic Ca2+ dynamics may also provide additional insight into the more macroscopic 
properties of repolarization variability.  
 
At the other end of the spectrum, multicellular tissue or whole-heart models can provide insight into 
macroscopic, emergent processes such as arrhythmias, which do not exist at the level of the single 
cell. Multicellular models can be classified as spatially discrete or continuous. In discrete models 
(also called network models), individual cell models that are coupled electrically are explicitly 
represented. Although this approach more closely reflects the biological structure of the heart, it is 
computationally extremely demanding. As such, simulations using this approach are usually confined 
to 1-dimensional strands or small sheets of 2-dimensional tissue.87, 88 The first continuum based 
simulations were performed using a generic excitable media model by Fitzhugh and Nagumo around 
the same time Noble presented the first ionic cardiac cell model.89 Detailed anatomical models that 
include fiber direction anisotropy were first developed at the University of Auckland, New Zealand, 
by Nielsen et al.90 Later generic models have been extended to reproduce macroscopic properties of 
cardiac tissue and combined with the anatomical models resulted in the first macroscopic tissue 
models with realistic geometry.91, 92 More recent approaches have used detailed ionic cell models 
incorporated in a monodomain or bidomain framework. Bidomain models use a continuum 
approach to represent two interpenetrating domains representing cardiac cells and the space 
surrounding them and include mechanistic descriptions of the ionic currents. Computational 
hardware is now powerful enough to produce organ level simulations (whole ventricle, whole heart) 
with detailed ionic models and geometry. Such models have been employed to study many aspects 
of cardiac electrophysiology, including organization of ventricular fibrillation,93 arrhythmogenic 
effects of heterogeneous restitution of repolarization94, effects of pharmacological interventions95, 
human atrial electrophysiology96 and synchronization of single cell behavior97. 
 
Several models, including some of the whole-heart models described above, also include the 
mechanical component of the cardiac function. At the subcellular level, contraction models have 
been designed to reproduce key characteristics of the contractile machinery as well as 
heterogeneous tension development.98, 99 Initially, the electrophysiological and mechanical models 
were developed independently and only weakly coupled. However, in the heart, activation and 
contraction are strongly coupled (via ECC and mechanoelectrical feedback).100 Kohl et al. provided 
one of the first computational analyses of mechanical effects on cardiac electrophysiology in a 
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multicellular network model of the sinoatrial node.101 Later, 3-dimensional models of cardiac 
electromechanics have been employed to study precordial thump efficacy,102 acute regional 
ischemia,103 reentrant wave stability,104 biventricular pacing in the failing heart105 and stretch-
induced initiation of atrial fibrillation,106 among other things.  
 
Finally, recent efforts have started to integrate signaling pathways in computational models of 
cardiac electrophysiology. These include models for the cAMP/PKA pathway, PKC pathway and 
CaMKII pathway, as well as models of ATP regulation. Although several studies had already 
simulated the electrophysiological effects of adrenergic stimulation, Saucerman and McCulloch were 
the first to integrate the cAMP/PKA signaling pathway in a model of the ventricular myocyte.107 
Recently, Iancu et al.108 described a model of cAMP signaling that also takes into account localized 
signaling domains. However, their model did not include downstream effects of cAMP or any 
electrophysiological targets. In 2004, Hund and Rudy65 were the first to integrate the CaMKII 
signaling pathway in a model of the canine ventricular electrophysiology. Since then, several studies 
have further investigated the signaling aspects109, 110, as well as the effects on cardiac 
electrophysiology111, 112 of CaMKII. The highly localized effects and the large number of interacting 
pathways and electrophysiological substrates of these signaling pathways make it difficult to 
characterize individual components experimentally. The rest of this thesis focuses on the 
computational analysis of (sub)cellular aspects of the adrenergic signaling pathway and 
electrophysiological substrates. 
1.4 AIMS AND LAYOUT OF THE THESIS 
Several experimental studies by our group have investigated the role of adrenergic stimulation in the 
genesis of torsades de pointes-type arrhythmias in the dog at both the in-vivo and in-vitro level. The 
aim of this thesis was to develop a detailed computational model of localized adrenergic signaling in 
the canine ventricular myocyte and apply this model, in conjunction with further experimental 
studies, to investigate the effects of adrenergic stimulation on the cellular electrophysiology and Ca2+ 
handling in physiological and pathophysiological conditions. This was performed via increasing levels 
of complexity starting from a model of the canine epicardial electrophysiology (Chapter 2), to 
adrenergic stimulation under physiological conditions (Chapter 3), to the role of adrenergic 
stimulation in arrhythmogenesis for a specific long-QT type 1 mutation (Chapter 4). Subsequently, 
we identified the role of IKs in beat-to-beat variability of repolarization duration during βAR 
stimulation (Chapter 5) and the role of abnormal Ca2+ handling in this process (Chapter 6). Finally, 
we analyzed the ionic contributors to beat-to-beat variability of repolarization during basal 
conditions and adrenergic stimulation (Chapter 7) and discuss the results of this thesis in a broader 
context (Chapter 8). 
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ABSTRACT 
Computational models of cardiac myocytes are important tools for understanding ionic mechanisms 
of arrhythmia. This work presents a new model of the canine epicardial myocyte that reproduces a 
wide range of experimentally observed rate-dependent behaviors in cardiac cell and tissue, including 
action potential (AP) duration (APD) adaptation, restitution, and accommodation. Model behavior 
depends on updated formulations for the 4-aminopyridine-sensitive transient outward current (Ito1), 
the slow component of the delayed rectifier K+ current (IKs), the L-type Ca
2+ channel current (ICa,L), 
and the Na+-K+ pump current (INaK) fit to data from canine ventricular myocytes. We found that Ito1 
plays a limited role in potentiating peak ICa,L and sarcoplasmic reticulum Ca
2+ release for propagated 
APs but modulates the time course of APD restitution. IKs plays an important role in APD shortening 
at short diastolic intervals, despite a limited role in AP repolarization at longer cycle lengths. In 
addition, we found that ICa,L plays a critical role in APD accommodation and rate dependence of APD 
restitution. Ca2+ entry via ICa,L at fast rate drives increased Na
+-Ca2+ exchanger Ca2+ extrusion and Na+ 
entry, which in turn increases Na+ extrusion via outward INaK. APD accommodation results from this 
increased outward INaK. Our simulation results provide valuable insight into the mechanistic basis of 
rate-dependent phenomena important for determining the heart’s response to rapid and irregular 
pacing rates (e.g., arrhythmia). Accurate simulation of rate-dependent phenomena and increased 
understanding of their mechanistic basis will lead to more realistic multicellular simulations of 
arrhythmia and identification of molecular therapeutic targets. 
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INTRODUCTION 
Cardiac arrhythmias and sudden death involve complex myocardial activation patterns, including 
unidirectional block, reentry, and fibrillation. To understand the relations and transitions between 
these patterns, the ionic determinants of the response of healthy and diseased cardiac myocytes to 
complex patterns of excitation must be understood. The single-cell response to such excitation 
patterns depends on the complex interaction between ionic currents, intracellular ion 
concentrations, and membrane voltage. Computational cell models provide critical tools for 
exploring these interactions, allowing the development and testing of hypotheses about underlying 
ionic mechanisms based on careful integration of available experimental data.1 The dog is a common 
animal model for studying cell electrophysiology in a range of disease states. Our group and others 
have developed detailed mathematical models of the canine action potential (AP).2-4 Although these 
models have been used to study arrhythmia mechanisms after heart failure4 and myocardial 
infarction,5, 6 as well as ionic mechanisms of alternans,2, 7 they are limited in their ability to simulate 
important rate-dependent phenomena,8 including the dependence of steady-state AP duration 
(APD) on pacing cycle length (CL; i.e., APD adaptation), the dependence of APD on diastolic interval 
(DI; i.e., APD restitution), and the time course of the adjustment of APD to changes in rate (short-
term memory9 or APD accommodation10). These limitations extend to ionic models of other species, 
including the human.8 We hypothesized that canine epicardial APD adaptation, restitution, and 
accommodation could be simulated and understood on the basis of available descriptions of 
subcellular ionic processes. We incorporated updated and validated formulations of the 4-
aminopyridinesensitive transient outward current (Ito1), the slow component of the delayed rectifier 
K+ current (IKs), the L-type Ca
2+ channel current (ICa,L), and the Na
+-K+ pump current (INaK) into a 
previously published model of the canine epicardial myocyte.3, 6, 7 Model behavior was examined in 
single cell and multicellular (strand) simulations. Our work provides new insight into ionic 
mechanisms underlying important rate-dependent AP properties, including APD restitution, 
adaptation, and accommodation. Specifically, our studies highlight the importance of Ito1 and IKs in 
APD restitution and the role of ICa,L and INaK in APD accommodation and rate-dependent APD 
restitution. 
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METHODS 
Model  
 
Figure 1. Hund-Rudy dynamic model of the canine epicardial myocyte. SR, sarcoplasmic reticulum; 
CTKCl, K+-Cl− cotransporter; CTNaCl, Na+-Cl− cotransporter; INaL, slowly activating late Na
+ current; INa, 
Na+ current; INab, background Na
+ current; INaCa,i, Na
+/Ca2+ exchanger (localized to myoplasm); ICab, 
background Ca2+ current; Ipca, sarcolemmal Ca
2+ pump; Ito1, 4-aminopyridine-sensitive transient 
outward current; IKr, fast component of delayed rectifier K
+ current; IKs, slow component of delayed 
rectifier K+ current; IK1, time-dependent K
+ current; INaK, Na
+-K+ pump current; Ileak, NSR leak flux; Idiff, 
ion diffusion, myoplasm-to-SR subspace; Itr, Ca
2+ transfer, NSR to JSR; Irel, JSR release flux; Idiff,ss, ion 
diffusion, subspace-to-local ICaL subspace; INaCa,ss, Na
+/Ca2+ exchanger (localized to SR subspace); ICa,L, 
L-type Ca2+ current; Ito2, Ca
2+-dependent transient outward Cl− current (ICl(Ca)); SS(CaL), ICaL subspace; 
SS(SR), SR subspace; PLB, phospholamban; SERCA, sarco(endo)plasmic reticulum Ca2+-ATPase; CSQN, 
calsequestrin; CaMKII, Ca2+/calmodulin-dependent kinase; NSR, network SR; JSR, junctional SR. (For 
additional model details, see Refs. 3 and 7, the appendix of this thesis, and 
http://rudylab.wustl.edu/.) 
 
The Hund-Rudy dynamic model (Figure 1) of the canine epicardial myocyte3, 6, 7 serves as the basis 
for these simulations. Updates to intracellular Ca2+ ([Ca2+]i) handling in a recent study of APD and 
[Ca2+]i transient (CaT) alternans are included.
7 Ion channel formulations, including ICa,L, Ito1, IKs, and 
INaK, have been updated on the basis of additional data from canine ventricular myocytes. Model 
parameters were fit to experimental data from the literature (Figure 2).  
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Figure 2. A and B: model ICa,L current-voltage (I-V) relationship and steady-state inactivation fit to 
experimental data from canine epicardial myocytes.11, 12 C and D: model Ito1 I-V curve and time to 
peak fit to data from canine epicardial myocytes.13 E and F: model IKs activation and accumulation fit 
to data from canine ventricular myocytes.14, 15 G and H: model INaK density and steady-state 
intracellular Na+ concentration ([Na+]i) fit to data from canine ventricular myocytes.
16 Vtest, test 
potential; CL, cycle length.  
 
A new Markov model of ICa,L was formulated to reproduce a wide range of experimental data while 
maintaining computational tractability to facilitate long-term multicellular simulations. The state 
structure (Figure 3C) of the model reflects the hypothesis that Ca2+ binding to calmodulin removes a 
“brake” and speeds up ICa,L voltage-dependent inactivation.
17, 18 The model reproduces the ICa,L 
current-voltage (I-V) relationship11 (Figure 2A), steady-state inactivation12 (Figure 2B), time constant 
of voltage-dependent inactivation,19 and recovery from inactivation20 in canine ventricular myocytes. 
A model of Ito1 was developed and fit to the I-V relationship (Figure 2C), time to peak (Figure 2D), 
time constant of inactivation,13 and slow time constant of recovery from inactivation21 in canine 
epicardial myocytes. A Markov model of IKs
22  previously developed in our laboratory was adopted 
and fit to data from canine ventricular myocytes. The model accurately reproduces the kinetics of IKs 
based on underlying voltage sensor transitions and has provided insight into the role of IKs in APD 
adaptation in the guinea pig and humans.22 The model fits canine ventricular data on the time course 
of activation15 (Figure 2E) and time dependence of current accumulation14 (Figure 2F). IKs density was 
scaled to fit data from canine epicardial myocytes.23 A recently developed formulation of INaK based 
on data from canine ventricular myocytes16 was also incorporated into the model. Model INaK density 
matches epicardial myocyte data (Figure 2G) and results in intracellular Na+ ([Na+]i) at rest and 
during pacing (CL = 0.5 s) consistent with experimental results (Figure 2H). See the appendix of this 
thesis for complete model equations and more detailed descriptions. 
11 
12 
13 13 
14 
15 16 16 
14 
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Notes on Experimental Data for Model Fits  
In general, experimental data that were chosen for model fitting and comparison represent 
either the consensus of a wide range of experimental results or the most complete experimental 
study. Data sets chosen for reproducing ICaL (I-V relationship, steady state inactivation, recovery 
from inactivation) and Ito1 behavior (I-V relationship, time to peak, time constant of inactivation, 
recovery from inactivation) are representative of multiple available experiments in canine 
ventricular myocytes (Figures 3-4). Model formulations for INaK and IKs are based on recent 
experimental studies that provide the most detailed information available on these currents in 
canine epicardial myocytes. Details are provided in the appendix of this thesis. 
 
 
Figure 3. A. Model ICaL current-voltage (I-V) relationship and B. steady-state inactivation compared to 
multiple data sets from canine ventricular cells.11, 12, 19, 24-27 For color figure, see page 242. 
 
 
Figure 4. A. Model Ito1 I-V curve. B. Time to peak compared to multiple data sets from canine left 
ventricular epicardial cells.13, 21, 28-30 For color figure, see  page 242. 
 
Model 
Liu13 
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Sun28 
Model 
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Single-cell simulations  
Steady-state results are shown after 1,800 s of pacing at a given CL with a conservative K+ stimulus.31 
This simulation time resulted in a beat-to-beat change in APD and maximum intracellular Na+ 
([Na+]i,max) and Ca
2+ ([Ca2+]i,max) < 0.1%. Restitution results were obtained for an additional beat after 
pacing to steady state as described. Accommodation simulations involved pacing to steady state at a 
given CL (CLS1) followed by pacing to steady state at a different CL (CLS2).  
 
Strand simulations 
A detailed description of computational methods for strand simulations is included in previous work 
from our laboratory.32 Briefly, propagation in a strand of serially connected HRd model cells was 
simulated via a finite difference approximation of the cable equation (see appendix of this thesis). 
No flux boundary conditions (δV/δx = 0) were set at the beginning and end of the strand. A 1-ms 
stimulus (-200 μA/μF) was applied to cell 1. One-dimensional simulations of propagation were 
performed in a strand of 96 cells following previous work from our laboratory.32 Cell 1 was directly 
stimulated, and simulation results are shown for a central cell (cell 48) where end effects were 
negligible. Simulation protocols were similar to those used for single cells (1,800 s of pacing), 
resulting in beat-to-beat changes in APD and [Na+]i,max and [Ca
2+]i,max < 0.1%. Gap junction 
conductance of 2.5 μS gave a maximum upstroke velocity (dV/dtmax)33 and conduction velocity34 
consistent with experimental results in canine epicardial tissue. 
RESULTS 
APD rate dependence in a single cell and a multicellular strand 
Figure 5 shows the rate dependence of APD in a cell and a strand during different pacing protocols. 
The rate dependence of simulated steady-state APs is shown in Figure 5A, left. Cell and strand 
simulations exhibit the spike-and-dome morphology characteristic of canine epicardium21 (Figure 
5A, right). Steady-state APs in the strand show a reduced upstroke amplitude and velocity compared 
with the single cell due to electronic load during propagation. Maximum upstroke voltage (Vmax) and 
dV/dtmax match experiments in canine ventricular epicardium at CL = 0.8 s:
33 experimental Vmax = 13.1 
± 4.7 mV, dV/dtmax = 151.8 ± 39.8 V/s; model Vmax = 9.24 mV, dV/dtmax = 162.6 V/s. The model 
reproduces the decreased rate dependence of the depth of the phase 1 notch generally observed in 
tissue21, 33, 35 (Figure 5A). The cause of different AP spike-and-dome morphology in different tissue 
experiments is unknown, but possibilities include heterogeneity in the density and recovery kinetics 
of Ito1 due to age,
38 sex,39 and precise apicobasal or transmural location.21, 40 We next characterized 
APD restitution in our single-cell and strand models. After pacing to steady state at a given CL (CLS1), 
additional stimuli (S2) scanning the DI were applied to generate restitution curves plotting APD vs. 
S2 coupling interval (CIS2) (Figure 5B, left). As the basic pacing CL (CLS1) decreases, restitution curves 
in the single-cell and strand models shift toward shorter APD, consistent with experimental 
measurements8, 36, 41, 42 (Figure 5B, right). The model also reproduces tissue AP restitution kinetics as 
a function of DI (see below and Figures 8-9). Figure 5C (left) shows the time course of APD in a 
model cell and a strand after pacing to steady state at CLS1 = 1 s followed by sustained pacing at CLS2 
= 0.5 s starting at time 0. APD at the new CL approaches steady state after several minutes of pacing, 
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a process referred to as accommodation,10 consistent with experiments in canine ventricle37 (Figure 
5C, right). 
 
 
Figure 5. A, left: model steady-state action potentials (APs) at CL = 0.3, 0.5, 1, and 2 s in single-cell 
and strand simulations. Vm, membrane potential. Inset: peak upstroke voltage and rate dependence 
of notch depth. A, right: experimental steady-state APs in a single cell and 3 tissue preparations. 
Experimental data for a single cell are from Ref. 21 (cell CL = 0.3, 0.5, 0.8, 2, and 8 s); experimental 
data for tissue are from Ref. 21 (tissue CL = 0.3, 1, 2, and 5 s), Ref. 33 (tissue CL = 0.3, 0.5, 0.8, and 2 
s), and Ref. 35 (tissue CL = 0.3, 1, and 5 s). B, left: model CLS1 dependence of AP duration (APD) 
restitution in single cell and strand. Gray traces denote adaptation (S2 coupling interval = CLS1). B, 
right: experimental results from study of CLS1 dependence of APD restitution in right ventricle of 
open-chest dogs.36 C, left: model accommodation of APD after change from CL = 1 s to CL = 0.5 s in 
single cell and strand. C, right: APD accommodation in canine ventricular muscle fiber experiments.37 
  
 
37 
36 
33,35  21 21 
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Figure 6. A. isolated single-cell stimulus (black trace, Istim) and strand axial current (gray trace, Iaxial). 
Inset: sustained repolarizing axial current. B–E. CLS1 dependence of maximum upstroke velocity 
(dV/dtmax), APD, Ca
2+ transient amplitude (CaTAMP), and maximal intracellular Na
+ concentration 
([Na+]i,max) in single-cell and strand simulations. 
 
Previous simulation studies8, 43 showed that direct stimulation in single cells and electrotonic loading 
in tissue can lead to different AP dynamics. Figure 6 compares cell and tissue steady-state APs and 
ion accumulation in the new model. A -80 pA/pF, 0.5-ms stimulus was used in single-cell simulations 
(Figure 6A). In the strand, excitatory axial current in well-coupled tissue (Figure 6A) consists of 1) an 
initial transient depolarizing current, 2) a transient repolarizing current as the cell supplies charge to 
depolarizing downstream cells, and 3) a small sustained repolarizing current (Figure 6A, inset). The 
biphasic axial current in the tissue reduces AP upstroke velocity relative to its value in the single cell 
(Figure 6B). In addition, steady-state tissue APD is reduced slightly (Figure 6C) as a result of the 
sustained repolarizing axial current (Figure 6A, inset). APD adaptation in cell and strand simulations 
is consistent with experimental results21. Cell and strand simulations show an increase in Ca2+ 
transient amplitude (CaTAmp; Figure 6D)
25 and maximum [Na+]i ([Na
+]i,max; Figure 6E)
16 with pacing 
rate, consistent with experimental results. Differences in CaTAmp and [Na
+]i,max in cell and strand 
simulations are minimal. Subsequent results are from strand simulations unless otherwise specified.  
 
Ito1, peak ICa,L, and CaTAmp in cell and strand  
 
Figure 7. CaTAMP (A), Vm (B), Ito1 (C), ICa,L (D), and Irel (E) in control and after 100% Ito1 block in single-cell 
(top) and strand (bottom) simulations. In B–E, CLS1 = 1 s. Arrows in B denote time and Vm at peak ICa,L. 
Action potential rate-dependence in canine epicardium 
36 | 
 
Experimental44 and computational29 studies have suggested that Ito1, by controlling phase 1 
repolarization, is an important modulator of ICa,L activation and sarcoplasmic reticulum (SR) Ca
2+ 
release. We examined differences in the effect of Ito1 on ICa,L activation and SR Ca
2+ release in cell and 
strand simulations. Figure 7A shows that although blockade of Ito1 leads to a significant reduction in 
CaTAmp in cell simulations, reduction of CaTAmp after Ito1 blockade in tissue simulations is minimal. The 
interplay between membrane potential (Vm), Ito1, ICa,L, and SR Ca
2+ release in a cell and a strand is 
examined in Figure 7, B–E. We note several important differences between simulated APs in the 
strand and in the isolated cell. These unique features of the strand AP include 1) reduced peak 
upstroke voltage (Figure 7B), 2) reduced Ito1 activation (Figure 7C), and 3) minimal dependence of 
peak ICa,L on Ito1 activation (Figure 7D). Reduced peak upstroke voltage in the strand leads to a 
reduction in peak Ito1 due to the approximately linear dependence of Ito1 activation on Vm. This 
reduction in Ito1 activation leads to a reduction in phase 0 repolarization. Arrows in Figure 7B denote 
Vm at the peak of ICa,L activation in a cell and a strand, respectively. In cell simulations, a large Ito1 
repolarizes Vm toward the peak of the ICa,L I-V relationship (Figure 7B), promoting ICa,L activation  and 
SR Ca2+ release. When Ito1 is blocked in the cell, ICa,L activation occurs at a Vm that is far from the peak 
of the I-V curve (Figure 7B), decreasing peak ICa,L  and SR Ca
2+ release. For a propagating action 
potential, however, increased load decreases peak up- stroke voltage, so that it is near the peak of 
the ICa,L I-V curve (Figure 7B, +10 mV). Maximal ICa,L activation occurs shortly after the peak upstroke 
Vm, such that the depth of the phase 1 notch plays little role in determining Vm as ICa,L is peaking. 
Consequently, blockade of Ito1 in the strand has little effect on peak ICa,L (Figure 7D) and SR Ca
2+ 
release. Furthermore, reduced phase 1 repolarization due to reduced Ito1 activation also suggests a 
diminished importance of Ito1 in the strand relative to the cell.  
 
Ito1 and APD restitution 
 
Figure 8. A. APD (normalized to maximum) as a function of diastolic interval (DI) during restitution at 
CLS1 = 2 s in control and after 100% Ito block in strand simulations. Results are compared with data 
from canine epicardial45 and endocardial46 tissue experiments. B–D. Vm, Ito, and IKr during APD 
restitution at S2 coupling intervals (CIS2) of 0.3 and 2 s in control and after Ito block in the strand. 
Inset in B shows very similar AP after Ito block at short CIS2 (thick gray trace) and long CIS2 (thin gray 
trace). 
 
46 
45 
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Although our results suggest a limited role for Ito1 in regulation of peak ICa,L and SR Ca
2+ release in 
multicellular strands, Ito1 was found to play an important role in APD restitution. Figure 8A shows 
that the time course of APD restitution is consistent with experiments in epicardial tissue.45 (See 
Figure 9 for comparison of model restitution kinetics with experiments for a range of CLS1.) In canine 
epicardium, APD gradually increases as DI increases beyond 0.3 s. After 100% Ito1 block, the increase 
in APD with increasing DI is more abrupt, as observed in canine endocardium,46 consistent with the 
absence of Ito1 in this tissue. Figure 8, B–D, examines the role of Ito1 in APD restitution time course. At 
short CIS2, Ito1 has not fully recovered from inactivation, resulting in minimal phase 1 repolarization 
(Figure 8B). As CIS2 increases, notch depth increases as Ito1 recovers from inactivation. Since 
activation of the fast component of the delayed rectifier K+ current (IKr) is slower at more negative 
voltages, increasing notch depth slows IKr activation (Figure 8D). The gradual increase in APD during 
restitution follows the slow time course of Ito1 recovery and the suppression of IKr activation due to 
increasing notch depth. When Ito1 is absent, increase in CIS2 beyond 0.3 s results in minimal phase 1 
voltage change (Figure 8B, overlapping gray traces), constant IKr activation, and minimal APD 
increase (Figure 8B inset, gray traces). This small increase in APD at CIS2 = 0.3 s results in a restitution 
curve resembling that recorded in endocardium.46 
 
 
Figure 9. Model and experimental APD (normalized to maximum) as a function of diastolic interval 
(DI) during restitution at (left-to-right) (A) CLS1 = 2 s, (B) CLS1 = 1 s, (C) CLS1 = 0.5 s and (D) CLS1 = 0.333 
s. Experimental data in Panel A are from canine left ventricle,45 while data in Panels B-D are from 
canine right ventricle.36 The time course of APD restitution in the model strand is consistent with 
experiments in canine epicardial tissue36, 45 for a range of CLS1. Comparison at CLS1 = 2 s is to left 
ventricular (LV) epicardial tissue experiment,36, 45 while CLS1 = 1 s, 0.5 s and 0.333 s is to right 
ventricular (RV) epicardial tissue experiment36, 45 because left ventricular data at these rates are not 
available. Model restitution kinetics show a modest dependence on CLS1, in part due to the effects of 
rate dependent SR Ca2+ loading and Ca2+ release on APD, but this phenomenon was not addressed in 
the present study. Differences in restitution kinetics between the model and the RV experiments are 
relatively small and may be due to differences in LV and RV Ito1 expression and kinetics,
33 Ca2+ 
handling or other heterogeneities. 
36 
45 
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IKs and APD adaptation 
 
Figure 10. A. percent increase in steady-state APD after 100% IKs block as a function of CLS1. B–E. IKs 
current density and state occupancy of zone 2, zone 1, and open state at steady-state for CLS1 = 0.25, 
0.5, and 1 s. 
 
The role of IKs in canine APD adaptation is examined in Figure 10. As shown in Figure 10A, 100% 
block of IKs leads to a modest prolongation of APD at steady state. Percent APD prolongation after IKs 
blockade decreases as CL decreases (“use-dependent” block), except at short CL, where percent 
prolongation begins to increase again. The biphasic effect of IKs block on APD is consistent with the 
rate dependence of IKs activation shown in Figure 10B. IKs activation is smallest at CLS1 = 0.5 s, 
corresponding to the smallest percent prolongation of APD after IKs block in Figure 10A. IKs activation 
at CLS1 = 0.25 and 1 s is increased relative to CLS1 = 0.5 s, leading to a relative increase in percent APD 
prolongation after IKs block at these rates. Figure 10, C–E, examines the rate dependence of IKs state 
occupancy, following previously published analysis in the guinea pig.22 The 17-state IKs model (Figure 
11) can be divided into two open states, five zone 1 closed states that can activate rapidly, and 10 
“deep” zone 2 closed states, which require slow transitions to zone 1 before activation is possible. At 
CLS1 = 0.5 and 1 s, all channels reside in zone 2 at the start of the AP (Figure 10C) and activate slowly 
upon depolarization (Figure 10B). Slow activation from zone 2 and small peak density in the dog 
dictate that IKs plays a limited role in AP repolarization at longer CL. At CLS1 = 0.25 s, the DI is 
insufficient for activated channels to return to zone 2. Channels activated during the previous beat 
remain in zone 1 (Figure 10D) and the open state (Figure 10E) as the next stimulus is applied, 
resulting in more rapid channel activation and an increased role for IKs in APD shortening at fast rate.  
IKs and APD restitution 
We also examined the role of IKs in APD restitution (Figure 12). Simulation results show that the 
percent increase in APD after 100% IKs block is largest at the shortest CIS2 (Figure 12B). At CIS2 = 0.26 
and 0.3 s, a significant fraction of channels activated during the previous AP remain in the open state 
(Figure 12D), while an additional fraction occupies zone 1 (Figure 12F). When a premature stimulus 
is applied, channels that are already open and those moving rapidly from zone 1 to the open state 
combine to yield prominent IKs activation (Figure 12C). Peak activation of IKs at CIS2 = 0.26 s is 
markedly increased relative to peak density during the S1 beat. This prominent IKs activation due to 
accumulation in the open state and zone 1 is required to achieve APD shortening at short DI 
consistent with experimental results.45 APD at CIS2 = 0.26 s is increased by +7.5% after IKs block. As DI 
increases, channels move from zone 1 and the open state to zone 2, resulting in less prominent IKs 
activation for more mature stimuli and reduced (+2.5%) APD prolongation after IKs block. 
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Figure 11. IKs Markov state diagram. 
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Figure 12. A. premature APs at S2 coupling intervals (CIS2) of 0.26, 0.3, and 0.4 s for CLS1 = 2 s. B. 
percent increase after 100% IKs block as a function of coupling interval. C–F. IKs activation and 
occupancy of open state, zone 2, and zone 1 for restitution protocol in A. 
 
APD accommodation 
 
Figure 13. A and B. accommodation of APD and [Na+]i,max after a change from CL = 1 s to CL = 0.5 s in 
control, after ICa,L block, after block of SR Ca
2+ release (Irel) and uptake (Iup), and with [Na
+]i clamped to 
its steady-state value at CL = 0.5 s. C. INaK for the 1st beat and a steady-state (SS) beat after change 
from CL = 1 s to CL = 0.5 s. 
 
We sought to gain insight into the ionic mechanism of APD accommodation by examining underlying 
ionic currents and concentrations. The transition from steady state at CL = 1 s to steady state at CL = 
0.5 s is examined in Figure 13. APD accommodation exhibits several properties consistent with 
experimental observations. Equilibration of APD after a change in CL occurs after several minutes of 
pacing, consistent with experiments in canine ventricular tissue.37 Consistent with the effect of 
nisoldipine on rabbit ventricular myocytes,47 100% block of ICa,L in the model diminishes APD 
accommodation. In addition, accommodation persists after 100% block of SR Ca2+ uptake (uptake 
current) and release (release current), consistent with effects of ryanodine and thapsigargin on 
rabbit myocytes.47 Figure 13B shows changes in [Na+]i during APD accommodation. In control and 
when SR release and uptake are blocked, accumulation of [Na+]i occurs with a time course similar to 
that of APD shortening. When ICa,L is blocked, APD shortening and [Na
+]i accumulation are 
diminished. When [Na+]i is clamped to its steady-state value at CL = 0.5 s, APD accommodation is 
eliminated. Figure 13C demonstrates that, in control, [Na+]i accumulation leads to a large increase in 
outward INaK from the first beat to the steady-state beat after a change in CL. After ICa,L block, there is 
a smaller difference in INaK from the first beat to the steady-state beat. Collectively, these simulations 
suggest that ICa,L is responsible for the increases in [Na
+]i and outward INaK that underlie APD 
accommodation.  
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Figure 14. Integrated Ca2+ (A) and Na+ (C) fluxes and maximum [Ca2+]i (B) calculated for each beat 
during transition from steady state at CL = 1 s to steady state at CL = 0.5 s. Integrated sarcolemmal 
Ca2+ influx was calculated as ICa,L + ICab and efflux as INaCa + Ipca. Integrated Na
+ influx was calculated as 
INaCa + INa + INaL + INab + CTNaCl and Na
+ efflux as INaK. 
 
To understand the link between ICa,L, [Na
+]i, and accommodation, we examined the sarcolemmal Ca
2+ 
and Na+ flux (μM/s) via currents, pumps, and exchangers after a change from CL = 1 s to CL = 0.5 s. 
Fluxes were calculated at steady state at CL = 1 s and for each subsequent beat after a change to CL 
= 0.5 s. At steady-state CL = 1 s, Ca2+ influx (primarily ICa,L) and efflux (primarily INaCa) are balanced 
(Figure 14A). After a change to CL = 0.5 s, the shorter DI does not provide sufficient time for INaCa to 
extrude Ca2+ that entered via ICa,L. Excess Ca
2+ influx leads to [Ca2+]i accumulation after the first beat 
and with continued pacing at CL = 0.5 s (Figure 14B). [Ca2+]i accumulation provides feedback 
(autoregulation48) by decreasing [Ca2+]i influx (through Ca
2+-dependent inactivation of ICa,L) and 
increasing [Ca2+]i efflux (through forward-mode INaCa). This feedback promotes decreased net Ca
2+ 
entry per cycle, so that [Ca2+]i approaches equilibrium within the 1
st minute of pacing at the new CL.  
 
Na+ influx exceeds efflux after change from CLS1 = 1 s to CLS2 = 0.5 s (Figure 15C). As with Ca
2+, the 
shortened DI provides insufficient time for complete extrusion of Na+ that entered during the AP, 
primarily via forward-mode INaCa and the fast Na
+ current (INa). Increased forward-mode INaCa as [Ca
2+]i 
accumulates further increases Na+ influx. The imbalance of Na+ influx and efflux drives [Na+]i 
accumulation (Figure 13B) until Na+ efflux via INaK increases to match influx after minutes of pacing 
(Figure 14C). The time course for equilibration of Na+ influx and efflux in our simulations (on the 
order of minutes) agrees with the slow time course of Na+ accumulation seen experimentally.16, 49 
The increasingly outward INaK as Na
+ influx and efflux approach equilibrium is the primary cause of 
APD shortening during accommodation. This ionic mechanism by which ICa,L drives [Na
+]i 
accumulation and INaK increase via INaCa is consistent with effects of nisoldipine and 
ryanodine/thapsigargin on rabbit ventricular myocytes.47 Block of ICa,L (nisoldipine) eliminates a 
critical driving force for [Na+]i accumulation (greater forward-mode INaCa, which promotes Ca
2+ 
extrusion and Na+ entry). After ICa,L blockade, Ca
2+ and Na+ influx barely exceeds Ca2+ and Na+ efflux 
after a change to CL = 0.5 s. [Ca2+]i (Figure 14A,B) and [Na
+]i (Figure 13A,B) accumulation after ICa,L 
block are diminished, resulting in diminished APD accommodation. Block of SR Ca2+ release 
(ryanodine) and SR Ca2+ uptake (thapsigargin) eliminates SR Ca2+ cycling, but the mechanism of ICa,L-
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driven increase in [Na+]i remains intact. Although block of SR function eliminates Ca
2+ transients, 
intact ICa,L leads to an increase in cell [Ca
2+]i. Forward-mode INaCa must increase to extrude Ca
2+, and 
[Na+]i accumulation and APD accommodation persist.  
 
Dependence of APD restitution on pacing rate 
 
Figure 15. A and B: dependence of APD restitution and [Na+]i,max on pacing rate (CLS1). C: dependence 
of INaK on pacing rate (CLS1) at constant S2 coupling interval (CIS2 = 2 s). 
 
Several experimental studies have shown that the APD restitution curve shifts to shorter APD as 
basic pacing CL decreases (shorter CLS1).
8, 36, 41, 42 Consistent with these experimental observations, 
our model reproduces the dependence of restitution on the rate of S1 pacing (Figure 15). These 
simulations also provide insight into the underlying ionic mechanism. Fast pacing (short CLS1; Figure 
15A) is accompanied by [Na+]i accumulation (Figure 15B), as described above in the case of 
accommodation (Figure 13). [Na+]i accumulation, in turn, promotes an increase in repolarizing INaK 
(Figure 15C), which decreases APD, thereby shifting the APD restitution curve to shorter APDs. 
DISCUSSION 
The rate-dependent phenomena examined in this study are thought to play an important role in the 
dynamics of arrhythmia.50-52 The model presented here reproduces experimentally observed APD 
adaptation, restitution, and accommodation in cell and tissue. Although the rate dependence of 
model APD, CaT, and [Na+]i accumulation is similar in cell and strand, our simulation results show 
that the effects of Ito1 block on ion accumulation differ. Other simulation results
43 have suggested 
that APD restitution kinetics and the transition to APD alternans and more complex excitation 
patterns in cell and tissue also differ. Taken together, these results suggest that experimental 
findings in isolated myocytes should be extrapolated to the multicellular tissue with caution.  
 
Recent studies have emphasized limitations in our mechanistic understanding of the rate 
dependence of APD.8 The detailed, physiologically based mathematical descriptions of critical ionic 
currents, pumps, and exchangers incorporated into the model lead to novel insight into underlying 
ionic mechanisms. Specific mechanistic insights generated by our study include the following. 1) Ito1 
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potentiates ICa,L and SR Ca
2+ release during early AP repolarization in isolated cells, but not in 
multicellular tissue. 2) Ito1 plays an important role in APD restitution because of its slow recovery 
kinetics. As DI increases, Ito1 recovery and phase 1 notch depth increase, suppressing IKr activation 
and lengthening APD. 3) IKs plays a limited role in repolarization of paced APs but plays an important 
role in APD shortening for premature stimuli. 4) ICa,L plays a critical role in APD accommodation and 
memory. As a response to Ca2+ entry via ICa,L at fast rates, forward-mode INaCa increases, leading to 
increased Ca2+ efflux and Na+ influx. Na+ accumulates and repolarizing INaK increases, leading to APD 
shortening during accommodation. 5) ICa,L-dependent increase in [Na
+]i and INaK at fast rates is 
responsible for the shift in APD restitution curves toward shorter APD.  
 
Previous experiments and simulation studies have suggested that Ito1, by increasing phase 1 
repolarization, increases peak ICa,L (the trigger for SR release) and, consequently, SR Ca
2+ release.29, 44 
These studies showed enhanced ICa,L and SR Ca
2+ release when phase 1 repolarization increases the 
ICa,L driving force. Although this scenario is relevant to an isolated, directly stimulated myocyte, 
model simulations indicate that it does not apply to the situation in vivo, where electrotonic loading 
from neighboring cells weakens the AP upstroke. Our simulations suggest that, for propagating APs, 
Ito1-dependent phase 1 repolarization has little effect on peak ICa,L and SR Ca
2+ release. In addition, 
simulations show that the weakened AP upstroke in the tissue decreases Ito1 activation and phase 1 
repolarization. Ito1 has been accorded a role in conduction
53, 54 and in electrophysiological remodeling 
in various diseased states.13, 55, 56 Our results suggest that predictions of the effect of Ito1 and Ito1 block 
based on single-cell simulations and experiments may not apply to the in vivo situation. In contrast, 
model simulations predict that Ito1 plays a significant role in APD restitution. The interplay between 
IKr activation and the slow recovery kinetics of Ito1 leads to a gradual increase in APD during 
restitution, whereas Ito1 block results in a more abrupt APD increase. This result provides a 
mechanistic explanation for the correlation between notch depth and APD observed in canine 
ventricular tissue.46 The time course of APD restitution is thought to play an important role in the 
stability of ventricular arrhythmias51. Our results suggest that experimentally observed 
heterogeneity in Ito1 density and recovery kinetics
57, 58 may play a role in the stability of arrhythmias 
in different species, regions of tissue, or pathophysiological states. Canine experiments have shown 
transmural heterogeneity in INaK,
59 Ito1,
21 IKs,
23 and INaCa.
60 The epicardial model accurately reproduces 
endocardial restitution kinetics after blocking only Ito1, suggesting that Ito1 is the dominant 
determinant of heterogeneity in restitution between the two cell types.  
 
Experimental measurements of the effect of IKs block on APD in canine ventricle have ranged from 
near 014 to as much as 30%.61 Varro et al.62 report a modest prolongation (3–7%) and biphasic CL 
dependence after chromanol block, consistent with our simulation results. Although the role of IKs in 
repolarization remains controversial, LQT mutations linked to genes for IKs α- and β-subunits
63 argue 
for an important role in repolarization. Our simulations demonstrate that slow activation and 
relatively low density limit the role of IKs in AP repolarization at physiological heart rates in the 
absence of β-adrenergic stimulation, consistent with our previous modeling studies.3 Simulations 
with a detailed Markov model of IKs predict an important role for IKs in APD restitution. During 
deactivation, channels accumulate in closed states (zone 1), where rapid activation in response to a 
Action potential rate-dependence in canine epicardium 
44 | 
premature stimulus is possible, leading to an important role for IKs in APD restitution at short DI. A 
role for IKs in APD shortening at fast CLS1 via accumulation in closed states has been shown in the 
guinea pig and humans22. Despite major differences between IKs density and kinetics in the guinea 
pig and dog, the mechanism for enhanced participation of IKs at fast CLS1 during adaptation and at 
short DI during restitution are similar in the two species. Importantly, although large density in the 
guinea pig ensures an important role for IKs at all rates, we find that IKs plays a major role in canine 
restitution at short DI, despite a limited role at longer physiological CL. Although the effect of IKs 
block on paced APs has been studied experimentally, no studies on the role of IKs in restitution have 
been reported. IKs is also likely to play an important role in repolarization in the presence of β-
adrenergic stimulation15 or for abnormally prolonged APD.62  
 
Recent simulations have addressed the role of APD accommodation and short-term memory in the 
dynamics of arrhythmia.50, 52 Simulations50 and experiments47 have emphasized uncertainty about 
the ionic mechanisms underlying this phenomenon. The results presented here predict a major role 
for ICa,L-driven [Na
+]i accumulation in this phenomenon. A role for [Na
+]i and INaK in gradual APD 
changes during long-term pacing has been proposed.41, 64, 65 Similarities between the effect of block 
of ICa,L and SR function in simulations and experiments
47 support for this hypothesis. Although a 
similar time course of APD accommodation after a CL change has been observed in a range of 
preparations, APD accommodation in other species and preparations is often more rapid.9, 47, 66 This 
suggests that other mechanisms may play a role or, alternatively, that additional experiments are 
required to improve our understanding of equilibration of [Na+]i and [Ca
2+]i during long-term pacing. 
A role for ICa,L in the dynamics of arrhythmia has been proposed by many investigators, usually 
through effects on APD restitution.41, 67 Our simulations suggest that the effect of ICa,L on [Na
+]i and 
APD accommodation should also be considered. The importance of [Na+]i in determining the rate 
dependence of APD also points to an important limitation of simplified computational models, 
where intracellular ion concentrations are often held constant.  
 
The predictive value of multicellular simulations of arrhythmia depends on the ability of cell models 
to reproduce experimental observation. Despite variability across species, cell type, and preparation, 
APD adaptation, restitution, and accommodation are qualitatively similar in many species. Our 
model examines the ionic basis of these rate-dependent phenomena in the dog but may provide 
insight into ionic mechanisms in other species, including humans. In addition, our model will provide 
a valuable tool for linking initiation and maintenance of arrhythmia to underlying cellular processes 
and ionic currents through multicellular simulations. 
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ABSTRACT 
Local signaling domains and numerous interacting molecular pathways and substrates contribute to 
the whole-cell response of myocytes during β-adrenergic stimulation (βARS). We aimed to elucidate 
the quantitative contribution of substrates and their local signaling environments during βARS to the 
canine epicardial ventricular myocyte electrophysiology and calcium transient (CaT). We present a 
computational compartmental model of βARS and its electrophysiological effects. Novel aspects of 
the model include localized signaling domains, incorporation of β1 and β2 receptor isoforms, a 
detailed population-based approach to integrate the βAR and Ca2+/Calmodulin kinase (CaMKII) 
signaling pathways and their effects on a wide range of substrates that affect whole-cell 
electrophysiology and CaT. The model identifies major roles for phosphodiesterases, adenylyl 
cyclases, PKA and restricted diffusion in the control of local cAMP levels and shows that activation of 
specific cAMP domains by different receptor isoforms allows for specific control of action potential 
and CaT properties. In addition, the model predicts increased CaMKII activity during βARS due to 
rate-dependent accumulation and increased Ca2+ cycling. CaMKII inhibition, reduced 
compartmentation, and selective blockade β1AR are predicted to reduce the occurrence of delayed 
afterdepolarizations during βARS. Finally, the relative contribution of each PKA substrate to whole-
cell electrophysiology is quantified by comparing simulations with and without phosphorylation of 
each target. In conclusion, this model enhances our understanding of localized βAR signaling and its 
whole-cell effects in ventricular myocytes by incorporating receptor isoforms, multiple pathways and 
a detailed representation of multiple-target phosphorylation; it provides a basis for further studies 
of βARS under pathological conditions. 
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INTRODUCTION 
Maximal β-adrenergic receptor (βAR) stimulation (βARS) in ventricular myocytes activates the βAR / 
G-protein / adenylyl cyclase (AC) / cyclic AMP (cAMP) / protein kinase A (PKA) pathway that results 
in the phosphorylation of numerous intracellular proteins (“substrates”) including the L-type Ca2+ 
channel (ICa,L), slowly activating delayed rectifier K
+ channel (IKs), phospholamban (PLB) and the 
inhibitory troponin subunit (TnI). In addition, there are several feedback loops, such as βAR 
desensitization, that control the temporal response of βARS.1, 2 Observations in living myocytes using 
fluorescent techniques have demonstrated the importance of localized signaling domains in βAR 
cascade function. Moreover, many interdependencies were identified between PKA substrates that 
influence the cardiac action potential (AP) and calcium transient (CaT).3, 4  
 
Localized signaling results from physical subcellular domains with restricted diffusion of the second 
messenger cAMP (e.g., caveolae), from specific subcellular localization of signaling molecules (e.g., 
cAMP and phosphodiesterases; PDEs) and from targeting of PKA to specific substrates by A-kinase 
anchoring proteins (AKAPs).5-7 Localized signaling in subcellular domains is essential for precise 
specific regulation (“local control”); it allows multiple signaling cascades that affect cAMP to target 
specific substrates. This local organization may change in pathology such as heart failure.8 The 
relative contribution of each local signaling domain and substrate to the whole-cell 
electrophysiological response during βARS is extremely difficult to determine experimentally, 
especially in large mammals. Moreover, an increasing number of interactions between the βAR 
signaling cascade and other signaling cascades, most prominently the Ca2+/Calmodulin kinase 
(CaMKII), are discovered to play an important role in normal physiology and in pathology.9 Currently, 
our understanding of the complex interactions between signaling cascades and substrates and their 
effects on cellular electrophysiology is rather limited. 
 
Computational approaches have been employed to enhance our understanding of various 
(patho)physiological processes.10 The computational approach is particularly useful when the system 
under investigation is complex, highly interactive and nonlinear, as is the case with the βAR cascade 
and its effects on cellular electrophysiology. Quantitative studies of cAMP signaling have been 
performed11-13 but did not include electrophysiological effects. Several studies have modeled 
different aspects of the adrenergic system in the ventricular myocyte in various levels of detail.14-18 
However, none of these studies described the effects of localized signaling domains or included all 
interacting PKA substrates. Here, we present the first detailed computational model of βARS in the 
canine ventricular myocyte that includes both localized signaling domains and a wide range of 
electrophysiological substrates. We use this model to study the local effects of βARS on subcellular 
targets and their consequences in terms of whole-cell electrophysiology and CaT. 
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METHODS 
Details of the computational model (Figure 1) are provided in the appendix of this thesis. 
 
Figure 1. A. Schematic of the canine ventricular cell model including Ca2+ handling, 
electrophysiology, CaMKII signaling pathway and βAR signaling domains. Substrates modulated by 
PKA phosphorylation are indicated. Model CaMKII targets include PLB/Serca and RyR. B-D, Detailed 
schematics of the interactions in the extracaveolar (ECAV; B), cytosolic (CYT; C) and caveolar (CAV; D) 
signaling domains. Abbreviations are defined in the appendix of this thesis. Model code is provided 
in the Research Section of http://rudylab.wustl.edu. For color figure, see page 243. 
 
βAR signaling cascade 
A recent compartmental model of cAMP signaling in ventricular myocytes11 served as starting point 
for the βAR-signaling model of this study. Three functional compartments represent the caveolar 
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(CAV), extracaveolar membrane (ECAV) and cytosolic (CYT) signaling domains. Each compartment 
contains signaling proteins at local concentrations. We extend the cAMP signaling cascade with 
differential localization of β1AR and β2AR, local PKA activation (high affinity PKAI in CYT, lower 
affinity PKAII in CAV and ECAV), PKA-dependent feedback loops, PKA targeting to ICaL, IKs and RyR by 
AKAPS, and eight substrates of direct PKA-dependent phosphorylation. Figure 1 B-D shows 
schematics of the compartmental signaling cascades in the model.  
 
All biochemical reactions were modeled either as differential equations (e.g., cAMP production, PKA 
activation, receptor desensitization) or as algebraic equations based on steady-state assumptions for 
reactions occurring much faster than changes in cAMP and substrate phosphorylation. Time-
dependent concentrations of the βAR agonist isoproterenol (ISO, in combination with blockade of 
either β1AR or β2AR in some simulations) and/or the PDE inhibitor IBMX served as inputs to the 
adrenergic signaling cascade.  
 
Choice and localization of PKA substrates 
The model contains eight PKA substrates which are included in specific compartments of the 
signaling model (Table 1) based on experimental evidence (in particular association with caveolin-3 
for CAV substrates). It is important to note that our compartments are defined as functional entities. 
For example, although caveolae are small cellular invaginations of less than 100 nM in size,19 we still 
consider the ryanodine receptor part of this compartment because of its intimate interaction with 
ICaL, even though it will not physically reside in this small invagination, but is localized at the opposing 
SR membrane surface. L-type Ca2+ channels are known to reside predominantly in T-tubules in the 
ventricular myocyte.20 However, since caveolin has been implicated in T-tubular biogenesis21 and L-
type Ca2+ channels have indeed been shown to colocalize with caveolin,22 we decided to include both 
ICaL and RyR in the functional caveolar compartment.  
 
Substrate Compartment Evidence 
ICaL CAV Colocalization with caveolin-3.
22 
IKs ECAV Based on membrane targeting with yotiao, but no K
+ channels 
associate with caveolin22. Although certain studies have found 
that Kv7.1 (KCNQ1, the α subunit of the IKs channel) localizes to 
low density membrane fractions, no co-immunoprecipitation of 
Kv7.1 and caveolin-3 has been shown so far.23 
IKur ECAV Membrane ion channel, not found in caveolae in dog.
24 
INa
 CAV Colocalization with caveolin-3.22 
INa,K CAV Predominantly located in caveolae, depending on subunit 
composition.25 
RyR CAV Based on close association with ICa,L, and regulation of RyR by 
caveolin-associated eNOS.26 
PLB CYT Influenced by cytosolic protein Inh1,27 phosphorylated by PKAI.14 
TnI CYT  
Table 1: Localization of PKA substrates. 
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The following targets are not included in the current model: ICl,cAMP is a cAMP activated Cl
- current 
that is present in guinea pig, but not canine ventricular myocytes.28, 29 Karle and co-workers found 
evidence that IKr is modulated by PKA in guinea pig ventricular myocytes
30 and similarly a small but 
significant alteration in IKr was found recently in response to IBMX and forskolin in CHO cells 
31. 
However, no such modulation was found in dogs.32 Because of the absence in dog, and the small 
effects in CHO cells, IKr modulation by PKA was not incorporated. Similarly, no consensus exists 
concerning the modulating effect of PKA on Na+-Ca2+ exchanger INa,Ca.
33, 34 Relatively little is known 
about the adrenergic modulation of ITo, however Van der Heyden et al. argue that only α-adrenergic 
modulation has a significant impact on ITo.
35 As a result, we do not include direct modulation of ITo in 
our model of βAR stimulation, although it should be noted that ITo is known to be modulated by 
CaMKII36 which shows increased activity during βAR stimulation (see below). Finally, many disparate 
results exist concerning the modulation of the inward rectifier potassium current IK1 by PKA, which 
has a consensus phosphorylation site on S425.37 Although recent studies suggest a role for IK1 
mutations that alter its adrenergic responsiveness in catecholaminergic polymorphic ventricular 
tachycardia (CPVT)-like arrhythmias, the major differences in WT IK1 in the presence and absence of 
adrenergic stimulation occur at potentials below the normal physiological range, with no difference 
at -80 mV.38  This is further strengthened by the unaltered resting membrane potential in canine 
ventricular myocytes in the presence of adrenergic stimulation.39, 40 As such, adrenergic stimulation 
of IK1 is not included in the model.  
 
Definition of the level of phosphorylation of PKA substrates 
The effective level of phosphorylation of a PKA substrate X, denoted by f̂Xp is defined relative to the 
baseline phosphorylation level. That is, the level in the absence of catecholamine stimulation is 
defined as f̂Xp = 0, although in an actual myocyte there may be a certain number of phosphorylated 
proteins under basal conditions. Similarly, for the research described here, the phosphorylation level 
is defined to be 1 under a saturating concentration of isoproterenol (although this does not 
necessarily mean that all channels are phosphorylated). This functional definition facilitates the use 
of a population-based approach to link the signaling cascade and the electrophysiology. Although a 
cocktail of agonists may increase cAMP beyond the levels observed with maximal ISO stimulation, 
this will not be reflected in the electrophysiological properties of the model, because no substrate 
data were available under these conditions and hence no extrapolations to higher cAMP levels could 
be made. When these electrophysiological data become available, the population-based approach 
(see below) makes it possible to set a new upper limit and have a larger range of cAMP levels for 
which the electrophysiological properties can be simulated. It should also be noted that although 
this functional definition is a simplification, it does not prevent simulation of other adrenergic 
agonists (e.g., Forskolin or PDE inhibition with IBMX), particularly for cAMP levels within the range 
observed with ISO stimulation. This is consistent with the observations by Hohl and Li, who showed 
that various adrenergic agonists over a wide range of concentrations produced a similar range of 
changes in peak amplitude and decay time of the calcium transient.41 
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Analysis of cAMP compartmentation 
Experimentally, compartmentation of cAMP is revealed by differential effects of signaling pathways 
that affect cAMP on phosphorylation of cytosolic versus sarcolemmal proteins,5, 42 and by differences 
in cytosolic cAMP and subsarcolemmal cAMP levels measured with fluorescent probes and cyclic 
nucleotide-gated channels,43 respectively. This has illustrated that selective augmentation of cAMP 
in specific compartments occurs and is critical for specific regulation of subcellular targets. Here, we 
focus on the effects of βARS. Other signaling pathways affecting cAMP (e.g., the prostaglandin 
receptor PGE1) are not included. Compartmentation has also been shown through differences in 
βAR isoform stimulation. In mammalian ventricle, three isoforms have been reported. In canine, 
approximately 80% are β1AR.
44 Functional effects of β2AR stimulation are highly dependent on 
species and experimental conditions. In rodents, β2ARS only affects local cAMP concentrations, 
whereas cAMP increases elicited by β1ARS diffuse throughout the cell.
45, 46 Studies in the failing 
canine ventricle show a reduction in β1AR without changes in β2AR and consequently an important 
role of β2ARS.
47 Under normal physiological conditions, differential effects of β2ARS on whole cell 
behavior have been reported.47-49 The model includes β1AR and β2AR with cell-wide and CAV 
localization respectively, based on experimental data.8 The functional significance of β3AR in large 
mammals is incompletely understood and not included here.50 Virtual knock-out models of selected 
signaling proteins were created by setting their concentration to 0. Reduced compartmentation was 
simulated by increasing the cAMP diffusion rates by a factor 1000. 
 
Definition of the soluble and particulate fractions 
The model contains 3 compartments that provide the localized signaling characteristics that are vital 
for efficient and specific signaling: CAV, ECAV CYT. In Iancu et al. it is stated that51: “… the only 
information available on the subcellular location of the different PDE isoforms describes their 
presence in membrane (particulate) and/or cytosolic (soluble) fractions. How the membrane 
associated PDE activity is distributed between caveolar and extracaveolar domains is not known.” In 
accordance with this description, we define the particulate fraction as made up of the CAV and ECAV 
compartments and let the soluble fraction correspond to the CYT compartment. In order to relate 
protein activities that are expressed as pmol / mg cell protein (e.g. cAMP from Hohl and Li 41) to the 
intracellular concentrations used in the model, we compare the values normalized to the total 
cellular activity, thereby taking into account the relative contribution of the compartments based on 
their volume. 
 
CaMKII signaling cascade 
The baseline model52 (Chapter 2) includes phosphorylation of PLB and RyR by CaMKII. We included 
populations for CaMKII-dependent phosphorylation of ICaL, INa and late INa (INa,L) based on recently 
published formulations53, as well as CaMKII-dependent changes in ITo and IK1 (see Appendix of this 
thesis). CaMKII is activated by localized Ca2+ in the Ca2+ subspace, consistent with previous modeling 
studies, but no further localization is included. Additional crosstalk between βARS and CaMKII occurs 
via PKA-dependent activation of Inhibitor 1 and subsequent deactivation of PP1 that controls CaMKII 
deactivation, consistent with experimental observations.9 
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Changes to electrophysiological substrates after phosphorylation 
Phosphorylation effects were incorporated by including populations of phosphorylated and non-
phosphorylated channels with distinct properties for the eight substrates affected by βARS. 
Properties of non-phosphorylated (baseline) substrates were based on the recently published model 
of the canine epicardial ventricular myocyte52 (Chapter 2) and properties of phosphorylated 
channels were determined from experimental data in the presence of a saturating dose of ISO. At 
each time instant, the  current/flux for a given substrate is determined for both (phosphorylated and 
non-phosphorylated) populations. The fraction of phosphorylated channels, which is determined by 
the βAR cascade, is then used to interpolate between these values to determine the net 
current/flux. We assume that phosphorylation by PKA and CaMKII is independent and have 
integrated the βAR and CaMKII cascades using four populations for these targets (PKA 
phosphorylated, CaMKII phosphorylated, PKA and CaMKII phosphorylated and non-phosphorylated). 
 
The population-based approach is based on the assumption that phosphorylation is a binary process 
that is independent of channel gating. It captures the distinct conformations of phosphorylated and 
non-phosphorylated channels as they coexist in the ventricular myocyte.  Most previous modeling 
approaches employed only one homogeneous population and shifted model parameters (such as the 
V1/2 of activation) based on phosphorylation levels.
14, 17 Although both approaches coincide at 
phosphorylation levels of 0% and 100%, they are different for other levels (Figure 2). 
 
Figure 2. ICaL traces at various levels of phosphorylation elicited during a 300 ms depolarizing pulse to 
-20 mV using the population based approach (Pop) with the specified fraction (fICaL) of channels 
phosphorylated (solid lines), or using a shift of parameters in a single homogeneous population (Par; 
dashed lines). Results are identical only at 0% and 100% phosphorylation, but differ for intermediate 
phosphorylation levels. fICaL indicates the fraction of phosphorylated L-type Ca
2+ channels. 
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Parameter estimation 
Parameters for the model were obtained either directly from the cited literature source (possibly 
after conversion of units), or derived using minimization of the squared difference between 
experimental data and model output. Initial exploration of the parameter space was performed 
using evolutionary algorithms. Bounds on parameters were determined based on physiological 
considerations (e.g., requirement of positive concentrations and rate constants), or centered around 
values used in existing models. Highest scoring parameter sets were further optimized using the 
Nelder-Meade simplex algorithm. All optimizations were performed in Matlab (Mathworks®, Natick, 
MA). In some optimizations of electrophysiological substrates the Matlab optimizations were 
connected to the custom C++ software to generate model output. 
 
A number of reparametrizations were performed to facilitate the optimization process by reducing 
the number of ill-constrained parameters. Let [P]CAV,  [P]ECAV, [P]CYT denote the 3 parameters 
describing the concentrations of protein P in the caveolar, extracaveolar and cytosolic 
compartments respectively. Furthermore, let [P]CELL, fPCAV, fPECAV, represent the total cellular 
concentration of P, the fraction of P located in the caveolar compartment and the fraction of P 
located in the extracaveolar compartment respectively. The following transformations are applied: 
[P]CAV = fPCAV ∙ [P]CELL ∙ VCELLVCAV  [P]ECAV = fPECAV ∙ [P]CELL ∙ VCELLVECAV [P]CYT = (1 − fPCAV − fpECAV) ∙ [P]CELL ∙ VCELLVCYT  
Here Vx represents the volume of compartment x. This has as an advantage that the value of [P]CELL can be much better constrained based on the available literature (using 1 pmol / mg cell 
protein = 1.084 μmol/L2 whenever necessary). In a similar fashion we use the forward rate constant 
𝑘𝑓 and the equilibrium constant 𝐾𝑒 to define a general reversible reaction. The backward rate 
constant is then given by 𝑘𝑏 = 𝑘𝑓 ∙ 𝐾𝑒. The equilibrium constant is better constrained based on 
available experimental data. 
 
Using these parametrizations, a parameter estimation procedure was followed, designed to 
minimize parameter uncertainties (Figure 3). After fixing the parameters that were directly available 
from literature (e.g., βAR affinities for ISO), parameters were first estimated for direct steps in the 
adrenergic cascade (e.g., adenylyl cyclase activity as a function of G-protein activation). These 
estimations produce, in general, a well defined, unique set of parameters within the physiological 
range. Subsequently more global data (e.g., adenylyl cyclase activity as function of isoproterenol) 
that cover multiple steps of the cascade were used to determine missing parameter values. Finally, 
the parameters of the PKA substrates were fit based on the intracellular cAMP concentrations 
resulting from the previously estimated parameters and the substrate isoproterenol dose-response 
and time-dependence of phosphorylation curves. The combined global exploration and subsequent 
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local optimization of promising parameter sets should reduce the risks of getting trapped in a local 
minimum. For the electrophysiological properties of the phosphorylated population, parameter 
values were either set directly based on literature (e.g., Km, half-maximal activation voltage, etc.) or 
resulted from a Nelder-Meade simplex optimization to the experimental data starting from the 
properties of the non-phosphorylated population. 
 
Figure 3. Simplified signaling schematic indicating parameter estimation procedure. Parameters that 
were directly available in the experimental literature or characterized carefully based on 
experimental data in previous modeling studies were fixed (Step 0). Subsequently, data representing 
direct steps in the cascade were used whenever possible to determine missing parameter values 
(Steps 1a-c, each of which could be performed independently due to the direct relation between 
quantities). Thereafter, more global aspects (e.g., the relationship between ISO and cAMP levels) 
were used simultaneously to constrain remaining parameters (Step 2a-c). Finally, the substrate 
parameters were inferred using the experimental ISO concentration response curve for each 
substrate and the PKA activity obtained in steps 1 and 2. In Figures 7-24 the relation between 
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experimental and simulation data is presented and the experimental source reference and species 
information are indicated. All signaling validation was performed in the absence of 
electrophysiological changes (all state variables for the electrophysiological model were fixed). 
 
Parameter sensitivity analysis 
For the parameters in the βAR signaling cascade, a one-factor-at-a-time sensitivity analysis was 
performed to investigate the individual contribution of each parameter. Each parameter 𝑋𝑖  was 
altered to 99% and 101% of its original value and the changes in output measures were evaluated:  
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Because of the modular structure of the βAR signaling cascade, properties of the endpoints of the 
cascade that connect with the electrophysiological module were chosen as output measures. The 
ISO affinity of each substrate was determined for each parameter set using a fit of the Hill equation 
to steady-state phoshorylation levels over a wide range of ISO concentrations. The other two output 
measures that were determined are the time to half maximal activation of a substrate and the 
amount of desensitization (difference between maximum and steady-state levels) in the presence of 
an intermediate dose of ISO (20 nmol/L) for each substrate. The 10 parameters with the highest 
impact (based on the mean ∆𝑓𝑖
(𝑘) over all eight substrates) and the 10 with the lowest impact are 
shown in Figures 4-6.  
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Figure 4. The 10 parameters with the smallest (A) and largest (B) impact on the mean change in ISO 
affinity over all substrates. Note different impact scale in (B) for IKs. For color figure, see page 244. 
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Figure 5. The 10 parameters with the smallest (A) and largest (B) impact on the mean change in time 
to half maximal activation in the presence of 20 nmol/L ISO over all substrates. Note different impact 
scale in (B) for PLB. For color figure, see page 245. 
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Figure 6. The 10 parameters with the smallest (A) and largest (B) impact on the mean change in the 
amount of desensitization (difference between peak phosphorylation level and level after 30 min) in 
the presence of 20 nmol/L ISO over all substrates. For color figure, see page 246. 
 
The sensitivity analysis is based on a 2% change in parameter values (+1% and -1% from the values 
reported here) using a one-factor-at-a-time approach. Simulations with +5% and -5% indicated a 
similar ordering of parameters with respect to their effect on the three output measures: ISO 
affinity, time to half maximal phosphorylation (in the presence of 20 nmol/L ISO) and amount of 
desensitization. These three outputs were determined for all eight substrates. 
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From the sensitivity analysis it is clear that the extracaveolar compartment and in particular the 
affinity and desensitization of IKs are the most sensitive to parameter changes. This may be explained 
by the high basal cAMP levels in the ECAV (10 μmol/L, within the micromolar range reported by 
Iancu et al.11), which result in small dynamic range of PKA activity. With respect to the 
phosphorylation time-course, PLB is the most sensitive substrate. PLB is also the substrate with the 
fastest kinetics, based on experimental data (Figure 16), which may partly explain this sensitivity. 
Additionally, it becomes clear that parameters that affect whole cell properties (and hence multiple 
substrates) have a large impact on these output measures. Such parameters include cell volume, 
whole cell PKA levels and distribution of PKA. Consistent with experimental observations,5, 43 these 
simulations also further emphasize a major role for PDEs and their specific subcellular localization in 
controlling substrate phosphorylation levels, as evident from the large impact of parameters such as 
fPART,PDE. 
 
The sensitivity analysis also indicates aspects of the model that could be simplified. In particular, the 
dynamics of cAMP/PKA binding as well as PKI-dependent inhibition of PKA appear to have little 
impact on phosphorylation. Indeed, the reaction rates for these interactions are significantly faster 
than cAMP production or substrate phosphorylation. This indicates that the cAMP/PKA pathway 
could also be modeled as a set of algebraic equations. Although this would significantly reduce the 
number of states (by 15 / 57 states in the signaling module), the reduction in the number of 
parameters would be modest (by 6 parameters). Finally, the parameters representing the affinities 
between substrates and AKAPs and between AKAPs and signaling molecules are determined to have 
a low impact. Experimentally, AKAPs are considered critical elements in the localization of PKA close 
to specific substrates.7 Their small effect in these simulations can be explained by the fact that the 
binding affinities involved are very high. Thus, a small change in affinity does not significantly affect 
the distribution of bound/free substrates. 
 
The parameter sensitivity analysis described here provides insight into the contribution of individual 
parameters. It is possible that alteration of a subset of parameters is able to compensate for changes 
in a different parameter. This would provide further possibilities to simplify the model. However, 
such a combinatorial examination was found to be too demanding in terms of computation time and 
data storage. 
 
Validation 
The model is validated (Figures 7-24) with a wide range of experimental data at the levels of the 
signaling cascade, individual electrophysiological components and whole-cell response. 
 
Local control of β-adrenergic stimulation 
64 | 
 
Figure 7. Comparison between adenylyl cyclase (AC) properties of model (lines) and experimental 
data (symbols). A. Gs-dependence of AC 5/6 in experiments and model. B. Inactivation of AC6 by Gi 
at various levels of Gs-stimulation in experiments54 and model. No error bars provided in 
experimental source. C. Simulated and measured whole-cell AC activity: (i) at peak (red), (ii) after 5 
min (green) and (iii) at steady-state (white symbols; black line) in canine ventricular myocytes55, 56 
(circles, triangles) and Chinese hamster fibroblasts with human β1ARs expressed (squares; no error 
bars provided in experimental source)57. For color figure, see page 247. 
 
 
Figure 8. Comparison between cAMP properties of model (lines) and experimental data (symbols). A. 
Simulated and measured41 cAMP levels in whole-cell (filled) and particulate fraction (defined as CAV 
and ECAV compartmens in the model; open) of canine ventricular myocytes as function of [ISO]. B. 
Same as A in the presence of 10 μmol/L of the PDE inhibitor IBMX. Values in A and B are normalized 
to the maximal whole-cell cAMP level in the absence of IBMX. C. Temporal response of whole cell 
cAMP levels during stimulation with ISO in the model (line), canine41 (circles) and rat58 (squares) 
ventricular myocytes.  
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Figure 9. Comparison between effects elicited by β1AR or β2AR stimulation in model (white bars and 
lines) and experiments (shaded bars, symbols). A. Fractional increase in whole-cell cAMP compared 
to baseline elicited by 100 nmol/L ISO (left), ISO + β2AR antagonist (ICI; middle) and ISO + β1AR 
antagonist (CGP; right) in model and canine ventricular myocytes49. B. FRET changes of the HCN 
cAMP sensor in T-tubule or cell-membrane crest in response to local stimulation of β1AR (ISO + ICI) 
or β2AR (ISO + CGP) in rat ventricular myocytes8 compared to cAMP changes after stimulation of 
CAV domain only (corresponding to T-tubule; e.g., containing ICaL channels) or ECAV domain only 
(corresponding to cell crest) of model. Values are normalized to ECAV response with β1AR 
stimulation. β1AR stimulation produces a cell wide signal, whereas β2AR response is local. 
Magnitude differs because of species differences and nonlinearity of the sensor.  C. Time course of 
PLB phosphorylation during β2AR stimulation (with zinterol) in rat ventricular myocytes in the 
absence (white) or presence (red) of pertussis toxin (PTX)59 compared to β2AR stimulation in the 
model (0.1 μmol/L ISO + CGP). Treatment with PTX is simulated by setting the concentration of Gi to 
0.0. Both in model and experiments, stimulation of β2AR does not result in phosphorylation of 
cytosolic proteins unless PTX is added. 
 
 
Figure 10. Validation of PDE properties. A. Relative PDE activity under basal conditions in model 
(white bars) and adult rat ventricular myocytes60 (grey bars) in the presence of 1 μmol/L of cAMP as 
assessed by specific inhibition of each isoform. Quantitative differences between contribution of 
PDE3 and PDE4 can be explained by species differences.61 B. Relative whole-cell PDE activity under 
baseline conditions or in the presence of ISO in model (white) and adult rat ventricular myocytes43 
(blue) showing increased PDE activity resulting from PKA-dependent phosphorylation. 
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Figure 11. Comparison between PKA properties of model (lines) and experimental data (symbols). A. 
Simulated and measured62 cAMP dependence of activation of PKA type I (filled symbols) and II (open 
symbols). B. cAMP dependence of high (red) and low (black) concentrations of PKA type II 
holoenzyme. C. Effect of PKI on PKAII activity in the presence of high concentration of holoenzyme. 
No error bars provided in experimental sources.63 
 
 
Figure 12. Validation of protein phosphatase inhibitor 1 (Inh1) properties. A. Relative Inh1 activity 
(compared to total Inh1 concentration) at baseline, during stimulation with 10 nmol/L ISO and 
during stimulation with 1 μmol/L ISO in model (white bars) and experiments in guinea-pig ventricular 
preparations (grey bars)64. B. Relative reduction in PP1 by Inh1 in the presence of 1 μmol/L ISO. Y-
axis shows fractional reduction relative to value in absence of Inh1  in model (white bar) and mouse 
ventricle (grey bar)65. 
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Figure 13. Relative phosphorylation level of CAV substrates as function of ISO in model (lines) and 
experiments (symbols). A. ICaL phosphorylation compared to relative increase in peak I-V during 
voltage-clamp experiments in canine-ventricular myocytes.66 B. RyR phosphorylation compared to 
intensity obtained with a Ser 2030 phosphospecific RyR antibody in rat cardiac myocytes.67 C. INa 
phosphorylation compared to relative increase in peak INa during voltage-clamp to 0 mV in rat 
papillary muscle.68 D. INaK phosphorylation dose-response compared to relative increase in pump 
current (DHO sensitive at -60 mV) in guinea-pig ventricular myocytes.69 
 
 
Figure 14. Relative phosphorylation level of ECAV substrates as function of ISO in model (lines) and 
experiments (symbols). A. IKs phosphorylation in model and relative IKs (HMR1556 sensitive) increase 
in canine ventricular myocytes during 3 s. depolarizing pulses to + 50 mV70. B. IKur phosphorylation 
compared to relative change in IKur (separated from ITo by an inactivating prepulse) during 140 ms 
depolarizing pulses to + 50 mV in canine atrial myocytes.71 
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Figure 15. Relative phosphorylation level of CYT substrates as function of ISO in model (lines) and 
experiments (symbols). A. PLB phosphorylation compared to relative intensity obtained with a Ser 16 
phosphospecific  PLB antibody in rat heart preparations after treatment with various doses of ISO.72 
B. TnI phosphorylation compared to radioblots of 32P incorporation in TnI in rat cardiac myocytes (no 
error bars provided in experimental source).73 
 
 
Figure 16. Time-dependence of substrate phoshorylation. A. Phosphorylated fraction of ICaL channels 
in unpaced model (f̂Ca,LP ; line) compared to relative increase in peak ICaL during repetitive voltage-
clamp commands to 0 mV, elicited every 60 seconds in canine ventricular myocytes in the presence 
of 0.5 μmol/L ISO.48 B. Fraction of phosphorylated PLB (fupPKA) in unpaced model (line) compared to 
relative 32P incorporation in PLB in unpaced mouse ventricular myocytes treated with 1.0 μmol/L 
ISO.74 C. Same as (B) for TnI. The time-instant t = 0 indicates the start of βAR stimulation. All other 
substrates (INa, INaK, IKs, IKur, RyR) for which no rate of phosphorylation was available, were given the 
same phosphorylation time-course as ICaL. Validation of CaMKII-dependent phosphorylation time-
courses can be found in Figure 24. 
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Figure 17. Simulated characteristics of PKA phosphorylated (red), CaMKII phosphorylated (orange) 
and non-phosphorylated (black) populations of ICaL. Experimental data are shown as symbols, model 
output as lines. A. Peak I-V relationship.75 B. Voltage dependence of steady-state ICaL inactivation.
76 C. 
Fold increase in peak ICaL I-V with ISO or maximal CaMKII activation (left) and shift in peak I-V and 
midpoint of inactivation (V1/2 Inact; right) during stimulation with ISO in model (white) and 
experiments48, 77, 78 (blue). D. Recovery from inactivation. Inset shows time-constants under baseline, 
ISO or CaMKII conditions based on a mono-exponential fit in model (white bars) and canine 
epicardial myocytes (blue bar).79 E. Time course of ICaL inactivation during a 200 ms depolarizing 
pulse to 0 mV. Inset shows the relative change in time constant of inactivation with 1.0 μmol/L ISO 
or maximal CaMKII activation. CaMKII-dependent effects are consistent with experiments in rabbit 
ventricular myocytes.78 For color figure, see page 247. 
 
  
Figure 18. Simulated characteristics of phosphorylated (filled symbols) and non-phosphorylated 
(open symbols) populations of IKs and IKur. Experimental data are shown as symbols, model output as 
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lines. A. IKs tail-current amplitude after 300-ms depolarizing pulses in model and canine ventricular 
myocytes.80 B. Same as A, after 3000-ms depolarizing pulses. C. IKur I-V in canine ventricular myocytes 
(in response to 100 nmol/L ISO)81 and model. 
 
 
Figure 19. Simulated characteristics of phosphorylated (filled symbols) and non-phosphorylated 
(open symbols) populations of INa. Experimental data are shown as symbols, model output as lines. 
A. INa peak I-V relationship in model and canine ventricular myocytes.
82 B. Steady-state INa 
inactivation. 
 
 
Figure 20. Characteristics of ITo recovery from inactivation at baseline (black), with maximal CaMKII 
activity (orange) or in the presence of 1.0 μmol/L ISO (red; identical to baseline). A. Simulated (line) 
time course of ITo recovery from inactivation (assessed using a double-pulse protocol to +40 mV for 
200 ms from a holding potential of -80 mV) compared to experimental data (white circles) from 
canine ventricular myocytes under baseline conditions.83 B. Comparison of model fast and slow 
recovery time constants (based on a biexponential fit to the data in A). C. Validation of the effect of 
CaMKII on ITo recovery from inactivation in model (white) compared to data in rabbit ventricular 
myocytes acutely overexpressing CaMKII (blue).84 For color figure see page 248. 
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Figure 21. Effects of ISO on RyR, PLB, TnI and INaK. A. Simulated (white bars) relative change in total 
(∫Release; left) and maximum SR-Ca2+-release flux (Max. Release; right) for phosphorylated RyRs 
compared to baseline (no βARS) under conditions of identical SR-Ca2+ loading and ICaL trigger 
strength. Corresponding experimental data85 (from rabbit ventricular myocytes) are shown in grey 
bars. B. Relative change in PLB Ca2+ affinity (left), troponin Ca2+ affinity (middle) and INaK intracellular 
Na+ affinity (right) in the presence of ISO (compared to baseline without ISO). Simulation shown in 
white bars; experimental data in grey bars.86-88 
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Figure 22. Concentration-dependent effects of ISO on APD (A; CL = 1000 ms) and CaT amplitude (B; 
CL = 2000 ms) in canine ventricular myocytes (symbols39, 89) and model (lines). C. Time course of APD 
changes during application of 100 nmol/L ISO in 4 canine ventricular myocytes (symbols) and model 
(line). APDs were normalized between 1 (baseline) and 0 (maximal response to ISO) to account for 
baseline cell to cell differences (see also Figure 26). CL = 1000 ms. For experimental protocol, see 
Johnson et al.90 For color figure see page 248. 
 
 
Figure 23. A. CaT recorded in canine ventricular myocytes in the absence of adrenergic stimulation at 
CL of 4000 ms, 2000 ms, 1000 ms and 500 ms. Reproduced from Ref.91, with permission. B. CaT in 
the model under similar conditions shows a comparable increase with rate in CaT amplitude and rate 
of decay. C. CaT in the model during maximal adrenergic stimulation shows increased CaT amplitude 
and rate of decay at all CLs. D. Quantification of the effect of ISO on CaT amplitude and rate of decay 
expressed as the ratio of CaT amplitude (Amp; left bars) and time-constant (of a mono-exponential 
fit; τ, right bars) in the presence and absence of 1.0 μmol/L ISO at all (same) CLs. Experimental data89, 
92, 93 are shown in grey, model data in white. 
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Figure 24. Validation of CaMKII signaling and phosphorylation. A. Time course of CaMK 
phosphorylation of PLB at Thr 17 during pacing at 2 Hz under baseline conditions. Model data (solid 
black line) were determined based on data from experiments in rat ventricular myocytes using a Thr 
17 phosphospecific antibody after 2 Hz pacing at room temperature (symbols).94 Time constant of 
phosphorylation was subsequently adjusted by a factor of 2.0 to perform simulations at 37°C 
(dashed lines). All data were normalized to the maximum PLB phosphorylation at room temperature. 
B. Similar to panel A for deactivation of PLB Thr 17 phosphorylation at 0.2 Hz after pacing for 5 min 
at 2 Hz. C. Similar to panel A for CaMKII phosphorylation of RyR during pacing at 2 Hz, compared to 
experimental data obtained with a Ser 2815 phosphospecific RyR antibody. D. CaMKII dependent 
phosphorylation of PLB at steady state under various conditions in model (bars) compared to 
experimental Western blots with an antibody against phosphorylated PLB at Thr 17.94 The model 
shows strong CaMKII-dependent PLB phosphorylation during pacing (2 Hz) in the presence of high 
[Ca2+]o or ISO, or with phosphatase inhibition (with okadaic acid, OA, simulated as 80% reduction in 
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whole cell PP1); consistent with experimental observations. E. Western blots showing CaMKII 
autophosphorylation at Thr 287 that occurs only in the presence of OA and pacing.94 The model 
shows qualitatively similar behavior of CaMKtrap, although lower levels of autonomous CaMKII 
activity can also be observed with ISO or high [Ca2+]o during pacing, or with OA in the absence of 
pacing. 
 
Simulation protocols 
The model consists of a coupled system of 134 ordinary differential equations governed by the 
equations described in the appendix of this thesis. Numerical integration was performed in custom 
C++ software using a forward Euler method with variable time step. The Matlab (The Mathworks, 
Natick, MA) ODE15s steady-state solution and our custom C++ forward Euler method produced 
identical action potentials and calcium transients. 
 
The model was paced for 2000 seconds at any given setting (cycle length (CL) and ISO concentration) 
with a conservative K+ stimulus95 to achieve a pseudo steady-state in which APD (determined at 95% 
of repolarization) and maximum intracellular ion concentrations change less than 0.05% on a beat-
to-beat basis. Restitution data were obtained for one additional beat after pacing to steady-state for 
a range of S2 coupling intervals. Temporal effects of βAR stimulation were determined by pacing to 
steady-state in the absence of ISO, followed by pacing in the presence of a given ISO concentration. 
ISO levels ranged between 0 µmol/L (no βAR stimulation) and 1.0 µmol/L (maximum βAR 
stimulation), with 0.02 µmol/L producing approximately half-maximal effects. 
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RESULTS 
Whole-cell effects of βARS on APD and CaT  
 
Figure 25. Effect of βARS on whole-cell AP and CaT. Baseline shown in solid lines, maximal βARS in 
dashed lines. A. Steady-state AP at CL = 1000. B. Simulated calcium transient at CL = 1000 ms in the 
presence of βARS shows increased amplitude and rate of relaxation compared to baseline. C. Steady-
state APD as a function of pacing CL. D. Steady-state CaT amplitude rate-dependence.  
 
Subcellular alterations of various substrates in response to βARS combine at the cellular level to 
change the AP morphology and CaT. Figure 25A shows that βARS results in shortening of APD and 
increase in AP plateau amplitude, consistent with experimental data.80 Experimentally, there is 
considerable cell-to-cell variation in the magnitude of the response (Figure 26) and model output is 
within this range. At CL = 1000 ms, CaT amplitude is significantly enhanced and CaT decay is faster, 
as observed experimentally (Figure 23; Figure 25B). We analyzed the rate-dependence of these APD 
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and CaT changes by pacing the model to steady-state in absence or presence of a saturating dose of 
ISO at various CL. APD shortening and increased CaT amplitude are observed at all CL (Figure 25C,D). 
Changes in CaT amplitude and Ca2+ loading are most pronounced at fast rates. 
 
 
Figure 26. Examples of action potentials recorded in the absence (Base) or presence (ISO) of β-
adrenergic stimulation with ISO in 5 different canine ventricular myocytes at CL = 1000 ms. 
Stimulation with ISO increases plateau amplitude and shortens APD but there is considerable cell-to-
cell variation in the magnitude of the response. For experimental protocol, see Johnson et al.90 
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Contribution of individual PKA substrates to whole-cell AP and CaT changes 
in response to βARS 
 
Figure 27. Summary of contributions of individual substrates to APD and CaT changes in the 
presence of ISO (complete data are provided in Figure 28). A. Steady-state APD at CL = 350 ms (left) 
and CL = 2000 ms (right) at baseline (no ISO), in the presence of maximal βARS and during maximal 
βARS when PKA-dependent phosphorylation of a specific substrate is disabled (e.g., indicated by ICaL 
P for inhibition of ICaL phosphorylation). CaMKII phosphorylation remained intact. The horizontal 
dashed-dotted line indicates the reference value during maximal βARS with all substrates 
phosphorylated. Inset shows the % increase in APD when IKur phosphorylation is disabled (versus 
when it is present) in the presence or absence of IKs. B. Similar to (A) for CaT amplitude. C. Similar to 
(A) for the time-constant of CaT decay based on a monoexponential fit. 
 
The relative contribution of a substrate was analyzed by pacing the model to steady-state in the 
absence of βARS, in the presence of 1.0 μmol/L ISO and with 1.0 μmol/L ISO but with the 
phosphorylation of the substrate of interest disabled. Figure 27 summarizes the effects of 
phosphorylation of each substrate on APD (Figure 27A), CaT amplitude (Figure 27B) and CaT rate of 
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decay (Figure 27C) at CL = 350 ms (left) and CL = 2000 ms (right). AP and CaT traces underlying these 
data can be found in Figure 28. 
 
 
Figure 28. Contribution of individual substrates to APD and CaT changes in response to βAR 
stimulation at CL = 350 ms. Steady-state AP and CaT are shown in the absence of βAR stimulation 
(black solid line), in the presence of a saturating dose of ISO (gray dashed line), or in the presence of 
βAR stimulation without PKA-dependent phosphorylation (red dashed-dotted line) of ICaL, IKs, IKur, or 
INaK (top two rows; left to right) or without PKA-dependent phosphorylation of INa, PLB, RyR or TnI 
(bottom two rows; left to right). For color figure, see page 249. 
 
IKs has only a small impact on steady-state APD under baseline conditions
52 (Chapter 2) but plays a 
major role in APD shortening during βARS, consistent with experimental observations.80 Previous 
studies have identified kinetic channel states (termed available reserve) that modulate the rate-
dependent contribution of IKs to repolarization
96, 97 and their alteration by βARS.98, 99 Consistent with 
these studies, the model predicts an increased available reserve during βARS in the canine 
ventricular myocyte (Figure 29). IKs channel gating is characterized by two major conformational 
changes of the voltage-sensors of each of the four channel subunits, followed by a final voltage-
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independent cooperative step to open the channel.97, 100 This structural information is reflected in 
the 17-state Markov model described by Silva and Rudy.97 Because the second voltage-sensor 
transition is significantly faster than the first, two zones of closed-states are distinguished. ”Zone 2” 
of deep closed states consists of all states in which at least one voltage-sensor still needs to make a 
slow transition, whereas “Zone 1” is the available reserve which contains those states that only 
require the second, faster transitions. In the presence of βARS, there is significant increase of IKs of a 
premature beat elicited after a short diastolic interval compared to longer diastolic intervals or to 
baseline conditions in the absence of βARS (Figure  29D). The mechanisms underlying this larger IKs 
at the level of channel gating kinetics are analyzed by plotting the (fractional) zone occupancy of all 
IKs channels at a diastolic interval of 25 ms (left) and 125 ms (right) under baseline conditions (solid 
lines) and in the presence of βARS (dashed-dotted lines; Figure 29E). Decreased deactivation rates of 
the phosphorylated IKs channel due to βARS result in a larger fraction of channels in Zone 1 (greater 
available reserve) from which they can open quickly to generate a large IKs current during the AP 
repolarization phase. The increased IKs offsets the increased ICaL resulting from reduced Ca
2+-
dependent inactivation due to the reduced CaT at short diastolic intervals (Figure 29C) as a result of 
incomplete JSR refilling. This ensures appropriate APD shortening at short diastolic intervals in the 
presence of adrenergic stimulation. These simulations of IKs gating during βARS are consistent with 
results reported previously98, 99 and show that similar mechanisms apply in the canine ventricular 
myocyte. 
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Figure 29.  Kinetic changes of IKs due to βARS result in altered gating modes and increased available 
reserve for channel opening. A. APD restitution as function of diastolic interval after pacing to 
steady-state at CL = 2000 ms in the absence (solid black) or presence (dash-dotted red) of 1.0 μmol/L 
ISO. B. AP of premature beat at diastolic intervals of 25 ms (left) or 125 ms (right). C. CaT 
corresponding to these APs. D. Corresponding IKs. E. Corresponding zone occupancies of IKs channels 
during the AP. Zone 2 (red) represents the deep closed states, Zone 1 (green) represents the closed 
states adjacent to the open state, termed “available reserve”. Open state occupancy is shown in blue 
on a separate y-axis. Data in the absence of ISO are shown in solid lines, data in the presence of ISO 
in dashed-dotted lines. For color figure, see page 250. 
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Consistent with simpler models16 and experimental evidence40, 98, the model predicts a major role for 
ICaL in the increased AP plateau potentials and increased inotropy observed during βARS. PLB 
phosphorylation is primarily responsible for the increased rate of CaT decay, particularly at slow 
rates. At fast rates, CaMKII phosphorylation (which is not inhibited in Figure 27) reduces the impact 
of PKA-dependent phosphorylation. βARS increases Ca2+ leak from the SR.101 Consistent with this 
observation, disabling RyR phosphorylation increases CaT, particularly at long CL. 
 
The model provides new insights into the contribution of other substrates. Inhibition of IKur was 
recently predicted to have a significant APD-prolonging effect in canine ventricular myocytes81 and, 
as such, augmentation of IKur by phosphorylation is expected to result in APD shortening. 
Interestingly, we do not find any effect on APD and only a modest effect on AP plateau amplitude 
when comparing normal βARS to βARS in the absence of IKur phosphorylation (Figures 27-28). 
However, in the absence of IKs, inhibition of IKur phosphorylation results in a significant additional 
prolongation of APD (2.7% increase compared to IKs block alone versus < 0.1% increase in the 
presence of IKs, Figure 27A, inset), as expected based on the dependence of APD prolongation on 
initial APD.102 As such, IKur phosphorylation may still have important effects in pathological conditions 
and provide “repolarization reserve” when IKs is compromised by disease or drugs. 
 
Figure 27B indicates that phosphorylation of INaK (through the accessory protein phospholemman) 
reduces cardiac inotropy (i.e., inhibition of INaK phosphorylation increases CaT amplitude). This was 
previously shown in mouse ventricular myocytes by Despa et al.103 and we show that similar 
mechanisms apply in the dog, despite significant differences in Ca2+ handling between these species. 
The increase in CaT results from increased steady-state intracellular Na+ levels that reduce Ca2+ 
extrusion via Na+-Ca2+ exchange. Similar Na+ accumulation resulting from βARS in the absence of INaK 
phosphorylation was previously shown in a model of the guinea-pig ventricular myocyte, although 
CaT amplitude was not quantified.17 Interestingly, despite a reduction in repolarizing INaK when 
phosphorylation is inhibited, the increased CaT is accompanied by a shortening of APD (Figure 27A). 
This occurs via reduced forward mode INaCa and enhanced Ca
2+-dependent inactivation of ICaL. When 
Ca2+-dependent inactivation was disabled for the final beat after pacing to steady state, APD 
shortening in the absence of INaK phosphorylation was reduced from 7.7 ms to 2.4 ms (Figure 30). 
Similarly, inhibition of INaCa reduced APD shortening to 2.5 ms. When both CDI and INaCa were 
disabled, APD in the absence of INaK was prolonged compared to the presence of INaK phosphorylation 
(by 1 ms, not shown). Thus, it appears that both CDI and INaCa contribute to the APD shortening 
observed in the absence of INaK phosphorylation. INaCa and/or CDI were only disabled for a single beat 
to prevent secondary changes in Ca2+ loading or [Na+]i. 
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Figure 30. Effect of inhibition of INaK phosphorylation in the presence of βARS (left),  βARS with INaCa 
inhibition (right) or βARS without Ca2+-dependent inactivation (CDI) of ICaL (right). Results are shown 
at steady state during pacing at CL = 2000 ms in the presence (thin black lines) or absence (thick grey 
lines) of INaK phosphorylation. A. Membrane potential. B. CaT (solid lines) and intracellular Na
+ 
(dashed lines). C. ICaL D. INaK E. INaCa (solid lines) and SR Ca
2+ release (Jrel; dashed lines). CDI was only 
blocked for the last beat shown to prevent secondary changes in Ca2+ loading. INaK P. denotes INaK 
phosphorylation. 
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Localized cAMP signaling 
 
Figure 31. Compartmentation of βARS in the control model with normal compartments (left) or in 
simulations with reduced compartmentation (right). A. Time dependent changes in cAMP levels in 
CAV (solid line), ECAV (dashed) and CYT (dash-dotted) during stimulation with 100 nmol/L ISO (top) 
or in the presence of β2AR stimulation only (100 nmol/L ISO and 100% block of β1AR; bottom). B. 
Differential effects of combined (β1AR + β2AR) stimulation (solid) or β2ARS only (dashed) on APD 
(top) and CaT amplitude (bottom) at a cycle length of 1000 ms. C. Steady-state ICaL, IKs and PLB 
phosphorylation levels during the simulations in (B). 
 
Experimentally, it is established that cAMP levels are localized in subdomains. The control model 
with normal compartmentation shows distinct cAMP concentrations in CAV, ECAV and CYT domains 
at baseline, as well as in response to βARS (Figure 31A; top-left panel). The relative distribution of 
cAMP at baseline (micromolar range for ECAV, high nanomolar range for CAV and CYT) is consistent 
with that reported by Iancu et al.11 Activation of different signaling pathways can elicit specific 
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subcellular cAMP responses. For example, β2AR are predominantly located in caveolae
8 and 
simulated β2ARS elevates CAV cAMP with only modest effects on cAMP in ECAV and CYT domains 
(Figure 31A; bottom-left panel). In contrast, when cAMP diffusion barriers are reduced (e.g., 
simulating application of MβC, a cholesterol depleting agent that, among other things, disrupts local 
cAMP domains), cAMP concentrations become uniform throughout the cell and βARS results in cell-
wide increase in cAMP independent of the activated receptor isoform, consistent with experiment8 
(Figure 31A; right panels). In the control (compartmental) model (left panels), in contrast to APD 
shortening with whole-cell βARS, selective stimulation of β2AR prolongs APD (Figure 32B; top-left 
panel). However, increases in CaT are present for both types of βARS (bottom-left panel). When 
compartmentation is reduced (right), the subsarcolemmal cAMP levels in CAV and ECAV are too 
small to allow regulation of APD or CaT, which show a similar time-dependent change, independent 
of the receptor isoform that is stimulated (Figure 31B; right panels). The mechanism underlying the 
distinct responses to whole cell (β1+ β2) βARS and β2ARS-only in the compartmental model is shown 
in Figure 31C. Whole cell βARS phosphorylates substrates throughout the cell, including IKs, which is 
responsible for APD shortening (Figure 27). In contrast, β2ARS does not phosphorylate IKs or PLB 
(Figure 31C; left panel). When compartmentation is reduced, the differential control of 
phosphorylation by the two isoforms is lost (Figure 31C; right panel). Since MβC application alters 
the distribution of other signaling molecules in addition to cAMP diffusion, it is difficult to relate the 
predicted functional responses to experimental measurements in the presence of MβC.46 
 
 
Figure 32. Contribution of βAR signaling components to cAMP compartmentation. A. Effect of virtual 
knock-outs of PDE3, PDE4, AC5/6, AC4/7 or PKA on steady-state cAMP concentration in CAV, ECAV 
and CYT domains in the absence of βARS. B. Identical to A, in the presence of 1.0 μmol/L ISO. Note 
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separate y-scale for cAMP in ECAV and different y-scales in (A) and (B). C. Mechanisms behind 
prominent cAMP increase resulting from virtual PKA knock-out in the presence of βARS. Difference 
in βAR availability (left), PDE3/4 Activity (at 1.0 μmol/L cAMP; middle) or Gi activity (right) in the 
presence and absence of PKA during stimulation with 1.0 μmol/L ISO for each compartment. 
 
To identify the main signaling components involved in establishing local cAMP levels, virtual knock-
outs of these components were simulated in the absence and presence of βARS (Figure 32). Specific 
sub-cellular distributions of PDEs, ACs and PKA cause inter-domain differences in local cAMP 
concentrations. In the absence of βARS, PDE3 (and to a lesser extent PDE4) and AC5/6 
predominantly determine cAMP in CYT and CAV, while AC4/7 determine cAMP in ECAV. As expected, 
cAMP levels increase in all compartments upon βARS in control conditions and in all virtual knock-
outs. In general, the localized differences occurring in knock-outs remain present during βARS 
(Figure 32B). Several negative feedback loops exist in the βAR signaling cascade. In these loops PKA 
activated by cAMP modifies upstream elements in the cascade to limit excessive cAMP production. 
The model predicts that PKA-dependent feedback loops have important effects on steady-state 
cAMP levels and that this occurs in a localized manner (right-most bar graphs). There is a prominent 
increase in cAMP in the absence of PKA during βARS (Figure 32B; far-right). This increase occurs via 
several feedback loops (Figure 32C). Without PKA there is increased availability of βAR (Figure 32C; 
left panel), due to reduced βAR desensitization. Moreover, there is reduction in cAMP hydrolyzing 
activity of PDE3 and PDE4 (Figure 32C; middle panel). PDE3 and PDE4 can be phosphorylated by 
PKA, thereby increasing their activity. In the PKA knock-out model this negative-feedback on cAMP is 
removed, resulting in increased cAMP levels. Finally, there is no activation of Gi (due to β2AR 
phosphorylation) in the absence of PKA, reducing inhibition of AC5/6.  
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Downstream effects of βARS on CaMKII 
 
Figure 33. A. Rate-dependence of steady-state CaMKII activity averaged per beat at baseline (solid 
black) and in the presence of 10 nmol/L ISO (dash-dotted, grey), 1.0 μmol/L ISO (dashed, grey) or 1.0 
μmol/L ISO with virtual knock-out of Inh1 (dash-double dot,  black). B. Steady-state AP and 
subsarcolemmal Ca2+  transient in the dyadic cleft at baseline (solid black) and during maximal βARS 
(dashed grey) at CL = 1000 ms. Horizontal line in magnified inset indicates the half maximal Ca2+ level 
for CaMKII activation. C. Accumulation of CaMKII activity during the first 25 seconds of pacing in the 
absence and presence of βARS at CL = 350 ms and CL = 1000 ms. Black lines indicate the average 
CaMKII per beat. Right part shows corresponding steady state unaveraged CaMKII traces. D. 
Phosphorylation of PLB by PKA at Ser 16 (left) and CaMKII at Thr 17 (right) at rest and during pacing 
in the absence or presence of adrenergic stimulation in the model (white bars) and in rat ventricular 
myocytes104 (shaded bars). 
 
In addition to cAMP compartmentation, Ca2+ signaling is also highly localized. High subsarcolemmal 
Ca2+ concentrations in dyadic clefts (CaSS
2+) activate the CaMKII signaling pathway which 
phosphorylates several substrates that are also targeted by PKA. CaMKII activity in the model is rate-
dependent, consistent with experimental observations105, 106. ISO increases CaMKII activity in a 
concentration-dependent manner, particularly at fast rates (Figure 33A). Increased CaMKII is caused 
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by a larger peak Cass
2+ transient and a larger duration with Cass
2+ levels close to CaMKII affinity 
(Figure 33B). In addition, there is an important role for reduction in PP1 via PKA-dependent 
activation of Inh1, since virtual knock-out of Inh1 significantly reduces CaMKII activity during 
maximal βARS (Figure 33A; dash-double-dotted line), consistent with the effect of PP1 inhibition by 
okadaic acid in rat ventricular myocytes.94 The rate-dependent increase in CaMKII is more 
pronounced than the increase due to enhanced Ca2+ cycling with βARS (e.g., CaMKII activity at CL = 
350 ms without βARS is 0.15, compared to 0.06 at CL = 1500 ms with βARS). Therefore, the slow rate 
of CaMKII deactivation (time constant of deactivation is approximately 1500 ms105), which results in 
accumulation of active CaMKII at fast rates (Figure 33C), has a larger impact on steady-state CaMKII 
activity than enhanced activation due to βARS-dependent increases in Ca2+ cycling. PLB is 
phosphorylated by PKA on Ser16 and by CaMKII on Thr17. Hagemann et al.104 analyzed the rate- and 
adrenergic-stimulation dependent modulation of PLB phosphorylation in rat ventricular myocytes. 
The simulation results in Figure 33D show an important role of pacing rate for CaMKII-dependent 
phosphorylation of PLB, whereas PKA-dependent phosphorylation is rate-independent, in agreement 
with Hagemann’s experimental observations. Knock-out of Inh1 increases PP1 activity and reduces 
both Ser16 and Thr17 PLB phosphorylation.  
 
Calcium overload and delayed afterdepolarizations 
For the final set of simulations, the model was extended with a formulation for store-overload 
induced SR Ca2+ release. After cessation of pacing at CL = 500 ms in the presence of 1.0 μmol/L ISO, 
the model shows four Ca2+ after- transients and corresponding delayed afterdepolarizations (DADs; 
Figure 34A). DAD characteristics are consistent with those measured in canine ventricular 
myocytes39 (Figure 34B). The effects of βAR isoforms, compartmental signaling and CaMKII on DADs 
are shown in Figure 34C for various pacing CLs. At faster CL, Ca2+ load increases, more DADs are 
generated, their average amplitude increases (Figure 34C) and coupling interval decreases (not 
shown). Inhibition of β1AR and, to a lesser extent, reduced compartmentation (via increased cAMP 
diffusion) reduce the number of DADs, in line with the lower CaT amplitudes observed in Figure 31, 
although DADs were still observed at the fastest rates. Virtual knock-out of CaMKII, on the other 
hand, prevented DADs even at the fastest rate (3 Hz) investigated. Although all conditions reduce 
the incidence of DADs, this occurs via different mechanisms. β1AR blockade predominantly affects 
PKA-dependent phosphorylation of PLB, reduced compartmentation modestly reduces PKA-
dependent phosphorylation of ICaL and RyR, and CaMKII inhibition abolishes CaMKII-dependent 
phosphorylation of all substrates without altering the PKA-dependent phosphorylation (Figure 34D). 
β1AR block or CaMKII inhibition strongly reduce the maximum JSR Ca2+ levels (Figure 34E). This 
reduction in JSR Ca2+ explains the low incidence of DADs in these conditions since the threshold for 
spontaneous release is reached less often. To investigate which substrate has the largest impact on 
JSR Ca2+ levels and the incidence of DADs, we selectively inhibited either the PKA- or CaMKII-
dependent phosphorylation of these 3 targets individually. The model predicts that PKA-dependent 
phosphorylation of ICaL (in line with the strong reduction in CaT amplitude shown in Figure 27), and 
both PKA- and CaMKII-dependent modulation of SR Ca2+ uptake (via SERCA2a & PLB 
phosphorylation) have the largest impact (not shown). Consistent with previous modeling studies107, 
when an effect of RyR phosphorylation (by CaMKII and/or PKA) to lower the threshold for 
spontaneous Ca2+ release is included, this target also has a significant impact, enhancing DAD 
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incidence (not shown). However, the functional consequences of RyR phosphorylation by both 
kinases are still actively debated in the literature.108 
 
 
Figure 34. A. DADs (top, indicated with #) and Ca2+ after- transients (bottom) after cessation of 
pacing (CL = 500 ms; last paced beat shown) in the presence of 1.0 μmol/L ISO. B. Comparison of 
DAD properties from A to experimental data from canine ventricular myocytes.39 DAD amplitude 
(left), DAD coupling interval (middle) and number of DADs (right). C. Modulation of number of DADs 
(left) and DAD amplitude (right) at different CLs by 1.0 μmol/L ISO (solid line), ISO + β1AR blockade 
(dashed), ISO with reduced compartmentation (dash-dotted),  or ISO + CaMKII inhibition (dash-
double dot). D. Phosphorylation of ICaL, SERCa2a & PLB (“SR Upt.”), and RyR by PKA (white bars) or 
CaMKII (shaded bars) relative to 1.0 μmol/L ISO at CL= 500 ms, for the conditions in C. E. Maximum 
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JSR Ca2+ levels during β1AR blockade, reduced compartmentation, or CaMKII inhibition, relative to 
1.0 μmol/L ISO at CL= 500 ms. K.O.=  knock out. 
 
DISCUSSION 
This study investigates the interplay between compartmentalization of the β-adrenergic signaling 
cascade and the different isoforms of the βAR in determining responses of whole-cell 
electrophysiology and calcium transient to βARS. The main novel mechanistic insights include: (i) 
compartmentation of cAMP is mainly controlled by PDEs, AC and PKA and allows for selective effects 
of β1ARS and β2ARS (see below); (ii) INaK modulation by phospholemman phosphorylation alters [Na
+]I 
and consequently [Ca2+]i to limit inotropy in large mammals; this alters APD via INaCa and Ca
2+-
dependent inactivation of ICaL; (iii) IKur phosphorylation enhances repolarization reserve when IKs is 
reduced, but does not affect APD for control IKs; (iv) inhibition of CaMKII, blockade of β1AR and 
reduced compartmentation reduce the incidence of DADs during βARS at fast rates. 
 
Substrates experience local signaling environments depending on their subcellular localization. The 
model identifies restricted diffusion and localized expression of PDEs, AC and PKA as the main 
elements controling cAMP compartmentation. Knock-out of PKA has a particularly strong effect on 
cAMP during βARS via disruption of 3 different negative-feedback loops (βAR desensitization, PDE 
stimulation and Gi activation via β2AR phosphorylation). Increased cAMP after PKA inhibition was 
also reported by Rochais et al. in rat ventricular myocytes,109 although their increase is less 
pronounced. Differences between specific PKA knock-out and (possibly incomplete) PKA inhibition 
with H89 may explain this difference. Interestingly, H89 has also been shown to block βAR in human 
airway cells,110 which would disable the disruption of one of the negative feedback loops.  
 
Activation of specific cAMP domains by localized G-protein-coupled receptors can modulate whole-
cell responses such as APD and CaT selectively. For example, activation of β2AR alone does not 
phosphorylate IKs or PLB and prolongs APD, but has a modest positive inotropic effect. However, 
β1AR stimulation has a cell-wide response resulting in decreased APD and increased CaT amplitude. 
This specific control is lost when compartmentation is removed. Knowing which signaling 
components are affected by which receptors, and which cAMP pools and downstream effectors they 
control, is a critical first step to develop pharmaceutical compounds that act locally, thereby 
ensuring their specificity and avoiding arrhythmogenic side-effects. 
 
We integrated the novel compartmental cAMP/PKA pathway with the CaMKII pathway present in 
the baseline model52, 105 (Chapter 2) via a physiological, population based approach. Soltis and 
Saucerman107 recently described a computational model that includes both CaMKII and PKA 
pathways and identified a synergistic effect of these pathways on CaT amplitude. Consistent with 
their data, we find that βARS enhances CaMKII activity and phosphorylation of CaMKII substrates. 
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This enhanced activity is due to enhanced Ca2+ cycling. In addition, we show that this effect is dose-
dependent and more pronounced at fast rates. Enhanced CaMKII activity with increasing pacing rate 
(due to the accumulation of CaMKII activity) is larger than that due to βARS at a given rate, 
consistent with the concept that CaMKII is predominantly a frequency sensor.106 Because βARS has 
important chronotropic effects in-vivo, a synergistic increase in CaMKII activity via both mechanisms 
is predicted. Experimental techniques for real-time monitoring of CaMKII activity in specific myocyte 
compartments are needed to fully characterize the βARS-CaMKII interactions and their mechanisms. 
Other interactions, such as those via cAMP-dependent activation of EPAC which has downstream 
effects on CaMKII, may be important. Recently, Mangmool et al. showed that this interaction is 
β1AR-specific and involves translocation of EPAC and CaMKII to the receptor complex via β-
arrestin.111 When more quantitative aspects of EPAC-dependent CaMKII activation become available, 
the compartmental model presented here will be able to include these localized and isoform specific 
interactions. 
 
Comparison to existing models 
Many simulation studies have included functional effects of βARS on cardiac electrophysiology (see 
Table 2 for model comparisons). Most studies included only functional effects on substrates via a 
shift in parameters for a single pathway. Saucerman et al.14 were the first to integrate a global model 
of the cAMP signaling cascade into a model of ventricular cell electrophysiology. Recently, these 
authors expanded their model107 by combining the effects of CaMKII and cAMP/PKA on 
electrophysiological targets. Iancu et al.11 were the first to develop a model which included localized 
aspects of cAMP signaling but not electrophysiological effects. These pioneering studies formed the 
basis for the model presented here, whose main novel characteristics include: (i) compartmental 
model of βARS and its effects on electrophysiology and CaT in canine ventricular myocyte; (ii) 
incorporation of both β1AR and β2AR isoforms to study physiological effects of compartmentation; 
(iii) a detailed population-based approach to integrate the cAMP/PKA and CaMKII pathways and 
their effects on a wide range of substrates.  
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Table 2. Comparison of current study to existing models. 
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Limitations 
Due to the inherent complexity of the simulated system, the resulting model is complex and involves 
many parameters. This is because it is based on the actual mechanistic interactions between many 
proteins for both the signaling pathway and the electrophysiological model. Parameter sensitivity 
analysis (Figures 4-6) provides insight into the contributions and relative importance of individual 
parameters. To facilitate application of this model, model code, including validation protocols, is 
available online in the Research Section of http://rudylab.wustl.edu. In addition, the model can be 
decomposed into two simpler modules (signaling and electrophysiology) that are connected through 
the phosphorylation levels. Thus, in investigations involving only electrophysiological measures, the 
phosphorylation levels can simply be fixed and only the electrophysiological module can be used. 
Similarly, other investigations may only require the signaling pathway. 
 
Not all parameters are currently available from experimental data. In addition, certain characteristics 
of the βAR signaling cascade are only available for rodents or are determined in biochemical reaction 
systems. However, major elements of the cascade (βAR density, AC activity, cAMP levels, ICaL and IKs 
ISO concentration-dependence) and most electrophysiological properties of PKA substrates are 
available from canine ventricular myocytes. Nonetheless, a model based entirely on canine-specific 
experimental data is currently not feasible. Importantly, all parameters have a physiological 
interpretation and can in principle be determined experimentally. The parameter estimation 
procedure was designed such that parameters were determined from data reflecting direct steps in 
the βAR cascade whenever possible, in order to minimize uncertainties. 
 
The exact effect of phosphorylation is still debated for some substrates, particularly the RyR.124 
Because the substrate data are based on whole-cell properties in the presence of maximal ISO 
stimulation, we do not distinguish between specific phosphorylation sites per substrate. For 
example, the ICaL channel has multiple subunits with various PKA phosphorylation sites. The model 
reproduces the net effect on ICaL of all phosphorylation sites combined. However, we do distinguish 
between the phosphorylation mechanisms (i.e., CaMKII versus PKA) using separate populations. 
Once electrophysiological and signaling data become available for individual phosphorylation sites, 
the population-based approach introduced here can be readily extended to incorporate this level of 
detail. 
 
Long pacing sequences must be simulated to capture the phosphorylation time course, which means 
that it is computationally prohibitive to simulate microscopic Ca2+ events (e.g., Ca2+ sparks). As such, 
the model is limited to reproducing macroscopic Ca2+ properties. Similarly, the model employs a 
macroscopic, threshold-based SR store-overload induced Ca2+-release mechanism. 
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ABSTRACT 
The mutation A341V in the S6 transmembrane segment of KCNQ1, the α-subunit of the slowly-
activating delayed-rectifier K+ (IKs) channel, predisposes to a severe long-QT1 syndrome with 
sympathetic-triggered ventricular tachyarrhythmias and sudden cardiac death. Several genetic risk-
modifiers have been identified in A341V patients, but the molecular mechanisms underlying the 
pronounced repolarization phenotype, particularly during β-adrenergic receptor stimulation, remain 
unclear. We aimed to elucidate these mechanisms and provide new insights into control of cAMP-
dependent modulation of IKs. We characterized the effects of A341V on the IKs macromolecular 
channel complex in transfected Chinese-hamster ovary (CHO) cells and found a dominant-negative 
suppression of cAMP-dependent Yotiao-mediated IKs upregulation on top of a dominant-negative 
reduction in basal current. Phosphomimetic substitution of the N-terminal position S27 with aspartic 
acid rescued this loss of upregulation. Western blot analysis showed reduced phosphorylation of 
KCNQ1 at S27, even for heterozygous A341V, suggesting that phosphorylation defects in some 
(mutant) KCNQ1 subunits can completely suppress IKs upregulation. Functional analyses of 
heterozygous KCNQ1 WT : G589D and heterozygous KCNQ1 WT : S27A, a phosphorylation-inert 
substitution, also showed such suppression. Immunoprecipitation of Yotiao with KCNQ1-A341V (in 
the presence of KCNE1) was not different from WT. Our results indicate the involvement of the 
KCNQ1-S6 region at/or around A341 in cAMP-dependent stimulation of IKs, a process which is under 
strong dominant-negative control, suggesting that tetrameric KCNQ1 phosphorylation is required. 
Specific long-QT1 mutations, including heterozygous A341V, disable this regulation. 
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INTRODUCTION 
The slowly-activating delayed-rectifier K+ current (IKs) contributes importantly to cardiac 
repolarization. In large mammals, including humans, it has small amplitude under basal isolated-
myocyte conditions, but forms a sizable repolarization reserve that is recruited when the action-
potential duration (APD) prolongs, and during β-adrenergic receptor (βAR) stimulation.1, 2 
 
IKs is carried by a macromolecular channel complex consisting of a homotetramer of pore-forming α-
subunits encoded by KCNQ1 (Kv7.1), KCNE1 β-subunits3, 4 and the regulatory A-kinase anchoring 
protein Yotiao, which binds to the KCNQ1 C-terminus.5 There are also multiple interactions with 
other proteins. During βAR stimulation, when cAMP levels rise, phosphorylation of KCNQ1 at N-
terminal position S27 is controlled by protein kinase A (PKA) and protein phosphatase 1 that are 
localized to the complex by Yotiao, thereby providing local control of IKs enhancement.
5 Anchored 
PKA also phosphorylates Yotiao itself, thereby further enhancing IKs.
6 An intact C-terminus of KCNE1 
is critical for the PKA-dependent upregulation of IKs.
7 
 
Congenital defects (long-QT syndrome types 1 and 5; LQT1, LQT5; Jervell and Lange-Nielsen 
syndrome), pharmacological inhibition8 and acquired loss of IKs
9 can all result in QT-interval 
prolongation and enhanced susceptibility to ventricular tachyarrhythmias, notably torsades de 
pointes. These arrhythmias occur predominantly during conditions of exercise and/or sympathetic 
stress.10 In 2005, the loss-of-function mutation A341V in KCNQ1 (S6 transmembrane segment) was 
reported in a large South-African founder population.11 This hot-spot LQT1 mutation, found globally, 
results in an unusually severe clinical phenotype compared to other LQT1 mutations, irrespective of 
their amino-acid location (transmembrane versus N/C terminal) or dominant-negative 
characteristics.12 Brisk variations in autonomic response increase the arrhythmic risk in A341V LQT1 
patients.13 Also, polymorphisms in α- and β-adrenergic receptors (enhancing the autonomic 
response) are found more often in symptomatic than non-symptomatic KCNQ1-A341V carriers.13  
 
In this study, we investigated the molecular control of IKs during βAR stimulation, hypothesizing that 
A341V provides a useful case to advance understanding of the IKs macromolecular signaling complex, 
and to obtain novel insights into the determinants of phenotypic severity by A341V and other LQT1 
mutations. 
 
METHODS 
Molecular Biology 
Wild-type (WT) human KCNQ1 (also known as KvLQT1 or Kv7.1) in a pIRES2-GFP vector and human 
KCNE1 (minK, IsK) in a pBK-CMV vector, as well as human KCNH2 were kindly provided by Prof. Dirk 
J. Snyders, University of Antwerp, Antwerp, Belgium. Yotiao was subcloned in a pGW1 vector (a gift 
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from Prof. Robert S. Kass, Columbia University, New York, NY, USA). KCNH2 was subcloned in a 
pcDNA3 vector. 
 
The KCNQ1 mutations A341V, K557E and G589D were generated by site-directed mutagenesis using 
the QuickChange® II XL system  (Stratagene, La Jolla, CA, USA). Oligonucleotide design and reaction 
conditions (extension time of 2 minutes/kb) were according to the manufacturer’s instructions 
(Stratagene). All constructs were completely sequenced (BigDye® Terminator Ready kit v1.1, 
Applied Biosystems) and analyzed on an ABI PRISM® 3100 Genetic Analyzer. Plasmid DNA for 
mammalian expression was grown in DH5α cells (Invitrogen Co, Carlsbad, CA, USA) and then isolated 
from the bacterial cells using a miniprep spin kit (Qiagen). Similar procedures were used to combine 
the phosphomimetic substitutions S27D and S27A in WT KCNQ1 or A341V-KCNQ1. 
 
The KCNQ1-myc construct was generated by inserting the c-myc epitope (N-EQKLISEEDL-C) in the S1-
S2 external loop of KCNQ1 after nucleotide position 438 (between glutamate 146 and glutamine 
147). Two initial PCR reactions were performed to generate c-myc containing KCNQ1 products (PCR 
1 and 2 in Table 1). Once c-myc-epitope-containing KCNQ1 complementary cDNA strands were 
synthesized, the conditions were set for further PCR amplification: 95 °C for 2 min, 1 min at the 
corresponding annealing temperature (see Table 1), and 70 °C for 1 and 2 min, respectively. These 
settings were applied for 25 cycles. The amplified PCR products were subsequently hybridized using 
a fusion PCR (PCR 3 in Table 1). After fusion-PCR product purification, KCNQ1-myc construct was 
subcloned into PGEMT-easy cloning vector (Promega Corp. Madison, WI, USA) using Spe I and 
BamH1 restriction sites for ligation and was sequenced as described above. For expression in 
Chinese Hamster Ovary (CHO-K1) cells (CHO cells), the KCNQ1-myc construct was subcloned into a 
pBK-CMV vector. In all PCR reactions, KOD Hot Start DNA polymerase Kit (Novagen, EMD 
Biosciences, La Jolla, CA, USA) was used according to the manufacturer’s instructions. Restriction 
enzymes were from Fermentas (Fermentas GmbH, Germany). 
 
PCR Primer Sequence 
Length 
(bp) 
Annealing 
(°C) 
PCR 1 hKCNQ1_mycF 
F: 5’- 
GAGCAGAAGCTGATCTCAGAGGAGGA 
CCTGggaggaCAGTATGCCGCCCTGGCC-3’ 
534 57 °C 
PCR 2 hKCNQ1_mycR 
R: 5’- CAGGTCCTCCTCTGAGATCAGCTTCT 
GCTCtcctccCTCGATGGTGGACAGCACGC-3’ 
1852 67 °C 
PCR3 
hKCNQ1 Nterm_Fspe1 
hKCNQ1_CtermR_BamH1 
F: 5’-actagtAACCGTCAGATCCGCTAG-3’ 
R: 5’- ggatccCCAGACAGCATGGTCCAT-3’ 
2386 72 °C 
Table 1. PCR settings for the generation of KCNQ1-myc construct. All PCRs were performed in the 
KCNQ1 gene with accession number NM_000218. 
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Cell Culture and Transfection for Electrophysiology Experiments 
CHO cells were cultured at 37 °C/5% CO2 in Ham’s F-12 medium (Gibco, Invitrogen, Co.) 
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin. For patch-clamp recordings 
in WT or homozygous mutant experiments KCNQ1 (0.5 µg; WT or mutant of interest) and KCNE1 (1 
µg) cDNA were transiently co-transfected in CHO cells using Fugene 6 (Roche Diagnostics Nederland 
B.V., Almere, The Netherlands). In coexpression studies (examining heterozygous conditions) 0.25 μg 
WT KCNQ1 and 0.25 μg mutant KCNQ1 were co-transfected with 1.0 μg KCNE1. In addition, Yotiao (2 
µg) was co-transfected in all patch-clamp experiments in which WT or mutant IKs was studied, unless 
specified otherwise. In experiments assessing the α-α-subunit interactions between KCNQ1 and 
KCNH2, 0.5 μg WT or A341V KCNQ1 was co-transfected with 0.5 μg KCNH2. Cells were used for 
analysis 24 hrs after transfection. 
 
Electrophysiology 
For electrophysiological studies, CHO cells were harvested from the 35-mm culture dish by brief 
trypsinization, washed twice with culture medium (Ham’s F-12 medium supplemented with 10% 
fetal calf serum and 1% penicillin/streptomycin) and placed in a perfusion chamber on an inverted 
microscope that was continuously perfused with external Tyrode solution containing (in mmol/L): 
NaCl 132, KCl 4.8, MgCl2 1.2, CaCl2 2, HEPES 10, and glucose 5 (pH = 7.4 with NaOH). Pipettes were 
filled with pipette solution containing (in mmol/L): K-aspartate 110, ATP-K2 5, MgCl2 1, CaCl2 1, EGTA 
11, HEPES 10 (pH = 7.3 with KOH). In some experiments, 0.2 μmol/L okadaic acid (OA; EMD 
Biosciences, La Jolla, CA, USA) and 200 µmol/L cAMP (Sigma-Aldrich Chemie B.V. Zwijndrecht, The 
Netherlands), indicated as +cAMP/OA throughout, were added to the pipette solution to activate 
PKA and thereby mimic stimulation of β-adrenergic receptors. In KCNQ1 (WT or A341V) / KCHN2 co-
transfections HMR1556 (500 nmol/L in DMSO; a kind gift of Dr. H. Gögelein, Sanofi-Aventis, 
Frankfurt am Main, Germany) was used to selectively inhibit the current carried by KCNQ1. 
Experiments were performed by the whole-cell patch-clamp technique at room temperature (23±1 
°C) using an Axopatch 200B amplifier and pCLAMP software (Axon Instruments, Union City, CA, USA). 
Patch pipettes were pulled using a DMZ-Universal-Puller (Zeitz-Instruments Vertriebs GmbH, 
Martinsried, Germany), using 2 mm borosilicate glass capillaries (World Precision Instruments 
Germany GmbH, Berlin, Germany). Pipette resistance ranged between 1.5 and 3 MΩ. Access 
resistance was accepted when below 8 MΩ and was electronically compensated at 60-80% series 
resistance. Currents were sampled at 2 kHz after low-pass filtering at 1 kHz through a Digidata 1322A 
data acquisition system (Axon Instruments). Current densities (pA/pF) were obtained after 
normalization to cell capacitance determined with Clampex 9. 
 
For WT and mutant IKs studies, the following voltage-clamp protocols were used: (i) a cAMP/OA-
wash-in protocol started after membrane rupture and correction for cell capacitance and consisted 
of 20 pulses (given at 15-second intervals for a total of 5 minutes) to +60 mV for 2 seconds (from a 
holding potential of -70 mV) followed by 2 seconds at a holding potential of -40 mV to measure tail 
currents during wash in of cAMP and OA; (ii) an activation protocol consisting of a 5-s depolarizing 
pulse (between -50 mV and +90 mV, 10 mV increments) to determine peak currents and activation 
kinetics followed by 6 s at -40 mV to measure tail currents, and (iii) a deactivation protocol of 4 s at + 
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60 mV followed by repolarization to a potential between -120 mV and -30 mV (in steps of 10 mV). 
For KCNH2/HERG studies, 1-s depolarizing pulses from -50 mV to +50 mV were used, followed by a 
2-s step to -50 mV. 
 
Phosphorylation Assays, Protein Extracts, Immunoprecipitation and Western 
Blots 
Phosphorylation of KCNQ1 channels in CHO cells was induced by incubating cells at 37 °C under 5% 
CO2 atmosphere with 300 µmol/L CPT-cAMP (Biaffin GmbH & Co, Kassel, Germany) plus 0.2 µmol/L 
OA (EMD Biosciences, La Jolla, CA, USA), or with vehicle solution, diluted in F12 medium without 
serum and without antibiotics during 10 min. For total protein extraction, cells were washed twice in 
chilled phosphate-buffered saline (PBS) and centrifuged at 3,000 × g for 10 min to separate cells 
from PBS. The pellet was then lysed on ice with HES buffer (20 mmol/L HEPES pH 7.4, 1 mmol/L 
EDTA, 255 mmol/L sucrose), supplemented with Complete Protease Inhibitor Cocktail Tablets (Roche 
Diagnostics Nederland B.V., Almere, The Netherlands) and lysates were homogenized by repeated 
passing (10 times) through a 25G (0.45 x 16 mm) needle. 
 
Total protein extracts (20 µg) were resuspended in SDS 4× (40% glycerol, 5% β-mercaptoethanol, 8% 
SDS, 0.04% bromophenol blue, 240 mmol/L Tris/HCl pH 6.8) and heated at 55 °C during 5 min. 
Samples were then centrifuged during 5 min at 13,000 rpm at room temperature and 20 μl of the 
protein extract was loaded and run in SDS-PAGE (6% acrylamide/bisacrylamide) with Mini-Protean 
Tetra-Cell (Bio-Rad, Hercules, CA, USA) and transferred to a PVDF membrane (Amersham, GE 
Healthcare, Fairfield, CT, USA)  using Mini Trans-Blot cell (Bio-Rad).  
 
For co-immunoprecipitation studies, CHO cells were transfected with KCNQ1-WT or KCNQ1-A341V 
(in pBK vector) + KCNE1 + Yotiao. CHO cells were lysed in 150 mmol/L NaCl, 20 mmol/L Tris (pH 7.5), 
5 mmol/L EDTA and 1% Triton X-100 supplemented with Complete Protease Inhibitor Cocktail 
Tablets (Roche Diagnostics Nederland B.V., Almere, The Netherlands). Cell extracts were incubated 
for 30 min at 4 °C under agitation. The cell lysates were centrifuged for 15 min at 13,000 rpm and 
supernatants were separated. Protein G-sepharose beads (40 μl; Santa Cruz Biotech., CA, USA) were 
washed 3 times with 500 μl IPB buffer (150 mmol/L NaCl, 1% NP40, 10 mmol/L HEPES, 10% glycerol; 
pH 7.8), centrifuged for 1 min at 5000 rpm and subsequently incubated with 2 μg of anti-KCNQ1 
antibody (Santa Cruz Biotech. CA, USA) under rotation for 2 h at 4 °C. After incubation, the beads 
were centrifuged (5000 rpm for 1 min), washed 3 times with 500 μl IPB and incubated overnight with 
300 μg of protein extract under orbital shaking. After centrifugation (5000 rpm for 1 min) and 
washing with 500 μl IPB at 4 °C (3 times), the beads were resuspended in 30 μl SDS 1x, denaturated 
at 55 °C for 5 min and centrifuged at 5000 rpm for 5 min. 20 μl of the immunocomplex was then 
loaded and run in SDS-PAGE (7% acrylamide/bisacrylamide) with Mini-Protean Tetra-Cell (Bio-Rad, 
Hercules, CA, USA) and transferred to a PVDF membrane (Amersham, GE Healthcare, Fairfield, CT, 
USA)  using Mini Trans-Blot cell (Bio-Rad). 
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Mouse monoclonal anti-KCNQ1 (1:1000, Neuromab, UCDavis, Ca, USA) and rabbit polyclonal anti-
KCNQ1-S27-phospho (1:500, kindly provided by Prof. Robert S. Kass, University of Columbia, NY, 
USA) were used to test KCNQ1-channel phosphorylation at Serine 27.  Anti-KCNQ1 (Neuromab) and 
anti-Yotiao (Santa Cruz Biotecht. CA, USA) were used for co-immunoprecipitation studies. Secondary 
antibodies were horseradish peroxidase linked rabbit anti-mouse (1:2500; DAKO, Glostrup, 
Denmark) or goat anti-rabbit (1:2500; Santa Cruz Biotech., CA, USA). Proteins were detected using 
ECL-Plus Western blotting reagent (Amersham, GE Healthcare, Fairfield, CT, USA). The Yotiao band at 
230 kD and the KCNQ1-monomer band of approximately 70 kD were quantified using Image J 
(http://rsb.info.nih.gov/ij; developed by Dr. Wayne Rasband, National Institutes of Health, Bethesda, 
MD), in both S27-phospho and total KCNQ1 blots and the fraction of Yotiao interaction or 
phosphorylated KCNQ1 was quantified. 
 
Confocal Imaging 
CHO cells seeded in sterilized coverslips were cultured in Ham’s F12 medium containing 10% FBS and 
1% penicilin/streptomycin antibiotics until they reached 60% confluency. Cells were then transiently 
transfected with KCNQ1-GFP, KCNQ1-A341V-GFP or, KCNQ1-myc + A341V-GFP + KCNE1 + Yotiao 
cDNAs using Lipofectamine LLTX and PLUS Reagent (Invitrogen Co.). 48 Hours after transfection, cells 
were incubated in vivo, under 5% CO2 atmosphere and at 37 °C during 1 hour with 1:500 mouse 
monoclonal anti-myc antibody (Sigma-Aldrich). Cells were washed 3 times with PBS and fixed with 
4% paraformaldehyde in PBS for 10 min. Coverslips were further incubated with Texas Red 
conjugated goat anti-mouse antibody (1:80, ITK Southern Biotech, Uithoorn, The Netherlands) 
during 45 min. Stainings with a secondary antibody were performed at room temperature and cells 
were washed 3 times in PBS after all of the steps. No permeabilization was applied in the 
immunostainings. Finally, coverslips were mounted in 75% glycerol, 0.02 mol/L TRIS-HCl (pH = 8.0), 
0.8% NaN3, 2% 1,4-diazabicyclo[2.2.2]octane (DABCO; pH = 8.0). 
 
Confocal analysis was performed at least 24 hours after the stainings, and the immunostained 
samples were visualized using a Leica TCS-SPE (Leica Microsystems GmbH, Wetzlar, Germany) 
confocal microscope and further analyzed by Image J. Transfection efficiency was determined by 
counting the fraction of cells that showed both GFP signal and DAPI staining. Determination of cells 
showing membrane GFP signal was performed independently by multiple investigators who were 
blinded with respect to transfection type (WT versus A341V). For cells showing clear membrane 
expression, fluorescence intensity at the membrane was subsequently determined at 3 separate 
membrane sites per cell for identical settings of the microscope using ImageJ. 
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Computational Modeling 
 
Figure 1. Computational modeling approach. A.a. Schematic overview of the structure of a single cell 
model, including all ion channels, pumps, exchangers, Ca2+-handling proteins, Ca2+/Calmodulin-
dependent kinase and compartmental βAR signaling pathway, as published recently (Chapter 3).14 
A.b. Structure of the 17-state Markov model that was fitted to WT IKs, heterozygous or homozygous 
mutant channel characteristics in the absence and presence of βAR stimulation. For color figure, see 
page 251. 
 
Parameters of the 17-state IKs Markov model proposed by Silva and Rudy
15 (Figure 1A.b) were fitted 
to the normalized I-V relationship, time constants of activation and time constants of deactivation 
obtained in CHO cells expressing WT or mutant IKs channels in the absence or presence of cAMP/OA 
(Figure 2). Quantitative values of time constants of activation and deactivation of WT unstimulated 
IKs were scaled to those obtained in canine ventricular myocytes
16, 17 at 37 °C (at +20 mV and -80 mV, 
respectively) to compensate for differences due to temperature and effects of the expression 
system. We determined one correction factor for the activation time-constant and one for 
deactivation for WT IKs in our CHO cells at room temperature at these holding potentials to obtain 
similar half-maximal activation and deactivation times. All WT time constants were then scaled by 
these values, to maintain the voltage dependence of activation and deactivation measured in CHO 
cells. The adjusted time constants were used as input in the parameter fitting procedure. The time 
constants in the presence of adrenergic stimulation and/or A341V mutation were subsequently 
scaled to produce a similar relative difference as observed in the heterologous expression systems 
(e.g., the time constant of activation at +20 mV is 2.2 fold slower in A341V compared to WT). 
Similarly, baseline current amplitude of WT unstimulated IKs was fit to that in canine epicardial 
myocytes.18 The approximately 60% increase in current amplitude observed with cAMP/OA 
stimulation in CHO cells was scaled to resemble the approximately 200% increase in IKs observed in 
ventricular myocytes during β-adrenergic stimulation17 and the relative difference in tail current 
amplitude between WT and A341V observed in CHO cells was preserved.  IKs model parameters are 
given in the appendix of this thesis. The adjustments were necessary to apply the results obtained in 
the heterologous expression system in the model. The phosphorylated and non-phosphorylated IKs 
models were incorporated into a recently developed model of the canine epicardial myocyte 
incorporating detailed localized effects of β-adrenergic stimulation14 (Figure 1A.a; Chapter 3). This 
model uses a population-based approach to distinguish between phosphorylated and non-
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phosphorylated channels. The net current is the sum of the currents produced by the channels in 
each population. The WT IKs profile during the cardiac action potential in the presence or absence of 
β-adrenergic stimulation was similar to that of the original model, based entirely on canine data (not 
shown).  
 
 
Figure 2. Validation of IKs model properties. A. Relative IKs-tail amplitude in WT (squares), 
heterozygous A341V (diamonds) and homozygous A341V (circles) conditions in the absence (left) 
and presence (right) of cAMP stimulation in experiments (symbols) and model (lines). B. Same as 
panel A for time constants of activation based on a mono-exponential fit. C. Same as panel A for 
time constants of deactivation. Time constants were scaled to match values found in canine 
ventricular myocytes at 37 °C. Insets show voltage-clamp protocols used.  
 
The complete model consists of a coupled system of ordinary differential equations. Numerical 
integration was performed in custom C++ software using a forward Euler method with adaptive time 
step. The Matlab (The Mathworks, Natick, MA) ODE15s steady-state solution and C++ forward 
Euler method produced identical action potentials and calcium transients. 
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The model was paced for 2000 seconds at any given setting (cycle length and isoproterenol 
concentration) with a conservative K+ stimulus19 to achieve a pseudo steady-state in which action-
potential duration (determined at 95% of repolarization) and maximum intracellular ion 
concentrations change less than 0.05% on a beat-to-beat basis. Isoproterenol levels ranged between 
0 µmol/L (no β-adrenergic stimulation) and 1.0 µmol/L (maximum stimulation). Simulations were 
performed using WT and mutant IKs formulation in the absence and presence of adrenergic 
stimulation. 
 
Data Analysis 
The voltage dependence of activation (evaluated from normalized tail-current amplitudes) was fitted 
with a Boltzmann equation, G/Gmax (or I/Imax) = 1/(1 + exp((V-V1/2)/k) to determine the membrane 
potential for half-maximal activation (V1/2) and the slope factor (k). The time courses of activation 
and deactivation were fitted with a single exponential function I/Imax = A x (1-exp(-t/τ)) + C where A is 
amplitude and τ is time constant. Data are expressed as mean±SEM. Unpaired Student’s t-test or 1-
way ANOVA with Tukey’s Post Hoc test were used to assess differences between groups. P<0.05 was 
considered statistically significant. 
 
RESULTS 
KCNQ1-A341V Results in a Dominant-Negative Suppression of cAMP-
Dependent Upregulation of IKs on Top of a Dominant-Negative Reduction in 
Basal Current 
The KCNQ1-A341 residue is located in the middle of the S6-transmembrane domain, just before the 
PAG ‘hinge’ motif20 and is extremely well conserved among the families of voltage-gated K+ channels 
(Figure 3).  
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Figure 3. Location and conservation of A341 in KCNQ1. A. Multiple sequence alignment of the 
KCNQ1-S6 region with other members of the Kv7.x family and other voltage-gated potassium 
channels. Conserved residues are bold and highlighted in blue, partially conserved residues are 
highlighted in green and red. The conserved K+ selectivity filter and the PAG (in Kv7.x) or PXP (in 
other Kv channels) hinge motifs are indicated below the alignment. A341 is indicated in red and is 
extremely conserved among all Kv channels. B. Location of A341 in the closed-state tetrameric 
KCNQ1 homology model described by Kang et al.21 Left panel shows top view from the extracellular 
side. Residues F340, A341 and A344 are shown as ‘ball-and-stick’ models. Black arrow indicates the 
viewing direction for the right panel. Right panel shows front view of two KCNQ1-subunits (only S5, 
pore and S6 region are shown). Residues F340 – A344 are shown. Distances between residue A341 
of the right subunit and its two nearest residues are indicated with dashed lines. For color figure, see 
page 251. 
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Figure 4. Dominant-negative suppression of cAMP-dependent IKs stimulation on top of dominant-
negative suppression of basal current by the KCNQ1 mutation A341V. A. Averaged current traces of 
WT (left), A341VHet (middle) or A341VHom (right) channels during a 5-s depolarizing pulse to +60 mV 
in the absence (-) or presence (+) of intrapipette cAMP/OA. Inset shows voltage-clamp protocol. WT 
IKs, but not A341V, is upregulated in response to stimulation with cAMP/OA. B. Tail I-V relationship 
after 5-s depolarizing pulses from -50 mV to +90 mV in the absence (open symbols) or presence 
(filled symbols) of stimulation with cAMP/OA for the conditions in panel A. C. Normalized tail 
currents for WT (circles), A341VHet (squares) and A341VHom (triangles) with (open) or without (filled 
symbols) cAMP/OA. D. Membrane potential resulting in half-maximal activation based on data in 
panel C. cAMP responsiveness of WT IKs is characterized by a significant leftward shift in half-maximal 
activation (*, P<0.05) that is not present in A341V. 
 
Consistent with previous results,11 we found that the KCNQ1-A341V mutation resulted in a 
significant reduction of IKs. The IKs-tail amplitude after 5-s depolarizing pulses at +60 mV was reduced 
by 96% and 46% in homozygous (A341VHom) and heterozygous (A341VHet) conditions, respectively 
(Figure 4A,B). A significant rightward shift in channel activation was also observed (Figure 4C,D). In 
addition, there was a significant slowing of activation kinetics (time constants at +60 mV were 
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1306±156 ms, 1947±265 ms and 7303±1486 ms in WT, A341VHet and A341VHom, respectively) as well 
as faster deactivation (time constants at -80 mV: 501±61 ms, 205±14 ms and 144±24 ms; P<0.05 vs. 
WT for both A341VHet and A341VHom). Together, these altered kinetics contributed to the dominant-
negative reduction in repolarizing current for depolarizations of physiological duration in A341VHet 
(74% reduction in peak IKs after 300-ms depolarizing pulses, not shown). No differences were found 
in the number of cells showing membrane expression or the fluorescence intensity at the membrane 
between WT and A341VHom
 (Figure 5), indicating that the observed reduction in IKs is unlikely to be 
due to reduced expression. We also found no differences in the effect of WT and A341VHom on 
KCHN2 current, which has been reported for other trafficking-deficient KCNQ1 mutations (Figure 6). 
 
 
Figure 5. Membrane expression of KCNQ1-WT and KCNQ1-A341V. A. Confocal image of a 
representative CHO cell expressing KCNQ1-WT-GFP (left panel) or KCNQ1-A341V-GFP (right panel). 
The white scale bar at the bottom of the right panel indicates 10 μm. Bottom panels show relative 
fluorescence intensity along the cross sections indicated with white lines. Both signals show 
increased intensities at the cell boundaries, indicating membrane expression. B.  Average data from 
confocal images of KCNQ1-WT or KCNQ1-A341V cells for transfection efficiency (left panel, 
determined as percentage of cells showing GFP signal compared to the number showing DAPI 
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staining), percentage of cells with clear membrane signal (middle panel),  and fluorescence intensity 
at the membrane for cells with clear membrane signal. Numbers in bars indicate the number of cells 
analyzed. There is no difference in transfection efficiency, the number of cells showing a clear 
membrane signal, or the fluorescence intensity at the membrane between WT and A341V. 
 
To study the effect of simulated βAR (as part of sympathetic) stimulation on WT and A341V IKs 
channels, transfected CHO cells were stimulated with cAMP/OA in the pipette solution.5 WT IKs was 
significantly upregulated in the presence of cAMP/OA (Figure 4A, left panel; 63% increase in tail-
current amplitude). In contrast, both A341VHet and A341VHom channels showed a negligible increase 
in current amplitude (Figure 4A,B). The leftward shift in I-V relationship that occurred during cAMP-
dependent stimulation for WT IKs channels was also absent (Figure 4C,D). This cAMP desensitivity, 
even in A341VHet, suggested that IKs modulation is under dominant-negative control, whereby 
presence of one defect subunit may be sufficient to abolish IKs upregulation. 
 
 
Figure 6. A341V phenotype is not mediated by effects on KCNH2. A. Averaged current traces during 
depolarization to +60 mV in CHO cells transfected with KCNH2 alone (solid black line), KCNH2 + 
KCNQ1-WT (dashed grey line) or KCNH2 + KCNQ1-A341V (solid grey line) before application of 
HMR1556 (left) or after application of HMR1556 (right; giving the HMR-resistant KCNH2 current). 
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Inset on the right shows voltage-clamp protocol used. B. Tail I-V relationships before (left) or after 
(right) application of HMR1556 for the conditions in panel (A). KCNH2-only current is indicated with 
triangles, KCNH2+KCNQ1-WT with circles and KCNH2+KCNQ1-A341V with squares. Cotransfection of 
KCNQ1-WT increased the KCNH2 tail current, consistent with previous results.22 A similar increase in 
KCNH2 could be observed with KCNQ1-A341V. 
 
Effect of Combined Dominant-Negative A341V Effects on Ventricular 
Repolarization 
Patients carrying the A341V mutation can show pronounced QTc prolongation (see Figure 7; 
adapted from Shimizu23), and QTc is longer among symptomatic than among asymptomatic 
carriers.11 Moreover, QTc duration can prolong during exercise, despite an increase in heart rate 
(Figure 7, right panel23). 
 
 
Figure 7. Effect of A341V on ventricular repolarization in the absence or presence of increased 
sympathetic tone. A. Body-surface ECGs (lead V5) from a 12-year old male A341V carrier at rest (left) 
and during exercise (right); adapted from Shimizu23 with permission. QTc and cTpeak-end are 
increased during exercise. B. Steady-state action potential (top) and IKs (bottom) in the absence (left) 
or presence (right) of βAR stimulation (βARS) in a computational model of the canine ventricular 
myocyte electrophysiology,14 simulating WT (solid line) or A341VHet (dashed line) conditions at CL = 
1000 ms. Note different scale for IKs in the presence of βAR stimulation. C. APD rate dependence 
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with or without βAR stimulation. APD is significantly prolonged in A341VHet conditions during βAR 
stimulation compared to WT. 
 
We examined the effect of A341V on ventricular repolarization using a computational model of βAR 
stimulation in the canine ventricular myocyte (Figure 1; Chapter 3).14 The A341V mutation caused a 
major reduction in IKs amplitude during the action potential, even in heterozygous conditions (Figure 
7B, bottom panels). Under basal conditions IKs plays a minor role in ventricular repolarization and, 
consistently, loss of IKs by A341V resulted only in minimal APD prolongation (Figure 7B, top left; 
∆APD = 2.6 ms). In contrast, during βAR stimulation APD was significantly prolonged in A341VHet 
versus WT (Figure 7B, top right; ∆APD = 23 ms) at all pacing cycle lengths (CL; Figure 7C). Thus, these 
modeling studies confirmed that the biophysical alterations to IKs by A341V in heterozygous 
conditions result in a pronounced cellular-action-potential phenotype, predominantly during βAR 
stimulation, in line with the ECG changes observed in A341V carriers. 
 
Mechanisms Underlying the Suppressed cAMP Responsiveness of A341V IKs 
The A341V mutation could disrupt the βAR modulation of IKs through various mechanisms, including: 
(i) disruption of the conformational changes occurring after phosphorylation of KCNQ1-S27; (ii) 
disruption of KCNQ1 interaction with Yotiao thereby reducing local PKA availability; or (iii) disruption 
of phosphorylation of S27, even in the presence of Yotiao (e.g., by a defective transfer of PKA from 
C-terminal Yotiao to N-terminal S27). 
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Figure 8. The phosphomimetic substitution S27D ‘rescues’ cAMP-dependent upregulation of the 
A341V mutation. A. Averaged current traces of WT (left), A341VHet (middle) or A341VHom (right) 
channels cotransfected with KCNE1 and Yotiao in the absence or presence of stimulation with 
intrapipette cAMP/OA, or in the presence of the phosphomimetic substitution S27D. Voltage-clamp 
protocol as in Figure 4. B. Tail I-V relationship for the conditions in panel A. Note different y-scales 
(indicated with arrows). C. Membrane potential resulting in half-maximal activation. cAMP 
responsiveness of WT IKs is characterized by a significant leftward shift in half-maximal activation (*, 
P<0.05) that is not present in A341VHet or A341VHom. In contrast, the S27D substitution results in 
significant shifts for all conditions. 
 
Mechanism (i) was tested using the phosphomimetic substitution KCNQ1-S27D. Kurokawa et al.24 
have previously shown that the S27D substitution reproduces most of the effects of βAR stimulation 
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on IKs. Indeed, in WT conditions, S27D led to an upregulation of IKs-tail  amplitudes (Figure 8A,B, left 
panels) and a significant leftward-shift of the half-maximal activation potential, similar to that 
observed after the application of cAMP/OA (Figure 8C). In contrast to cAMP/OA, the S27D 
substitution resulted in a significant upregulation of A341V in both heterozygous and homozygous 
conditions (Figure 8A,B middle and right panels), as well as a significant leftward shift in half-
maximal activation potential (Figure 8C). These data refuted hypothesized mechanism (i) to explain 
the disrupted cAMP responsiveness of A341V. 
 
 
Figure 9. KCNQ1/Yotiao interaction remains intact in the presence of the A341V mutation. A. 
Representative Western blots of Yotiao and KCNQ1 in lysates (top) of non-transfected CHO cells, 
CHO cells transfected with KCNQ1-WT + KCNE1 + Yotiao (WT) or KCNQ1-A341V + KCNE1 + Yotiao 
(A341V). Bottom blots are probed with anti-Yotiao and anti-KCNQ1 antibodies after precipitation of 
the immunocomplex from lysates using an anti-KCNQ1 antibody in the same conditions. B. 
Quantification of KCNQ1/Yotiao interaction in WT and A341VHom. Intensity of Yotiao signal from 
immunocomplexes was corrected for KCNQ1-signal intensity in all conditions and results were 
normalized to KCNQ1-WT + KCNE1 + Yotiao. C. I-V relationship for A341VHom currents in the absence 
of cAMP/OA, presence of cAMP/OA, presence of the S27D phosphomimetic substitution, or S27D 
without co-transfection of Yotiao (empty vector). Voltage-clamp protocol is identical to Figure 4. 
Increase in tail-current amplitude by the S27D substitution occurs only in the presence of Yotiao. 
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Yotiao serves a dual function: not only is it required for phosphorylation of S27 by PKA, it also 
actively participates in the conformational changes of the channel complex after phosphorylation of 
S27.24 We investigated the interaction between KCNQ1 and Yotiao via co-immunoprecipitation 
experiments in CHO cells expressing KCNQ1-WT or KCNQ1-A341V + KCNE1 + Yotiao. Whole-cell 
lysates or immunocomplexes precipated from lysates using an anti-KCNQ1 antibody were probed 
with anti-KCNQ1 and anti-Yotiao antibodies (Figure 9A). Yotiao could be detected in both WT and 
A341V immunocomplexes, but not in negative controls (non-transfected CHO cells or cells 
transfected with KCNQ1-WT + KCNE1 but without Yotiao). The intensity of the Yotiao signal from 
immunocomplexes was corrected by the intensity of the KCNQ1 signal and results were normalized 
to WT conditions. In the presence of A341V, KCNQ1/Yotiao interaction was not statistically different 
from WT (0.92±0.10 of WT; Figure 9B). Moreover, whereas A341V-mutant IKs was markedly 
increased by the S27D substitution when Yotiao was co-transfected, there was no such increase in 
the absence of the anchoring protein (Figure 9C). We found no difference between basal WT IKs in 
the presence or absence of Yotiao (not shown), indicating that the observed increase in KCNQ1-
A341V-S27D was not due to enhanced expression and suggesting that Yotiao can indeed modulate 
IKs in the presence of A341V-S27D. This indicated that hypothesized mechanism (ii) cannot explain 
the dominant-negative reduction in cAMP-dependent IKs upregulation by the A341V mutation. 
 
To test hypothesis (iii), cells transfected with KCNQ1-WT+KCNE1+Yotiao or KCNQ1-
A341V+KCNE1+Yotiao were incubated with either 300 µmol/L membrane-permeable cAMP and 0.2 
µmol/L OA for 10 min, or with external solution. Lysates were run on SDS-PAGE, transferred onto 
PVDF membranes, and probed with anti-phospho-S27 KCNQ1 and anti-KCNQ1 antibodies. Non-
transfected CHO cells were used as negative controls. A significant increase in the fraction of 
phosphorylated KCNQ1 was observed in response to stimulation with cAMP/OA in KCNQ1-WT 
(Figure 10A). Although increased phosphorylation was also observed in A341V-expressing cells, the 
fraction of phosphorylated IKs channels was significantly lower than that in WT cells (by 25%), both 
for A341VHom and A341VHet (Figure 10A,B). Thus, defective phosphorylation of KCNQ1-A341V is 
responsible, at least partly, for the loss of cAMP-dependent IKs upregulation. 
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Figure 10. The A341V mutation results in reduced phosphorylation of S27 during cAMP-dependent 
stimulation. A. Representative Western blot of lysates of non-transfected CHO cells, CHO cells 
transfected with KCNQ1-WT + KCNE1 + Yotiao (WT) or KCNQ1-A341V + KCNE1 + Yotiao (A341VHom), 
incubated in the absence or presence of 8-CPT-cAMP and OA, and probed with anti-phospho-
KCNQ1-S27 (top blot) or anti-KCNQ1 (bottom blot) antibodies. The lower two blots show similar 
results for WT and heterozygous co-transfection of WT and A341V. B. Quantification of fractions of 
KCNQ1-PS27 (relative to total KCNQ1) for WT, A341VHom (5 blots from 4 samples) or A341VHet (9 blots 
from 3 different samples) in the absence or presence of stimulation with 8-CPT-cAMP/OA. Results 
are normalized to KCNQ1-WT + 8-CPT-cAMP/OA. There is a significant reduction of KCNQ1 
phosphorylation at S27 in the presence of A341V. 
 
Dominant-negative suppression of cAMP/PKA-dependent IKs upregulation in 
LQT1 
The reduction in KCNQ1-A341V phosphorylation is similar to that observed by Chen et al.25 for the 
Yotiao mutation S1570L. They also show a complete loss of IKs enhancement (in this case due to 
reduced KCNQ1-Yotiao interaction). Combined, our data and those by Chen et al.25 suggest that 
cAMP-dependent IKs upregulation is under strong dominant-negative control of KCNQ1-S27 
phosphorylation, which is further supported by the functional finding of a striking loss of cAMP-
dependent upregulation of heterozygous KCNQ1-A341V. 
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Figure 11. Localization of KCNQ1-WT and KCNQ1-A341V after co-transfection of both subunits with 
KCNE1 and Yotiao. A c-Myc epitope was inserted in the extracellular loop between transmembrane 
segments 1 and 2 of KCNQ1-WT and the KCNQ1-A341V was tagged with GFP at the C-terminus. Top-
left panel shows a confocal image of KCNQ1-WT obtained with an anti-c-Myc antibody in a 
representative CHO cell. Top-right panel shows GFP signal in the same cell. When the two signals are 
overlayed (bottom-left panel), a clear colocalization of WT and A341V KCNQ1 subunits can be 
observed at the cell membrane (yellow), confirming “heterozygous” channel expression. The 
bottom-right panel shows the relative signal-intensity profiles of KCNQ1-WT and KCNQ1-A341V 
along the cross-sections at the light-green line. Both signals show increased activity at the cell 
boundaries. The lower-left white scale-bar indicates 10 µm. For color figure, see page 252. 
 
To further investigate the disruption of upregulation in heterozygous conditions, we first confirmed 
that KCNQ1-WT and KCNQ1-A341V are both expressed in the membrane by immunolocalization. 
Coexpression of KCNQ1-WT-c-Myc and KCNQ1-A341V-GFP constructs allowed simultaneous 
detection of WT (using an anti c-Myc antibody) and A341V subunits. Figure 11 shows individual 
signals of KCNQ1-WT (top-left panel) and KCNQ1-A341V (top-right panel). The overlay of these 
signals (Figure 11, bottom-left panel) indicates strong colocalization (yellow color) of WT and A341V 
subunits in the cell membrane. This is confirmed by the cross-section profile of both signal 
intensities (Figure 11, bottom-right panel), which shows enhanced intensity at the membrane. 
Correlation between c-Myc and GFP signal intensity profiles was 0.81±0.01 in 50 cells of 4 
transfections. 
 
We next compared the loss of cAMP-dependent upregulation by KCNQ1-A341V with the LQT1 
mutations KCNQ1-A344V,26 KCNQ1-G589D27 and KCNQ1-K557E. Suppression of IKs upregulation has 
previously been reported for the KCNQ1-G589D (KCNQ1-Fin) mutation, which disrupts the binding of 
Yotiao to the KCNQ1 C-terminus.5 We have recently reported on the LQT1 mutation K557E found in a 
Dutch family with a relatively mild clinical phenotype in which cAMP-dependent IKs enhancement is 
intact.28 Responsiveness to cAMP was quantified by an increased tail-current amplitude over the 
entire population of cells studied (Figure 12A) as well as an increase in current amplitude for each 
individual cell during a 5-min cAMP/OA wash-in protocol (Figure 12B,C). WT, heterozygous and 
homozygous K557E, and heterozygous and homozygous A344V all showed a pronounced 
responsiveness to cAMP. In contrast, A341V and G589D IKs were unresponsive to stimulation, even 
when co-expressed with WT IKs (Figure 12). These results demonstrate that the loss of upregulation 
observed by A341V does not apply to the very similar mutation A344V (same amino-acid 
substitution, only three residues apart and, based on the KCNQ1 homology model, in close proximity 
to A341; Figure 3). Nonetheless, dominant-negative suppression of cAMP-dependent IKs 
upregulation is not exclusive for A341V, as indicated by our heterozygous G589D data.  
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Figure 12. Comparison of cAMP-dependent upregulation of WT and A341V-, A344V-, K557E- or 
G589D-mutated IKs. A. Tail-current amplitudes after 5-s depolarizing pulses to +60 mV (voltage-clamp 
protocol identical to Figure 1) in the absence or presence of cAMP/OA for WT current and 
heterozygous or homozygous expression of mutant IKs. Numbers in/above bars indicate number of 
cells for each condition. B. Time course of IKs augmentation during application of cAMP/OA in WT, 
K557EHet, A341VHet and G589DHet. Data are normalized to tail-current amplitude after 1 min for each 
condition. Inset: voltage-clamp protocol. C. IKs increase in WT or heterozygous K557E, A341V or 
G589D conditions after 5 min of cAMP/OA, relative to 1 min (vertical dashed lines in panel B). K557E 
and A344V are significantly upregulated by cAMP/OA. In contrast, A341V and G589D which disrupt 
βAR sensitivity in homozygous conditions, have dominant-negative loss of cAMP-dependent 
upregulation. In the absence of cAMP/OA, IKs was stable and no significant difference in current 
amplitude between 5 min and 1 min was found (left-most bar).   
 
To determine if the dominant-negative suppression of cAMP-dependent upregulation by A341V and 
G589D could be due to their common effects on KCNQ1-S27, and to investigate if alterations in 
KCNQ1-S27 alone can exert dominant-negative control of cAMP/PKA-dependent IKs upregulation, 
independent of other known pathogenic mutations, we analyzed a 1:1 co-expression of WT KCNQ1 
with KCNQ1-S27A (together with KCNE1 and Yotiao). This heterozygous S27A condition will disable 
the PKA phosphorylation site in approximately half of the KCNQ1 subunits. In contrast to the 
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pronounced increase observed with cAMP/OA treatment in WT IKs, there was no significant increase 
in IKs-tail current amplitude in heterozygous KCNQ1-S27A cells stimulated with cAMP/OA (Figure 13). 
Although there was still a small (but non-significant) increase in IKs in heterozygous S27A, this 
increase was also present in cells with homozygous S27A expression after treatment with cAMP/OA 
(19% increase in tail current after 5-s depolarizing pulses to +90 mV in both cases, not shown) and 
no significant differences were found between heterozygous S27A in the absence or presence of 
cAMP (Figure 13).  
 
 
Figure 13. Loss of cAMP-dependent IKs upregulation with heterozygous KCNQ1-S27A. Left, tail I-V 
relationship (voltage-clamp protocol as in Figure 1). Right, averaged current traces at +60 mV for WT 
IKs or heterozygous expression of KCNQ1-S27A (n=9 and n=11) in the absence or presence of 
cAMP/OA, after co-transfection of KCNE1 and Yotiao. Heterozygous KCNQ1-S27A results in a 
dominant-negative reduction of cAMP-dependent IKs upregulation that is indistinguishable from 
homozygous KCNQ1-S27A (not shown).  
 
DISCUSSION 
In the present study we provide novel mechanistic insights into cAMP-dependent upregulation of IKs 
and its alteration by the S6 transmembrane LQT1 mutation A341V. We show that A341V confers a 
dominant-negative suppression of current upregulation. This loss of cAMP sensitivity is not due to a 
restriction of the conformational changes that occur after S27 phosphorylation, but instead is due to 
the inability of PKA to phosphorylate KCNQ1-S27 despite the presence of Yotiao. The combined 
dominant-negative reduction in basal current and loss of cAMP sensitivity result in a pronounced 
prolongation of repolarization during βAR stimulation in a computational model. Moreover, we 
show that dominant-negative suppression of upregulation is shared by other LQT1 mutations that 
show loss of βAR modulation in homozygous conditions (e.g., KCNQ1-G589D5) and by heterozygous 
substitutions at S27. Our results suggest that tetrameric phosphorylation of KCNQ1 is required. This 
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finding has important implications for the clinical severity of KCNQ1 mutations similar to A341V, 
because genetically heterozygous carriers will exhibit a ‘homozygous phenotype’ with respect to βAR 
modulation. The present data stress the importance of investigating molecular signaling besides 
basal function of IKs in the human congenital LQT syndrome.  
 
Requirement of a Macromolecular Signaling Complex for IKs Modulation 
Specific macromolecular signaling is required for the modulation of voltage-gated ion channels.29 
Modulation of IKs by PKA requires a complex comprising KCNE1,
7 Yotiao,5 and β-tubulin,30 besides the 
pore-forming α-subunit KCNQ1. In pathological conditions, the composition of the macromolecular 
complex is even further complicated by the fact that most LQT1 mutations (including A341V) are 
inherited in an autosomal-dominant mode. In these conditions, variable mixtures of normal and 
mutant KCNQ1-subunits interact in the membrane-expressed IKs channels. 
 
KCNE1 and β-tubulin appear to operate downstream of channel phosphorylation in mediating the 
conformational changes that increase IKs, since no difference in KCNQ1 phosphorylation was found 
after disruption of KCNE131 or microtubular interaction,30 despite altered IKs regulation. Interactions 
between KCNQ1 and KCNE1 have been reported for the extracellular, transmembrane and 
intracellular parts of the subunits.32, 33 Panaghie et al.32 have shown that KCNE1 interacts with the 
KCNQ1 pore region through residues F339 and F340. Based on a homology model of the structure of 
KCNQ1, Smith et al.34 determined that A341V does not face the lipid bilayer but instead interacts 
with S6-residues of other subunits (Figure 3). This makes it unlikely that A341 interacts directly with 
KCNE1. However, the A341V mutation may induce conformational changes in the KCNQ1-S6 
segment that indirectly alter KCNQ1/KCNE1 interactions. Our S27D data show a clear upregulation in 
the presence of A341V, indicating that the interaction between KCNQ1 and KCNE1 is preserved, at 
least partly. In agreement, a recent study showed that KCNQ1-A341V in the absence of KCNE1 or in 
the presence of the mutant KCNE1-T58A results in non-functional channels.35 However, the exact 
role of KCNE1 in influencing A341V-mutated IKs and its upregulation requires further study.  
 
Our S27D data also indicate that the Yotiao contribution downstream of phosphorylation is intact.  
Previously, Kurokawa et al.24 showed that S27D is unable to upregulate WT IKs when Yotiao is not 
included. Here we confirm these results for A341V-mutant IKs. 
 
Analysis of KCNQ1 with a phospho-sensitive antibody indicated that, despite the presence of Yotiao, 
phosphorylation of KCNQ1 is reduced in the presence of A341V. The exact molecular mechanism by 
which this occurs is currently unclear but may involve a reduced functional interaction between the 
KCNQ1 C-terminal-coupled Yotiao and the N-terminal phosphorylation site S27. Interestingly, 
however, the A341V mutation is located in the S6 transmembrane spanning domain of KCNQ1, a 
region that has not previously been reported to play a role in cAMP-dependent modulation of IKs. 
However, the intact upregulation in the presence of the very similar mutation A344V suggests that 
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the role of S6 in cAMP-dependent IKs upregulation involves specific residues. The fact that A341 is an 
extremely conserved residue located just prior to the S6 ‘hinge domain’20 (Figure 3), indicates that 
even small perturbations of the amino-acid sequence at this position may cause pronounced 
alterations of channel structure. 
 
Marx et al.5 have shown that the KCNQ1-G589D mutation in homozygous conditions results in loss of 
cAMP-dependent IKs upregulation due to disruption of the KCNQ1-Yotiao interaction. Here we report 
that this abolishment of upregulation occurs also in heterozygous conditions. This illustrates that at 
least two KCNQ1 mutations (G589D and A341V), in different parts of the channel, show such 
dominant-negative suppression.  
 
Marx et al.5 and Yang et al.36 have demonstrated that the substitution KCNQ1-S27A disables the N-
terminal phosphorylation site and reduces cAMP-dependent IKs upregulation. Yang et al.
36 also 
observed a contribution of the ‘atypical’ PKA sites S468/T470, whereas Marx et al.5 demonstrate a 
complete loss of cAMP-dependent IKs upregulation in the presence of S27A, consistent with our data. 
These differences may be related to the absence of Yotiao co-transfection in the experiments of 
Yang et al., but further studies are clearly required to explore this. We found that the 
phosphomimetic substitutions KCNQ1-S468D/T470D were unable to upregulate IKs (not shown), 
further indicating that S27 is the main phosphorylation site involved in cAMP-dependent IKs 
upregulation. Importantly, we show here that the lack of cAMP-dependent IKs upregulation was also 
observed upon heterozygous KCNQ1-S27A substitution (a condition in which half of the N-terminal 
phosphorylation sites are disabled). In heterozygous conditions, a binomial distribution of subunit 
composition is expected in which 93.75% of the channels will have at least one mutation in the 
KCNQ1 tetramer. The complete lack of upregulation in this case indicates that PKA-dependent 
channel upregulation is under dominant-negative control by alterations at S27 in which a single 
defective subunit is sufficient to abolish upregulation and suggests a requirement for tetrameric 
phosphorylation or a strong cooperation between the four subunits in cAMP-dependent channel 
modulation.  
 
Mechanisms Underlying Phenotypic Severity of A341V and Role of Genetic 
Risk Modifiers 
Schwartz et al.13 found that increased autonomic sensitivity, e.g., resulting from polymorphisms in 
adrenergic receptors, was an arrhythmia-risk modifier in A341V mutations. This observation is in line 
with our computational simulations that indicate the most pronounced APD prolongation during 
high levels of βAR stimulation. The data presented here readily explain why genetic variants of 
adrenergic receptors that boost sympathetic responsiveness of the heart are risk modifiers in A341V 
carriers due to the combined loss of basal IKs and its cAMP-dependent upregulation.  
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Both A341V and G589D show complete loss of cAMP-dependent upregulation in heterozygous 
conditions but have different clinical severities. Although there are important differences in peak 
basal currents at physiological potentials for 300-ms depolarizations (1.03±0.27 pA/pF vs 3.07±0.30 
pA/pF at 20 mV for A341VHet and G589DHet, respectively; P<0.05), which may contribute to their 
phenotypic differences, it is clear that ionic mechanisms within IKs itself do not provide the complete 
picture of repolarization instability in vivo.  Variants in NOS1AP have been shown to affect QT 
duration in the normal population37 and have been reported as risk modifiers in A341V carriers. 
Chang et al. have shown that NOS1AP overexpression affects repolarization through IKr and ICaL. 
Previously, we have shown that the effect of reduced IKs is larger when repolarization is impaired by 
pharmacological blockade of IKr.
17 Thus, NOS1AP variants likely function next to KCNQ1 mutations, 
affecting among other things IKr. The important role of IKs as a repolarization reserve
15, 17 may then 
partly explain their role as risk modifiers in A341V carriers.38 
 
Conclusions 
Loss of cAMP-dependent upregulation of IKs, even under heterozygous conditions, on top of a 
dominant-negative reduction in basal current, is a biophysical characteristic of KCNQ1-A341V that 
may contribute to its phenotypic severity in patients. This loss of upregulation is related to reduced 
phosphorylation of KCNQ1 at S27. Moreover, we show in general that cAMP/PKA-dependent IKs 
upregulation is under strong dominant-negative control of KCNQ1 phosphorylation at S27. These 
data have important implications for future studies of LQT1 mutations, because they highlight the 
importance of studying the effects of heterozygous expression of mutations, similar to their 
occurrence in most patients, and they indicate that baseline I-V characteristics alone are insufficient 
to determine the electrophysiological consequences of LQT1 mutations. Finally, our data point to an 
as yet unknown involvement of the S6 region of KCNQ1 at and/or around A341 in mediating βAR 
modulation of IKs.  
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ABSTRACT 
In vivo studies have suggested that increased beat-to-beat variability of ventricular repolarization 
duration (BVR) is a better predictor of drug-induced torsades de pointes than repolarization 
prolongation alone. Cellular BVR and its dynamics before proarrhythmic events are poorly 
understood. We investigated differential responses of BVR in single myocytes during IKs blockade 
versus IKr blockade and late-INa augmentation, under the influence of β-adrenergic receptor 
stimulation. Transmembrane action potentials were recorded from isolated canine left-ventricular 
midmyocytes at various pacing rates. IKs was blocked by HMR1556, IKr by dofetilide. Late INa was 
augmented by sea anemone toxin-II. Isoproterenol was added for β-adrenergic receptor stimulation. 
BAPTA-AM buffered intracellular Ca2+. SEA0400 partially inhibited the Na+–Ca2+ exchanger. BVR was 
quantified as variability of action-potential duration at 90% repolarization: Σ(|APD90; i+1 minus 
APD90; i|)/[nbeats×√2] for 30 consecutive action potentials. Baseline BVR was significantly increased 
by IKr blockade and late-INa augmentation, especially at slow pacing rates. β-adrenergic stimulation 
restabilized these BVR changes. In contrast, IKs blockade caused very little change in repolarization 
when compared to baseline conditions, but predisposed the myocyte to increased BVR during β-
adrenergic stimulation, especially at fast rates. BAPTA-AM and SEA0400 reduced this excessive BVR 
and eliminated early afterdepolarizations. In conclusion, β-adrenergic receptor stimulation 
exaggerates BVR during IKs blockade, indicating a BVR-stabilizing role of β-adrenergic-sensitive IKs. 
Loss of IKs plus overriding of Ca
2+-dependent membrane currents, including inward Na+–Ca2+ 
exchange current, conspire to proarrhythmic BVR under these conditions. 
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INTRODUCTION 
Beat-to-beat variability of ventricular repolarization duration (BVR) occurs as an apparently random 
alteration of the repolarization duration (measured from transmembrane or monophasic action 
potentials (APs), local activation-recovery intervals or QT intervals) in consecutive heart beats at 
stable rates. Proarrhythmic conditions caused by IKr blockade,
1-3 IKr-plus-IKs blockade
3 and late-INa 
augmentation4 are characterized by significant increases of BVR. When increased, BVR is a better 
predictor of drug-induced torsades de pointes (TdP) than repolarization prolongation alone, at least 
in canine and rabbit models,1-3 and in selected human patients.5 
 
In the case of selective IKs inhibition in vivo, BVR remains unchanged despite mild QT prolongation.
3, 6 
However, upon the addition of intense β-adrenergic receptor stimulation (βAS) pronounced 
repolarization instability occurs, as evident from amplified BVR, and this precedes the triggering of 
early afterdepolarizations (EADs), ventricular extrasystoles and TdP.6 Various antiarrhythmic 
interventions (e.g., intravenous KCl administration, IK,ATP activation, steady-state ventricular pacing) 
that prevent TdP are characterized by stabilization of BVR when often the QT interval is still 
prolonged.7 Collectively, these data indicate that a prominent rise of BVR heralds torsadogenic 
instability of the heart, whereas its decline is an expression of restabilization of electrical activity. 
 
Cellular studies have revealed that the mechanisms underlying BVR reside, at least partly, in the 
cardiac myocyte. Under baseline conditions at fixed-rate pacing, isolated ventricular myocytes 
express temporal (i.e., beat-to-beat) variability of the action-potential duration (APD).1, 8 A direct 
relationship exists between rate-dependent APD and BVR, even during random changes in pacing 
rate.9 Pharmacological interventions to influence ion channels that operate during the AP plateau 
can markedly alter baseline BVR. IKr blockade
1, 8, 10 not only increases the cellular APD, but also BVR, 
while promoting the generation of EADs. Similar effects were noted for late-INa augmentation with 
sea anemone toxin-II (ATXII).11 Conversely, the blockade of late-INa with tetrodotoxin
8 or ranolazine11, 
12 largely suppresses these proarrhythmic repolarization changes. Finally, intracellular Ca2+ chelation 
with EGTA reduces BVR in myocytes.8  
 
In contrast, little is known about the contribution of the K+ current IKs to BVR stability in cardiac 
myocytes. IKs function is prominent during βAS when it promotes AP shortening by increased 
protein-kinase-A-dependent activation, and during IKr block when it limits AP prolongation by time-
dependent activation,10, 13, 14 thus providing critical “repolarization reserve” when other repolarizing 
currents are impaired.15, 16 BVR exaggerates significantly when IKs is inhibited after AP 
preprolongation with the IKr blocker almokalant.
10 
 
In this study we investigated the properties of BVR in single canine left-ventricular (LV) myocytes 
during superfusion with standardbuffer solution containing physiological concentrations of ions 
(baseline) and the differential responses of BVR during selective IKs blockade versus IKr blockade and 
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late-INa augmentation, in the absence or presence of βAS. Our findings indicate a protective role of IKs 
in preventing excessive BVR and EAD generation during βAS, and a mechanistic contribution of 
inward Na+–Ca2+ exchange to these proarrhythmic sequelae. 
METHODS 
This investigation conformed with the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Animal handling 
was in accordance with the European Directive for the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes (86/609/EU). 
 
Cell-isolation procedure 
Twenty-three adult female beagle dogs weighing 12.8±0.3 kg (range: 10.5–15.0 kg; 9–31 months of 
age) were used for the myocyte isolations. Anesthesia was induced with 45 mg/kg pentobarbital. 
Once full anesthesia was reached, the chest was opened via a left thoracotomy and the heart was 
excised and placed in an O2-gassed Ca
2+-free standard buffer solution at approximately 4 °C. The cell 
isolation procedure was the same as previously described.17 Briefly, the left anterior descending 
coronary artery was cannulated and perfused. After ∼20 min of collagenase perfusion and 
subsequent washout of the enzyme, the epicardial surface layer was removed from the LV wedge 
until a depth of ≥3 mm was reached. Softened tissue samples were collected from the 
midmyocardial layer underneath while contamination with the endocardium was avoided. Samples 
were gently agitated, filtered and washed. LV midmyocytes were stored at room temperature in 
standard buffer solution and only quiescent rod-shaped cells with clear cross-striations were used 
for the experiments. 
 
Cellular recordings 
Transmembrane APs were recorded at 37 °C bath temperature using high-resistance (30–60 MΩ) 
glass microelectrodes filled with 3 mol/L KCl. Intracellular pacing was done at various cycle lengths 
(CLs) and only cells that showed a spike-and-dome AP morphology were accepted for the 
experiments. Myocyte contractions were recorded with a video edge motion detector (Crescent 
Electronics, Sandy, UT, USA). 
 
Solutions and agents 
The standard buffer solution used for the experiments was composed of (in mmol/L): NaCl 145, KCl 
4.0, CaCl2 1.8, MgCl2 1.0, glucose 11 and HEPES 10, pH 7.4 with NaOH at 37 °C. HMR1556 ((3R,4S)-
(+)-N-[3-hydroxy-2,2-di methyl-6-(4,4,4-tri fluo robutoxy)chroman-4-yl]-N-methyl methane sulfon 
amide) was used to block IKs. At 500 nmol/L it blocks the current completely,
10 while exerting 
minimal, if any, effects on IKr and other ion currents.
6, 18, 19 IKr was selectively blocked by 1 μmol/L 
dofetilide (Apin Chemicals, Abingdon, United Kingdom). Late INa was augmented by 20 nmol/L ATXII 
(Sigma-Aldrich, Zwijndrecht, The Netherlands). Intracellular Ca2+ was buffered with 5 μmol/L BAPTA-
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AM (Invitrogen, Breda, The Netherlands). The Na+–Ca2+ exchanger was inhibited by 300 nmol/L or 1 
μmol/L SEA0400. At these concentrations SEA0400 has little effect on ICaL, the cytosolic Ca
2+ transient 
or contraction of canine ventricular myocytes, whereas it blocks Na+–Ca2+ exchange by 28-80% 
(reverse mode & forward mode) depending on cytosolic Ca2+ concentration.20, 21 HMR1556, 
dofetilide, ATXII, BAPTA-AM and SEA0400 were initially dissolved in dimethyl sulfoxide and then 
diluted so that the concentration of the solvent was ~0.1% in the superfusate, a concentration that 
has no measurable effects on AP or ionic currents. βAS was applied as 100 nmol/L isoproterenol. 
This agent was originally dissolved in distilled water containing 30 μmol/L ascorbic acid and then 
stored in the dark at 4 °C until use. 
 
Data analysis and statistics 
BVR was quantified as variability of APD at 90% repolarization (APD90): Σ(|APD90; i+1 minus APD90; 
i|)/[nbeats×√2] for 30 (or a minimum of 10) consecutive APs.1 In addition, we calculated the 
coefficient of variability (CV) of APD90 as the percentage of standard deviation/mean APD90.
8 
Quantitative data are expressed as mean±SEM. Intergroup comparisons were made with Student's t 
test for unpaired and paired data groups, after testing for the normality of distribution. Differences 
were considered statistically significant if P<0.05. 
RESULTS 
Baseline characteristics of BVR in canine LV myocytes 
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Figure 1. Baseline characteristics of BVR in canine LV myocytes. A. Histogram of APD90 from 300 
consecutive cycles in a representative cell with Gaussian fit (solid line) to the histogram data. Bins of 
2 ms width. B. Single-cell (30 APs) and average APD90 as a function of pacing CL (Top panel). Bottom 
panel illustrates the CL dependence of both BVR and CV. Average parameters are shown±SEM. C. 
Representative AP and contraction recordings from the same cell paced at 350 ms and 4000 ms CL. 
D. Poincaré plots of APD90 from the cell shown in C at the CL of 350 ms (left) and 4000 ms (right). Of 
note is the repetitive behavior seen at 350 ms, whereas at 4000 ms the recordings are more chaotic. 
APD represents APD90. CV, coefficient of variability. CL, cycle length. A.U., arbitrary units. 
 
Figure 1A shows a histogram of 300 consecutive APD90s in a representative contracting myocyte 
during pacing at a CL of 1000 ms. APD90 was normally distributed about a mean of 276 ms with a 
SEM of 0.5 ms. Similar results were obtained from 13 cells. A correlation coefficient of 0.90 was 
calculated between the histogram and a normal Gaussian fit. This indicated that APD90 variability 
within the canine myocyte occurs randomly, which is consistent with previous data from guinea pig.8 
In 33 cells, pacing rate was varied between CLs of 350 and 4000 ms. APD90 increased on slowing of 
the pacing rate, as expected.22 Single representative and pooled APD90 data are shown in Figure 1B. 
 
BVR averaged 5.9±0.5 ms at CL 1000 ms (Figure 1B). Significant increases were calculated at both the 
fastest and slowest pacing rates; at CL 350 ms BVR was 10.3±2.3 ms and at CL 4000 ms 11.3±1.3 ms 
(both P<0.05 vs. CL 1000 ms). Similar patterns were found for CV. At CL 1000 ms CV averaged 
2.6±0.2%, increasing to 4.7±0.8% and 4.4±0.5% at the same extreme rates (both P<0.05 vs. CL 1000 
ms; Figure 1B). Thus, at (very) fast pacing, rate-dependent adaptation of APD90 (further decrease) 
was clearly discordant with that of both BVR and CV (increases). Beat-to-beat alternans of both 
APD90 and contraction amplitude explained this discordance, as demonstrated in Figure 1C, left 
panel. APD90 alternans occurred as a very ordered process (interchanging between two values), 
whereas BVR was apparent as a more random APD90 behavior, generally at slower rates (Figure 1C, 
right panel; same cell). This is further exemplified in the Poincaré plots of Figure 1D. These data 
suggest distinct mechanisms for BVR and APD90 alternans. 
 
Both BVR and CV expressed similar patterns of rate-dependent repolarization variability. As BVR 
incorporates the beat-to-beat consecutiveness of APD90 in its formulation whereas CV does not, we 
used BVR in the remaining analyses. 
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Influences of hyper- and hypokalemia on BVR 
 
Figure 2. Response of APD and BVR to changes in [K+]o. A. APs recorded from 30 consecutive cycles in 
a single canine LV myocyte paced at a cycle length of 2000 ms under various [K+]o. BVR and APD 
values and [K+]o are indicated above. B. Poincaré plots of APD90 of each of these traces are shown. An 
increase in BVR is seen during a state of hypokalemia, and a decrease in a state of hyperkalemia. 
 
Next, we examined the influences of hyper- and hypokalemia. Representative results are shown in 
Figure 2. Myocytes (n=4) were constantly paced at CL 2000 ms. For hyperkalemia, [K+]o was raised to 
7.0 mmol/L in the superfusate. Along with APD90 shortening (−15% from 264±35 ms), BVR decreased 
from 5.3±1.2 ms (normokalemia) to 3.0±0.3 ms (P<0.05). For hypokalemia, [K+]o was lowered to 2.5 
mmol/L. Now, APD90 prolonged (+26%) and BVR increased to 9.0±0.8 ms (P<0.05). No EADs were 
observed. Resting membrane potentials varied with the [K+]o changes, as expected (Figure 2A). 
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BVR instability and EAD generation during IKr blockade or late-INa 
augmentation, and rescue by βAS 
 
Figure 3. Increases in repolarization instability caused by both IKr blockade and late-INa augmentation 
and rescue by βAS. Representative examples showing the effects of dofetilide 1 μmol/L (panel A) or 
ATX II 20 nmol/L (panel B) on BVR at 1000 ms CL and rescue by βAS. AP recordings showing the 
minimum, maximum and median beats are shown for each condition and the ADP90 and BVR are 
indicated (left). Poincaré plots for each condition are also shown. Group data from all cells is shown 
on the right. Data is shown as mean±SEM. *P<0.05 versus baseline; #P<0.05 versus drug challenge. 
 
IKr blockade with dofetilide (1 μmol/L) and late-INa augmentation with ATXII (20 nmol/L) increased 
APD90 and BVR at pacing CLs of 500, 1000 and 2000 ms, but most significantly at the slower rate. This 
is shown in Figure 3. In the case of dofetilide and for CL 1000 ms, BVR changed from 5.6±0.5 ms at 
baseline to 16.1±2.9 ms (P<0.05; 19 cells; APD90+37% from297±15ms), as calculated fromAPD90s 
before the first occurrence of EADs (if present; see below). Similarly, in the case of ATXII, BVR 
increased from 4.4±0.5 ms to 15.5±1.8 ms (P<0.05; 12 cells; APD90 +47% from 255±17 ms). APD90 
histograms remained normally distributed during both dofetilide and ATXII (data not shown). During 
these drug challenges, the addition of βAS (isoproterenol; 100 nmol/L) drastically reduced APD90 and 
BVR at all cycle lengths, even to values below baseline (Figure 3). EADs were also abolished. For 
dofetilide at CL 1000 ms, BVR decreased from 16.1±2.9 ms to 3.5±0.7 ms (P<0.05; APD90 –102% to 
201±23 ms). For ATXII at the same CL, BVR was reduced from15.5±1.8 ms to 2.8±0.3ms (P<0.05; 
APD90 –40% to 180±10 ms). In some cells, delayed afterdepolarizations (DADs) appeared during βAS 
and drug challenge, however these did not reach the threshold for triggering APs. 
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BVR instability and EAD generation by βAS during IKs blockade 
 
Figure 4. βAS unmasks repolarization instability caused by IKs blockade. Representative traces 
showing the minimum, maximum and median AP under baseline conditions, IKs blockade and IKs 
blockade plus βAS during pacing at 1000 ms. Poincaré plots, APD90 and BVR values for the particular 
cell are also shown. Group data from all cells are shown on the right showing mean±SEM. *P<0.05 
versus baseline; #P<0.05 versus drug challenge. 
 
IKs blockade with HMR1556 (500 nmol/L) did not affect APD90 at pacing CLs of 500, 1000 and 2000 
ms, in line with previous results.10, 23 For example, at CL 1000 ms APD90 was 249±8 ms at baseline 
compared to 250±8 ms under HMR1556. Likewise, BVR remained unaltered at CLs of 500 and 1000 
ms. However at CL 2000 ms, it increased moderately but significantly (Figure 4, bar graph; n=16). 
APD90 histograms remained normally distributed during HMR1556. No EADs or DADs were observed 
during HMR1556 only.  
 
The addition of βAS during IKs blockade changed this picture drastically: BVR increased at all CLs, but 
most apparently at CL 500 ms and during the window of DAD occurrence (Figures 4 and 5). DADs 
were generated in all cells (n=10), and EADs in most of them. At pacing CL 1000 ms, BVR increased to 
5.7±0.3 ms during HMR1556 plus isoproterenol before the occurrence of DADs from a value of 
4.2±0.2 under HMR1556 alone. During the subsequent phase with DADs, BVR increased further to 
14.8±1.5 ms (P<0.05). APD90 also showed a significant increase at all CLs. For example at CL 1000 ms, 
APD90 averaged 291±15 ms (+17% versus baseline) during HMR1556 plus isoproterenol in the phase 
with DADs. Obviously, EADs exaggerated BVR and APD90 even further (Figure 5). BVR and APD90 
changes, and the generation of DADs and EADs, were completely reversible upon washout of 
isoproterenol. 
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Figure 5. Time course of increased repolarization instability during IKs blockade plus βAS. Upper 
panel shows consecutively paced APs at 1000 ms CL, together with Poincaré plots during initial 
perfusion of HMR1556. Addition of βAS increases APD and BVR before DADs are seen (2nd panel 
from above). The occurrence of DADs (3rd panel) increases APD and BVR further, and DAD-triggered 
APs and EADs are subsequently observed (4th panel). Arrows indicate timings of paced beats, and * 
indicate EADs. Low amplitude EADs are also generated under these conditions. 
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Differential magnitudes of BVR in cells with or without EAD generation, and 
rate dependence of EADs under different conditions 
 
Figure 6. Magnitude of BVR in cells with or without EADs, and rate dependence of EADs under 
various conditions. Magnitude of BVR in cells with or without EADs, and rate dependence of EADs 
under various conditions. A. Bar graph showing BVR values in cells that show EADs compared to 
those that did not during various drug treatments. Insets show examples of EADs caused by IKr block 
and late-INa augmentation together with the preceding beat and the baseline AP. Mean data 
shown±SEM; BL represents baseline. *P<0.05 versus BVR in cells with no EADs. B. Bar graph showing 
the rate dependence of EADs. Number of EADs per 10 beats are plotted at various CLs during all 3 
treatment groups. Mean data shown+SEM. 
 
During IKr blockade and late-INa augmentation, BVR increases (most pronounced at slow rates) were 
significantly larger in myocytes in which EADs ensued, even though BVR was calculated before the 
first EAD occurred, (n=8/19 for dofetilide and n=5/12 for ATXII) versus those cells in which no EADs 
were seen (n=11/19 and n=7/12, respectively). This is shown in Figure 6A (for CL 2000 ms). In 
contrast, EADs generated during IKs blockade plus βAS were clearly fast-rate dependent (Figure 6B). 
Under these conditions, BVR was not statistically different for myocytes with ensuing EADs (n=5/10) 
versus those without (n=5/10). βA-stimulated EADs were always preceded by DADs and were always 
accompanied by early aftercontractions (Figures 7 and 8, middle panels). Early aftercontractions 
usually took off before EAD upstrokes (inset, Figure 7, middle panel) and, in fact, occurred often 
without concrete EADs. Collectively, these data indicated that EADs and DADs during IKs blockade 
plus βAS are generated as the consequence of cellular Ca2+ overload and spontaneous Ca2+ release 
from the sarcoplasmic reticulum, and they suggested a mechanistic contribution of inward Na+–Ca2+ 
exchange.24, 25 
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Influences of BAPTA-AM and SEA0400 on BVR instability and EAD generation 
during IKs blockade plus βAS 
 
Figure 7. Ca2+ chelator BAPTA-AM rescues from excessive BVR during IKs blockade plus βAS. 
Representative traces showing 30 consecutive AP and contraction recordings overlapped from the 
same cell under IKs blockade (left panel), plus βAS (middle panel) and together with 5 μmol/L BAPTA-
AM (right panel) while being paced at 1000 ms. Inset shows an example EAD caused by IKs blockade 
plus βAS. EADs are eliminated during intracellular calcium buffering despite APD lengthening. 
Dashed line indicates the initiation of the early aftercontraction which preceded the EAD upstroke. 
Poincaré plots, APD90 and BVR values for this particular cell are also shown. 
 
As a final series of experiments, we examined the effects of the intracellular Ca2+ chelator BAPTA-AM 
(5 μmol/L) and the Na+–Ca2+ exchange blocker SEA0400 (300 nmol/L or 1 μmol/L) on BVR instability 
and EAD generation by βAS during IKs blockade. Data were obtained in 6 cells. As shown in Figure 7, 
BAPTA-AM significantly reduced excessive BVR and eliminated all EADs (and DADs). At pacing CL 
1000 ms, BVR changed from 12.9±1.6 ms during HMR1556 plus isoproterenol (before first EADs) to 
4.2±0.1 ms (P<0.05) during additional BAPTA-AM, even despite extra AP prolongation (APD90 +56%). 
The latter is likely caused by a reduction in ICaL inactivation
26 and an IKr blocking side-effect of BAPTA-
AM.27 BVR restabilization was maximal when all (after)contractile activity was inhibited by the Ca2+ 
buffer. Figure 8 illustrates the effects of SEA0400 (300 nmol/L) at CL 500 ms. BVR decreased 
significantly from 12.2±1.5 ms during HMR1556 plus βAS to 2.4±0.2 ms (P<0.05) during additional 
SEA0400. Effects were less pronounced at CLs 1000 and 2000 ms. All EADs were eliminated upon the 
addition of SEA0400. BVR effects were quantitatively similar for 300 nmol/L and 1 μmol/L SEA0400, 
as were reductions of APD90 and contraction amplitude. At CL 500 ms, APD90 decreased from 246±16 
ms during HMR1556 plus βAS to 201±13 ms (P<0.05) during additional SEA0400, while contraction 
amplitudes were decreased by 52±5%. 
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Figure 8. Na+-Ca2+ exchange inhibitor SEA0400 rescues from excessive BVR during IKs blockade plus 
βAS. Representative traces showing 30 consecutive AP and contraction recordings from the same 
cell under IKs blockade (left panel) plus βAS (middle panel) plus 300 nmol/L SEA0400 (right panel) at 
CL 500 ms. EADs are seen under IKs blockade plus βAS which are eliminated during application of 
SEA0400. Poincaré plots, APD90 and BVR values for this particular cell are also shown. 
 
DISCUSSION 
The mechanisms underlying BVR at the single-cell level are poorly understood. In the present study, 
we used canine ventricular myocytes to investigate BVR responses at baseline and during various 
proarrhythmic challenges. Our data indicate that IKs stabilizes BVR at slow pacing rates under 
baseline conditions, despite the absence of changes in APD90. βAS of IKs rescues from excessive 
repolarization instability and EAD generation during IKr block and late-INa augmentation. 
Furthermore, our results support the notion that βAS during drug-induced IKs block promotes altered 
Ca2+ handling and enhanced activation of Ca2+-dependent membrane currents, including inward Na+–
Ca2+ exchange, thus exaggerating BVR. Although single myocyte BVR is not the sole contributor to in-
vivo QT variability, our novel insights are crucial for the understanding of BVR at the whole organ 
level such as seen after IKr blockade and βAS.
6 
 
Distinction between BVR and repolarization alternans 
At baseline, BVR is mainly dependent on APD which in turn is reliant on cycle length. At very fast 
rates, however, APD90 and BVR become discordant as the result of beat-to-beat repolarization 
alternans (Figure 1). The latter is an ordered process, characterized by interchanging between two 
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APDs and concomitant contraction amplitudes. Although repolarization alternans is considered 
arrhythmogenic, EADs are not normally seen under these conditions, at least not in our experiments. 
Repolarization and contraction alternans arise from beat-to-beat alteration in cellular Ca2+ cycling.28 
BVR, on the other hand, is characterized by an apparently random behavior of APD, generally at 
intermediate and slow rates. Even during pronounced BVR instability, e.g., by hypokalemia, IKr 
blockade and late-INa augmentation, contraction amplitudes remain relatively stable (contraction 
data not shown). Our data thus indicate that in the majority of cases BVR and APD90 show parallel 
changes. However, in specific conditions they can deviate, for example during IKs blockade plus βAS, 
and during IKs blockade plus βAS and BAPTA-AM. This suggests that BVR is not necessarily dependent 
on APD90 at all times, which has major mechanistic implications. 
 
Cellular BVR likely results from the stochastic activities of transmembrane ion transporters, including 
ion channels, during the AP plateau phase. During this phase, around the 0 mV level, the membrane 
resistance is very high,8 meaning that minute changes of the ion fluxes across the membrane can 
significantly affect the membrane potential which in turn will alter the repolarization duration.29 
Interventions that reduce net outward current will cause a prolongation of this vulnerable phase, 
meaning that there is an extended period at which the voltage is around the 0-mV level. Stochastic 
behavior of the ion channels may then increase BVR. It is also possible that this stochastic behavior 
results indirectly from subsarcolemmal Ca2+ fluctuations that lead to modification of Ca2+-dependent 
ion currents. Modeling data has shown that during isoproterenol stochastic ICaL gating in mode 2 
results in APD variability as well as EAD generation,30 and this could contribute to the BVR seen in 
this study. 
 
Cellular BVR during βAS 
In the present study, we have shown that BVR is drastically increased under conditions of IKr 
blockade or late INa augmentation in isolated canine LV midmyocytes. The addition of βAS, however, 
causes a major reduction in BVR and eliminates EAD activity (Figure 3). As IKs is the main βA-sensitive 
outward current in the canine ventricular AP, this current appears responsible for the restabilization 
of repolarization. If true, βAS would provoke BVR instability during IKs blockade, as IKs could no longer 
compensate for the increased ICaL caused by βAS, which leads to increased cellular Ca
2+ load and 
APD90. This was indeed the case: BVR increased significantly, despite only moderate increases in 
APD90 (Figure 4). In this phase, βAS also evoked DADs and EADs (Figure 5). BVR increased after the 
first generation of DADs (even before EADs occurred; Figure 5), which supports the concept that 
dynamic subsarcolemmal Ca2+ fluxes during cellular Ca2+ overload and diastolic spontaneous Ca2+ 
release from the sarcoplasmic reticulum influence the subsequent (paced) APs and BVR via 
mechanisms yet to be elucidated. Our finding that BVR and EAD generation by IKs blockade and βAS 
were most pronounced at fast pacing rates (as opposed to IKr blockade and late-INa augmentation; 
Figure 6) fits with this concept. Additional support comes from the result that intracellular Ca2+ 
chelation with BAPTA-AM reduces beat-to-beat repolarization instability (Figure 7). Moreover, in 
preliminary experiments in which we used ryanodine (1 μmol/L) during IKs blockade and βAS (data 
not shown), blockade of sarcoplasmic-reticulum Ca2+ release reduced excessive BVR (while inhibiting 
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the generation of afterdepolarizations), again supporting that Ca2+-dependent membrane currents 
contribute to BVR. 
 
Our results on afterdepolarization occurrence are partially in agreement with data from the canine 
LV-wedge preparation.31 Burashnikov and Antzelevitch31 reported that under combined IKs blockade 
and βAS, DADs were induced in LV epi-, mid- and endocardium. Transmural dispersion of 
repolarization was accentuated. However, no EAD activity was seen. This apparent discrepancy with 
our observations in isolated myocytes could be explained by the difference in cell-to-cell electrotonic 
coupling. The latter, which acts in the LV wedge preparation but not in the isolated cell, has been 
shown to reduce BVR.8 
 
The Na+–Ca2+ exchange inhibitor SEA0400 attenuates excessive BVR and EADs 
during IKs blockade plus βAS 
Various groups have used the Na+–Ca2+ exchange inhibitor SEA0400 in attempts to prevent TdP 
under conditions of IKr block
32, 33 and INa augmentation
32 with mixed results. Milberg et al.32 showed 
that the application of SEA0400 (1 μmol/L) in the presence of sotalol or veratridine resulted in a 
significant decrease of monophasic APD and an attenuation of EADs in paced Langendorff-perfused 
rabbit hearts with complete atrioventricular block, supporting the hypothesis that the Na+-Ca2+ 
exchanger is an important mediator of EADs.25  However in the study of Farkas et al.33 SEA0400 (1 
μmol/L) did not suppress dofetilide-induced TdP nor decrease QT variability in unpaced Langendorff-
perfused rabbit hearts with complete atrioventricular block. The major difference between these 
two studies was that in the study of Milberg et al.32 hearts were paced at constant cycle lengths, 
whereas in the alternate study33 hearts were allowed to beat at their intrinsic ventricular rate. Upon 
administering SEA0400 in addition to dofetilide, the rate instability increased, and this additional 
factor could have increased the susceptibility to TdP, at variance with the results of Milberg et al.32 
 
To the best of our knowledge this report is the first to describe the use of Na+-Ca2+ exchange 
inhibition in the presence of IKs block combined with βAS (as such mimicking long-QT syndrome type 
1 (LQT1)). In line with Milberg et al.,32 the application of SEA0400 resulted in a significant decrease of 
transmembrane APD and an attenuation of EADs (Figure 8). Moreover, SEA0400 rescued from 
excessive BVR, suggesting a repolarization-destabilizing role of inward Na+-Ca2+ exchange under 
conditions of IKs blockade combined with βAS.
24 
 
Clinical perspectives 
In LQT1 patients, sympathetic stimulation and epinephrine challenges prolong the QT interval,34 
increase beat-to-beat QT variability35 and promote EAD generation.34 Our present cellular results 
may thus have important clinical implications, as they support the use of Ca2+ antagonists,36 βA-
receptor blockers34, 36 and even IK,ATP openers
34 to restrain BVR and reduce the risk of TdP in these 
patients. Indeed, βA-receptor blockade, the cornerstone of pharmacological treatment in LQT1, 
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decreases epinephrine-prolonged monophasic APD and transmural dispersion of repolarization in 
LQT1.34 Likewise, βA-receptor blockade can decrease transmural dispersion of repolarization in LQT1 
patients, but causes it to increase in LQT2 patients.37 Whether the Na+.Ca2+ exchanger is a suitable 
target for antiarrhythmic treatment in LQT1 patients is currently under debate. 
 
Conclusions 
The repolarizing potassium current IKs stabilizes BVR in single canine LV myocytes. During conditions 
of IKr blockade and late-INa augmentation, βAS of IKs rescues from excessive BVR, AP prolongation and 
EAD generation. However, during IKs blockade βAS provokes excessive BVR, while promoting the 
generation of DADs and EADs. The loss of IKs plus overriding of Ca
2+-dependent inward currents, 
including inward Na+-Ca2+ exchange current, likely conspire to cellular proarrhythmia under these 
conditions.  
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ABSTRACT 
Spontaneous Ca2+ release from the sarcoplasmic reticulum (SCR) can cause delayed 
afterdepolarizations (DADs) and triggered activity, contributing to arrhythmogenesis during Ca2+ 
overload. Excessive beat-to-beat variability of repolarization duration (BVR) is a proarrhythmic 
marker. Previous research has shown that BVR is increased during Ca2+ overload in isolated 
myocytes. We aimed to determine ionic mechanisms controlling BVR during abnormal Ca2+ handling. 
Membrane potentials and cell shortening or Ca2+ transients were recorded from isolated canine left-
ventricular myocytes in the presence of the β-adrenergic agonist isoproterenol to induce Ca2+ 
overload. Action-potential (AP) durations following DADs were significantly prolonged. Addition of IKs 
blockade led to further AP prolongation after SCR and this strongly correlated with exaggerated BVR. 
Suppressing SCR via inhibition of ryanodine receptors, CaMKII inhibition, or by using Mg2+ or 
flecainide eliminated DADs and decreased BVR, which was independent of effects on AP duration. 
Caffeine led to a similar decrease in BVR, due to the occurrence of SCR before every AP. 
Computational analyses and voltage-clamp experiments measuring ICaL with and without prior SCR 
demonstrated that ICaL was increased during Ca
2+-induced Ca2+ release after SCR, contributing to AP 
prolongation. SCR promotes BVR by interspersed prolongation of myocyte AP duration, which is 
exacerbated during IKs blockade. Attenuation of Ca
2+-induced Ca2+ release by SCR underlies AP 
prolongation via increased ICaL. These data provide insight into arrhythmogenic mechanisms during 
Ca2+ overload besides triggered activity, as well as illustrating the importance of IKs function in 
preventing excessive BVR. 
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INTRODUCTION 
Enhanced cellular Ca2+ load, for example during β-adrenergic receptor (βAR) stimulation, results in 
augmentation of Ca2+ release from the sarcoplasmic reticulum (SR), larger Ca2+ transients (CaT), and 
enhanced contractile force.1 Under certain conditions Ca2+ load is increased beyond a certain 
threshold, leading to spontaneous Ca2+ release (SCR) from the SR during diastole.2  In turn, this 
diastolic leak causes a transient inward current (Iti), causing delayed afterdepolarizations (DADs), 
mainly due to activation of the electrogenic Na+-Ca2+ exchanger (NCX), with the Ca2+-activated Cl- 
current (IClCa) contributing in some species.
3, 4 Previous work has also shown that both DADs and 
early afterdepolarizations (EADs) may share a common mechanism, at least during βAR stimulation 
and Ca2+ overload, namely SCR-induced currents.5 Both types of afterdepolarizations have been 
incriminated in the formation of ventricular tachycardia (VT), via triggered activity (TA) and/or by 
increasing dispersion of repolarization.6 
   
Beat-to-beat variability of repolarization duration (BVR) occurs as an apparently random alteration in 
repolarization duration, and can be observed at all levels of cardiac repolarization, from the action 
potential (AP) of the single cardiac myocyte to the QT interval on the body surface.7-9 Exaggerated 
BVR has been reported to be a more reliable indicator of arrhythmogenic risk than repolarization 
prolongation per se, at least in several experimental  VT models10-12 and in selected human subjects, 
for example in patients with acquired or inherited long QT syndrome, or nonischemic heart failure.8, 
13  
 
Mechanisms underlying BVR at the single-cell level remain poorly understood. Pharmacological 
interventions influencing ion channels that operate during the AP plateau can markedly alter BVR.7, 
14  Recently, we have shown that during Ca2+ overload in myocytes subjected to blockade of the 
slowly-activating delayed-rectifier K+ current (IKs) in combination with βAR stimulation, BVR is 
significantly enhanced, even before the occurrence of  EADs and TA.14  
 
In the present study, we investigated the relationship between SCR and BVR using a combined 
experimental and computational approach in canine ventricular myocytes subject to βAR 
stimulation. We show that SCRs not only lead to Iti and DAD formation, but also to a prolonged 
duration of the following AP via increased L-type Ca2+ current (ICaL), which in turn leads to increased 
BVR when analyzing multiple consecutive APs. Pharmacological interventions that inhibit SCR (either 
with reduced or preserved systolic contraction) prevent this SCR-associated AP prolongation and 
reduce BVR. 
 
METHODS 
This investigation conformed with the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Animal handling 
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was in accordance with the European Directive for the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes (86/609/EU). 
 
Cell-isolation procedure 
Adult female beagle dogs were used for the myocyte isolations. Anesthesia was induced with 45 
mg/kg pentobarbital. Once full anesthesia was reached, the chest was opened via a left thoracotomy 
and the heart was excised and placed in an O2-gassed Ca
2+-free standard buffer solution at 
approximately 4 °C. The cell-isolation procedure was the same as previously described.15 Briefly the 
left anterior descending coronary artery was cannulated and perfused. After ~20 min of collagenase 
perfusion and subsequent washout of the enzyme, the epicardial surface layer was removed from 
the LV wedge until a depth of ≥3 mm was reached. Softened tissue samples were collected from the 
midmyocardial layer underneath while contamination with the endocardium was avoided. Samples 
were gently agitated, filtered and washed. LV midmyocytes were stored at room temperature in 
standard buffer solution (vide infra) and only quiescent rod-shaped cells with clear cross-striations 
were used for the experiments. Cells were used within 48 h of isolation. 
 
Sharp-electrode action potential recordings 
Transmembrane action potentials (APs) were recorded at 37 °C using high-resistance (30–60 MΩ) 
glass microelectrodes filled with 3 M KCl with a microelectrode amplifier (Axoclamp-2B, Axon 
Instruments, Inc). Intracellular pacing was done at various cycle lengths (CLs; 500 ms – 2000 ms). 
Only cells showing a stable spike-and-dome AP morphology and resting membrane potential were 
accepted for the experiments. Myocyte contractions were recorded with a video edge motion 
detector (Crescent Electronics, Sandy, UT, USA).  
 
Ca2+ measurements 
Isolated myocytes were loaded with the acetoxymethyl ester of indicator Fluo-3 or Fura-2 
(Molecular Probes; 5 μmol/L, 5 min loading and 30 min de-esterification). Electrophysiological 
control for current clamp and voltage clamp experiments with simultaneous [Ca2+]i measurements 
was achieved using the perforated patch clamp technique with amphotericin-B (240 μg/ml). The 
switch-clamp facility (frequency 1–3 kHz and gain 1–3) of the Axoclamp-2B voltage clamp amplifier 
(Axon Instruments, CA, USA) was used to overcome the access resistance of the perforated patch. All 
experiments were performed at 37°C. 
 
Drugs and experimental solutions 
The standard buffer solution used for the experiments was composed of (in mmol/L): NaCl 145, KCl 
4.0, CaCl2 1.8, MgCl2 1.0, glucose 11 and HEPES 10, pH 7.4 with NaOH at 37 °C. In a subset of 
experiments, extracellular [Mg2+] was increased to 5 mmol/L by the addition of 4 mmol/L MgSO4. In 
other experiments, extracellular [Ca2+] was increased to 3.6 mmol/L to further increase cellular Ca2+ 
loading. 
Chapter 6 
| 155 
 
500 nmol/L HMR1556 ((3R,4S)-(+)-N-[3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy)chroman-4-
yl]-N-methylmethanesulfonamide; a gift from Dr. H. Gögelein, Sanofi-Aventis Germany GmbH, 
Frankfurt, Germany) was used to selectively and completely block IKs.
16-18 Sarcoplasmic reticulum (SR) 
Ca2+ release through the ryanodine receptor (RyR) was inhibited with 1 μmol/L ryanodine (RBI, 
Natick, MA, USA) or stabilized using 5 μmol/L tetracaine (Sigma-Aldrich Zwijndrecht, The 
Netherlands). Caffeine (Sigma-Aldrich Zwijndrecht, The Netherlands; maximally 500 μmol/L) was 
used to increase RyR open probability. Ca2+/Calmodulin-dependent kinase (CaMKII) activity was 
modulated using the CaMKII inhibitor KN93 (Sigma-Aldrich Zwijndrecht, The Netherlands; 5 μmol/L) 
and the calmodulin inhibitor W7 (Tocris Bioscience, Bristol, UK; 1 μmol/L). The class-1C 
antiarrhythmic agent flecainide (MedaPharma, Amstelveen, The Netherlands) was employed in a 
subset of experiments. At 6 μmol/L, flecainide results in a 40% decrease in RyR activity19 as well as 
affecting multiple other targets (40% inhibition of ITo
20, significant inhibition of (late) INa
21 and ~50% 
inhibition of HERG K+ channels22). 
 
For perforated patch experiments the patch pipette solution contained (in mmol/L): KCH3O3S 125, 
KCl 20, NaCl 10, HEPES 10, MgCl2 5, K2EGTA 0.1, titrated to 7.2 with KOH with patch pipette 
resistance being 2-3 MΩ. In voltage clamp experiments, K+ currents were blocked by addition of 500 
nmol/L HMR1556, 5 mmol/L 4-aminopyridine and 100 nmol/L BaCl2 to the standard buffer solution. 
Extracellular Ca2+ was raised (to 3.6 or 5.0 mmol/L) to further enhance cellular Ca2+ loading.  
 
HMR1556, ryanodine, tetracaine, caffeine, W7 and KN93 were initially dissolved in dimethyl 
sulfoxide (DMSO) and then diluted so that the concentration of the solvent was maximally 0.1% in 
the superfusate, a concentration that has no measurable effects on AP or ionic currents.  
 
βAS was applied as 100 nmol/L isoproterenol in all experiments. This agent was originally dissolved 
in distilled water containing 30 μmol/L ascorbic acid and then stored in the dark at 4 °C until use. 
 
Computational Analysis 
A recent model of the canine ventricular myocyte electrophysiology including βAR stimulation23 
(Chapter 3) was extended with a method to induce diastolic SR Ca2+ release in a controlled fashion, 
similar to a recent approach by Xie et al.24 Both timing (start, duration) and amplitude of diastolic SR 
Ca2+ release could be controlled.  
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Figure 1. Schematic overview of the computational model of the canine ventricular myocyte. 
Adapted from Heijman et al.23 (Chapter 3). The model was divided into two identical domains to 
simulate the local origin of SCR. Only components on the left side of the model are labeled for 
clarity, identical components are located on the right side. The domains are coupled via diffusion of 
Ca2+ (Idiff,cyt and Idiff,nsr). All other abbreviations are as previously described.
23 For color figure, see page 
253. 
 
In particular, the model was divided into two identical domains (Figure 1) coupled by Ca2+ diffusion 
between cytosol and network SR to simulate the local origin of SCR. Diffusion time constants were 
based on the local control model by Restrepo et al.25 and diffusion was significantly slower in SR 
compared to cytosol, consistent with experimental observations26. The late component of INa (INaL) 
was increased in the model to simulate the midmyocardial origin of the myocytes used in our 
experiments, consistent with experimental data from Zygmunt et al.27 Model APD rate dependence 
at baseline, in the presence of ISO and in the presence of ISO+HMR1556 (simulated as 100% 
inhibition of IKs) was consistent with experimental data (Figure 2A).   Parameters of the L-type Ca
2+ 
current were adjusted based on the experiments in the presence of ryanodine to obtain quantitative 
agreement on the amount of APD prolongation in the absence of SR Ca2+ release.  
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Figure 2. Validation of model properties. A. Steady-state APD-rate dependence under baseline 
conditions (left panel), in the presence of ISO (middle panel) or in the presence of ISO + HMR1556 
(right panel) for APs without prior DAD. Average APD for each cell is shown in blue. Average APD 
over all myocytes is indicated with symbols. Model APD is shown in black. Model APD-rate 
dependence falls within experimental range and is close to the experimental average for all 
conditions and CLs. B. Average APD difference between APs preceded by a DAD and those without 
prior DAD in the presence of ISO or ISO + HMR1556. Average APD difference for each cell is shown in 
grey. Average group data is indicated with symbols. Model APD prolongation after SCR is indicated 
with grey bars. Model APD prolongation is consistent with experimental observations. 
 
To initiate SCR, steady-state RyR activation was set to a constant value in one of the two domains for 
the interval of diastolic SR Ca2+ release such that the desired reduction in local JSR Ca2+ was achieved. 
When steady-state RyR activation was set to 0.375 (SCRlevel = 0.375) from t = 925 ms until t = 950 
ms (at CL = 1000 ms), the SCR-induced prolongation of APD was consistent with experimental 
observations (Figure 2B). 
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The model was paced to steady state (2000 seconds of pacing) in the presence of βAR stimulation 
with or without IKs inhibition, to mimic experimental conditions. The effect of diastolic SR Ca
2+ 
release was examined by determining APD of a single beat at steady-state as a function of the timing 
and amplitude of the preceding diastolic Ca2+ release. In some simulations other currents / fluxes 
(ICaL, INaCa, ICl(Ca), Jrel) were blocked for the duration of this final beat. 
 
Data Analysis and Statistical Comparisons 
APD was quantified at 90% repolarization. BVR was quantified as variability of APD using the formula 
Σ(|APDi+1 - APDi|)/[nbeats×√2] for 30 consecutive APs in the absence of TA.
10 Detection of EADs, DADs 
and determination of APD, BVR and DAD parameters was done in a semi-automated fashion using a 
custom Matlab (The Mathworks, Natick, MA, USA) script. Briefly, Axon (Axon Instruments, CA, USA) 
data files were loaded into Matlab. AP upstroke was detected based on peaks in the numerically 
calculated dV/dt, and APD90 was determined. Subsequently, the diastolic interval between APD90 of 
one beat and the point of maximum dV/dt of the next beat was processed for all beats. The signal 
was low-pass filtered at 30 Hz to reduce noise. All peaks in the filtered signal were determined and 
resting membrane potential was defined as the average value between the smallest (most negative) 
local maximum and local minimum. The amplitude of all other peaks was determined relative to this 
resting membrane potential. DADs were identified as a local maximum in the filtered signal of more 
than 2 mV in amplitude and manually confirmed by the investigators. EADs were detected as 
positive local maxima in the low-pass filtered dV/dt signal preceded and followed by negative local 
minima. Detection of EADs was manually validated. 
 
Where applicable, data were reported as mean±standard error of the mean (SEM) of n 
experiments, and significance tested with either a t-test or 1 way ANOVA. Differences were 
considered statistically significant if P<0.05. 
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RESULTS 
DADs Prolong Subsequent APs and Increase BVR 
 
Figure 3. Occurrence of DADs in canine ventricular myocytes is associated with prolongation of 
subsequent APs and increased BVR. A. APD90 for 75 consecutive beats at 2000-ms CL at baseline (left 
panel: I), during wash-in of ISO (middle panel: II) and in the presence of HMR1556 and ISO (right 
panel: III). APDs preceded by a DAD are indicated with filled symbols, APDs without DADs depicted 
by open symbols. Dashed rectangle indicates a set of 5 beats for which cell shortening and 
membrane potential are depicted below. Insets show diastolic potentials at an expanded scale. 
Beats without prior SCR are indicated in black, beats with prior SCR in red. B. Membrane potential 
(top) and [Ca2+]i for four consecutive beats. APD90s are indicated below each AP. SCR is indicated with 
arrows. For color figure, see page 253.  
 
Under baseline conditions, a small beat-to-beat APD variability was observed (Figure 3A, left panel). 
βAR stimulation with isoproterenol (ISO) shortened APD and enhanced contraction (Figure 3A, 
middle panel). In the majority of cells, 100 nmol/L ISO caused DADs during pacing at 1000 ms CL. 
APs following a DAD were prolonged, leading to increased BVR due to interspersed occurrence of 
normal and prolonged APs (Figure 3A, middle panel). Pharmacological inhibition of IKs by HMR1556 
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(500 nmol/L) in the presence of ISO further prolonged APD and increased BVR (Figure 3A, right 
panel). In separate experiments, Ca2+ transients were recorded together with APs after HMR1556 
and ISO. APs following SCR were prolonged and had a reduced systolic Ca2+-transient amplitude 
compared to those where no diastolic release preceded the AP, indicating reduced SR Ca2+ load at 
the start of the AP (Figure 3B), consistent with the reduced cell shortening following an 
aftercontraction (Figure 3A).  
 
 
Figure 4. A. Group data for APD90 under baseline conditions, in the presence of ISO, or in the 
presence of ISO + HMR1556 at CLs of 500, 1000 and 2000 ms. DADs cause a significant prolongation 
during ISO and ISO + HMR1556 treatment. APD90 differences are indicated above each pair of bars. 
*; P<0.05  B. BVR values for the conditions in panel A. C. Cell shortening (top trace) and membrane 
potential (bottom trace) under baseline conditions with DAD-like electrical pulses (in the absence of 
SCR) applied every 4th beat (top panel) or with DADs after ISO + HMR1556 in the same cell (bottom 
panel). APD90 is indicated below each beat. D. Subthreshold diastolic pulses do not alter APD90 (left 
panel) nor BVR (right panel). 
 
A significant APD prolongation after the occurrence of DADs was observed at all CLs in the presence 
of ISO and ISO + HMR1556 (Figure 4A). APD prolongation was significantly more pronounced in the 
presence of ISO + HMR1556 compared to ISO alone at all CLs (e.g., 41±6 ms vs. 15±4 ms at CL = 1000 
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ms, P<0.05, Figure 4A). Moreover, a larger APD difference between beats with and without prior 
DAD was strongly associated with a larger BVR (Figure 4B). As such, HMR1556 was added in all 
subsequent experiments in the presence of ISO to maximize effects on APD, in effect creating a 
pharmacological cellular model of drug-induced long-QT1 (LQT1) syndrome, as previously 
described.14 
 
To determine whether DAD-like membrane-potential changes alone (i.e., without underlying 
alterations in intracellular Ca2+), influenced the subsequent AP, small diastolic voltages (25 mV 
amplitude, 150 ms duration) were injected under baseline conditions (Figure 4C top panel). There 
was no significant difference between APDs in the absence or presence of these diastolic pulses 
(Figure 4D), independent of the timing of the pulse (not shown). In contrast, when these cells were 
stimulated with HMR1556 + ISO, DADs occurred and subsequent APD was significantly prolonged 
(Figure 4C bottom panel), indicating that alterations in the subsequent APD were influenced by 
DAD-related events other than membrane-potential alterations per se. 
 
Coupling Between the Occurrence of DADs and EADs During Ca2+ Overload 
 
Figure 5. Relationship between diastolic SCR and EADs during Ca2+ overload. A.Top panel: Cell 
shortening (top trace) and membrane potential (bottom trace) for 5 consecutive APs followed by an 
AP with EAD (indicated with *) in a representative cell at 500-ms CL in the presence of HMR1556 + 
ISO. APD90 is given below each beat and DADs are indicated with arrows. Vertical line indicates 
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timing of start of aftercontraction. Bottom panel indicates the percentages of APs that showed a 
DAD in the 5 beats preceding every EAD. Horizontal dashed line indicates overall DAD occurrence at 
500-ms CL in the presence of HMR1556 + ISO, independent of EADs. The beat before an EAD has a 
DAD 95% of the time. *: P<0.05 compared to overall DAD occurrence. B. Similar to panel A (top) for 2 
beats in the presence of ISO only. A similar contraction pattern can be observed but APD 
prolongation is insufficient to promote EAD formation.  
 
In addition to DADs, EADs were observed during Ca2+ overload. EADs occurred predominantly at 500 
ms CL and exclusively in the presence of HMR1556 + ISO. Consistent with previous findings, we 
observed early aftercontractions preceding EAD upstrokes (Figure 5A), suggesting a primary 
mechanistic role of SCR for EAD formation under these specific conditions.5 We quantified the 
occurrence of DADs in the beats preceding an EAD and found that DADs were significantly more 
likely to occur in the 2 beats directly preceding an EAD (53% and 95% of APs) compared to the 
average DAD occurrence for all beats (34%; Figure 5A bottom panel). When APD was not sufficiently 
prolonged, as was often the case under conditions of ISO alone, a short-coupled DAD could be 
observed, but no EAD (Figure 5B). 
 
Blockade of (Spontaneous) SR Ca2+ Release Reduces BVR 
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Figure 6. Inhibition of (diastolic) SCR abolishes DADs and reduces BVR. Cell shortening (top panels; 
arbitrary units) and membrane potential (bottom panels) for 5 representative beats during 
treatment with ISO + HMR1556 (A), or ISO + HMR1556 + ryanodine (1 μmol/L) (B). APD90 is indicated 
below each beat and mean APD90 and BVR are shown for 30 beats in the Poincaré plot on the right. 
DADs are indicated with arrows. Panels C and D show similar data for treatment with tetracaine (5 
μmol/L). ISO + HMR1556 significantly enhances BVR and DAD occurrence. Ryanodine and tetracaine 
abolish DADs and reduce BVR. 
 
Ca2+ buffering with BAPTA-AM has previously been show to eliminate DADs and BVR during 
conditions of Ca2+ overload.14 We sought to further investigate how eliminating SCR, as opposed to 
buffering all cellular Ca2+, would affect APD and BVR. Blockade of the ryanodine receptor (RyR) with 
ryanodine eliminated DADs and led to a drastic reduction in BVR, despite leading to an increased 
APD (Figure 6A,B).  Results were similar at all tested CLs. APD prolongation under these conditions 
was not associated with any arrhythmogenic events. A drastic reduction in systolic contraction was 
also seen, as expected, indicating that blockade of RyRs was achieved effectively.  
 
Tetracaine reduces the open probability (Po) of RyR leading to a decrease in the frequency of SCR in 
unstimulated rat ventricular myocytes28 and an abolishment of ISO-induced SCR in stimulated 
voltage-clamped rat ventricular myocytes29. Similar to ryanodine, tetracaine led to an elimination of 
DADs in our experiments, and a reduction in BVR at all CLs. However, unlike ryanodine, cell 
shortening remained present, indicating that systolic Ca2+ release was still intact (Figure 6C,D).   
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Figure 7. Interventions that abolish or homogenize SCR lower BVR. A. APD90. B. DAD occurrence. C. 
BVR at CL = 1000 ms at baseline, in the presence of ISO, HMR1556 + ISO, or HMR1556 + ISO 
combined with interventions to modulate SCR. Interventions are grouped by type (RyR modulation, 
grey; Calmodulin/CaMKII modulation, black; or agents also used clinically; striped). All interventions 
except caffeine result in a significant lowering of DAD incidence and a concomitant reduction of BVR, 
with increased (ryanodine), decreased (tetracaine, flecainide (6 μmol/L)), or unaltered (W7 (1 
μmol/L), KN93 (5 μmol/L), [Mg+] (5 mmol/L)) APD90. Caffeine (maximally 500 μmol/L) regularizes SCR 
occurrence, increasing DAD occurrence but lowering BVR without changing APD90. *; P<0.05 versus 
HMR1556 + ISO. 
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To determine the effects of increasing the Po of RyRs, as opposed to decreasing it, we used low 
concentrations of caffeine (maximally 500 µmol/L).30 Under these conditions the percentage of APs 
showing DADs was increased at all CLs. Interestingly, this led to a significant decrease in BVR 
compared to HMR1556 and ISO alone, since DADs occurred before every AP (Figure 7, right-most 
grey bars).  
 
Several studies have shown that Ca2+/CaMKII is an important signaling molecule affecting Ca2+-
induced Ca2+ release (CICR) and that its inhibition can be antiarrhythmic.
31 Curran et al.32 
demonstrated that SR Ca2+ leak during βAR stimulation is mediated by CaMKII. In our experiments, 
inhibition of calmodulin using W7 reduced DAD incidence in all cells (from 44% to 8% at 1000 ms CL, 
P<0.05) and completely abolished them in 3/7 cells. The decrease in DAD occurrence was paralleled 
by a decrease in BVR. Average APD was unaltered by W7, and systolic contractions remained intact. 
Application of the CaMKII inhibitor KN93 led to similar results (Figure 7, black bars). 
 
Mg2+ has been shown suppress both EADs and DADs in different models33, 34 and is used clinically as a 
first-line agent against torsades de pointes. Increasing extracellular [Mg2+] from 1 mmol/l to 5 
mmol/l abolished DADs induced after HMR1556 and ISO in 4/7 cells. In the remaining 3 cells, DAD 
incidence was significantly reduced. A concomitant reduction in BVR was seen. APDs were not 
significantly altered, and although systolic contractions were slightly reduced compared to beats 
that did not show SCR events before Mg2+, they remained stable, indicating that the SR content 
remained constant (not shown). Similar results (albeit with reduced APD) were obtained with the 
class-IC antiarrhythmic agent flecainide (Figure 7, striped bars), which has recently been shown to be 
effective in preventing catecholaminergic polymorphic VT due to its effects on RyR and Na+ 
channels.35  
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Increases in [Ca2+]o Can Reinstate SCR Only When (Residual) RyR Function Is 
Available 
 
Figure 8. Effect of increased [Ca2+]o on APD90 (top panels), DAD occurence (middle panels), and BVR 
(bottom panels) under baseline conditions, HMR1556 + ISO, HMR1556 + ISO + Intervention or 
HMR1556 + ISO + Intervention + 3.6 mmol/L [Ca2+]o. A. Ryanodine. B. Tetracaine. C. W7. * indicates 
P<0.05. Only significance of intervention versus intervention in the presence of high [Ca2+]o is 
indicated for clarity reasons. Inset in lower-right panel shows APD90 in the presence of HMR1556 + 
ISO + W7 + increased [Ca2+]o for beats in the absence or presence of a preceding DAD.  
 
We hypothesized that increases in [Ca2+]o after interventions that reduced DAD occurrence would 
lead to a recurrence of SCR, DADs and increase BVR. Therefore, we raised the [Ca2+]o from 1.8 
mmol/L to 3.6 mmol/L after application of ryanodine, tetracaine, or W7. This led to a reinduction of 
DADs after tetracaine or W7, and a significant decrease of APD (Figure 8A-C). However, raising 
[Ca2+]o after ryanodine did not lead to DADs, nor did it alter BVR, indicating that RyR function is 
required for SCR and without this, BVR cannot be altered under conditions of Ca2+ overload. 
Interestingly, BVR was not significantly reincreased after W7 and high [Ca2+]o, whereas after 
tetracaine and high [Ca2+]o it was, despite DADs being reinstated under both conditions (Figure 8B,C). 
In the presence of W7, APs following SCR were no longer prolonged (Figure 8C, inset). These data 
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suggest that calmodulin inhibition has a direct effect on the coupling between SCR and APD, possibly 
via ICaL. 
 
Reduced Ca2+-Dependent Inactivation of ICaL Underlies APD Prolongation 
After SCR 
 
Figure 9. Computational model of the canine ventricular myocyte implicates reduced SR Ca2+-
dependent inactivation of ICaL to cause APD prolongation. A. AP, intracellular Ca
2+, ICaL and IKs (top to 
bottom) with (dashed lined) or without (solid lines) prior SR Ca2+ release for a single beat after 
pacing to steady state in the presence of ISO at CL of 1000 ms. The DAD resulting from the SCR is 
indicated by an arrow. Inset in 3rd panel shows ICaL during AP plateau on an expanded scale.  B. 
Similar to panel A in the presence of ISO and complete inhibition of IKs. C. After pacing to steady 
state in the presence of ISO, SCR was triggered (shaded bars) or not (white bars) and individual 
currents / fluxes were blocked for one final beat. APD90 differences are indicated above each bar. 
Only inhibition of SR Ca2+ release (RyR) or ICaL CDI was sufficient to completely abolish the APD 
prolongation after SCR.  
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We employed a computational model of the canine ventricular myocyte to investigate in more detail 
the ionic basis of the coupling between SCR and APD prolongation. After pacing to steady state, a 
partial release of SR Ca2+ was induced during diastole. After this release, APD was prolonged, 
consistent with the experimental observations (Figure 9A; CL = 1000 ms in the presence of ISO). The 
prolonged APD was associated with a decreased CaT, an increase in the sustained component of ICaL 
and increased IKs. The increase in IKs was due to the increased plateau potential resulting from the 
larger ICaL and counteracted the repolarization delay. As such, APD prolongation was significantly 
larger when IKs was inhibited (Figure 9B). An increase in plateau Vm was also observed in 
experimental recordings (maximum amplitude of plateau is 114±1 mV without prior DAD and 118±1 
mV following DADs at 1000 ms CL in the presence of HMR1556 + ISO, P<0.05). 
 
Several currents underlying the ventricular AP are modified by intracellular Ca2+. To determine the 
relative contribution of each component, we used the computational model to selectively inhibit 
each current for one final beat at steady state following either a normal diastole or SCR. The main 
currents activated by SCR in the dog are INaCa and IClCa.
3, 36 However, inhibition of these currents only 
had a minor impact on the APD differences in the presence and absence of SCR (Figure 9C). In 
contrast, inhibition of ICaL or RyR was able to significantly reduce the DAD-provoked APD 
prolongation. More specifically, when only Ca2+-dependent inactivation (CDI) of ICaL was inhibited, 
APD after SCR was no longer prolonged compared to APD without prior SCR (Figure 9C). Further 
investigation showed any differences in APD in these conditions were due to ‘priming’ of CDI due to 
a transition of L-type Ca2+ channels to the Ca2+-dependent tier of the Markov model induced by the 
Ca2+ that was released during the SCR, prior to activation of inhibition. 
 
Combined, our data implicate reduced SR Ca2+-release-dependent inactivation of ICaL as the 
mechanism underlying APD prolongation after SCR. This prediction was confirmed under voltage-
clamp conditions in native canine ventricular myocytes when the extracellular solution was modified 
to isolate ICaL (Figure 10). During a voltage step to +10 mV from a holding potential of -80 mV a 
significant increase in the integral of ICaL was observed after SCR: ∫ICaL
 = 27.9±3.5 nC vs 33.0±3.5 nC in 
the absence or presence of SCR, respectively (P<0.05). 
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Figure 10. ICaL inactivation is slowed after SCR. A. Voltage-clamp protocol (top panel), intracellular 
Ca2+ (middle panel) and membrane current (bottom panel) in a representative canine ventricular 
myocyte in the presence of HMR1556 + ISO + increased [Ca2+]o (3.6 or 5.0 mmol/L) in the absence 
(black) or presence of prior SCR (red). Right inset shows membrane current at an expanded scale. 4-
AP (5.0 mmol/L) and BaCl2 (0.1 mmol/L) were used to isolate ICaL. Left inset shows model results 
under similar conditions. B. Quantification of average membrane current integral (shaded area in 
right inset of panel A) in 6 canine ventricular myocytes in the absence or presence of SCR. Prior SCR 
significantly increases total inward current (*: P<0.05). For color figure, see page 254. 
 
DISCUSSION 
In this study, we elucidated the relationship between SCR, AP prolongation and BVR in canine left-
ventricular midmyocytes. We demonstrated that during conditions of ISO-induced Ca2+ overload, 
SCR occurs over a wide range of pacing CLs and that APD following SCR is significantly prolonged. 
Reduced CICR-dependent inactivation of ICaL after SCR underlies this AP prolongation. The increase in 
BVR observed during Ca2+ overload was strongly dependent on the degree of APD prolongation after 
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SCR. Previous studies37-39 have shown that large CaTs result in abbreviation of APD, whereas a small 
CaT after SR Ca2+ depletion corresponds to prolonged APD. In agreement, we find substantial APD 
prolongation after application of ryanodine due to reduced CDI of ICaL. Moreover, our data indicate 
that ICaL CDI is sensitive to (partial) SR Ca
2+ unloading by SCR. These changes in CDI are sufficient to 
modulate APD on a beat-to-beat basis over a wide range of CLs. Interestingly, Spencer and Sham 
reported the opposite effect in guinea-pig ventricular myocytes: APD was shortened by inhibition of 
CICR with ryanodine.40 These authors attributed this to a reduced forward-mode NCX activity. 
Reduced CaT amplitude after SCR can also reduce forward-mode NCX. Thus, the net effect of SCR on 
APD will depend on the balance between reduced NCX and increased ICaL. This may explain why 
caffeine, which induces SCR on almost every beat, only results in a mild (non-significant) APD 
prolongation. 
 
The Importance of IKs Blockade 
We have previously shown that during βAR stimulation and IKs blockade (via KCNQ1 inhibition;
41 
mimicking LQT1), BVR is significantly increased and that this is, at least partly, dependent on [Ca2+]i.
14 
Here we extend this by determining an important role for CDI of ICaL, at least in the presence of SCR. 
During βAR stimulation, the role of IKs becomes more prominent, and hence inhibition of IKs leads to 
APD prolongation.14 Barandi et al.42 have shown that the degree of APD prolongation induced by 
pharmacological block of repolarizing currents or augmentation of depolarizing currents, depends on 
baseline APD. Consistent with these results, we find a more pronounced APD prolongation after SCR 
at slow CL and in the presence of IKs blockade. In our experiments, APD prolongation after SCR is 
particularly pronounced because the increase in ICaL also elevates the plateau potential which 
increases IKs activation and offsets the prolongation induced by ICaL (Figure 9A, bottom panel). This 
compensating mechanism is absent when IKs is inhibited. Thus, IKs inhibition exacerbates the effect of 
SCR on APD prolongation. 
   
Arrhythmogenesis During Conditions of Ca2+ Overload 
It has long been established that SCR-induced triggered activity is a major arrhythmogenic 
mechanism during Ca2+ overload and its occurrence is increased in various pathological conditions.6, 
43 Here, we show that as diastolic SCR prolongs the subsequent APD,  even SCR below the threshold 
for triggered activity has important cellular electrophysiological effects that may be proarrhythmic.  
Regional prolongation of APD after SCR in the intact heart may cause increased spatial dispersion of 
repolarization between regions with the highest Ca2+ load (generating SCR) and regions with lower 
Ca2+ loading. Regional heterogeneities in ion-channel expression or intercellular conduction may 
further amplify this dispersion. Combined, these mechanisms can promote functional reentry. 
Stabilization of Ca2+ handling may therefore not only reduce the incidence of arrhythmogenic 
triggers but also prevent their reentrant perpetuation. We have also shown that Ca2+ overload by the 
combination of ISO and fast pacing can give rise to diastolic SCR which prolongs APD sufficiently such 
that the next SCR occurs before the end of repolarization, generating an EAD. The common 
dependence of DADs and EADs on SCR in the presence of ISO has previously been described.5, 44 Our 
results provide novel mechanistic insights on the coupling between SCR, APD prolongation and EAD 
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occurrence and show that diastolic SCR is a central element in both triggered activity and 
repolarization instability.  
 
APD prolongation after SCR results from increased ICaL, which enhances Ca
2+ loading via increased 
sarcolemmal Ca2+ influx. Enhanced loading along with reduced Ca2+ efflux serve to restore and fine-
tune SR Ca2+ content to maintain CICR efficacy, as has previously been described in rat ventricular 
myocytes after SR depletion.37, 39 However, during Ca2+ overload these mechanisms will readjust, 
promoting Ca2+ extrusion via NCX, which facilitates the occurrence of afterdepolarizations. 
Consistent with this reasoning, we found that the probability of observing a DAD was not 
significantly altered by the presence of a DAD on the previous beat. This strongly implies that, under 
our experimental conditions, the reduction in myocyte Ca2+ load during a DAD is overcome by the 
increased sarcolemmal Ca2+ influx during the following prolonged AP. Thus, APD prolongation after 
SCR contributes to the vicious cycle of Ca2+ overload. 
 
We investigated the utility of several interventions to restabilize Ca2+ handling and repolarization 
variability during Ca2+ overload. Inhibition of SCR by ryanodine and tetracaine has previously been 
described,29, 44 and the results presented here agree with those data. We extend these observations 
by showing a concomitant decrease in BVR. Both ryanodine and tetracaine are useful for mechanistic 
studies but due to their deleterious effects in vivo cannot be used as therapeutic agents. In contrast, 
both magnesium and flecainide are commonly used antiarrhythmic agents. Here we show that both 
these agents can stabilize Ca2+ handling in the overloaded single myocyte, and that this leads to a 
reduction in BVR and arrhythmogenic events. Similarly, we confirm the usefulness of modulating 
Calmodulin/CaMKII during Ca2+ overload as an antiarrhythmic strategy.31  CaMKII phosphorylation 
has been shown to induce a different gating mode (mode 2) of the ICaL channel, thereby reducing 
inactivation, favoring Ca2+ entry and the occurrence of EADs and DADs.45 In this regard, the 
development of selective CaMKII modulators suitable for antiarrhtyhmic interventions in humans is 
awaited. 
 
Conclusions 
We have shown that reduced CICR-dependent inactivation of ICaL after SCR underlies APD 
prolongation and contributes to increased BVR during ISO-induced Ca2+ overload. The degree of APD 
prolongation is exacerbated by inhibition of IKs. Pharmacological interventions that regularize SCR or 
inhibit SCR with or without preserved systolic contractions reduce BVR. Our data provide novel 
insights into arrhythmogenic mechanisms during Ca2+ overload and suggest novel antiarrhythmic 
strategies. 
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ABSTRACT 
Beat-to-beat variability of repolarization duration (BVR) is an intrinsic characteristic of cardiac 
function. When increased by repolarization-undermining influences, it is a better marker of 
proarrhythmia than repolarization prolongation alone. The ionic mechanisms underlying baseline 
BVR in physiological conditions, the rate dependence of BVR, and the factors contributing to 
increased BVR in pathological conditions, all remain incompletely understood. Here, we employed 
computer modeling to provide novel insights into the subcellular mechanisms of BVR under 
physiological conditions and during simulated drug-induced repolarization prolongation, mimicking 
long-QT syndromes type 1, 2 and 3. We developed stochastic implementations of 13 major ionic 
currents and fluxes in a model of the canine ventricular myocyte electrophysiology. Combined 
stochastic gating of all targets resulted in short- and long-term BVR consistent with experimental 
data from isolated canine ventricular myocytes. The model indicated that the magnitude of 
stochastic fluctuations is rate dependent due to the rate dependence of action-potential (AP) 
duration (APD). Both this active process and the intrinsic nonlinear relation between membrane 
current and APD contribute to rate dependence of BVR. We identified a major role for stochastic 
gating of the (persistent) Na+ current (INa) and rapidly-activating delayed-rectifier K
+ current (IKr) 
under physiological conditions. Consistent with experimental results, inhibition of IKr or 
augmentation of INa significantly increased BVR whereas subsequent β-adrenergic receptor 
stimulation reduced it, similar to findings in isolated myocytes. In contrast, β-adrenergic stimulation 
increased BVR in simulated long-QT syndrome type 1. In addition to stochastic channel gating, APD, 
AP morphology and beat-to-beat variations in Ca2+ were found to modulate single-cell BVR. Cell-to-
cell coupling was able to decrease BVR and this was more pronounced when a cell with increased 
BVR was coupled to a cell with normal BVR. In conclusion, our results provide new insights into the 
ionic mechanisms underlying BVR and suggest that BVR reflects multiple potentially proarrhythmic 
parameters, including increased ion channel stochasticity, APD, AP morphology and abnormal Ca2+ 
handling.  
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INTRODUCTION 
Beat-to-beat variability of repolarization duration (BVR) is an intrinsic characteristic of cardiac 
function that can be observed at various levels of integration, from temporal variations in action 
potential (AP) duration (APD) of the single cardiac myocyte to instability of the QT interval on the 
body surface.1-3 When increased by repolarization-undermining influences, it is a better marker of 
proarrhythmia than repolarization prolongation per se in various experimental models of torsades-
de-pointes ventricular tachycardia4-6 and in human cardiac pathology.2, 7 Recently, we described an 
important role for (abnormal) Ca2+ handling and the slowly-activating delayed-rectifier rectifier K+ 
current (IKs) in the increased BVR observed during β-adrenergic stimulation in single canine 
ventricular myocytes.8 However, the exact mechanisms underlying BVR and its rate dependence 
under physiological conditions, as well as the various factors contributing to exaggerated BVR in 
pathological conditions, remain incompletely understood. 
 
Computational models of cardiac myocyte electrophysiology have a rich history, dating back more 
than 50 years.9 Recent models have provided detailed descriptions of various cardiac cell types in 
different species. They have created insight into the role of the different ion channels in rate-
dependent alterations in repolarization,10-14 have helped to elucidate arrhythmogenic mechanisms in 
various pathological conditions,15-19 and have facilitated analysis of the integration of regulatory 
pathways and electrophysiological responses.20-23 However, to date most computational models are 
deterministic and have an APD that converges to a fixed steady state or a limit cycle (e.g., APD 
alternans) for a given pacing cycle length (CL). As such, these models are unsuitable for the study of 
BVR. 
 
Tanskanen et al. 24 were among the first to investigate the effect of stochastic properties of local 
control Ca2+ models on ventricular repolarization. They showed that a variable occurrence of 
arrhythmogenic early afterdepolarizations (EADs) could be explained by the stochastic gating of the 
L-type Ca2+ channel. In contrast, Sato et al.25 described temporal repolarization variability due to the 
chaotic occurrence of EADs in a deterministic model of the H2O2-treated rabbit ventricular myocyte. 
These authors provided strong evidence that noise-induced transitions between states were 
insufficient to account for the large APD fluctuations observed under their experimental 
conditions.26 However, none of these studies addressed BVR under physiological or pathological 
conditions in the absence of EADs. 
 
Recently, the role of stochastic ion-channel gating in repolarization variability under physiological 
conditions has been described by Lemay et al.27 and Pueyo et al.28 These studies provide an 
important basis for modeling cardiac repolarization variability. Here we significantly extended these 
studies by developing a stochastic version of our recently published model of the canine ventricular 
myocyte including adrenergic stimulation.22 Stochastic formulations of 13 major ion channels and 
active ion-transporters were included, and APD dynamics were compared to results obtained in 
isolated canine ventricular myocytes. We employed the model to obtain novel insights into the 
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quantitative contribution of individual electrophysiological processes to cellular BVR under 
physiological conditions and the factors contributing to increased BVR during pathological 
conditions. 
 
METHODS 
Adaptations to the HRdβAR model 
Markov model formulation of the rapidly-activating delayed-rectifier K+ current (IKr) 
The original Hodgkin-Huxley based formulation of IKr was replaced with a 10-state Markov model 
based on the model structure described by Silva and Rudy29 extended with state-dependent block of 
IKr channels by dofetilide (Figure 1A), based on the approach by Brennan et al.
30 Model parameters 
were adjusted to reproduce IKr peak and tail I-V relationships, time constants of activation and time 
constants of deactivation measured in canine ventricular myocytes31 (Figure 1B-D). Channels can 
enter the blocked mode via open and inactivated states, based on a Vm-dependent modulation of 
the dofetilide EC50.
32 The model reproduces dofetilide dose-response relationship measured in rabbit 
ventricular myocytes,33 use-dependence of relative inhibition as determined in AT-1 cells,32 and Vm-
dependence of dofetilide EC50
32 (Figure 1E-G). 
 
 
Figure 1. Structure and validation of IKr Markov model properties. A. Model structure. B. Tail I-V 
relationship in model and canine ventricular myocytes.31 C. Time constant of activation based on a 
single-exponential fit in model and canine ventricular myocytes.31 D. Time constant of deactivation in 
model and canine ventricular myocytes.31 E. Dose-response curve of IKr block by dofetilide 
(experimental data from rabbit ventricular myocytes33). F. Use-dependent block of IKr by dofetilide in 
Chapter 7 
| 179 
AT-1 cells32 and model. G. Vm dependence of dofetilide concentration required for half-maximal IKr 
inhibition (relative to -30 mV) in model and AT-1 cells.32 
 
Markov model formulation of the Na+ current (INa) 
The Markov model structure of Clancy and Rudy16 was employed for both normal inactivation and 
slow inactivation populations (Figure 2). Model parameters were adjusted to reproduce 
characteristics of INa and INaL from the original Hodgkin-Huxley-based formulation, including PKA- and 
CaMKII-dependent alterations.22 Model INa peak I-V relationship and steady-state inactivation are 
consistent with those measured in isolated canine ventricular myocytes.34 
 
Figure 2. Structure and validation of INa Markov model properties. A. Model schematic of fast and 
late (persistent) INa components. B. Peak I-V relationship (left panel) and steady-state inactivation 
(right panel) in model (lines) and canine ventricular myocytes (symbols) at baseline or in the 
presence of β-adrenergic stimulation. 
 
Markov model formulation of sarcoplasmic reticulum (SR) Ca2+ release 
Ca2+-induced Ca2+ release (CICR) in the original HRdβAR model depends directly on the L-type Ca2+ 
current (ICaL) based on the formulation by Livshitz et al.
35 It is difficult to create a stochastic version of 
this formulation since it does not exhibit the strong positive feedback characteristic for CICR (where 
the Ca2+ released by some ryanodine receptors (RyRs) may activate other RyRs in the same 
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microdomain), which likely affects its stochastic properties. As such, the original phosphorylated and 
non-phosphorylated CICR formulations were replaced by two 4-state Markov Models proposed by 
Restrepo et al. in their local control model of Ca2+ handling in the rabbit ventricular myocyte.36 
Model parameters were adjusted to reproduce rate-dependent Ca2+ transient (CaT) properties 
(amplitude, time to peak, and time constant of decay) of the original HRdβAR model in the absence 
or presence of β-adrenergic stimulation (βARS). 
 
Additional alterations in model parameters 
Parameters of the non-phosphorylated and phosphorylated ICaL formulations were adjusted slightly 
compared to Heijman et al.22  to reduce the sensitivity of the model for the generation of EADs in 
response to IKr blockade (requiring 80% IKr reduction to generate EADs compared to 25% in the 
absence of these changes) and to match the amount of APD prolongation after IKs blockade in the 
presence of adrenergic stimulation, while maintaining peak I-V and inactivation characteristics 
similar to experimental recordings. 
 
Stochastic formulations of model components 
Random number generation 
The Mersenne-Twister random number generator37 was used in all stochastic simulations to 
generate random variables from uniform and normal distributions. Binomial random variables 
𝐵(𝑛, p) were generated using the Inverse Function Method or approximated from a normal 
distribution 𝑁(𝑛 ∙ 𝑝, 𝑛 ∙ 𝑝 ∙ (1 − 𝑝)) when  � 1
√𝑛
∙ ��
1−𝑝
𝑝
− �
𝑝
1−𝑝
�� < 0.3. 
 
Langevin-term-based stochastic simulations 
In a subset of experiments, stochastic ion-current behavior was simulated using stochastic 
differential equations through the addition of a Langevin term to all differential equations 
controlling the gating of that current:38 dXidt = f(X) + α ∙ �Xi ∙ 𝑁(0,1) 
 
The noise amplitude parameter α was scaled to obtain similar APD variability as that observed with 
stochastic channel gating. 
 
Stochastic formulations of Markov models 
Stochastic simulations of Markov models of ion currents were performed as previously described for 
local control models.24, 36, 39 Briefly, for a given state i in the Markov model with a state occupancy of n𝑖  channels at time t, the probability for any channel to move to state j in the time interval ∆t is 
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given by ri,j ∙ ∆t, where ri,j is the transition rate (in ms-1) of the deterministic ODE model. Thus, the 
number of channels leaving state i in the interval ∆t can be obtained from a multinomial distribution 
𝑀�𝑛𝑖, ri,1 ∙ ∆t, … , ri,i−1 ∙ ∆t, 1 − ∆t ∙ ∑ ri,j , ri,i+1 ∙ ∆t, rik ∙ ∆t�. For sufficiently small ∆t, the transition 
probabilities are small and can be assumed to be independent. In this case, the number of channels 
leaving state i can be approximated based on k independent binomial distributions 𝐵�𝑛𝑖, ri,j ∙ ∆t�, 
significantly reducing the computational complexity.36 The number of channels in state i is then 
updated at every time step by: ni(t + ∆t) = ni(t) + �𝐵�nj(t), rj,i(t) ∙ ∆t� −�𝐵�ni(t), ri,j(t) ∙ ∆t�
j≠ij≠i
 
This approach was employed for the Markov models of ICaL, IKr, IKs, INa and RyR. In the case of 
simulations involving β-adrenergic stimulation, both the non-phosphorylated and phosphorylated 
channel populations22 were simulated using this stochastic formulation. 
 
Stochastic formulations of Hodgkin-Huxley-based models and instantaneous currents 
Hodgkin-Huxley-based models are a subset of the class of Markov models with only independent 
transitions.40 As such, the methodology for stochastic simulation of Markov models was also applied 
to the Markov representation of the equivalent Hodgkin-Huxley model for ITo and ICl(Ca). For 
‘instantaneous’ currents that are defined by an algebraic equation in the deterministic model, a 
simple 2-state (Open and Closed) model was used. The steady state distribution between the two 
states was defined by the original algebraic equation and a global time constant of 0.1 ms was used 
to determine the forward and backward rates between the two states. This approach was employed 
for stochastic simulations of IK1 and IKur. 
 
Stochastic formulations of pumps and exchangers 
In contrast to channels, where gating is a stochastic process but the flux of ions through an open 
channel is instantaneous, ion transport through pumps and exchangers is an active process. A single 
iteration of the pump or exchanger transports a given number of ions across the electrochemical 
gradient. As such, there is not a single ‘open state’ that defines the flux of ions but instead there is a 
state transition (or combination of transitions) that determines the flux of ions. Because of this, the 
throughput of a single pump is much lower than that of a channel. However, the expression of 
pumps is much higher than that of channels,41 thereby ensuring that an ionic balance can be 
maintained. 
 
The SR and sarcolemmal Ca2+-ATPases (underlying Iup and IpCa, respectively) were simulated using the 
two-state, four-transition model structure of Tran et al.42 Parameters of the models were adjusted to 
reproduce the Ca2+ dependence of the deterministic formulations. We assumed that the state 
distribution changes more rapidly than the changes in ionic concentrations on both sides of the 
pump, resulting in a quasi-equilibrium situation in which individual rates are decoupled. The number 
Computational analysis of repolarization variability 
182 | 
of ions transported via each transition was derived from a binomial distribution and the net ion flux 
(or current) in the interval ∆t was determined. 
 
Smith and Crampin have previously described a detailed model of the Na+-K+-ATPase based on a 
consecutive (“ping-pong”) model for Na+ and K+ binding.43 In their model, ‘slippage’ of ions is 
negligible due to a tight coupling between conformational changes of the pump and ion binding, 
thereby ensuring a strict 3 Na+ : 2 K+ stoichiometry. Based on these assumptions and since both 
pumps belong to the family of P-type cation transporters,43 we employed a similar 2-state model 
structure as that used for SERCA. We set the ‘backward’ (counter-clockwise) rates to zero to ensure 
the strict stoichiometry. Forward rates were fitted to reproduce Na+, K+ and Vm dependence of the 
original INaK formulation for both the non-phosphorylated and phosphorylated populations. 
 
Number of channels / transporters 
The appropriate number of channels, pumps or exchangers of each type was estimated based on the 
whole-cell conductance in the model and experimentally-determined single-channel conductance 
(Table 1). It should be noted that N�x represents the maximum number of effective channels that can 
open (i.e., the number of channels open when open probability equals 1.0). There may be additional 
channels in a myocyte that do not open. In particular, if the deterministic formulation of a current x 
is adjusted such that the open probability is halved and the whole-cell conductance is doubled 
(giving the same net current), then N�x as given below would be increased by a factor of 2.0. 
However, because open probability is reduced, the number of channels that participate during the 
AP would not change. 
 
Current # Channels Source 
ICaL N�CaL = 110,000 Based on a single-channel conductance of 3.0 pS (at 2.0 mmol/L extracellular Ca2+ in rat ventricular myocytes.44 Consistent with 
~80,000 channels as in Restrepo et al.36 
ICl(Ca) N�Cl(Ca) = 47,500 Based on a single-channel conductance of 0.91 pS (at 150 mmol/L extracellular Cl- and 5.0 mmol/L intracellular Cl- in canine 
ventricular myocytes.45 
IK1 N�K1 = 15,500 
A single-channel conductance of approximately 30 pS has been 
reported at high (150 mmol/L) [K+]o in a number of species, 
including canine ventricular myocytes.46 Based on a square-root 
dependence of channel conductance on [K+]o, a single-channel 
conductance of approximately 5.0 pS is obtained at physiological 
[K+]o. 
IKr N�Kr = 2,200 Using a single-channel conductance of 2.25 pS as observed in 
mouse47 and rabbit48 ventricular myocytes, after a similar 
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correction as applied for IK1. 
IKs N�Ks = 10,500 
Based on a single-channel conductance of 4.50 pS obtained in 
Xenopus oocytes expressing KCNQ1 and KCNE1.49 There are, to 
the best of our knowledge, no data available from cardiac 
myocytes. Estimates in heterologous expression systems range 
from 0.58 pS50 to 16 pS.51 
IKur N�Kur = 100 Yue et al. determined a single-channel conductance of 20.3 pS in canine atrial myocytes at 5.4 mmol/L [K+]o.52 The low number of channels is consistent with the presence, but very low 
expression of an IKur-like channel in canine ventricle.
53  
INa N�Na = 160,000 Using a single-channel conductance of 20.1 pS as observed in canine, rabbit and guinea-pig ventricular myocytes.54 
INaCa N�NaCa = 2,000,000 Based on a density of 200-400 exchangers per μm2.55 
INaK N�NaK = 10,000,000 Pump-density estimates based on ouabain-sensitive transient currents range between 1000 and 3200 exchangers per μm2  in ventricular myocytes.56 We employ the ratio of approximately 1 
NaCa : 5 NaK that follows from these density estimates. 
IpCa N�pCa = 2,000,000 Assumed to be similar to N�NaCa. 
ITo N�To = 5,900 Based on a single-channel conductance of 13.0 pS as measured by Fedida and Giles in rabbit ventricular myocytes.57 
Irel N�RyR = 1,100,000 RyR density is 10 fold larger than N�CaL, consistent with previously published local control models.36, 39 
Iup N�SERCa = 2,200,000 Assumed to be of similar magnitude as N�RyR. 
Table 1. Number of channels/transporters simulated in the stochastic model. 
 
Experimental recordings in isolated canine ventricular myocytes 
This investigation conformed with the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Animal handling 
was in accordance with the European Directive for the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes (86/609/EU). 
 
Transmembrane APs were recorded from isolated left-ventricular canine midmyocardial myocytes as 
previously described.8, 58 Briefly, the left anterior descending coronary artery was cannulated and 
perfused. After 20 min of collagenase perfusion and subsequent washout of the enzyme, the 
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epicardial surface layer was removed from the LV wedge until a depth of ≥3 mm was reached. 
Softened tissue samples were collected from the midmyocardial layer underneath while 
contamination with the endocardium was avoided. Samples were gently agitated, filtered and 
washed. Cells were stored at room temperature in standard buffer solution. Only quiescent rod-
shaped cells with clear cross-striations were used for the experiments within 48 h of isolation. APs 
were recorded at 37 °C using high-resistance (30–60 MΩ) glass microelectrodes filled with 3 M KCl 
with a microelectrode amplifier (Axoclamp-2B, Axon Instruments, Inc). Intracellular pacing was 
applied at various cycle lengths (CLs; 500 ms – 2000 ms). Only cells showing a stable spike-and-dome 
AP morphology and resting membrane potential were accepted for the experiments. 
 
RESULTS 
 
Stochastic channel gating contributes to BVR 
AP recordings from isolated canine ventricular myocytes showed beat-to-beat variability in APD 
(Figure 3A, top panel) consistent with previous reports.1, 8 In contrast, under physiological 
conditions, APD in the deterministic model converged to a steady-state without APD variability 
(Figure 3A, second panel). In previous research, stochastic processes were simulated using either 
stochastic differential equations,28, 38 or by simulating stochastic state-transitions in the Markov 
models of various ion channels.24, 36, 39 Application of both methodologies to the Markov model of IKr 
resulted in BVR. However, these two approaches showed different temporal dynamics (Figure 3B). 
Poincaré plots of APDi+1 versus APDi have a circular shape under these conditions in experimental 
recordings and simulations with stochastic channel gating, indicating similar magnitudes of short- 
(STV) and long-term variability (LTV; average distance perpendicular to and along the line of identity, 
respectively; Figure 3B, inset). In contrast, BVR in simulations employing stochastic differential 
equations of gating variables (based on a Langevin term) was predominantly long-term, resulting in a 
STV to LTV ratio that was markedly different from experimental recordings (Figure 3C). As such, 
stochastic differential equations do not appear to be suitable to model BVR. All subsequent results 
are from simulations employing stochastic channel gating. 
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Figure 3. Stochastic channel gating contributes to BVR in a computational model of the canine 
ventricular myocyte. A. 5 consecutive APs in a representative canine ventricular midmyocardial cell, 
the deterministic computational model, the model with Langevin IKr formulation, or the model with a 
stochastic Markov formulation of IKr (top to bottom) at 1000-ms pacing CL. APD (ms) is indicated 
below each beat. B. Poincaré plot of 45 consecutive APDs for the conditions in (A). The white circle in 
each panel indicates the steady-state APD of the deterministic model. C. Relative amount of STV 
versus LTV in experiments, with Langevin IKr or with stochastic Markov formulation of IKr. Langevin 
and stochastic Markov formulations resulted in different compositions of BVR. 
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Ionic contributors to BVR in physiological conditions 
 
Figure 4. Contribution of channel density and conductance of individual stochastic ion currents to 
BVR, and rate dependence. A. STV magnitude induced by stochastic channel gating of individual 
currents in an otherwise deterministic model at CL of 500 ms, 1000 ms or 2000 ms. Top panel shows 
5-fold reduction in channel density (with 5-fold increase in single-channel conductance), middle 
panel shows channel density based on estimates from experimental data (Table 1) and bottom panel 
shows 5-fold increase in channel density with reduced single-channel conductance. B. Rate 
dependence of average APD (left), STV (middle) and LTV (right) in experiments and model with 
stochastic gating of all 13 targets combined at 100% channel density. 
 
To obtain insight in the direct contribution of the stochastic gating of ion currents/fluxes to whole-
cell BVR, we performed simulations with stochastic formulations of each individual 
channel/pump/transporter in an otherwise deterministic model at cycle lengths (CLs) of 500, 1000 
and 2000 ms (Figure 4A). The number of channels underlying each current was estimated based on 
experimentally obtained single-channel conductance and whole-cell conductance in the model 
(Table 1). To investigate the sensitivity of this parameter, we simulated normal channel density as 
well as a 5-fold increase or decrease in channel density (offset by a reciprocal change in single-
channel conductance to maintain the same total current). A lower channel density (with larger 
single-channel conductance) resulted in a larger STV for all stochastic simulations. Interestingly, 
Chapter 7 
| 187 
however, a large difference between the impacts of individual ion currents could be observed with 
the largest contribution by INa and IKr to STV under these conditions (Figure 4A). IKs also had a 
substantial impact on BVR, despite its small effect on APD under basal, isolated-myocyte 
conditions,59 consistent with results by Pueyo et al.28 In contrast, pumps and exchangers, which have 
relatively low individual throughput but high expression density,41 contributed little to BVR. In 
general, BVR increased with increasing CL. When all 13 stochastic targets were combined, STV was 
larger than that obtained with any individual stochastic formulation but the results were not 
additive, indicating that certain stochastic fluctuations cancel each-other out. The stochastic model 
showed APD and BVR rate dependence similar to that observed in canine ventricular myocytes 
(Figure 4B), indicating that stochastic channel gating (particularly of INa and IKr channels) is a major 
contributor to the ‘baseline’ BVR observed in physiological conditions. 
 
In addition to a direct impact on Vm fluctuations, stochastic channel gating may modulate STV 
indirectly (e.g., via fluctuations in intracellular ion concentrations which affect other currents). To 
quantify the overall contribution of individual ion currents to BVR in the fully stochastic model, we 
employed the linear regression method recently proposed by Sarkar and Sobie.60 We simulated 300 
parameter sets in which the current density of each of the currents was scaled based on a Gaussian 
distribution with mean 1.0 and standard deviation 0.3. For each parameter set, mean APD, STV and 
LTV were determined at steady-state during pacing at 1000-ms CL (Figure 5). The contribution of 
each current was determined by performing a linear regression on the parameter settings and 
output measures (Figure 5A). Consistent with the results based on the direct stochastic impact 
shown in Figure 4, the linear regression analysis identified major roles for INa and IKr in modulating 
both APD and STV (Figure 5B). In addition, this approach also identified a substantial impact of INaK, 
INaCa and SERCA on STV. Because the stochastic gating of these currents/fluxes did not result in 
significant BVR when simulated in an otherwise deterministic model, it follows that (cell-to-cell) 
variations in the maximal conductance of these targets affect STV via other parameters (e.g., APD, 
intracellular ion concentrations, etc.), which remains to be confirmed experimentally. 
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Figure 5. Contribution of currents to BVR determined via linear regression. A. Relative changes in the 
maximal conductance of the 13 currents/fluxes (lanes correspond to the column-pairs in panel B) for 
100 (out of 300) trials (left panel) and corresponding changes in outputs (APD, STV and LTV) during 
steady-state pacing at CL = 1000 ms (right panel). Middle panel shows the coefficients that indicate 
the contribution of each current to every output measure as determined via linear regression. B. Bar 
plot of the magnitude of the coefficients from panel A regarding their impact on APD (white bars) or 
STV (shaded bars). IKr and INa have a large impact on both APD and BVR, consistent with the results 
from Figure 4. In addition, INaK and Ca
2+ uptake (SERCA) also affect STV. LTV showed similar pattern 
as STV and was not shown for the sake of clarity. For color figure, see page 255. 
 
Zaniboni et al.1 have previously shown that the electrical coupling of two myocytes reduced their 
temporal variability, which was confirmed in the modeling study by Lemay et al.27 When identical 
cells were coupled, the overall temporal variability (coefficient of variance: 100% × std(APD) / 
mean(APD)) in the model was reduced from 2.02% to 1.57%, quantitatively similar to that observed 
by Zaniboni et al. in guinea-pig ventricular myocytes (2.3±1.2% in uncoupled cells vs. 1.5±0.6% in 
Chapter 7 
| 189 
cell-pairs). We observed a slight reduction in BVR (of 0.7 ms) in cell-pairs compared to uncoupled 
cells when two identical cells were coupled (Figure 6A). Gap junction conductance did not influence 
BVR over the range of values that would result in successful propagation in a 1-dimensional strand.61 
Interestingly, Zaniboni et al. also reported that there was an asymmetrical redistribution of APD 
when a cell with a long APD was coupled to a cell with short APD, whereby the long APD shortened 
more than the short APD prolonged.1 We hypothesized that this asymmetrical response may also 
apply to BVR and prolonged APD in one of the two cells through the injection of a constant, 
deterministic current for the duration of the APD (Figure 6B). BVR was larger in the prolonged cell, 
thereby increasing the average BVR. When the two cells were coupled, spatial APD dispersion was 
lost. Although BVR remained larger than that of the regular cell-pair, the decrease in average BVR 
compared to the uncoupled situation was more pronounced (1.0 ms; Figure 6B, inset). These data 
suggest that cell-to-cell coupling not only reduces spatial dispersion of repolarization but may also 
limit excessive BVR of vulnerable regions. As such, conditions in which coupling is reduced (e.g., in 
ischemia) may lead to increased BVR. 
 
 
Figure 6. Effect of cell-to-cell coupling on BVR. A. APD (top panel) and STV (bottom panel) of two 
identical cells for various degrees of electrical coupling. Normal coupling (left vertical dashed line) 
and critical coupling for successful conduction in a one-dimensional strand of virtual myocytes (right 
vertical dashed line) are indicated. B. Similar to panel A for two cells of which one is prolonged via 
current injection. Cell-to-cell coupling causes a mild decrease in average STV that is more 
pronounced in the case of an asymmetrical cell pair. 
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BVR rate dependence 
Recent research has shown that APD reverse rate dependence is an intrinsic property of canine 
cardiac preparations.62 We hypothesized that the reverse rate dependence of BVR (Figure 4B) could 
be due to at least two components: (i) rate-dependent changes in the magnitude of stochastic 
channel gating (“active component”) and/or (ii) dependence on APD and the intrinsic reverse rate-
dependence of APD (“intrinsic component”).62 To investigate the contribution of these components, 
membrane potential and net membrane current (Vm and Im) were recorded for 30 beats at steady 
state and the standard deviation over these 30 beats was determined at each time point. The 
magnitude of Im variation was CL dependent (Figure 7A,B), suggesting a role for the active 
component. Moreover, when the Std(Im)-Vm relationship at 1000-ms CL was used to generate a 
stochastic Im in the deterministic model paced at various CL, BVR rate dependence was blunted 
(Figure 7C) but not eliminated. The remaining BVR rate dependence reflects the intrinsic component 
(i.e., even with the same amount of ‘noise’ BVR is larger at long CL). BVR increased when APD was 
prolonged through injection of a (deterministic) current in either the stochastic model (Figure 7D) or 
the deterministic model with fixed Im stochastics (not shown). Interestingly however, there were no 
clear differences in BVR between CL of 500, 1000 or 2000 ms for any given APD (Figure 7D).  This 
indicated that although both CL dependence of stochastic properties and intrinsic components 
contribute to reverse rate dependence of BVR, the former was also strongly dependent on the 
intrinsically longer APD at slow CL.  
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Figure 7. Role of APD and stochastic gating in BVR reverse rate dependence. A. Magnitude of 
channel gating stochastics (assessed by Std(Im) for 50 beats) over time for CL of 350-4000 ms in the 
fully stochastic model under baseline conditions. B. Rate dependence of total magnitude of Im 
fluctuations (given by area under Std(Im) curve). C. STV rate dependence in the fully stochastic model 
during fixed-CL pacing (solid line) or fixed-DI pacing (dash-dotted line), or in the deterministic model 
during fixed-CL pacing with a CL-independent stochastic term added to Im (dashed line). CL-
independent stochastic behavior results in a blunted STV rate dependence. D. STV vs. APD 
relationship at CLs of 500 ms (dashed line), 1000 ms (dash-dotted line) or 2000 ms (solid line). APD 
was varied through injection of a deterministic stimulus current between -0.1 and 0.1 pA/pF for the 
duration of the AP. 
 
In the chaotic models of Sato et al. beat-to-beat APD differences occur through a steep APD/diastolic 
interval (DI) relationship.25 To assess the importance of restitution for BVR in the absence of EADs, 
we analyzed data from the stochastic model using fixed diastolic interval pacing. An identical BVR/CL 
dependence (determined via CL = mean APD + DI) was obtained with fixed CL and fixed DI pacing 
(Figure 7C), indicating that under these physiological conditions variations in DI do not contribute to 
BVR rate dependence. In agreement with this conclusion, we found only a weak correlation between 
the DI and APD of the following beat in canine ventricular myocytes and simulations (correlation 
coefficients of 0.39±0.06 and 0.15 at 1000-ms CL, respectively; data not shown). 
 
Mechanisms contributing to exaggerated BVR in pathological conditions 
We previously reported that BVR is increased in pharmacological models of long-QT syndrome (LQT) 
type 2 (using the IKr-blocking drug dofetilide) and LQT3 (increased persistent INa due to ATXII) and 
that this BVR could be reduced by β-adrenergic stimulation (βARS). In contrast, in a pharmacological 
LQT1 model, βARS + IKs inhibition (using HMR1556) increased BVR, whereas HMR1556 alone had no 
effect on BVR.8 The model was able to reproduce these experimental findings (Figure 8A,B), 
indicating that it can be employed to study the factors contributing to exaggerated BVR in LQT1-3. 
 
The contribution of both average APD and CL-dependent changes in Im stochastics to BVR rate 
dependence (Figure 7) suggest that the increased BVR observed in pharmacological models of long-
QT syndrome (Figure 8) could be due to APD prolongation and/or alterations in ion-channel gating. 
Similarly, the rescue of BVR by βARS in the LQT2 and LQT3 models could be due solely to a reduction 
in APD or could be due to other factors. To investigate the effect of APD prolongation on BVR, we 
employed a deterministic current injection to reduce average APD back to baseline levels. When APD 
was reduced, BVR also reduced to control values (STV equaled 3.5±0.4, 7.7±1.5 and 3.9±0.6 in 
control, LQT2, and LQT2 with reduced APD, respectively; Figure 9A). In contrast, removing the 
stochastic gating of IKr did not significantly alter BVR (8.1±1.5 ms). 
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Figure 8. BVR in simulated LQT syndromes type 1-3 in the absence or presence of βARS. A. Overlay 
of 30 consecutive APs in the absence (-βARS) or presence (+βARS) of β-adrenergic receptor 
stimulation in control conditions (top-left panel) or simulated LQT1 (top-right panel), LQT2 (bottom-
left panel), or LQT3 (bottom-right panel). Shortest and longest APs are shown in black, intermediate 
APs in grey. A Poincaré plot of the 30 APDs is shown below. B. Quantification of BVR in LQT1-3 at CL 
of 500, 1000 or 2000 ms in the absence or presence of βARS. HMR indicates simulation of the IKs 
blocker HMR1556 (simulated LQT1), Dof simulation of the IKr blocking drug dofetilide (LQT2) and 
ATXII indicates simulations with enhanced persistent INa (LQT3). βARS reduces BVR significantly in 
LQT2 and LQT3, but not in LQT1, consistent with experimental results.8 
 
When STV was plotted against average APD for individual canine ventricular myocytes or individual 
model cells generated based on a Gaussian distribution of conductances (similar to the approach for 
Figure 5A), an exponential relationship was obtained. There was no difference in the parameters for 
the STV vs. APD relationship between experiments and model or between control and LQT2 
conditions (Figure 9B,C). These data indicate that the model is able to quantitatively reproduce 
experimental BVR characteristics covering a range of cell-to-cell differences. Moreover, these data 
suggest that the APD prolongation is the main determinant for the increased BVR in LQT2. 
 
Chapter 7 
| 193 
 
Figure 9. Role of APD in the observed increase in BVR under simulated LQT2 conditions. A. Overlay of 
30 consecutive APs under control conditions, simulated LQT2, simulated LQT2 with deterministic IKr 
or simulated LQT2 with reduced APD due to injection of a deterministic stimulus current. Shortest 
and longest APs are shown in black, intermediate APs in grey. APD, STV and Poincaré plots are 
shown below each overlay. B. STV vs. APD relationship under control conditions (left panel) or LQT2 
conditions (right panel) in individual canine ventricular myocytes (filled symbols) or individual model 
cells (open symbols; based on whole-cell conductances drawn from a Normal distribution, as in 
Figure 5A). Data were fit with a monoexponential function (lines). C. Parameters of the 
monoexponential fits of panel B under control and LQT2  conditions in experiments (grey bars) and 
model (white bars). The model shows a quantitatively similar STV vs. APD relationship as 
experiments and this relationship is not different between control and LQT2 conditions. 
DISCUSSION 
In this study, we developed a novel model of the canine ventricular myocyte electrophysiology 
including stochastic gating of all major ion currents and SR Ca2+ handling processes. The model 
showed APD and BVR rate dependence consistent with experimental data from canine ventricular 
myocytes. Using this model, we obtained the following novel insights into the ionic contributors to 
BVR: i) stochastic channel gating (mainly of INa and IKr) strongly contributes to baseline BVR; ii) BVR is 
more pronounced in cells with a strong plateau than in cells with triangular AP morphology; iii) BVR 
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is reduced by cell-to-cell coupling, particularly in the case when one of the two cells has an increased 
BVR;  iv) the rate dependence of BVR is due to active components and intrinsic components, but not 
dependent on variations in DI; and v) APD prolongation strongly increases BVR but is not the sole 
determinant of exaggerated BVR in drug-related /-induced conditions. 
 
Relation to existing computational models 
Despite the experimental evidence of an important role for BVR as an indicator of proarrhythmic 
risk,2, 63 few computational models to date have incorporated temporal variability of repolarization. 
Wilders and Jongsma were among the first to examine stochastic channel gating in a computational 
cardiac cell model for their investigation of beating-rate variability in sinoatrial node cells.64 
Subsequently, Tanskanen et al. employed a local control model of the canine ventricular myocyte to 
investigate the role of stochastic gating of L-type Ca2+ channels in EAD formation.24 These authors 
also provided a mathematical analysis suggesting/indicating that increased voltage noise skewed the 
distribution of APD towards longer APDs, enhancing the susceptibility to EADs.65 In contrast, Sato et 
al. have shown that the EADs observed in their model of the H2O2-treated rabbit ventricular myocyte 
were chaotic and not due to stochastic fluctuations.26 However, stochastic channel gating resulted in 
an increased variety in temporal dynamics of the chaotic model.25 Pueyo et al. also found that 
stochastic channel gating favored the occurrence of alternans and EAD generation during IKr 
blockade.28 However, both Sato et al and Pueyo et al. only considered stochastic gating of IKs. Lemay 
et al. adapted the Luo-Rudy dynamic model of the guinea-pig ventricular myocyte to investigate the 
role of stochastic gating and protein turnover of a selected number of currents on APD variability 
and intercellular conduction delays under physiological conditions.27 
 
The results presented here provide a significant extension of these previously developed models by 
considering both stochastic gating of all major ion currents (except background currents) and Ca2+ 
handling processes. Moreover, we show that the stochastic model is quantitatively consistent with 
experimental measures of BVR in isolated canine ventricular myocytes and identify contributors to 
BVR in physiological and pathological conditions. 
 
BVR as a proarrhythmic marker 
Beat-to-beat variability of repolarization duration has been proposed as a more reliable 
proarrhythmic marker than prolongation of repolarization per se, at least for specific pathological 
conditions.2-4 However, its exact determinants remain incompletely understood. Our data indicate 
that BVR, determined largely by stochastic channel gating during baseline conditions, is modulated 
by a number of factors that may play a role in arrhythmogenesis. 
 
We find that AP morphology and duration (Figure 6) affect BVR. Increased APD and a pronounced AP 
plateau result in a larger window in which depolarizing and repolarizing currents are in balance, 
creating a vulnerable window in which relatively small fluctuations could induce an EAD which may 
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lead to triggered activity and/or regional dispersion of repolarization. Both Pueyo et al.28 and 
Tanskanen et al.24 have shown that stochastic fluctuations in channel gating (of IKs and ICaL, 
respectively) can indeed facilitate the development of EADs (however, see Sato et al.26). These data 
suggest that BVR reflects the robustness of repolarization and, when exaggerated, the risk of EAD 
development. 
 
In addition to EADs induced by reactivation of ICaL during a prolonged AP plateau, abnormal Ca
2+ 
handling has been shown to be able to induce early- and delayed afterdepolarizations.66 As such, the 
consideration of both stochastic Ca2+ handling and ion-channel gating in the model presented here is 
important. Previous experimental data from our group have shown that buffering of intracellular 
Ca2+ (using BAPTA) can suppress BVR during βARS and IKs blockade in single ventricular myocytes.8 
Furthermore, in a pharmacological LQT2 model in intact rabbit hearts, abnormal Ca2+ handling also 
preceded fluctuations in membrane potential.67 We found no direct contribution of individual Ca2+-
handling proteins to BVR under baseline conditions (Figure 4). However, alterations in Ca2+ 
homeostasis can have a significant impact on BVR, as is evident from the large impact of SERCA on 
STV observed in our regression analysis (Figure 5). Moreover, the strong positive feedback 
characteristics of Ca2+-induced Ca2+ release may amplify stochastic fluctuations within a 
subsarcolemmal microdomain and modulate BVR. Thus, BVR also reflects the stability of the 
intracellular Ca2+-handling system and Ca2+-sensitive currents.  
 
Dispersion of repolarization has been shown to be arrhythmogenic in a variety of conditions.68 Cell-
to-cell coupling is able to suppress both temporal and spatial dispersion of repolarization (Figure 6), 
suggesting that BVR can indicate the degree of (un)coupling of the myocardium. 
 
Combined, these data suggest that BVR reflects both the intrinsic temporal variability (stochastic 
channel gating and Ca2+ handling) as well as the sensitivity of the electrical system to these 
fluctuations (modulated by APD, AP morphology and cell-to-cell coupling). Our results highlight an 
important role for abnormal Ca2+ handling in BVR, consistent with experimental recordings, due to 
the presence of microdomains. Future experimental and computational studies should investigate 
the impact of Ca2+ on BVR at the subcellular level, providing a more extensive validation of local Ca2+ 
release and Ca2+ wave properties. 
 
Limitations and future directions 
Stochastic formulations of all 13 targets were based on the well-validated characteristics of the 
deterministic model12, 22 using the methodology employed in local control models.24, 36, 39 This 
approach allows tracking of single-channel behavior, however a formal validation of single-channel 
characteristics based on dwell times, open probability distributions, etc. is beyond the scope of this 
study. Furthermore, since single-channel recordings are often performed in non-physiological 
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solutions, it would be unclear whether any deviations in single-channel behavior observed in the 
model under these conditions would affect the stochastic properties relevant for BVR.  
 
We estimated the effective number of channels in the model based on experimentally obtained 
single-channel conductance. For several targets, the single-channel conductance or expression 
density is not well constrained. For example, to the best of our knowledge, there are no data on IKs 
single-channel conductance from native tissue, and experimental data from heterologous expression 
systems show considerable variability (Table 1). We performed simulations over a range of channel 
densities to investigate the impact of this parameter (Figure 4). Because single-channel conductance 
has a large impact on BVR (Figure 4), the contribution of these targets may therefore be under- or 
overestimated.  
 
In addition to single channel gating and Ca2+, other factors may modulate BVR. These factors include 
signaling pathways, changes in cell volume and pH, etc. and are beyond the scope of the current 
investigation. Moreover, most of these factors will change on a time scale of minutes, whereas BVR 
reflects the changes in repolarization duration in the order of seconds. Thus, although these factors 
can affect BVR, they are likely to do so via changes in repolarization duration, Ca2+ handling, or 
stochastic channel gating that have been investigated here. 
 
Finally, although the results presented here suggest that BVR reflects a combination of potentially 
proarrhythmic signals at the (sub)cellular level, its role as a marker for arrhythmogenesis can only be 
thoroughly investigated in a large multicellular model. The complexity of the cell model makes this 
computationally prohibitive for the current implementation. Our cell-pair simulations show that cell-
to-cell coupling will reduce but not eliminate BVR. Future studies should investigate the 
synchronization of variability during arrhythmogenesis in a multi-scale model.  
 
Conclusions 
We presented a novel stochastic model of the canine ventricular myocyte electrophysiology showing 
APD and BVR rate dependences consistent with experimental data from isolated canine ventricular 
myocytes under physiological conditions and in pharmacological models of LQT1-3. The model 
provides new insights into the (sub)cellular determinants of BVR and suggests modulating roles for 
several processes, including APD, AP morphology, Ca2+ handling, and cell-to-cell coupling. It provides 
a framework to further our understanding of the potential role that BVR can play as a proarrhythmic 
marker. 
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8.1 INSIGHTS INTO THE ROLE OF β-ADRENERGIC RECEPTOR STIMULATION IN 
ARRHYTHMOGENESIS 
In the studies that led to this thesis we have developed a detailed computational model of the 
canine ventricular myocyte electrophysiology (Chapter 2) and have integrated it with a system of 
localized β-adrenergic receptor stimulation (βARS) and CaMKII signaling (Chapter 3) to obtain a 
better quantitative understanding of the complex local processes linking βARS and 
arrhythmogenesis (Figure 1). We have focused predominantly on the effects of βARS on ventricular 
myocyte electrophysiology and the proarrhythmic marker beat-to-beat variability of repolarization 
(BVR; Figure 1, grey boxes).  
 
The sympathetic nervous system plays a crucial role in the modulation of cardiac output. 
Sympathetic stimulation results in an in increase in chronotropy, inotropy, lusitropy and dromotropy 
as a result of changes in cellular electrophysiology at various levels of the heart. In a number of 
pathological conditions sympathetic stimulation has been associated with an increased 
arrhythmogenic risk.1 The clinical importance of the connection between the autonomic nervous 
system and the heart is further supported by the fact that baroreflex sensitivity testing,2 exercise 
testing3 and epinephrine challenges4 are used for diagnostic stratification in clinical settings. At the 
therapeutic side, β-adrenergic receptor blockade is the mainstay of pharmacological treatment in 
various pathological conditions, and left or bilateral cardiac sympathetic denervation has proven 
valuable in the management of patients with intractable ventricular tachycardia (VT) in long-QT 
syndrome,5 catecholaminergic polymorphic VT,6 and electrical storm by other causes.7, 8  
 
In animal models and experimental preparations, numerous groups have identified 
electrophysiological changes in response to βARS (as part of sympathetic stimulation) that 
contribute to arrhythmogenesis in the predisposed heart.9-13 These studies have highlighted a 
complex network of interacting components linking βARS and arrhythmogenesis at various levels of 
electrophysiological integration (Figure 1).14  
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Figure 1. The effect of βARS on cardiac cellular electrophysiology and arrhythmogenesis. Vertical 
direction represents increasing level of electrophysiological integration from subcellular, 
macromolecular complexes to microdomains, cellular components and integrated tissue / organ. 
Grey boxes reflect focal points of the work presented in this thesis. Numbers 1-6 indicate 
interactions for which significant new insights were obtained (see text). 
 
We have shown in Chapter 3 that localized cAMP signaling is critical for a precise control of the 
phosphorylation status of individual protein kinase A-substrates (#1 in Figure 1). Moreover, localized 
βARS augmented Ca2+/Calmodulin kinase (CaMKII)-dependent signaling via [Ca2+]i, inhibitor protein 1 
and heart rate. These pathways had synergistic effects on cellular Ca2+ handling and spontaneous 
Ca2+ release (SCR) indicating that the link between βARS and arrhythmogenesis is, at least partly, 
mediated by CaMKII (#2 in Figure 1).15-17 
Advanced experimental techniques have facilitated the characterization of βAR signaling at the 
subcellular level, as well as its electrophysiological effects.18, 19 These studies have shown that 
localization of both signaling molecules and ions ensures precise control of substrate 
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phosphorylation. Fluorescent indicators of cyclic AMP (cAMP) targeted to specific subcellular 
domains have shown that there is restricted diffusion of this second messenger which is controlled 
by (caveolar) microdomains incorporating different receptors, adenylyl cyclases, 
phosphodiesterases, etc.20-23 Disruption of these microdomains, e.g., by the cholesterol depleting 
agent methyl-β-cyclodextrin, results in altered electrophysiological responses to βARS compared to 
control conditions.24 Importantly, a similar disruption of local signaling environments was observed 
in pathological conditions. Nikolaev et al. have shown that a redistribution of β2-adrenergic 
receptors occurs during heart failure25 and Kass and coworkers have shown that mutations in 
KCNQ126 or the A-kinase anchoring protein Yotiao27 can disrupt the macromolecular signaling 
complex of the slowly-activating delayed-rectifier K+ current (IKs). In all these conditions there is an 
important role for βARS in arrhythmogenesis. 
 
In Chapter 3, we also quantified the contribution of individual electrophysiological PKA substrates to 
the βARS-dependent alterations in action potential (AP) and Ca2+ transient (#3 in Figure 1). We 
showed, consistent with previous experimental work,28 that IKs has only a minor impact on cardiac 
repolarization under basal, isolated-myocyte conditions. However, during βARS IKs played a major 
role in the shortening of AP duration (APD). Consistent with these observations, we determined that 
the combination of reduced basal IKs and loss of cAMP-dependent IKs upregulation due to the long-
QT syndrome type-1 mutation KCNQ1-A341V results in a pronounced AP phenotype only during 
βARS (Chapter 4). The A341V data further underscored the importance of a correctly functioning 
local macromolecular complex in mediating the coupling between the βARS signaling pathway and 
the electrophysiological response. They provided novel evidence that the S6 transmembrane 
segment of KCNQ1 at and/or around residue A341 plays an important role in the βARS-dependent 
modulation of IKs (#4 in Figure 1). Interestingly, a complete loss of cAMP-dependent IKs upregulation 
was also observed in heterozygous A341V conditions. Moreover, this effect was not unique for 
A341V, since the mutation G589D in the KCNQ1 C-terminus also resulted in a loss of cAMP-
dependent upregulation in heterozygous conditions. This observation has important implications for 
the arrhythmogenic risk of mutation carriers because even a heterozygous genotype will result in a 
homozygous phenotype with respect to cAMP-dependent IKs upregulation. Consistent with this 
important role of IKs during βARS, we found that an intact IKs is required to prevent excessive BVR 
during βARS in isolated canine ventricular myocytes (Chapter 5). 
 
In addition to a direct effect on APD, a decreased function of IKs also reduces the heart’s capabilities 
to withstand additional challenges on repolarization. This ability has previously been termed 
“repolarization reserve” and several studies have shown that IKs provides an important repolarization 
reserve in ventricular myocytes.28-30 This reserve is recruited when the balance between inward and 
outward currents is shifted, for example during pharmacological inhibition of the rapidly-activating 
delayed-rectifier K+ current (IKr).
28 It has long been established that βARS can cause Ca2+ overload, 
SCR and triggered activity (TA). However, in most experimental studies SCR is investigated using a 
rapid-pacing protocol followed by a pause. Consequently, the effect of SCR on the following beat has 
received little attention. In Chapter 6, we provided novel evidence that SCR during regular pacing 
causes interspersed APD prolongation due to a reduced Ca2+-dependent inactivation of the L-type 
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Ca2+ current (ICaL) during the following AP (#5 in Figure 1). The role of IKs in repolarization reserve was 
evident from the fact that the SCR-induced APD prolongation was significantly more pronounced 
during pharmacological IKs blockade. 
 
Several studies have shown that BVR of QT duration is a more reliable proarrhythmic marker than 
QT prolongation per se, at least under specific experimental conditions,31 or in selected human 
subjects.32, 33 The exact ionic mechanisms contributing to BVR under physiological and pathological 
conditions remain incompletely understood, but cellular BVR of APD likely contributes significantly 
to temporal variability of QT duration. Our results (Chapter 7) suggest that cellular BVR reflects 
multiple factors that can contribute to arrhythmogenesis, including AP morphology, APD, Ca2+ 
handling, stochastic ion-channel gating, and cell-to-cell coupling (#6 in Figure 1). This indicates that 
BVR may be a potentially useful proarrhythmic marker but that additional data is required to identify 
the underlying (cellular) pathology and, consequently, optimal pharmacological treatment. 
 
In summary, in this thesis we have provided data that indicate that βARS affects both repolarization 
and Ca2+ handling via localized effects on subcellular targets. In the (severely) predisposed heart, 
these characteristics may increase dispersion of repolarization and triggered activity, resulting in an 
increased susceptibility to ventricular tachyarrhythmias. The βARS-dependent IKs upregulation plays 
a major role in both temporal and spatial dispersion of repolarization during βARS, highlighting a key 
role for IKs in the link between βARS and arrhythmogenesis. 
 
8.2 COMPARISON OF EXISTING CELL MODELS 
In recent years, numerous computational models of cardiac cellular electrophysiology have been 
developed. Although the models of the late 1990s and early 2000s were predominantly 
deterministic common-pool models, most of the recently developed models display mounting 
complexity, focusing on local stochastic aspects of cardiac electrophysiology and/or its regulation by 
signaling cascades. An overview of cellular models including their stochastic, βARS and CaMKII 
properties is provided in Table 1.  
 
ModelReference Species Cell-type Model Type 
Stochastic 
Targets 
CaMKII Targets βARS Targets 
Noble 196234 Generic PF 
Constant 
Concentr. 
- - - 
McAllister et al. 
197535 
Generic PF 
Constant 
Concentr. 
- - - 
Beeler & Reuter 
197736  
Generic VM 
Constant 
Concentr. 
- - - 
Kass & Wiegers 198237 Calf PF 
Constant 
Concentr. 
- - 
Isi, Ix (by 
noradrenaline) 
Rasmusson et al. 
199038, 39 
Bullfrog AM / SAN 
Constant 
Concentr. 
- - - 
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ModelReference Species Cell-type Model Type 
Stochastic 
Targets 
CaMKII Targets βARS Targets 
Liu et al.40 Rabbit AVN 
Constant 
Concentr. 
- - - 
Luo & Rudy 199441, 42 
Guinea-
Pig 
VM 
Common 
Pool 
- - - 
Zeng & Rudy 199543 
Guinea-
Pig 
VM 
Common 
Pool 
- - 
ICaL, IK, INa, INaK, 
PLB 
Courtemanche et al. 
199844 
Human AM 
Common 
Pool 
- - - 
Nygren et al. 199845 Human AM 
Common 
Pool 
- - - 
Winslow et al. 199946 Canine VM (Mid) 
Common 
Pool 
- - - 
Pandit et al. 200147 Rat 
VM 
(Transmural) 
Common 
Pool 
- - - 
Puglisi et al. 200148 Rabbit VM 
Common 
Pool 
- - - 
Greenstein et al. 
200249 
Canine VM (Mid) 
Local 
Control 
ICaL, RyR - - 
Oehmen et al. 200250 Rabbit SAN 
Common 
Pool 
- - - 
Saucerman et al. 
200351 
Rat VM 
Common 
Pool 
- - 
Global 
Signaling ICaL, 
RyR, PLB 
Ten Tusscher et al. 
200452 
Human VM 
Common 
Pool 
- - - 
Bondarenko et al. 
200453 
Mouse VM 
Common 
Pool 
- - - 
Hund & Rudy 200454 Canine VM (Epi) 
Common 
Pool 
- 
Local signaling  
ICaL, RyR, PLB 
 
Saucerman et al. 
200455 
Rabbit 
VM (Multi-
scale) 
Common 
Pool 
- - 
Global signaling 
ICaL, IKs, TnI, 
RyR, PLB 
Shannon et al. 200456 Rabbit VM 
Common 
Pool 
- - - 
Tanskanen et al. 
200557 
Canine VM (Mid) 
Local 
Control 
ICaL, RyR - ICaL, IKs, IKr, PLB 
Terrenoire et al. 
200558 
Guinea-
Pig 
VM 
Common 
Pool 
- - 
Global signaling 
ICaL, IKs,PLB 
Saucerman et al. 
200659 
Rat VM 
Common 
Pool 
- - Local signaling 
Flaim et al. 200660 Canine VM 
Common 
Pool 
- - - 
Iyer et al. 200761 Human VM 
Common 
Pool 
- - ICaL, PLB 
Iancu et al. 200762 - - - - - Local signaling 
Faber et al. 200763 
Guinea-
Pig 
VM 
Common 
Pool 
- - 
ICaL, IK1, IKs, INaK, 
PLB 
Grandi et al. 200764 Rabbit VM 
Common 
Pool 
- ICaL, INa, ITo - 
Fink et al. 200865 Human VM 
Common 
Pool 
- - - 
Kuzumoto et al. 
200866 
Guinea-
Pig 
VM 
Common 
Pool 
- - 
Global signaling 
ICaL, ICTFR, IKs, 
INaK, IpCa, TnI, 
PLB 
Mahajan et al. 200867 Rabbit VM 
Common 
Pool 
- - - 
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ModelReference Species Cell-type Model Type 
Stochastic 
Targets 
CaMKII Targets βARS Targets 
Violin et al. 200868 - - - - - Global signaling 
Xin et al. 200869 - - - - - Global signaling 
Hund et al. 200870 Canine VM (Epi) 
Common 
Pool 
- 
Local signaling 
ICaL, INa, INaL, 
RyR, PLB 
- 
Restrepo et al. 200871 Rabbit VM 
Local 
Control 
ICaL, RyR - - 
Saucerman & Bers 
200872 
Rabbit VM 
Common 
Pool 
- 
Local signaling 
(incl. 
calcineurin) ICaL, 
RyR 
- 
Sato et al. 200973 Rabbit 
VM (Multi-
scale) 
Common 
Pool 
IKs (Langevin) - - 
Maleckar et al. 200974 Human AM 
Common 
Pool 
- - - 
Decker et al. 200975 Canine VM (Epi) 
Common 
Pool 
- RyR, PLB - 
Ahrens-Nicklas et al. 
200976 
Guinea-
Pig 
VM 
(Transmural) 
Common 
Pool 
- - 
Global signaling 
ICaL, IKs 
Koivumaki et al. 
200977 
Mouse VM 
Common 
Pool 
- 
Local signaling 
(incl. 
calcineurin) ICaL, 
RyR, PLB 
- 
Christensen et al. 
200978 
Canine VM (Epi) 
Common 
Pool 
- 
Local signaling 
(incl. oxidation) 
ICaL, INa, INaL, 
RyR, PLB 
- 
Wolf et al. 201079 Mouse VM 
Common 
Pool 
- - ICaL, IKs, PLB 
Grandi et al. 201080 Human VM 
Common 
Pool 
- - - 
Sampson et al. 201081 Canine PF 
Common 
Pool 
- - - 
Hashambhoy et al. 
201082 
Canine VM (Mid) 
Local 
Control 
ICaL, RyR 
Local signaling 
ICaL, RyR, PLB 
- 
Soltis & Saucerman 
201015 
Rabbit VM 
Common 
Pool 
- 
Local signaling 
ICaL, INa, INaL, ITo, 
RyR, PLB 
Global signaling 
ICaL, ICFTR, IKs, 
TnI, RyR, PLB 
Koivumaki et al. 
201183 
Human AM 
Peripheral 
vs. Central 
- - - 
Heijman et al. 201116 Canine VM (Epi) 
Common 
Pool 
- 
Local signaling 
ICaL, IK1, INa, INaL, 
ITo, RyR, PLB 
Local signaling 
ICaL, IKs, IKur, INa, 
INaK, TnI, RyR, 
PLB 
Li & Rudy 201184 Canine PF 
Common 
Pool 
- 
Local signaling 
ICaL, RyR, PLB 
- 
Gaur & Rudy 201185 
Guinea-
Pig 
VM 
Local 
Control 
ICaL, RyR - - 
O’Hara et al. 201186 Human 
VM 
(Transmural) 
Common 
Pool 
- 
Local signaling 
ICaL, INa, INaL, ITo, 
RyR, PLB 
- 
Lemay et al. 201187 
Guinea-
Pig 
VM 
Common 
Pool 
ICaL, IK1, IKr, IKs, 
INa 
- - 
Tao et al. 201188 Rat 
SAN + 
Cardiac 
Neuron 
Common 
Pool 
- - 
Global signaling 
ICaL, If, IKs, Ist, 
RyR, PLB 
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ModelReference Species Cell-type Model Type 
Stochastic 
Targets 
CaMKII Targets βARS Targets 
Grandi et al. 201189 Human AM 
Common 
Pool 
- - 
ICaL, IKs, IKur, INaK, 
TnI, RyR, PLB 
Pueyo et al. 201190 
Guinea 
Pig & 
Human 
VM 
Common 
Pool 
IKs (Langevin) - - 
Heijman et al. 2012 Canine VM (Epi) 
Common 
Pool 
ICaL, ICl(Ca), IK1, 
IKr, IKs, IKur, INa, 
INaCa, INaK, IpCa, 
ITo, RyR, SERCA 
Local signaling 
ICaL, IK1, INa, INaL, 
ITo, RyR, PLB 
Local signaling 
ICaL, IKs, IKur, INa, 
INaK, TnI, RyR, 
PLB 
Table 1. Comparison of stochastic and signaling properties of existing computational myocyte 
models. Models are listed in chronological order. PF: Purkinje-fiber cell, VM: ventricular myocyte, 
SAN: sino-atrial node cell, AM: atrial myocyte, AVN: atrioventricular nodal cell. 
 
The model developed in Chapter 7 of this thesis (last row of Table 1) represents the state-of-the-art 
in cardiac myocyte modeling, integrating both the βARS and CaMKII signaling cascades in a 
compartmental model with stochastic gating of 13 major ion channels and Ca2+ handling proteins. 
The model provides an integration of several important modeling contributions by other groups, 
including:  i) the first integration of βARS signaling and electrophysiology by Saucerman et al.51, 55 ii) 
the first model of localized βARS signaling by Iancu et al.62, 91 iii) the first integration of CaMKII 
signaling and electrophysiology by Hund & Rudy54 and iv) several stochastic properties.57, 71, 85, 87 
Figure 2 also highlights this integration and presents a comparison of a selection of cellular 
computational models of cardiac electrophysiology over time, from 1993-2012. The complexity of 
each model was determined in four categories: i) electrophysiological complexity (quantified by the 
number of state variables); ii) complexity of the stochastic components; iii) complexity of the CaMKII 
components and iv) complexity of the βARS components. For categories ii-iv, the complexity of 
model i is determined by (Nix + 1) ∙ αx, where Nix represents the number of electrophysiological 
targets affected by category x and αx is a scaling factor that is 1.0 in the absence of an underlying 
signaling cascade and 3.0 otherwise. For example, for the Heijman et al. 2011 model (Chapter 3) the 
CaMKII complexity equals 24 (7 targets, with cascade, Table 1) and the stochastic complexity 1 (no 
targets, no local control). To compare the individual categories, each complexity was normalized 
between 0 (for the lowest value among all models) and 1 (for the highest value). The overall 
complexity (Figure 2) represents the average normalized model complexity over the four categories. 
It can be appreciated that in recent years computational cell models of cardiac electrophysiology 
have become increasingly complex and now provide the ability to not only investigate purely 
electrical phenomena but also electromechanical (not shown) and electrophysiological modulation 
by signaling pathways. 
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Figure 2. Comparison of cellular computational models of electrophysiology with a focus on the 
period 2000-2011. Models are identified based on the name of the first author and year of 
publication. Horizontal axis represents time on a logarithmic scale. Vertical axis represents average 
model complexity. Colored circles indentify models containing an integrated βARS cascade (blue), 
CaMKII-signaling cascade (orange) and stochastic electrophysiology (green). Models developed in 
this thesis (indicated with Decker09, Heijman11 and Heijman12 for Chapters 2, 3 and 7, respectively) 
are underlined. For color figure, see page 256. 
 
8.3 APPLICATIONS OF COMPUTATIONAL MODELS OF CARDIAC 
ELECTROPHYSIOLOGY 
8.3.1 Cellular applications 
In this thesis, we have shown that cellular computational models of cardiac electrophysiology are 
powerful tools to extrapolate experimental results (Chapter 4), enabling to make predictions about 
the effect of mutations in the integrated environment of the cardiac myocyte in which multiple ion 
currents interact to shape the AP. Until recently, studies of the arrhythmogenic effects of genetic 
alterations in-situ were primarily performed in transgenic mouse models. Although these models 
have provided seminal insights into different pathologies, their application to electrophysiological 
conditions requires particular care due to the large differences of cardiac electrophysiology between 
mice and humans.92, 93 Recent developments in research on induced pluripotent stem cells (IPS cells) 
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have resulted in alternative electrophysiological preparations based on IPS-derived cardiomyocytes 
that can be used for patient-specific investigations of arrhythmogenesis.94-96 However, these 
preparations are methodologically complex, expensive and time-consuming. More importantly, 
there are still considerable difficulties with IPS-derived cells, including atypical maturation, lack of 
specific control of cell type (atrial versus ventricular versus nodal) and abnormal electrophysiological 
activity (e.g., significant spontaneous/pacemaker activity).97 These aspects may improve over time 
when more advanced methods become available. Computational models remain of paramount 
importance for the extrapolation of altered biophysical properties of an ion channel to changes at 
the level of the cardiac action potential and/or tissue. These insights are important to determine the 
consequences of ion-channel mutations under dynamic conditions and can help to explain 
pleiotropic effects of single mutations. For instance, Clancy and Rudy were among the first to 
employ Markov models of the cardiac Na+ channel to study the 1795insD mutation in SCN5A.98 They 
found that heart rate determined whether this mutation exhibited Brugada syndrome or long-QT 
syndrome type-3 characteristics, extending on earlier experimental observations.99, 100 Moreover, 
these authors as well as several other groups have shown that computational models have utility in 
the field of electropharmacology. Models can be used to predict the optimal characteristics of 
pharmacological agents for specific conditions (e.g., predominant open versus inactivated state 
block of an ion channel101) as well as assist in the drug-discovery process.102-105 
  
Given the limitation that human cardiac preparations are only rarely available for experiments, 
computer models allow for a detailed quantitative investigation of generic, human 
electrophysiological mechanisms by manipulation of individual model components. This ability can 
help to direct further experimental investigations, thereby allowing for a more efficient use of 
experimental resources and is facilitated by the recent human-specific models of the cardiac 
myocyte developed by several groups.80, 83, 86, 89 We have employed our computational model for this 
purpose to study the mechanisms involved in APD prolongation after SCR (Chapter 6). The model 
corroborated preliminary experimental data and specifically identified reduced Ca2+-induced-Ca2+-
release-dependent inactivation of the L-type Ca2+ current as the APD prolonging mechanism. This 
finding was subsequently confirmed in isolated ventricular myocytes under voltage-clamp 
conditions. This example demonstrates that computational modeling studies can lead the way in 
experimental design as well as help to identify arrhythmogenic mechanisms. 
 
In addition to extrapolation and integration of experimental data, computational models can 
quantify the contribution of individual electrophysiological components to whole-cell properties, as 
was done in Chapter 3 for the determinants of localized cAMP signaling, and in Chapter 7 for the 
ionic contributors to BVR. Such an assessment can be performed by the selective inhibition of 
specific components, creating ‘virtual knock-out’ models. An alternative method was recently 
proposed by Sobie and coworkers based on multiple regression.106 In their approach, multiple 
parameter sets (effectively representing individual cells) were simulated and the output variables of 
interest were determined. Thereafter, a regression procedure was used to determine the impact of 
each parameter on the output variables. Such a modeling approach provides an overall picture of 
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the determinants of a given process that is impossible to obtain experimentally since not all 
parameters can be quantified. 
 
8.3.2 Clinical applications 
Despite the important role that computational models have played in basic cardiovascular sciences, 
their direct clinical application is still in its infancy. Indirectly, together with extensive additional 
experimental research, computational models can influence clinical practice by suggesting novel 
therapeutic targets or biomarkers.103 For example, our computational (Chapter 3) and cellular 
experimental (Chapter 6) results, together with data from other groups107 suggest that targeting 
CaMKII could be a promising pathway to reduce Ca2+-dependent arrhythmogenesis, when the right 
pharmacological compound becomes available.108 
 
An extremely interesting direct application of computational models in clinical practice would entail 
(arrhythmogenic) risk stratification of patients based on genotypic and phenotypic information. The 
major challenge is that cardiac pathologies are multifactorial and occur at all levels of 
electrophysiological integrity. Most computational models to date are concerned with cellular 
electrophysiology and as such cannot be applied directly to study arrhythmogenesis in patients, 
which is only visible at the level of the intact organ. However, (sub)cellular properties will likely 
determine the vulnerability of the organ to develop and sustain such arrhythmias. These properties 
can be evaluated in computational models and could in theory be used for risk-stratification 
purposes. However, recent research has indicated that even channelopathies which were originally 
considered monogenic diseases are not truly monogenic.109 Research in large founder populations 
has highlighted a remarkable diversity of clinical phenotypes, despite identical disease-causing 
mutations.110 These results have prompted the investigation of modifier genes that help to explain 
this phenotypic diversity.111-113 Often, these modifiers are common variants in non-protein coding 
regions of a gene, making it extremely difficult to include them in computational models. However, 
in order to accurately predict proarrhythmic risk in an individual patient these risk modifiers will 
have to be taken into account.  
 
Investigating arrhythmogenesis using computational models is even more complex for acquired 
diseases, in which the underlying pathology is diverse, and multiple intrinsic and extrinsic processes 
affect the cellular electrophysiology. In several acquired conditions including heart failure, digitalis 
intoxication and myocardial ischemia, the adrenergic signaling pathway and/or its effects on 
ventricular repolarization are affected, resulting in an increased proarrhythmic risk during 
sympathetic stimulation.114-116 In the general population, these pathological conditions are 
significantly more common than inherited. Cellular models of the electrophysiological effects of 
several acquired conditions, including heart failure,46 hypertension,117 and of cells surviving the 
epicardial borderzone after myocardial infarction,118 have been described. However, to the best of 
our knowledge, none of these models are human-specific or have incorporated the effects of 
sympathetic stimulation. To study sympathetic-triggered arrhythmias in the human heart, these 
models will have to be significantly extended with the functional and structural alterations that 
General discussion 
212 | 
occur under these conditions, including elements such as desensitization of the adrenergic signaling 
cascade,114 regional cardiac hyperinnervation,119 and arrhythmogenic ion-channel remodeling.120   
 
Thus, although there certainly is a clear short-term clinical relevance of computational models via 
the facilitation of drug development and improved understanding of arrhythmogenesis, the 
integration of computational models into daily clinical practice to support diagnostic and therapeutic 
decisions (i.e., “personalized medicine”) will still require a substantial concerted effort of 
multidisciplinary research teams. 
 
8.4 SYSTEMS BIOLOGY 
We consider the work presented in this thesis an example of a systems-biology approach to 
understand arrhythmogenesis at the level of the single cardiac myocyte. Kohl et al.121 stated that 
systems biology “necessarily involves the combined application of ‘reductionist’ and ‘integrationist’ 
research techniques, to allow identification and detailed characterization of the parts, investigation 
of their interaction with one another and with their wider environment, and elucidation of how 
parts and interactions give rise to maintenance of the entity” (Figure 3). Another major 
characteristic of systems biology according to Kohl et al. is that “it makes extensive use of 
mathematical modeling in order to represent and understand complex interactions of parts and 
biological entities.”121 
 
 
Figure 3. “A system as an ‘entity that maintains its existence through the mutual interaction of its 
parts’ (von Bertalanffy, 1968). Systems research must combine the (i) identiﬁcation and (ii) detailed 
characterisation of parts (orange boxes, as opposed to ‘look-alikes’, pale blue box, which need to be 
identiﬁed and excluded), with the exploration of their interactions (iii) with each other (orange 
arrows), and (iv) with the environment (pale blue dashed arrows affecting parts either directly, or 
indirectly through modulation of internal interactions), to develop a (v) systemic understanding (an 
important, but often overlooked, aspect is that the system itself not only enables, but also restricts, 
the type and extent of functions and interactions that may occur; dark-blue box). Systems research 
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therefore requires a combination of reductionist and integrative tools and techniques.” Reproduced 
from Kohl and Noble.122 For color figure, see page 256. 
 
Although several definitions of systems biology exist, we believe that the above definition 
exemplifies an optimal approach to improve understanding and treatment of cardiovascular disease. 
In this thesis, we employed a detailed computational model of the canine ventricular myocyte to 
identify the electrophysiological and signaling components operating during βARS, their interaction, 
and their contribution to the whole-cell response during βARS. This approach could be considered 
the starting point of a “middle-out” approach, in which comprehensive cellular models are extended 
towards the extremes of the spatial scales: from gene to organism.121 
 
8.4.1 Perspectives of computational electrophysiology 
Results such as those presented in this thesis have indicated that local subcellular processes are 
critical for the correct functioning of the heart, particularly during βARS. Recent studies have started 
to combine cellular electrophysiology and molecular dynamics.123 In the future, such models will 
provide an important mechanistic link between genotypes and phenotypes. For example, the 
mechanisms underlying the loss of KCNQ1 phosphorylation in the presence of the S6 mutation 
KCNQ1-A341V (Chapter 4) are currently unclear, but may involve a defective transfer of PKA from 
the C-terminally-bound Yotiao to the N-terminal phosphorylation site. Combined molecular and 
cellular computational models will provide information about the structural alterations due to 
A341V that could contribute to these biophysical alterations. In addition, some ion-channel 
mutations, particularly in the Na+ channel, have been related to macroscopic structural alterations 
including dilated cardiomyopathy.124, 125 The mechanisms relating these electrical and structural 
abnormalities are currently incompletely understood. Future computational modeling studies may 
help to investigate the abnormalities in Na+ homeostasis as well as the downstream signaling effects 
caused by these mutations. 
 
Similarly, there are many branches of the subcellular signaling pathways that require further 
integration in the computational cell models. Of particular interest in this respect are the interaction 
between βARS and CaMKII via the exchange protein activated by cAMP (EPAC)17, 126 and the 
interaction between cAMP and cyclic GMP (cGMP).127 Both EPAC and cGMP have downstream 
effects on protein kinase C which, like PKA, can phosphorylate many electrophysiological targets. 
The complex interplay between these networks will require novel computational approaches 
capable of simulating localized interactions within the cardiac myocyte to identify their role in 
arrhythmogenesis.  
 
On the other hand, in order to apply these models to clinical problems, whole-heart strongly-
coupled electromechanical simulations taking into account spatial heterogeneities in 
electrophysiology and signaling are required. Until now, the majority of computational models were 
General discussion 
214 | 
concerned with the cellular level of cardiac electrophysiology. As computational power has 
increased, recent studies have expanded to multicellular simulations and several groups have 
described whole-heart models of cardiac electrophysiology.128-131 
 
One of the major challenges in biomedical engineering in general and computational cardiac 
electrophysiology in particular, will be to bridge these microscopic and macroscopic worlds. In order 
to do this, both technical and theoretical advances will have to be made. Recently, several groups 
have reported on the use of graphics processing unit-based computations,132 or large multi-
processor systems133 to facilitate multi-scale simulations. In addition, more efficient computational 
techniques to solve the large systems of (partial) differential equations are being developed. Several 
simulation packages for cardiac electrophysiology are available. However, the example given by 
Plank et al.134 in which, using the CARP simulation package, 6.4 hours of CPU time were required to 
simulate 200-ms of electrical activity on a 862,515 node rabbit ventricular mesh using a simple ionic 
model, indicates that significant further improvements in simulation efficiency are required before 
detailed models can be employed at the whole-heart level.  
 
The Virtual Physiological Human (VPH) Initiative has as one of its goals to “understand human 
physiology quantitatively, as a dynamic system, and at all relevant levels between genes and the 
organism”122 and, as such, incorporates the connection of microscopic and macroscopic research 
domains. Recently, well-validated models of the human ventricular80, 86 and atrial83, 89 myocyte 
electrophysiology have been published. Although several structural properties of the human heart 
can be obtained using non-invasive imaging modalities (e.g., magnetic resonance imaging and 
computed tomography scanning),  local endocardial activation maps can only be obtained semi-
invasively using catheter-based mapping techniques. Obtaining direct measurements of epicardial 
activation would require open-chest surgery and, consequently, relatively unphysiological 
conditions. Thus, the validation of whole heart-models will also present a major challenge for future 
research, particularly in the case of human-specific computational models. One promising approach 
could be to employ non-invasive reconstructions of epicardial electrical activity based on 
geometrical information and body-surface maps to validate whole-heart models. This technique, 
termed electrocardiographic imaging (ECGI), has been used successfully to characterize physiological 
and abnormal electrical activity in patients135-137 and has as a major advantage that it can provide a 
continuous reconstruction of electrical activity throughout the entire heart that could be 
superimposed on a whole-heart model employing the same geometrical information. 
 
A comprehensive, systems-biology approach to human cardiac electrophysiology will provide a 
wealth of information that can be employed to improve the risk stratification and (pharmacological) 
treatment of patients at risk for sudden arrhythmic death and less malignant arrhythmias. Detailed 
cell models such as those developed in this thesis provide an important starting point for this 
approach. 
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SUMMARY 
The pump function of the heart is driven by a complex sequence of electrophysiological signals. 
Originating from the sinus node, electrical activation spreads rapidly through the atria. It is delayed 
in the atrioventricular node to allow time for the ventricles to fill with blood, after which the impulse 
travels through the specialized conduction system, initiating synchronized activation (and 
subsequent contraction) of the ventricular muscle. To meet varying demands, cardiac output is 
dynamically modulated by the autonomic nervous system via its effects on the electrophysiology of 
individual cardiac myocytes, including those of the impulse and conduction system. Sympathetic 
stimulation occurs during exercise or as part of the fight-or-flight response, and results in an increase 
in force of contraction, heart rate, rate of relaxation, and conduction velocity (called positive 
inotropy, chronotropy, lusitropy and dromotropy, respectively). In contrast, parasympathetic 
stimulation results in a decrease in these parameters. In a number of cardiovascular diseases, an 
increased sympathetic tone has been associated with the development of potentially lethal 
ventricular tachyarrhythmias. 
 
At the level of the single ventricular myocyte, activation of β-adrenergic receptors by norepinephrine 
released from cardiac sympathetic nerve endings activates an intracellular pathway resulting in 
modulation of a number of ion channels and Ca2+ handling proteins. These changes form the basis of 
the altered electrical and contractile function during sympathetic stimulation.  
 
Computational modeling has proven useful in enhancing our understanding of various components 
of normal cardiac electrophysiology but also arrhythmogenic mechanisms in a variety of pathological 
conditions. However, integrated models of sympathetic stimulation and cardiac electrophysiology 
have only recently become available. In this thesis we employ a combined computational and 
experimental approach to investigate β-adrenergic stimulation and its effects on ventricular 
electrophysiology in physiological and pathological conditions. 
 
Chapter 1 represents a general introduction to this thesis and provides a brief summary of cardiac 
cellular electrophysiology and its modulation by adrenergic stimulation. The single cardiac myocyte is 
a complex entity in which numerous processes interact to modulate the action potential and Ca2+ 
transient. Computational models provide the opportunity to integrate a wide range of experimental 
data and make testable predictions about the effect of various interventions in such complex 
systems. They have been applied successfully since the early 1960s and their use has expanded 
rapidly in the past decade. We provide a historical overview of computational modeling of cardiac 
electrophysiology and highlight recent developments. 
 
In Chapter 2, an improved computational model of the canine epicardial electrophysiology is 
presented. The model, an extension of the Hund-Rudy dynamic model (2004), is able to reproduce a 
wide range of experimentally observed rate-dependent behaviors in the single cardiac myocyte and 
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in tissue, including action potential (AP) duration (APD) adaptation, restitution, and accommodation. 
Our simulations provide valuable insights into the mechanistic basis of rate-dependent phenomena 
important for determining the heart’s response to rapid and irregular rates, such as those occurring 
during arrhythmias. 
 
The electrophysiological model of the canine epicardial muscle cell provides the basis for Chapter 3, 
in which the model is extended with a framework to simulate localized β-adrenergic stimulation and 
its electrophysiological effects through a population-based modeling approach of non-
phosphorylated and phosphorylated substrates. We show that localization of cyclic AMP is critical 
for a specific response of different substrates to stimulate different β-adrenergic-receptor isoforms. 
In addition, we determine the contribution of the different substrates to β-adrenergic-stimulation-
dependent changes in AP and Ca2+ transient in physiological conditions. 
 
The β-adrenergic stimulation model is employed in Chapter 4 to predict the AP changes by the long-
QT syndrome type 1 mutation KCNQ1-A341V.  We provide evidence that this mutation causes a 
dominant-negative reduction in cAMP-dependent upregulation of the slowly-activating delayed-
rectifier K+ current (IKs) on top of a dominant-negative reduction in baseline IKs. Combined, these 
alterations result in pronounced APD prolongation in the presence of β-adrenergic stimulation. The 
loss of cAMP-dependent IKs upregulation in the presence of heterozygous A341V is due to reduced 
phosphorylation of residue S27 and is also present in heterozygous KCNQ1-G589D and KCNQ1-S27A. 
These data provide mechanistic insights into cAMP-dependent regulation of IKs and its role in 
arrhythmogenesis in long-QT syndrome type 1, because heterozygous carriers will exhibit a 
homozygous phenotype with respect to IKs upregulation. 
 
The link between IKs and beat-to-beat variability of repolarization duration in isolated canine 
ventricular myocytes is made in Chapter 5. We show that β-adrenergic stimulation is able to rescue 
the increased variability of repolarization which occurs during blockade of the rapidly-activating 
delayed-rectifier K+ current (IKr) or during augmentation of the late component of the Na
+ current 
(INaL). In contrast, during IKs blockade, beat-to-beat variability of repolarization is only increased 
during β-adrenergic stimulation. The increased variability is sensitive to intracellular Ca2+ and, at 
least partly, mediated by the Na+-Ca2+ exchanger. 
 
In Chapter 6, we identify pronounced APD prolongation following spontaneous Ca2+ release during 
Ca2+ overload induced by β-adrenergic stimulation. This prolongation is exacerbated by 
pharmacological inhibition of IKs, resulting in a pharmacological model of long-QT syndrome type 1. 
The interspersed occurrence of APD prolongation explains the large beat-to-beat variability of 
repolarization observed under these conditions. A combined computational and experimental 
analysis identifies reduced Ca2+-dependent inactivation of the L-type Ca2+ channel after spontaneous 
Ca2+ release as a major contributor to the APD prolongation. 
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In Chapter 7, the β-adrenergic stimulation model is extended with detailed stochastic formulations of 
ion-channel gating to further investigate subcellular mechanisms of beat-to-beat variability of 
repolarization in physiological and pathological conditions. In addition to stochastic channel gating, 
we identify APD, AP morphology and beat-to-beat variations in Ca2+ as major modulators of single-
cell APD variability. Cell-to-cell coupling is able to reduce variability. This model provides a state-of-
the-art tool to investigate cellular electrophysiology, and particularly beat-to-beat variability of 
repolarization, in a wide variety of conditions. 
 
Finally, Chapter 8 contains a general discussion in which the results of these studies are discussed in a 
broader context. We provide potential applications of detailed cellular models of cardiac 
electrophysiology such as those developed for this thesis. The relevance of these models for clinical 
settings and limitations in their applicability are discussed, and we provide our definition of the term 
“systems biology” and its potential for personalized medicine.  
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SAMENVATTING 
De pompfunctie van het hart is het resultaat van een complex samenspel van elektrofysiologische 
signalen. De elektrische activatiegolf verspreidt zich vanuit de sinusknoop snel over de boezems om 
vervolgens te worden vertraagd in de atrioventrikulaire knoop zodat de kamers van het hart tijd 
hebben om te vullen met bloed. Hierna reist de elektrische impuls door het geleidingssysteem en 
zorgt voor een synchrone activatie (en de daaropvolgende contractie) van het spierweefsel in de 
hartkamers. Om aan wisselende energiebehoeften te kunnen voldoen, wordt het hart-minuut-
volume gereguleerd door het onwillekeurige zenuwstelsel via de elektrofysiologische eigenschappen 
van individuele spiercellen, waaronder die van het impuls- en geleidingssyteem. Stimulatie van het 
sympathisch zenuwstelsel, bijvoorbeeld tijdens inspanning of als onderdeel van een ‘vecht-of-vlucht’ 
reactie, resulteert in een toename in contractiekracht, hartfrequentie, relaxatie- en 
geleidingssnelheid (respectievelijk inotropie, chronotropie, lusitropie en dromotropie genaamd). 
Stimulatie van het parasympathisch zenuwstelsel daarentegen resulteert in een afname van deze 
eigenschappen. In een aantal hart- en vaatziekten is er een verband aangetoond tussen een 
toename in sympathische activatie en het ontstaan van potentieel dodelijke kamerritmestoornissen. 
 
Op het niveau van de individuele hartspiercel leidt sympathische stimulatie tot activatie van β-
adrenerge receptoren via norepinefrine dat vrijkomt uit cardiale sympathische zenuwuiteinden. 
Stimulatie van β-adrenerge receptoren activeert een intracellulaire cascade die resulteert in 
veranderingen in de verschillende ionkanalen en eiwitten die de Ca2+-huishouding beïnvloeden. Deze 
veranderingen vormen de basis voor de veranderde elektrische activiteit en contractie tijdens 
sympathische stimulatie. 
 
Computationele modellen hebben sterk bijgedragen aan ons begrip van de verschillende 
componenten die in de elektrofysiologie een rol spelen, waaronder ook het ontstaan van 
ritmestoornissen onder pathologische condities. Computermodellen die in staat zijn om 
sympathische stimulatie en cardiale elektrofysiologie te integreren zijn echter pas zeer recentelijk 
ontwikkeld. In dit proefschrift beschrijven we computationele en experimentele technieken om de 
effecten te bestuderen van β-adrenerge stimulatie op de elektrofysiologische eigenschappen van het 
hart onder normale en pathologische omstandigheden. 
 
Hoofdstuk 1 is de introductie tot dit proefschrift en geeft een korte samenvatting van de cellulaire 
elektrofysiologie van het hart en de veranderingen ten gevolge van adrenerge stimulatie. De 
individuele hartspiercel is een zeer complex systeem. De bij activatie optredende actiepotentiaal en 
Ca2+ golf worden beïnvloed door meerdere processen. Computermodellen stellen ons in staat om 
een grote verscheidenheid aan experimentele gegevens te integreren en verifieerbare 
voorspellingen te doen over het effect van veranderingen in een dergelijk complex systeem. Dit 
soort modellen wordt al succesvol toegepast sinds de jaren ‘60 en in het afgelopen decennium is het 
gebruik ervan sterk toegenomen. We geven een historisch overzicht van computermodellen van de 
elektrofysiologie van het hart en beschrijven de recente ontwikkelingen in dit vakgebied. 
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In Hoofdstuk 2 wordt een nieuw model van de elektrofysiologie van de epicardiale spiercel van het 
hondenhart gepresenteerd. Dit model, een uitbreiding van het Hund-Rudy model (2004), is in staat 
om een grote verscheidenheid aan experimentele frequentie-afhankelijke eigenschappen van 
individuele hartspiercellen na te bootsen. Hieronder vallen adaptatie, restitutie en accommodatie 
van de cardiale actiepotentiaal. De simulaties in dit hoofdstuk bieden nieuwe inzichten in de 
mechanismen die belangrijk zijn voor de respons van het hart tijdens snelle en onregelmatige 
hartritmestoornissen. 
 
Met het model van de epicardiale spiercel als basis wordt in Hoofdstuk 3 een framework 
gepresenteerd om lokale β-adrenerge stimulatie en de gevolgen daarvan voor de cellulaire 
elektrofysiologie te simuleren. Lokaal cyclisch AMP blijkt essentieel te zijn voor een gerichte 
beïnvloeding van individuele eiwitten tijdens stimulatie van verschillende types adrenerge 
receptoren. Daarnaast wordt in dit hoofdstuk de bijdrage bepaald van ieder ionkanaal en eiwit van 
de Ca2+-huishouding aan de veranderingen in actiepotentiaal en Ca2+ golf tijdens β-adrenerge 
stimulatie. 
 
Het β-adrenerge model wordt in Hoofdstuk 4 gebruikt om voorspellingen te doen over de 
actiepotentiaal-veranderingen in patiënten met het lange-QT syndroom type 1 door de genmutatie 
KCNQ1-A341V. We laten zien dat deze mutatie zorgt voor een dominant-negatief effect op zowel de 
basale stroom van het zogenaamde ‘slowly-activating delayed-rectifier’ kaliumkanaal IKs als op de 
cAMP-afhankelijke toename in IKs. Samen zorgen deze veranderingen voor een sterke verlenging van 
de actiepotentiaal tijdens β-adrenerge stimulatie. Het verlies van de cAMP-afhankelijke IKs-toename 
in heterozygote A341V condities komt door een verminderde fosforylatie van aminozuur S27 en 
komt ook voor in de heterozygote mutaties KCNQ1-G589D en KNQ1-S27A. Deze data geven nieuwe 
inzichten in de cAMP-afhankelijke regulatie van IKs en de rol hiervan bij de ontwikkeling van 
ritmestoornissen. 
 
De invloed van IKs op de slag-op-slag veranderingen in repolarisatie in individuele kamerspiercellen 
van het hondenhart wordt onderzocht in Hoofdstuk 5. We laten zien dat adrenerge stimulatie in 
staat is om de toegenomen slag-op-slag variabiliteit in repolarisatie door inhibitie van de 
zogenaamde IKr-stroom of door toename in de late component van de Na
+-stroom te verminderen. 
De slag-op-slag variabiliteit in repolarisatie neemt daarentegen toe tijdens adrenerge stimulatie 
indien IKs geïnhibeerd is. IKs-inhibitie zonder adrenerge stimulatie heeft geen effect op de 
repolarisatievariabiliteit. Deze kan worden gereduceerd door manipulatie van het intracellulaire Ca2+ 
of de Na+-Ca2+ uitwisselaar. 
 
In Hoofdstuk 6 worden de potentiële mechanismen waardoor β-adrenerge stimulatie 
ritmestoornissen opwekt verder onderzocht. Tijdens cellulaire Ca2+-overlading ten gevolge van β-
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adrenerge stimulatie ontstaat het spontane vrijkomen van Ca2+-ionen uit het sarcoplasmatisch 
reticulum dat resulteert in een sterke verlenging van de daaropvolgende actiepotentiaal. Deze 
verlenging neemt toe tijdens farmacologische inhibitie van IKs. De onregelmatige verlenging van de 
actiepotentiaal verklaart de grote slag-op-slag variabiliteit van repolarisatie die onder deze 
omstandigheden kan worden waargenomen. Een combinatie van computationele en experimentele 
analyses toont aan dat een verminderde Ca2+-afhankelijke inactivatie van het L-type Ca2+ kanaal in 
belangrijke mate bijdraagt aan de actiepotentiaal-verlenging. 
 
In Hoofdstuk 7 wordt het β-adrenerge model verder uitgebreid met een gedetailleerde stochastische 
beschrijving van de kinetiek van ionkanalen om de subcellulaire mechanismen van slag-op-slag 
variabiliteit in repolarisatie in fysiologische en pathologische condities verder te onderzoeken. Naast 
stochastische aspecten van ionkanalen, vinden wij belangrijke bijdragen van de actiepotentiaal-
morfologie en -duur, alsmede van veranderingen in intracellulair Ca2+. Elektrische koppeling tussen 
twee cellen is in staat om deze repolarisatievariabiliteit te verminderen. Ons model biedt een state-
of-the-art mogelijkheid om de cellulaire elektrofysiologie, en in het bijzonder de slag-op-slag 
variabiliteit in repolarisatie, te bestuderen onder verschillende omstandigheden. 
 
Tot slot bevat Hoofdstuk 8 een algemene discussie waarin de resultaten van de verschillende studies 
van dit proefschrift in een bredere context worden geplaatst. We beschrijven toekomstige 
mogelijkheden van de gedetailleerde cellulaire computermodellen zoals wij die ontworpen hebben. 
De relevantie van deze modellen voor de kliniek, en hun voornaamste beperkingen, worden 
besproken en we geven onze definitie van de term “systeem-biologie” en haar potentiële rol in 
persoonspecifieke geneeskunde.  
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Chapter 2 - Figure 3 (Page 32). A. Model ICaL current-voltage (I-V) relationship and B. steady-state 
inactivation compared to multiple data sets from canine ventricular cells.11, 12, 19, 24-27 C. ICaL Markov 
model structure. 
 
 
Chapter 2 - Figure 4 (Page 32). A. Model Ito1 I-V curve. B. Time to peak compared to multiple data 
sets from canine left ventricular epicardial cells.13, 21, 28-30 
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Chapter 3 - Figure 1 (Page 52). A. Schematic of the canine ventricular cell model including Ca2+ 
handling, electrophysiology, CaMKII signaling pathway and βAR signaling domains. Substrates 
modulated by PKA phosphorylation are indicated in red. Model CaMKII targets include PLB/Serca 
and RyR. B-D, Detailed schematics of the interactions in the extracaveolar (ECAV; B), cytosolic (CYT; 
C) and caveolar (CAV; D) signaling domains. Abbreviations are defined in the appendix of this thesis. 
Model code is provided in the Research Section of http://rudylab.wustl.edu.    
Color Figures 
244 | 
 
Chapter 3 - Figure 4 (Page 60). The 10 parameters with the smallest (A) and largest (B) impact on the 
mean change in ISO affinity over all substrates. Note different impact scale in (B) for IKs.  
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Chapter 3 - Figure 5 (Page 61). The 10 parameters with the smallest (A) and largest (B) impact on the 
mean change in time to half maximal activation in the presence of 20 nmol/L ISO over all substrates. 
Note different impact scale in (B) for PLB.  
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Chapter 3 - Figure 6 (Page 62). The 10 parameters with the smallest (A) and largest (B) impact on the 
mean change in the amount of desensitization (difference between peak phosphorylation level and 
level after 30 min) in the presence of 20 nmol/L ISO over all substrates. 
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Chapter 3 - Figure 7 (Page 64). Comparison between adenylyl cyclase (AC) properties of model 
(lines) and experimental data (symbols). A. Gs-dependence of AC 5/6 in experiments and model. B. 
Inactivation of AC6 by Gi at various levels of Gs-stimulation in experiments54 and model. No error 
bars provided in experimental source. C. Simulated and measured whole-cell AC activity: (i) at peak 
(red), (ii) after 5 min (green) and (iii) at steady-state (white symbols; black line) in canine ventricular 
myocytes55, 56 (circles, triangles) and Chinese hamster fibroblasts with human β1ARs expressed 
(squares; no error bars provided in experimental source)57.  
 
 
Chapter 3 - Figure 17 (Page 69). Simulated characteristics of PKA phosphorylated (red), CaMKII 
phosphorylated (orange) and non-phosphorylated (black) populations of ICaL. Experimental data are 
shown as symbols, model output as lines. A. Peak I-V relationship.75 B. Voltage dependence of 
steady-state ICaL inactivation.
76 C. Fold increase in peak ICaL I-V with ISO or maximal CaMKII activation 
(left) and shift in peak I-V and midpoint of inactivation (V1/2 Inact; right) during stimulation with ISO 
in model (white) and experiments48, 77, 78 (blue). D. Recovery from inactivation. Inset shows time-
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constants under baseline, ISO or CaMKII conditions based on a mono-exponential fit in model (white 
bars) and canine epicardial myocytes (blue bar).79 E. Time course of ICaL inactivation during a 200 ms 
depolarizing pulse to 0 mV. Inset shows the relative change in time constant of inactivation with 1.0 
μmol/L ISO or maximal CaMKII activation. CaMKII-dependent effects are consistent with 
experiments in rabbit ventricular myocytes.78 
 
 
Chapter 3 - Figure 20 (Page 70). Characteristics of ITo recovery from inactivation at baseline (black), 
with maximal CaMKII activity (orange) or in the presence of 1.0 μmol/L ISO (red; identical to 
baseline). A. Simulated (line) time course of ITo recovery from inactivation (assessed using a double-
pulse protocol to +40 mV for 200 ms from a holding potential of -80 mV) compared to experimental 
data (white circles) from canine ventricular myocytes under baseline conditions.83 B. Comparison of 
model fast and slow recovery time constants (based on a biexponential fit to the data in A). C. 
Validation of the effect of CaMKII on ITo recovery from inactivation in model (white) compared to 
data in rabbit ventricular myocytes acutely overexpressing CaMKII (blue).84 
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Chapter 3 - Figure 22 (Page 71). Concentration-dependent effects of ISO on APD (A; CL = 1000 ms) 
and CaT amplitude (B; CL = 2000 ms) in canine ventricular myocytes (symbols39, 89) and model (lines). 
C. Time course of APD changes during application of 100 nmol/L ISO in 4 canine ventricular myocytes 
(symbols) and model (line). APDs were normalized between 1 (baseline) and 0 (maximal response to 
ISO) to account for baseline cell to cell differences (see also Figure 26). CL = 1000 ms. For 
experimental protocol, see Johnson et al.90 
 
 
Chapter 3 - Figure 28 (Page 78). Contribution of individual substrates to APD and CaT changes in 
response to βAR stimulation at CL = 350 ms. Steady-state AP and CaT are shown in the absence of 
βAR stimulation (black solid line), in the presence of a saturating dose of ISO (gray dashed line), or in 
the presence of βAR stimulation without PKA-dependent phosphorylation (red dashed-dotted line) 
of ICaL, IKs, IKur, or INaK (top two rows; left to right) or without PKA-dependent phosphorylation of INa, 
PLB, RyR or TnI (bottom two rows; left to right). 
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Chapter 3 - Figure 29 (Page 80).  Kinetic changes of IKs due to βARS result in altered gating modes 
and increased available reserve for channel opening. A. APD restitution as function of diastolic 
interval after pacing to steady-state at CL = 2000 ms in the absence (solid black) or presence (dash-
dotted red) of 1.0 μmol/L ISO. B. AP of premature beat at diastolic intervals of 25 ms (left) or 125 ms 
(right). C. CaT corresponding to these APs. D. Corresponding IKs. E. Corresponding zone occupancies 
of IKs channels during the AP. Zone 2 (red) represents the deep closed states, Zone 1 (green) 
represents the closed states adjacent to the open state, termed “available reserve”. Open state 
occupancy is shown in blue on a separate y-axis. Data in the absence of ISO are shown in solid lines, 
data in the presence of ISO in dashed-dotted lines. 
 
Color Figures 
| 251 
 
Chapter 4 - Figure 1 (Page 110). Computational modeling approach. A.a. Schematic overview of the 
structure of a single cell model, including all ion channels, pumps, exchangers, Ca2+-handling 
proteins, Ca2+/Calmodulin-dependent kinase and compartmental βAR signaling pathway, as 
published recently (Chapter 3).14 A.b. Structure of the 17-state Markov model that was fitted to WT 
IKs, heterozygous or homozygous mutant channel characteristics in the absence and presence of βAR 
stimulation. 
 
 
Chapter 4 - Figure 3 (Page 113). Location and conservation of A341 in KCNQ1. A. Multiple sequence 
alignment of the KCNQ1-S6 region with other members of the Kv7.x family and other voltage-gated 
potassium channels. Conserved residues are bold and highlighted in blue, partially conserved 
residues are highlighted in green and red. The conserved K+ selectivity filter and the PAG (in Kv7.x) or 
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PXP (in other Kv channels) hinge motifs are indicated below the alignment. A341 is indicated in red 
and is extremely conserved among all Kv channels. B. Location of A341 in the closed-state tetrameric 
KCNQ1 homology model described by Kang et al.21 Left panel shows top view from the extracellular 
side. Residues F340, A341 and A344 are shown as ‘ball-and-stick’ models. Black arrow indicates the 
viewing direction for the right panel. Right panel shows front view of two KCNQ1-subunits (only S5, 
pore and S6 region are shown). Residues F340 – A344 are shown. Distances between residue A341 
of the right subunit and its two nearest residues are indicated with dashed lines. 
 
 
Chapter 4 - Figure 11 (Page 122). Localization of KCNQ1-WT and KCNQ1-A341V after co-transfection 
of both subunits with KCNE1 and Yotiao. A c-Myc epitope was inserted in the extracellular loop 
between transmembrane segments 1 and 2 of KCNQ1-WT and the KCNQ1-A341V was tagged with 
GFP at the C-terminus. Top-left panel shows a confocal image of KCNQ1-WT obtained with an anti-c-
Myc antibody in a representative CHO cell. Top-right panel shows GFP signal in the same cell. When 
the two signals are overlayed (bottom-left panel), a clear colocalization of WT and A341V KCNQ1 
subunits can be observed at the cell membrane (yellow), confirming “heterozygous” channel 
expression. The bottom-right panel shows the relative signal-intensity profiles of KCNQ1-WT and 
KCNQ1-A341V along the cross-sections at the light-green line. Both signals show increased activity at 
the cell boundaries. The lower-left white scale-bar indicates 10 µm. 
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Chapter 6 - Figure 1 (Page 156). Schematic overview of the computational model of the canine 
ventricular myocyte. Adapted from Heijman et al.23 (Chapter 3). The model was divided into two 
identical domains to simulate the local origin of SCR. Only components on the left side of the model 
are labeled for clarity, identical components are located on the right side. The domains are coupled 
via diffusion of Ca2+ (Idiff,cyt and Idiff,nsr). All other abbreviations are as previously described.
23 
 
Color Figures 
254 | 
Chapter 6 - Figure 3 (Page 159). Occurrence of DADs in canine ventricular myocytes is associated 
with prolongation of subsequent APs and increased BVR. A. APD90 for 75 consecutive beats at 2000-
ms CL at baseline (left panel: I), during wash-in of ISO (middle panel: II) and in the presence of 
HMR1556 and ISO (right panel: III). APDs preceded by a DAD are indicated with filled symbols, APDs 
without DADs depicted by open symbols. Dashed rectangle indicates a set of 5 beats for which cell 
shortening and membrane potential are depicted below. Insets show diastolic potentials at an 
expanded scale. Beats without prior SCR are indicated in black, beats with prior SCR in red. B. 
Membrane potential (top) and [Ca2+]i for four consecutive beats. APD90s are indicated below each AP. 
SCR is indicated with arrows. 
 
 
Chapter 6 - Figure 10 (Page 169). ICaL inactivation is slowed after SCR. A. Voltage-clamp protocol (top 
panel), intracellular Ca2+ (middle panel) and membrane current (bottom panel) in a representative 
canine ventricular myocyte in the presence of HMR1556 + ISO + increased [Ca2+]o (3.6 or 5.0 mmol/L) 
in the absence (black) or presence of prior SCR (red). Right inset shows membrane current at an 
expanded scale. 4-AP (5.0 mmol/L) and BaCl2 (0.1 mmol/L) were used to isolate ICaL. Left inset shows 
model results under similar conditions. B. Quantification of average membrane current integral 
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(shaded area in right inset of panel A) in 6 canine ventricular myocytes in the absence or presence of 
SCR. Prior SCR significantly increases total inward current (*: P<0.05). 
 
 
Chapter 7 - Figure 5 (Page 188). Contribution of currents to BVR determined via linear regression. A. 
Relative changes in the maximal conductance of the 13 currents/fluxes (lanes correspond to the 
column-pairs in panel B) for 100 (out of 300) trials (left panel) and corresponding changes in outputs 
(APD, STV and LTV) during steady-state pacing at CL = 1000 ms (right panel). Middle panel shows the 
coefficients that indicate the contribution of each current to every output measure as determined 
via linear regression. B. Bar plot of the magnitude of the coefficients from panel A regarding their 
impact on APD (white bars) or STV (shaded bars). IKr and INa have a large impact on both APD and 
BVR, consistent with the results from Figure 4. In addition, INaK and Ca
2+ uptake (SERCA) also affect 
STV. LTV showed similar pattern as STV and was not shown for the sake of clarity.  
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Chapter 8 - Figure 2 (Page 209). Comparison of cellular computational models of electrophysiology 
with a focus on the period 2000-2011. Models are identified based on the name of the first author 
and year of publication. Horizontal axis represents time on a logarithmic scale. Vertical axis 
represents average model complexity. Colored circles indentify models containing an integrated 
βARS cascade (blue), CaMKII-signaling cascade (orange) and stochastic electrophysiology (green). 
Models developed in this thesis (indicated with Decker09, Heijman11 and Heijman12 for Chapters 2, 
3 and 7, respectively) are underlined. 
 
Chapter 8 - Figure 3 (Page 212). “A system as an ‘entity that maintains its existence through the 
mutual interaction of its parts’ (von Bertalanffy, 1968). Systems research must combine the (i) 
identiﬁcation and (ii) detailed characterisation of parts (orange boxes, as opposed to ‘look-alikes’, 
pale blue box, which need to be identiﬁed and excluded), with the exploration of their interactions 
(iii) with each other (orange arrows), and (iv) with the environment (pale blue dashed arrows 
affecting parts either directly, or indirectly through modulation of internal interactions), to develop a 
(v) systemic understanding (an important, but often overlooked, aspect is that the system itself not 
only enables, but also restricts, the type and extent of functions and interactions that may occur; 
dark-blue box). Systems research therefore requires a combination of reductionist and integrative 
tools and techniques.” Reproduced from Kohl and Noble.122 
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1. ELECTROPHYSIOLOGICAL MODELS 
1.1 General constants, concentrations and volumes 
Symbol Description Value 
𝑭 Faraday constant 96487 C/mol 
𝑹 Gas constant 8314 J/kmol/K 
𝑻 Temperature 310 °K 
𝐂𝐦 Specific membrane capacitance 1 μF / cm
2 
𝐳𝐂𝐚 Valence of Ca
2+ ion 2 
𝐳𝐂𝐥 Valence of Cl
- ion -1 
𝐳𝐊 Valence of K
+ ion 1 
𝐳𝐍𝐚 Valence of Na
+ ion 1 
𝐍𝐀 Avogrado’s number 6.02214E+23 
Table 1: General constants 
 
Symbol Description Value 
𝐥 Cell length 0.010 cm 
𝐫 Cell radius 0.0011 cm 
𝐀𝐠𝐞𝐨 
Geometric membrane area (2 ∙ π ∙ r2 + 2 ∙ π ∙ r ∙l) 0.767 ∙ 10−4cm2 
𝐑𝐂𝐆 Capacitive to geometric ratio 2 
𝐀𝐜𝐚𝐩 Capacitive membrane area (RCG ∙ Ageo) 1.534 ∙ 10−4 cm2 
𝐕𝐜𝐞𝐥𝐥 Cell volume (π ∙ r2 ∙ l) 3.801 ∙ 10−5μL 
𝐕𝐦𝐲𝐨 Myoplasmic volume (0.68 ∙ Vcell) 2.584 ∙ 10−5μL 
𝐕𝐦𝐢𝐭𝐨 Mitochondrial volume (0.238 ∙ Vcell) 9.047 ∙ 10−6μL 
𝐕𝐉𝐒𝐑 Junctional SR volume (0.0048 ∙ Vcell) 1.820 ∙ 10−7μL 
𝐕𝐍𝐒𝐑 Network SR volume (0.0552 ∙ Vcell) 2.098 ∙ 10−6μL 
𝐕𝐒𝐒,𝐒𝐑 SR subspace volume (0.02 ∙ Vcell) 7.600 ∙ 10−7μL 
𝐕𝐒𝐒,𝐂𝐚𝐋 L-type Ca2+ channel subspace volume (0.002 ∙Vcell) 7.600 ∙ 10−8μL 
Table 2: Geometric properties 
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Symbol Description Value 
�𝐂𝐚𝟐+�
𝐨
 Extracellular Ca2+ concentration 1.800 mmol/L [𝐂𝐥−]𝐨 Extracellular Cl- concentration 100.0 mmol/L [𝐊+]𝐨 Extracellular K+ concentration 5.400 mmol/L [𝐍𝐚+]𝐨 Extracellular Na+ concentration 140.0 mmol/L 
Table 3: Composition of the extracellular solution 
 
The reversal potential for the different currents is determined by their permeability to the ionic 
species, the (varying) intracellular and (constant) extracellular concentrations: 
ECl = −R ∙ TF ∙ log�[Cl−]o[Cl−]i � PNa/K = 0.01833 EKs = R ∙ TF ∙ log�[K+]o + PNa/K ∙ [Na+]o[K+]i + PNa/K ∙ [Na+]i � EK = R ∙ TF ∙ log�[K+]o[K+]i � ENa = R ∙ TF ∙ log�[Na+]o[Na+]i � 
 
1.2 Initial state vector 
# Variable Description Initial 
Applies 
to  
1 Vm Membrane potential (mV) -8.7491E01 Ch. 1-6 
2 [Ca2+]i,tot Ca2+ concentration in myoplasm (mmol/L) 1.3394E-02  
3 [Ca2+]SS Ca2+ concentration in restricted subspace (mmol/L) 2.3413E-02  
4 [Ca2+]SS,CaL Ca2+ concentration in subspace surrounding L-type Ca2+ channel (mmol/L) 2.3413E-02  
5 [Ca2+]JSR Ca2+ concentration in junctional sarcoplasmic reticulum (mmol/L) 6.8659E+00  
6 [Ca2+]NSR Ca2+ concentration in network sarcoplasmic reticulum (mmol/L) 1.1910E+00  
7 CaMKtrap Fraction of CaMKII that has trapped calmodulin 1.7546E-03  
8 [Na+]i Na+ concentration in myoplasm (mmol/L) 6.8909E+00  
9 [Na+]SS Na+ concentration in restricted subspace (mmol/L) 6.8909E+00  
10 [K+]i K+ concentration in myoplasm (mmol/L) 1.4562E+02  
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11 [Cl−]i Cl- concentration in myoplasm (mmol/L) 2.0273E+01  
12 [Cl−]SS Cl- concentration in restricted subspace (mmol/L) 2.0273E+01  
13 IRelNP  Ca2+ release flux from JSR through non-phosphorylated ryanodine receptors 3.6675E-09  
14 mNP INa activation gate for non-phosphorylated channels 6.8172E-03  
15 hNP INa fast inactivation gate for non-phosphorylated channels 9.0163E-01  
16 jNP INa slow inactivation gate for non-phosphorylated channels 9.9709E-01  
17 mL INa,L activation gate 7.0530E-04  
18 hL INa,L inactivation gate 3.6003E-01  
19 ITo,a Activation gate of the 4-AP sensitive transient outward K+ current 1.7687E-05  
20 ITo,if Fast inactivation gate of the 4-AP sensitive transient outward K+ current 9.9798E-01  
21 ITo,is Slow inactivation gate of the 4-AP sensitive transient outward K+ current 9.8747E-01  
22 Xr IKr activation gate 1.2306E-08  
23 i2 ITo,2 inactivation gate 9.9604E-01  
24 CCaLNP  Fraction of NP ICaL channels in closed, non inactivated, non Ca2+ gated mode 1.0000  
25 OCaLNP  Fraction of NP ICaL channels in open, non inactivated, non Ca2+ gated mode 0.0000  
26 CsCaLNP  Fraction of NP ICaL channels in closed, non inactivated, Ca2+ gated mode 0.0000  
27 OsCaLNP  Fraction of NP ICaL channels in open, non inactivated, Ca2+ gated mode 0.0000  
28 CICaLNP  Fraction of NP ICaL channels in closed, inactivated, non Ca2+ gated mode 0.0000  
29 OICaLNP  Fraction of NP ICaL channels in open, inactivated, non Ca2+ gated mode 0.0000  
30 CIsCaLNP  Fraction of NP ICaL channels in closed, inactivated, Ca2+ gated mode 0.0000  
31 OIsCaLNP  Fraction of NP ICaL channels in open, inactivated,  Ca2+ gated mode 0.0000  
32 C1KsNP Fraction of non-phosphorylated IKs channels in closed state 1 9.1141E-01  
33 C2KsNP Fraction of non-phosphorylated IKs channels in closed state 2 8.4395E-02  
34 C3KsNP Fraction of non-phosphorylated IKs channels in closed state 3 2.9306E-03  
35 C4KsNP Fraction of non-phosphorylated IKs channels in closed state 4 4.5228E-05  
36 C5KsNP Fraction of non-phosphorylated IKs channels in closed state 5 2.6175E-07  
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37 C6KsNP Fraction of non-phosphorylated IKs channels in closed state 6 1.1424E-03  
38 C7KsNP Fraction of non-phosphorylated IKs channels in closed state 7 7.9337E-05  
39 C8KsNP Fraction of non-phosphorylated IKs channels in closed state 8 1.8366E-06  
40 C9KsNP Fraction of non-phosphorylated IKs channels in closed state 9 1.4172E-08  
41 C10KsNP Fraction of non-phosphorylated IKs channels in closed state 10 5.3696E-07  
42 C11KsNP Fraction of non-phosphorylated IKs channels in closed state 11 2.4861E-08  
43 C12KsNP Fraction of non-phosphorylated IKs channels in closed state 12 2.8776E-10  
44 C13KsNP Fraction of non-phosphorylated IKs channels in closed state 13 1.1217E-10  
45 C14KsNP Fraction of non-phosphorylated IKs channels in closed state 14 2.5967E-12  
46 C15KsNP Fraction of non-phosphorylated IKs channels in closed state 15 8.7874E-15  
47 O1KsNP Fraction of non-phosphorylated IKs channels in open state 1 9.3722E-16  
48 O2KsNP Fraction of non-phosphorylated IKs channels in open state 2 1.6595E-17  
49 CCaLP  Fraction of P ICaL channels in closed, non inactivated, non Ca2+ gated mode 1.0000  
50 OCaLP  Fraction of P ICaL channels in open, non inactivated, non Ca2+ gated mode 0.0000  
51 CsCaLP  Fraction of P ICaL channels in closed, non inactivated, Ca2+ gated mode 0.0000  
52 OsCaLP  Fraction of P ICaL channels in open, non inactivated, Ca2+ gated mode 0.0000  
53 CICaLP  Fraction of P ICaL channels in closed, inactivated, non Ca2+ gated mode 0.0000  
54 OICaLP  Fraction of P ICaL channels in open, inactivated, non Ca2+ gated mode 0.0000  
55 CIsCaLP  Fraction of P ICaL channels in closed, inactivated, Ca2+ gated mode 0.0000  
56 OIsCaLP  Fraction of P ICaL channels in open, inactivated,  Ca2+ gated mode 0.0000  
57 C1KsP  Fraction of phosphorylated IKs channels in closed state 1 9.5624E-01  
58 C2KsP  Fraction of phosphorylated IKs channels in closed state 2 4.2127E-02  
59 C3KsP  Fraction of phosphorylated IKs channels in closed state 3 6.9597E-04  
60 C4KsP  Fraction of phosphorylated IKs channels in closed state 4 5.1101E-06  
61 C5KsP  Fraction of phosphorylated IKs channels in closed state 5 1.4070E-08  
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62 C6KsP  Fraction of phosphorylated IKs channels in closed state 6 9.0269E-04  
63 C7KsP  Fraction of phosphorylated IKs channels in closed state 7 2.9826E-05  
64 C8KsNP Fraction of phosphorylated IKs channels in closed state 8 3.2850E-07  
65 C9KsP  Fraction of phosphorylated IKs channels in closed state 9 1.2060E-09  
66 C10KsP  Fraction of phosphorylated IKs channels in closed state 10 3.1956E-07  
67 C11KsP  Fraction of phosphorylated IKs channels in closed state 11 7.0390E-09  
68 C12KsP  Fraction of phosphorylated IKs channels in closed state 12 3.8763E-11  
69 C13KsP  Fraction of phosphorylated IKs channels in closed state 13 5.0277E-11  
70 C14KsP  Fraction of phosphorylated IKs channels in closed state 14 5.5374E-13  
71 C15KsP  Fraction of phosphorylated IKs channels in closed state 15 2.9664E-15  
72 O1KsP  Fraction of phosphorylated IKs channels in open state 1 1.1201E-15  
73 O2KsP  Fraction of phosphorylated IKs channels in open state 2 1.6613E-18  
74 mP,PKA INa activation gate for PKA phosphorylated channels 1.2360E-03  
75 hP,PKA INa fast inactivation gate for PKA phosphorylated channels 7.9472E-01  
76 jP,PKA INa slow inactivation gate for PKA phosphorylated channels 9.9123E-01  
77 mP,CaMKII INa activation gate for CaMKII phosphorylated channels 6.8127E-04  
78 hP,CaMKII INa fast inactivation gate for CaMKII phosphorylated channels 8.3805E-01  
79 jP,CaMKII INa slow inactivation gate for CaMKII phosphorylated channels 9.9281E-01  
80 IRelP  Ca2+ release flux from JSR through phosphorylated ryanodine receptors 7.3074E-09  
81 ITo,ifp,CaMKII Fast inactivation gate of the 4-AP sensitive transient outward K+ current for CaMKII phosphorylated 
channels 
9.9798E-01  
82 ITo,isP,CaMKII Slow inactivation gate of the 4-AP sensitive transient outward K+ current for CaMKII phosphorylated 
channels 
9.8747E-01  
 
1.3 Intracellular concentrations: Ca2+ 
1.3.1 HRd2009 version (Chapter 2) d[Ca2+]i,totdt = −��ICa,b + IpCa − 2 ∙ INaCa,i� ∙ ACap ∙ CmzCa ∙ F ∙ Vmyo + Iup ∙ VNSRVmyo − IDiff,Ca ∙ VSS,SRVmyo � 
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BuffCa,ib = �cmdn�������� + [trpn������] − [Ca2+]i,tot + Km,trpn + Km,cmdn BuffCa,ic = Km,trpn ∙ Km,cmdn − [Ca2+]i,tot ∙ �Km,trpn + Km,cmdn�+ �cmdn�������� ∙ Km,trpn + [trpn������]
∙ Km,cmdn BuffCa,id = −Km,trpn ∙ Km,cmdn ∙ [Ca2+]i,tot [Ca2+]i = −BuffCa,ib3 + 23 ∙ ��BuffCa,ib �2 − 3 ∙ BuffCa,ic
∙ cos�13 ∙ cos−1 �9 ∙ BuffCa,ib ∙ BuffCa,ic − 2 ∙ �BuffCa,ib �3 − 27 ∙ BuffCa,id2 ∙ ��BuffCa,ib �2 − 3 ∙ BuffCa,ic �1.5 �� 
 d[Ca2+]ss,totdt = 2 ∙ INaCa,ss ∙ ACap ∙ CmzCa ∙ F ∙ VSS,SR + IRel ∙ VJSRVSS,SR − IDiff,Ca − IDiff,SS BuffCa,ssb = [BSL�����] + [BSR�����] − [Ca2+]ss,tot + Km,BSL + Km,BSR BuffCa,ssc = Km,BSL ∙ Km,BSR − [Ca2+]ss,tot ∙ �Km,BSL + Km,BSR� + [BSL�����] ∙ Km,BSR + [BSR�����] ∙ Km,BSL BuffCa,ssd = −Km,BSL ∙ Km,BSR ∙ [Ca2+]ss,tot [Ca2+]ss = −BuffCa,ssb3 + 23 ∙ ��BuffCa,ssb �2 − 3 ∙ BuffCa,ssc
∙ cos�13 ∙ cos−1 �9 ∙ BuffCa,ssb ∙ BuffCa,ssc − 2 ∙ �BuffCa,ssb �3 − 27 ∙ BuffCa,ssd2 ∙ ��BuffCa,ssb �2 − 3 ∙ BuffCa,ssc �1.5 �� 
 d[Ca2+]ssCaL,totdt = −ICaL ∙ ACap ∙ CmzCa ∙ F ∙ VSS,CaL + IDiff,SS ∙ VSS,SRVSS,CaL BuffCa,ssCaLb = [BSL�����] + [BSR�����]− [Ca2+]ssCaL,tot + Km,BSL + Km,BSR BuffCa,ssCaLc = Km,BSL ∙ Km,BSR − [Ca2+]ssCaL,tot ∙ �Km,BSL + Km,BSR�+ [BSL�����] ∙ Km,BSR + [BSR�����]
∙ Km,BSL BuffCa,ssCaLd = −Km,BSL ∙ Km,BSR ∙ [Ca2+]ssCaL,tot [Ca2+]ssCaL = −BuffCa,ssCaLb3 + 23 ∙ ��BuffCa,ssCaLb �2 − 3 ∙ BuffCa,ssCaLc
∙ cos�13
∙ cos−1 �9 ∙ BuffCa,ssCaLb ∙ BuffCa,ssCaLc − 2 ∙ �BuffCa,ssCaLb �3 − 27 ∙ BuffCa,ssCaLd2 ∙ ��BuffCa,ssCaLb �2 − 3 ∙ BuffCa,ssCaLc �1.5 �� 
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d[Ca2+]JSR,totdt = Itr − IRel BuffCa,JSRb = [CSQN�������]− [Ca2+]JSR,tot + Km,CSQN BuffCa,JSRc = Km,CSQN ∙ [Ca2+]JSR,tot [Ca2+]JSR = −BuffCa,JSRb2 + 12 ∙ ��BuffCa,JSRb �2 + 4 ∙ BuffCa,JSRc  
 d[Ca2+]NSRdt = Iup − Itr ∙ VJSRVNSR 
 
Parameter Value Description Ref 
�cmdn�������� 0.05 mmol/L Maximum Calmodulin concentration  [trpn������] 0.07 mmol/L Maximum Troponin concentration  Km, cmdn 0.00238 mmol/L Affinity of Calmodulin for Ca2+  Km, trpn 0.00050 mmol/L Affinity of Troponin for Ca2+  [BSL�����] 1.124 mmol/L Anionic Ca2+ binding sites on sarcolemma  [BSR�����] 0.047 mmol/L Anionic Ca2+ binding sites on SR  Km,BSL 0.0087 mmol/L Affinity of anionic Ca2+ binding sites on sarcolemma  Km,BSR 0.00087 mmol/L Affinity of anionic Ca2+ binding sites on SR  [CSQN�������] 10.0 mmol/L Maximum Calsequestrin concentration  Km,CSQN 0.800 mmol/L Affinity of Calsequestrin for Ca2+  
 
1.3.2 HRdβARS and HRdβARSStoch version (Chapters 3,4,5,7) 
In addition to PLB phosphorylation, the lusitropic effect of βAR stimulation is also mediated through 
phosphorylation of the inhibitory subunit of troponin (TnI), although the relative contribution of 
each process is still unclear.1, 2 The phosphorylation of TnI results in a 50% increase in Km, thereby 
decreasing myofilament sensitivity. Because our model does not contain a mechanical component, 
TnI phosphorylation only affects Ca2+ handling because of this altered affinity and its effect on the 
Ca2+ buffering property of troponin. The other equations regarding Ca2+ buffering and 
concentrations are identical to those in section 1.3.1. 
Km,trpnNP = 0.0005 mmolL , Km,trpnP = 1.5 ∙ 0.0005 mmolL , Km,cmdn = 0.00238 mmolL  f̂TnIP = fTnIP − 0.67350.9992 − 0.6735 Km,trpn = �1 − f̂TnIP � ∙ Km,trpnNP + f̂TnIP ∙ Km,trpnP  
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BuffCa,ib = �cmdn�������� + [trpn������] − [Ca2+]i,tot + Km,trpn + Km,cmdn BuffCa,ic = Km,trpn ∙ Km,cmdn − [Ca2+]i,tot ∙ �Km,trpn + Km,cmdn�+ �cmdn�������� ∙ Km,trpn + [trpn������]
∙ Km,cmdn BuffCa,id = −Km,trpn ∙ Km,cmdn ∙ [Ca2+]i,tot [Ca2+]i = −BuffCa,ib3 + 23 ∙ ��BuffCa,ib �2 − 3 ∙ BuffCa,ic
∙ cos�13 ∙ cos−1 �9 ∙ BuffCa,ib ∙ BuffCa,ic − 2 ∙ �BuffCa,ib �3 − 27 ∙ BuffCa,id2 ∙ ��BuffCa,ib �2 − 3 ∙ BuffCa,ic �1.5 �� 
 
1.3.3 HRdβARS SCR version (Chapter 6) 
The HRdβARS equations (section 1.3.2) were extended to simulate two identical Ca2+ domains with 
Ca2+ diffusion between NSR and cytosolic domains. The superscript symbol x is used to designate one 
of the two identical Ca2+ domains. Whole-cell concentrations / currents are defined as the average of 
both domains and are indicated without superscript x. 
IDiff,cytx = [Ca2+]iy − [Ca2+]ixτDiff,cyt , τDiff,cyt = 1.00 ms, y: other Ca2+ domain IDiff,nsrx = [Ca2+]NSRy − [Ca2+]NSRxτDiff,nsr , τDiff,nsr = 25.0 ms, y: other Ca2+ domain d[Ca2+]i,totxdt = −��ICa,bx + IpCax − 2 ∙ INaCa,ix � ∙ Acap ∙ CmzCa ∙ F ∙ Vmyo + Iupx ∙ VNSRVmyo − IDiff,Cax ∙ VSS,SRVmyo − IDiff,cytx � d[Ca2+]NSRxdt = Iupx − Itrx ∙ VJSRVNSR + IDiff,nsrx  
 
1.4 Intracellular concentrations: Cl- 
1.4.1 HRd2009, HRdβARS and HRdβARSStoch version (Chapters 2-7) d[Cl−]idt = −�ICl,b ∙ ACap ∙ CmzCl ∙ F ∙ Vmyo − CTNaCl − CTKCl − IDiff,Cl ∙ VSS,SRVmyo � d[Cl−]ssdt = −�ICl(Ca) ∙ ACap ∙ CmzCl ∙ F ∙ VSS,SR + IDiff,Cl� 
 
1.5 Intracellular concentrations: K+ 
1.5.1 HRd2009, HRdβARS and HRdβARSStoch version (Chapters 2-7) d[K+]idt = −�(IK1 + IKr + IKs + IKur + ITo + Istim − 2 ∙ INaK) ∙ ACap ∙ CmzK ∙ F ∙ Vmyo − CTKCl� 
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1.6 Intracellular concentrations: Na+ 
1.6.1 HRd2009, HRdβARS and HRdβARSStoch version (Chapters 2-7) d[Na+]idt = −��INa + INa,b + INaL + 3 ∙ INaK + 3 ∙ INaCa,i� ∙ ACap ∙ CmzNa ∙ F ∙ Vmyo − CTNaCl − IDiff,Na ∙ VSS.SRVmyo � d[Na+]ssdt = −�3 ∙ INaCa,ss ∙ ACap ∙ CmzNa ∙ F ∙ VSS,SR + IDiff,Na� 
 
1.7 Co-transporters (CTNaCl and CTKCl) 
1.7.1 HRd2009, HRdβARS and HRdβARSStoch version (Chapters 2-7) 
Background Na+ current (INab) and co-transporter fluxes were required to maintain a resting [Na
+]i 
concentration consistent with measurements in canine epicardial myocytes.3 K+-Cl- (CTKCl) and Na
+-Cl- 
(CTNaCl) cotransporter formulations were based on those in the original HRd model,
4 with modified 
density. 
CT����NaCl = 2.461 ∙ 10−5 mmolL ∙ ms , CT����KCl = 1.770 ∙ 10−5 mmolL ∙ ms CTNaCl = CT����NaCl ∙ (ENa − ECl)4(ENa − ECl)4 + 87.834 CTKCl = CT����KCl ∙ EK − EClEK − ECl + 87.83  
1.8 Background Ca2+ current (ICa,b) 
1.8.1 HRd2009, HRdβARS and HRdβARSStoch version (Chapters 2-7) 
The formulation for the background calcium current is equivalent to that in the original HRd model.4 PCa,b = 1.9950 ∙ 10−7  cms , γCa,i = 1.0, γCa,o = 0.341 
ICa,b = PCa,b ∙ (zCa)2 ∙ Vm ∙ F2R ∙ T ∙ γCa,i ∙ [Ca2+]i ∙ exp �zCa ∙ Vm ∙ FR ∙ T� − γCa,o ∙ [Ca2+]oexp �zCa ∙ Vm ∙ FR ∙ T� − 1   
1.9 L-type Ca2+ current (ICaL) 
1.9.1 HRd2009 version (Chapter 2) 
A Markov model of ICaL was developed and fit to data from canine left ventricular epicardial 
myocytes wherever possible. The structure of the ICaL Markov model is shown in Figure 3C of 
Chapter 2. Activation is voltage dependent (α and β transitions). In Ca2+ free conditions, inactivation 
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and recovery from inactivation are voltage dependent (x and y transitions), with constants fit to data 
on inactivation5 and recovery from inactivation6 using Ba2+ in canine ventricular myocytes. Elevation 
of Ca2+ in a local subspace ([Ca2+]SS,CaL)) moves channels from the Ca
2+-free gating tier to an upper tier 
(θ and δ transitions) characterized by accelerated inactivation (x* and y* transitions). This structure 
reflects the hypothesis that Ca2+ binding to calmodulin removes a “brake” and speeds up ICaL voltage 
dependent inactivation.7, 8 [Ca2+]SS,CaL elevation depends on ICaL Ca
2+ entry and diffusion of Ca2+ (Idiff,SS) 
after SR Ca2+-induced Ca2+ release. This phenomenological approach allows reproduction of slowed 
ICaL Ca
2+ dependent inactivation when SR function is blocked or intracellular Ca2+ buffering is high. 
Model ICaL I-V curve is compared to several experimental data sets from canine ventricular cells
5, 9-13 
(Figure 3A of Chapter 2. The Rubart I-V curve data11 was chosen for fitting because it falls in the 
middle range of data recorded at body temperature. Model ICaL steady state inactivation is compared 
to multiple experimental data sets in Figure 3B of Chapter 2. The Szabo steady state inactivation 
data13 chosen for model fitting has a slope and V1/2 consistent with multiple experiments from 
canine ventricle at body temperature.10, 11, 13, 14 ICaL steady state inactivation data with lesser degrees 
of inactivation at steady state11 resulted in model APD outside the range observed in canine 
experiments. 
ACTτ = 0.59 + 0.8 ∙ exp�0.052 ∙ (Vm +  13)�1 + exp�0.132 ∙ (Vm +  13)� ACT∞ = 11 + exp �−Vm −  13.569.45 � 
αCa,L = ACT∞ACTτ , βCa,L = 1 − ACT∞ACTτ  IV,τ = 1124.828 ∙ �1 + exp�(Vm + 49.10)/10.349�� + 130.553 ∙ �1 + exp(−(Vm + 0.213)/10.807)� IV,∞ = 11.25 ∙ �0.25 + 11 + exp�(Vm + 17.5)/3�� xCa,L = IV,∞IV,τ , yCa,LNP = 1 − IV,∞IV,τ  IsCa = 25 − 17.51 + �3.000 ∙ 10−3[Ca2+]SS,CaL �4 IsV,τ = 1124.828 ∙ �1 + exp�(Vm + 49.10)/10.349��+ 1IsCa ∙ �1 + exp(−(Vm + 0.213)/10.807)� IsV,∞ = 11.0001 ∙ �0.0001 + 11 + exp�(Vm + 17.5)/3�� xsCa,L = IsV,∞IsV,τ , ysCa,L = 1 − IsV,∞IsV,τ  
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δCa,L = 31 + �3.000 ∙ 10−3[Ca2+]SS,CaL�4 , θCa,L = 1 
θICa,L = 1.0 ∙ 10−6, δICa,L = θICa,L ∙ xCa,L ∙ ysCa,L ∙ δCa,LyCa,L ∙ xsCa,L ∙ θCa,L  
 dCCaLdt = −�αCa,L + δCa,L + yCa,L� ∙ CCaL + βCa,L ∙ OCaL + θCa,L ∙ CsCaL + xCa,L ∙ CICaL dOCaLdt = −�βCa,L + δCa,L + yCa,L� ∙ OCaL + αCa,L ∙ CCaL + θCa,L ∙ OsCaL + xCa,L ∙ OICaL dCsCaLdt = −�αCa,L + θCa,L + ysCa,L� ∙ CsCaL + δCa,L ∙ CCaL + βCa,L ∙ OsCaL + xsCa,L ∙ CIsCaL dOsCaLdt = −�βCa,L + θCa,L + ysCa,L� ∙ OsCaL + δCa,L ∙ OCaL + αCa,L ∙ CsCaL + xsCa,L ∙ OIsCaL dCICaLdt = −�αCa,L + δICa,L + xCa,L� ∙ CICaL + yCa,L ∙ CCaL + θICa,L ∙ CIsCaL + βCa,L ∙ OICaL dOICaLdt = −�βCa,L + δICa,L + xCa,L� ∙ OICaL + yCa,L ∙ OCaL + θICa,L ∙ OIsCaL + αCa,L ∙ CICaL dCIsCaLdt = −�αCa,L + θICa,L + xsCa,L� ∙ CIsCaL + δICa,L ∙ CICaL + ysCa,L ∙ CsCaL + βCa,L ∙ OIsCaL dOIsCaLdt = −�βCa,L + θICa,L + xsCa,L� ∙ OIsCaL + δICa,L ∙ OICaL + ysCa,L ∙ OsCaL + αCa,L ∙ CIsCaL 
 PCa,L = 1.5552 ∙ 10−4  cms , γCa,i = 1.0, γCa,o = 0.341 
IC̅a,L = PCa,L ∙ (zCa)2 ∙ Vm ∙ F2R ∙ T ∙ γCa,i ∙ [Ca2+]SS,CaL ∙ exp �zCa ∙ Vm ∙ FR ∙ T� − γCa,o ∙ [Ca2+]oexp �zCa ∙ Vm ∙ FR ∙ T� − 1  ICa,L = IC̅a,L ∙ �OCaL + OsCaL� 
 
1.9.2 HRdβARS version (Chapters 3-5) 
The cardiac L-type Ca2+ channel is modulated through multiple pathways including phosphorylation 
by PKA. It plays a major role in the inotropic effect of βAR stimulation. Both the α and β subunits of 
the channel contain potential phosphorylation sites but the exact role of each subunit in mediating 
the PKA-dependent effects remains an area of active investigation.15, 16 At the level of the channel, 
phosphorylation results in a mode of gating characterized by more frequent, longer lasting channel 
openings.17, 18 The macroscopic effect in the (canine) ventricular myocyte is a 3-4 fold increase in 
peak ICaL, a 10-15 mV leftward shift in the activation I-V relationship and a 10 mV leftward shift in the 
inactivation I-V relationship.19, 20 These characteristics are all reproduced by the phosphorylated 
version of the eight state Markov model that was adapted based on the baseline model.21 
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Furthermore, it has been shown that βAR stimulation shifted the inactivation of L-type Ca2+ channels 
from largely voltage-dependent to mainly Ca2+-dependent.22 This is incorporated in our model by 
increasing the rate from the lower to the upper, Ca2+ controlled tier such that, upon activation, more 
channels reside in this upper tier of the Markov model during βAR stimulation compared to baseline 
conditions. Namiki et al. performed a detailed analysis of the time-course of recovery from 
inactivation of ICaL in adult and newborn rabbit ventricular myocytes.
23 They concluded that, in the 
presence of Ca2+ buffers EGTA or BAPTA, Forskolin did not alter ICaL recovery from inactivation in 
adult myocytes, although with the perforated patch technique differences were seen. These 
differences are likely due to altered [Ca2+]I and/or CaMKII (see below), and not due to direct PKA 
dependent phosphorylation (since they were not present with EGTA or BAPTA). As such, ICaL recovery 
from inactivation is identical in non-phosphorylated and PKA-phosphorylated populations. 
 
The ICaL formulation for both populations was extended to include CaMKII-dependent alterations in 
channel kinetics based on a previous computational model.24 Parameters were chosen to obtain a 
30% increase in peak ICaL and slowed Ca
2+-dependent inactivation during maximal CaMKII activation 
under baseline conditions, consistent with experimental observations in rabbit ventricular 
myocytes.25 In addition, CaMKII-phosphorylated ICaL channels were modeled with accelerated 
recovery from inactivation, consistent with several experimental studies that showed slowed 
recovery of inactivation with pharmacological26 or genetic27, 28 CaMKII inhibition. The time constant 
of diffusion between the subspace (SS) and L-type Ca2+ channel subspace (SSICaL) was increased to 
have a larger contribution of SR-Ca2+ release to Ca2+-dependent inactivation of ICaL, consistent with 
experimental results in rabbit ventricular myocytes7. Ca2+-dependent inactivation of ICaL also plays a 
major role in APD responses during altered Ca2+-cycling. For example, Grandi et al. show that Ca2+-
dependent inactivation is critical for the APD shortening observed when extracellular Ca2+ is 
increased.29 Papp et al. show that an increased CaT (as a result of caffeine-induced Ca2+ release from 
the SR) corresponds to a reduced APD, whereas the subsequent APD in the presence of a small CaT 
is prolonged.30 The model presented here is able to qualitatively reproduce these experimental 
observations. Baseline ICaL parameters were adjusted such that rate-dependent APD and CaT 
properties and ICaL I-V characteristics validated in the baseline model
21 remain intact. 
 
Nonphosphorylated Channels: ACTτ = 0.59 + 0.8 ∙ exp�0.052 ∙ (Vm +  13)�1 + exp�0.132 ∙ (Vm +  13)� ACT∞NP = 1
�1 + exp �−Vm −  13.569.45 �� ∙ �1 + exp �−Vm + 255 �� 
αCa,LNP = ACT∞NPACTτ , βCa,LNP = 1 − ACT∞NPACTτ  IV,τNP = 1170.0 ∙ �1 + exp�(Vm + 49.10)/10.349��+ 126.553 ∙ �1 + exp(−(Vm + 0.213)/10.807)� 
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IV,∞NP = 11.2474 ∙ �0.2472 + 11 + exp�(Vm + 17.5)/3�� xCa,LNP = IV,∞NPIV,τNP , yCa,LNP = 1 − IV,∞NPIV,τNP  
∆τCa,CaMK = 5.0 ∙ fICaLP,CaMKII IsCaNP = 13.825 − 6.3836 − ∆τCa,CaMK1 + �1.100 ∙ 10−3[Ca2+]SS,CaL �4 −
3.36961 + �1.200 ∙ 10−2[Ca2+]SS,CaL �10 IsV,τNP = 1170.0 ∙ �1 + exp�(Vm + 49.10)/10.349�� + 1IsCaNP ∙ �1 + exp(−(Vm + 0.213)/10.807)� IsV,∞NP = 11.001 ∙ �0.001 + 11 + exp�(Vm + 17.5)/3�� xsCa,LNP = IsV,∞NPIsV,τNP , ysCa,LNP = 1 − IsV,∞NPIsV,τNP  
δCa,LNP = 14.91861 + �1.100 ∙ 10−3[Ca2+]SS,CaL�4 , θCa,L = 1 
θICa,L = 1.0 ∙ 10−6, δICa,LNP = θICa,L ∙ xCa,LNP ∙ ysCa,LNP ∙ δCa,LNPyCa,LNP ∙ xsCa,LNP ∙ θCa,L  
 dCCaLNPdt = −�αCa,LNP + δCa,LNP + yCa,LNP � ∙ CCaLNP + βCa,LNP ∙ OCaLNP + θCa,L ∙ CsCaLNP + xCa,LNP ∙ CICaLNP  dOCaLNPdt = −�βCa,LNP + δCa,LNP + yCa,LNP � ∙ OCaLNP + αCa,LNP ∙ CCaLNP + θCa,L ∙ OsCaLNP + xCa,LNP ∙ OICaLNP  dCsCaLNPdt = −�αCa,LNP + θCa,L + ysCa,LNP � ∙ CsCaLNP + δCa,LNP ∙ CCaLNP + βCa,LNP ∙ OsCaLNP + xsCa,LNP ∙ CIsCaLNP  dOsCaLNPdt = −�βCa,LNP + θCa,L + ysCa,LNP � ∙ OsCaLNP + δCa,LNP ∙ OCaLNP + αCa,LNP ∙ CsCaLNP + xsCa,LNP ∙ OIsCaLNP  dCICaLNPdt = −�αCa,LNP + δICa,LNP + xCa,LNP � ∙ CICaLNP + yCa,LNP ∙ CCaLNP + θICa,L ∙ CIsCaLNP + βCa,LNP ∙ OICaLNP  dOICaLNPdt = −�βCa,LNP + δICa,LNP + xCa,LNP � ∙ OICaLNP + yCa,LNP ∙ OCaLNP + θICa,L ∙ OIsCaLNP + αCa,LNP ∙ CICaLNP  dCIsCaLNPdt = −�αCa,LNP + θICa,L + xsCa,LNP � ∙ CIsCaLNP + δICa,LNP ∙ CICaLNP + ysCa,LNP ∙ CsCaLNP + βCa,LNP ∙ OIsCaLNP  dOIsCaLNPdt = −�βCa,LNP + θICa,L + xsCa,LNP � ∙ OIsCaLNP + δICa,LNP ∙ OICaLNP + ysCa,LNP ∙ OsCaLNP + αCa,LNP ∙ CIsCaLNP  
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PCa,L/NP = 1.5552 ∙ 10−4 ∙ �1 + 0.4 ∙ fICaLP,CaMKII� cms , γCa,i = 1.0, γCa,o = 0.341 
IC̅a,LNP = PCa,L/NP ∙ (zCa)2 ∙ Vm ∙ F2R ∙ T ∙ γCa,i ∙ [Ca2+]SS,CaL ∙ exp �zCa ∙ Vm ∙ FR ∙ T� − γCa,o ∙ [Ca2+]oexp �zCa ∙ Vm ∙ FR ∙ T� − 1  ICa,LNP = IC̅a,LNP ∙ �OCaLNP + OsCaLNP � 
 
Phosphorylated Channels: ACT∞P = 1
�1 + exp �−Vm −  −4.7987.5699 �� ∙ �1 + exp �−Vm + 255 �� 
αCa,LP = ACT∞PACTτ , βCa,LP = 1 − ACT∞PACTτ  IV,τP = 1170.0 ∙ �1 + exp�(Vm + 49.10)/10.349��+ 130 ∙ �1 + exp(−(Vm + 0.213)/10.807)� IV,∞P = 11.100 ∙ �0.100 + 11 + exp�(Vm + 29.979)/3.1775�� xCa,LP = IV,∞PIV,τP , yCa,LP = 1 − IV,∞PIV,τP  
∆τCa,CaMK = 0.1 ∙ fICaLP,CaMKII IsCaP = 32.5 − 18.0 − ∆τCa,CaMK1 + � 0.002[Ca2+]SS,CaL�4 −
10.01 + � 0.010[Ca2+]SS,CaL�10 IsV,τP = 1170.0 ∙ �1 + exp�(Vm + 49.10)/10.349�� + 1IsCaP ∙ �1 + exp(−(Vm + 0.213)/10.807)� IsV,∞P = 11.0001 ∙ �0.0001 + 11 + exp�(Vm + 29.979)/3.1775�� xsCa,LP = IsV,∞PIsV,τP , ysCa,LP = 1 − IsV,∞PIsV,τP  
δCa,LP = 6.0001 + � 0.002[Ca2+]SS,CaL�4  δICa,LP = θICa,L ∙ xCa,LP ∙ ysCa,LP ∙ δCa,LPyCa,LP ∙ xsCa,LP ∙ θCa,L  
 dCCaLPdt = −�αCa,LP + δCa,LP + yCa,LP � ∙ CCaLP + βCa,LP ∙ OCaLP + θCa,L ∙ CsCaLP + xCa,LP ∙ CICaLP  
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dOCaLPdt = −�βCa,LP + δCa,LP + yCa,LP � ∙ OCaLP + αCa,LP ∙ CCaLP + θCa,L ∙ OsCaLP + xCa,LP ∙ OICaLP  dCsCaLPdt = −�αCa,LP + θCa,L + ysCa,LP � ∙ CsCaLP + δCa,LP ∙ CCaLP + βCa,LP ∙ OsCaLP + xsCa,LP ∙ CIsCaLP  dOsCaLPdt = −�βCa,LP + θCa,L + ysCa,LP � ∙ OsCaLP + δCa,LP ∙ OCaLP + αCa,LP ∙ CsCaLP + xsCa,LP ∙ OIsCaLP  dCICaLPdt = −�αCa,LP + δICa,LP + xCa,LP � ∙ CICaLP + yCa,LP ∙ CCaLP + θICa,L ∙ CIsCaLP + βCa,LP ∙ OICaLP  dOICaLPdt = −�βCa,LP + δICa,LP + xCa,LP � ∙ OICaLP + yCa,LP ∙ OCaLP + θICa,L ∙ OIsCaLP + αCa,LP ∙ CICaLP  dCIsCaLPdt = −�αCa,LP + θICa,L + xsCa,LP � ∙ CIsCaLP + δICa,LP ∙ CICaLP + ysCa,LP ∙ CsCaLP + βCa,LP ∙ OIsCaLP  dOIsCaLPdt = −�βCa,LP + θICa,L + xsCa,LP � ∙ OIsCaLP + δICa,LP ∙ OICaLP + ysCa,LP ∙ OsCaLP + αCa,LP ∙ CIsCaLP  
 PCa,L/P = 2.579 ∙ 10−4 ∙ �1 + 0.1 ∙ fICaLP,CaMKII� cms  
IC̅a,LP = PCa,L/P ∙ (zCa)2 ∙ Vm ∙ F2R ∙ T ∙ γCa,i ∙ [Ca2+]SS,CaL ∙ exp �zCa ∙ Vm ∙ FR ∙ T� − γCa,o ∙ [Ca2+]oexp �zCa ∙ Vm ∙ FR ∙ T� − 1  ICa,LP = IC̅a,LP ∙ �OCaLP + OsCaLP � 
 
Combined current: 
f̂Ca,LP = fICa,Lp −  �0.0269 + [ICaL]ARN[ICaL]tot �0.9273 – �0.0269 + [ICaL]ARN[ICaL]tot � ICa,L = f̂Ca,LP ∙ ICa,LP + (1 − f̂Ca,LP ) ∙ ICa,LNP   
1.9.3 HRdβARS SCR version (Chapter 6) 
The model structure and majority of parameters are identical to those in section 1.9.2. Parameters 
that control Vm and Ca
2+-dependent inactivation are as follows: 
IV,τP = 1170.0 ∙ �1 + exp�(Vm + 49.10)/10.349��+ 175 ∙ �1 + exp(−(Vm + 0.213)/10.807)� IV,∞P = 11.02 ∙ �0.02 + 11 + exp�(Vm + 29.979)/3.1775�� IsV,∞P = 11.0004 ∙ �0.0004 + 11 + exp�(Vm + 29.979)/3.1775�� 
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1.9.4 HRdβARS Stoch version (Chapter 7) 
The model structure and majority of parameters are identical to those in section 1.9.2. Parameters 
that control Vm and Ca
2+-dependent inactivation of the non-phosphorylated and phosphorylated ICaL 
formulations were adjusted slightly to reduce the sensitivity of the model for the generation of early 
afterdepolarizations (EADs) in response to IKr blockade (requiring 80% IKr reduction to generate EADs 
compared to 25% in the absence of these changes) and to match the amount of action potential 
duration (APD) prolongation after IKs blockade in the presence of adrenergic stimulation, while 
maintaining peak I-V and inactivation characteristics similar to experimental recordings. 
IV,τ NP = 1170.0 ∙ �1 + exp�(Vm + 49.10)/10.349�� + 126.553 ∙ �1 + exp(−(Vm + 0.213)/10.807)� IV,∞NP = 11.2474 ∙ �0.2474 + 11 + exp�(Vm + 19.0)/2.5�� IsV,∞NP = 11.04 ∙ �0.04 + 11 + exp�(Vm + 19.0)/2.5�� 
 
IV,τP = 1170.0 ∙ �1 + exp�(Vm + 49.10)/10.349��+ 175 ∙ �1 + exp(−(Vm + 0.213)/10.807)� IV,∞P = 11.02 ∙ �0.02 + 11 + exp�(Vm + 29.979)/3.1775�� IsV,∞P = 11.0007 ∙ �0.0007 + 11 + exp�(Vm + 29.979)/3.1775�� 
 
1.10 Sarcolemmal Ca2+ pump (IpCa) 
1.10.1 HRd2009 and HRdβARS version (Chapters 2-6) 
The formulation for the sarcolemmal calcium pump is equivalent to that in the original HRd model.4 G�pCa = 0.0575 mS/μF, Km,pCa = 5.00 ∙ 10−4 mmol/L IpCa = G�pCa ∙ [Ca2+]iKm,pCa + [Ca2+]i 
 
1.10.2 HRdβARS Stoch version (Chapter 7) 
The SR and sarcolemmal Ca2+-ATPases (underlying Iup and IpCa, respectively) were simulated using the 
two-state, four-transition model structure of Tran et al.31 Parameters of the models were adjusted to 
reproduce the Ca2+ dependence of the deterministic formulations (section 1.10.1). We assumed that 
the state distribution changes more rapidly than the changes in ionic concentrations on both sides of 
the pump, resulting in a quasi-equilibrium situation in which individual rates are decoupled. The 
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number of ions transported via each transition was derived from a Binomial distribution and the net 
ion flux (or current) in the interval ∆t was determined. N�pCa = 2.00 ∙ 106 pumps kpCa,1+ = 5.2272 ∙ 103 ∙ [Ca2+]i ∙ 1.00 ∙ 105N�pCa , kpCa,1− = 1.7362 ∙ 1.00 ∙ 105N�pCa  kpCa,2− = 0.2503 ∙ 1.00 ∙ 105N�pCa  npCa = kpCa,2−kpCa,1+ + kpCa,1− + kpCa,2− ∙ N�pCa IpCa = B�npCa, kpCa,1+ ∙ ∆t� ∙ zCa ∙ 109 ∙ F∆t ∙ NA ∙ Cm ∙ Acap  
 
1.11 Background Cl- current (ICl,b) 
1.11.1 HRd2009, HRdβARS and HRdβARSStoch version (Chapters 2-7) 
The formulation for the background chloride current is equivalent to that in the original HRd model.4 GCl,b = 2.2500 pA/pF ICl,b = GCl,b ∙ (Vm − ECl)  
1.12 Ca2+-dependent Cl- current (ICl(Ca) / ITo,2) 
1.12.1 HRd2009, HRdβARS and HRdβARSStoch version (Chapters 2-7) 
A formulation for ICl(Ca)/ITo,2 was developed and fit to data from canine epicardial myocytes.
32 The 
formulation reflects the following properties of ICl(Ca): i) Cl
- carrying current ii) activation by SR [Ca2+] 
release and iii) current voltage relationship32. kCa,Cl = 0.4, τCl(Ca) = 8 ms, PCl = 9.0 ∙ 10−7 cm/s KCl(Ca) = 11 + � JRelkCa,Cl�2 
αCl(Ca) = 0.0251 + exp �Vm + 585.0 � 
βCl(Ca) = 15 ∙ �1 + exp �Vm + 19−9.0 �� iCl(Ca),∞ = αCa,ClαCa,Cl + βCa,Cl 
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diCl(Ca)dt = iCl(Ca),∞ − iCl(Ca)τCl(Ca)  
 
IC̅l(Ca) = PCl ∙ (zCl)2 ∙ Vm ∙ F2R ∙ T ∙ [Cl−]i − [Cl−]o ∙ exp �−zCl ∙ Vm ∙ FR ∙ T�1 − exp �−zCl ∙ Vm ∙ FR ∙ T�  ICl(Ca) = IC̅l(Ca) ∙ iCl(Ca) ∙ KCl(Ca) 
 
1.13 Diffusion between subcellular compartments (Idiff,Ca, Idiff,Cl, Idiff,Na, Itr) 
1.13.1 HRd2009 version (Chapter 2) 
L-type Ca2+ channels are located in a local subspace (SS,CaL). Ryanodine receptors, ICl(Ca) 
channels and 20% of Na+-Ca2+ exchangers are located in a Ca2+ release subspace (SS,SR). Ca2+ 
diffusion occurs between SS,CaL and SS,SR (Idiff,SS) and diffusion of Ca
2+, Na+ and Cl- occur 
between the SS,SR and the bulk myoplasm (Idiff,Ca, Idiff,Na and Idiff,Cl). The time constant of NSR/JSR 
Ca2+ transfer (Itr) was adjusted to 25 ms. 
Itr = [Ca2+]NSR − [Ca2+]JSRτtr , τtr = 25 ms IDiff,SS = [Ca2+]SS,SR − [Ca2+]SS,CaLτDiff,SS , τDiff,SS = 2.0 ms IDiff,Ca = [Ca2+]SS,SR − [Ca2+]iτDiff , τDiff = 0.2 ms IDiff,Na = [Na+]SS,SR − [Na+]iτDiff  IDiff,Cl = [Cl−]SS,SR − [Cl−]iτDiff  
 
1.13.2 HRdβARS and HRdβARS stoch version (Chapters 3,4,5,7) 
Model structure in the HRdβARS models is identical to that of the HRd2009 model. The time 
constant of recovery for the SR Ca2+ system, represented by τtr which is independent of RyR 
phosphorylation, is increased to 75 ms, closer to the value in the original HRd model4 in order to 
prevent premature secondary Ca2+ induced Ca2+ release events due to the high SR Ca2+ load and large 
ICaL during β-adrenergic stimulation which would result in nonmonotonic decay of the Ca
2+ transient, 
which is not observed experimentally. The time constant of Ca2+ diffusion is also adjusted. 
τDiff,SS = 0.02 ms 
τtr = 75 ms 
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1.13.3 HRdβARS SCR version (Chapter 6) 
The time constant of Ca2+ transfer from NSR to JSR was further slowed to 100 ms to match 
experimental data on the amount of APD prolongation after spontaneous Ca2+ release (Chapter 5). 
τDiff,SS = 0.02 ms 
τtr = 100 ms 
 
1.14 Inward rectifier K+ current (IK1) 
1.14.1 HRd2009 version (Chapter 2) 
The formulation for the inward rectifier potassium current is equivalent to that in the original HRd 
model.4 
αK1 = 1.021 + exp �2.385 ∙ 10−1 ∙ (Vm − EK − 59.22)� 
βK1= 0.4912 ∙ exp�8.032 ∙ 10−2 ∙ (Vm − EK + 5.476)� + exp�6.175 ∙ 10−2 ∙ (Vm − EK − 5.943 ∙ 102)�1 + exp�−0.5143 ∙ (Vm − EK + 4.753)�  K1 = αK1αK1 + βK1 
G�K1 = 0.500 ∙ �[K+]o5.400 IK1 = G�K1 ∙ K1 ∙ (Vm − EK) 
 
1.14.2 HRdβARS and HRdβARSStoch version (Chapters 3-7) 
Wagner et al recently described complex regulation of IK1 by CaMKII.
33 CaMKII overexpression (either 
transgenic or acutely with adenovirus) resulted in 30% decrease in IK1 channel protein. However, IK1 
current was increased in rabbit ventricular myocytes acutely overexpressing CaMKII, and this effect 
was abolished by CaMKII inhibition with AIP. Thus, it is likely that CaMKII phosphorylation increases 
IK1 and that this effect can offset the reduction in channel protein expression resulting from long 
term CaMKII activity. Based on this mechanism, we included a 20% upregulation of IK1 in CaMKII 
phosphorylated channels.   
 
Nonphosphorylated Channels:  
αK1 = 1.021 + exp(0.2385 ∙ (Vm − EK − 59.215)) 
βK1 = 0.49124 ∙ exp�0.08032 ∙ (Vm − EK + 5.476)� + exp�0.06175 ∙ (Vm − EK − 594.31)�1 + exp(−0.5143 ∙ (Vm − EK + 4.753))  
Model definition and equations 
280 | 
G�K1 = 0.500 ∙ �[K+]𝑜5.400 IK1NP = G�K1 ∙ αK1αK1 + βK1 ∙ (Vm − EK)  
CaMKII phosphorylated Channels: IK1CaMKII = 1.200 ∙ G�K1 ∙ αK1αK1 + βK1 ∙ (Vm − EK)  
Combined IK1 current: IK1 = �1 − fK1P,CaMKII� ∙ IK1NP + fIK1P,CaMKII ∙ IK1P,CaMKII 
 
1.15 Rapidly activating delayed rectifier K+ current (IKr) 
1.15.1 HRd2009 and HRdβARS version (Chapters 2-6) 
The formulation for the rapid component of the delayed rectifier potassium current is equivalent to 
that in the original HRd model.4 
τXr = 16.000 ∙ 10−4 ∙ (Vm − 1.738)1 − exp�−0.136 ∙ (Vm − 1.738)� + 3.000 ∙ 10−4 ∙ (Vm + 38.36)exp�0.152 ∙ (Vm + 38.36)� − 1 Xr,∞ = 11 + exp(−(Vm + 10.08)/4.250) RKr = 11 + exp�(Vm + 10.00)/15.40� 
 dXrdt = Xr,∞ − XrτXr  
 
G�Kr = 1.385 ∙ 10−2 ∙ �[K+]o5.400 IKr = G�Kr ∙ Xr ∙ RKr ∙ (Vm − EK) 
 
1.15.2 HRdβARS Stoch version (Chapter 7) 
The original Hodgkin-Huxley based formulation of IKr was replaced with a 10-state Markov model 
based on the model structure described by Silva and Rudy34 extended with state-dependent block of 
IKr channels by dofetilide (Figure 1A of Chapter 7). Model parameters were adjusted to reproduce IKr 
peak and tail I-V relationships, time constants of activation and time constants of deactivation 
measured in canine ventricular myocytes35 (Figure 1B-D of Chapter 7). Channels can enter the 
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blocked mode via open and inactivated states, based on a Vm-dependent modulation of the 
dofetilide EC50.36 The model reproduces dofetilide dose-response relationship measured in rabbit 
ventricular myocytes,37 use-dependence of relative inhibition as determined in AT-1 cells36 and Vm-
dependence of dofetilide EC5036 (Figure 1E-G of Chapter 7). 
αKr,2 = 4.8712 ∙ 10−3 ∙ exp �2.5082 ∙ Vm ∙ FR ∙ T� 
βKr,2 = 5.0582 ∙ 10−4 ∙ exp �0.8035 ∙ Vm ∙ FR ∙ T� 
αKr,1 = 3.1224, βKr,1 = 2.3685 
αKr = 1.1070 ∙ 10−2 ∙ exp �1.5816 ∙ Vm ∙ FR ∙ T� 
βKr = 3.7892 ∙ 10−3 ∙ exp �1.1872 ∙ Vm ∙ FR ∙ T� 
αKr,i = 4.8457 ∙ 10−1 ∙ exp �0.7296 ∙ Vm ∙ FR ∙ T� ∙ 4.5[K+]o 
βKr,i = 1.2120 ∙ exp �0.5816 ∙ Vm ∙ FR ∙ T� ∙ � 4.5[K+]o�0.3 
μKr = αKr,i ∙ βKr,2βKr,i  kDof,on = 5.2353 ∙ 10−3 ∙ [Dof],  kDof,off = 3.2172 ∙ 10−4 kDof,on,i = 2.7898 ∙ 10−2 ∙ [Dof], kDof,off,i = 8.7055 ∙ 10−4 
αKr,i,Dof = kDof,off,i ∙ αKr,i ∙ kDof,onkDof,off ∙ kDof,on,i  
μKr,Dof = αKr,i,Dof ∙ βKr,2βKr,i   dC3Krdt = βKr ∙ C2Kr − αKr ∙ C3Kr dC2Krdt = βKr,1 ∙ C1Kr + αKr ∙ C3Kr − �αKr,1 + βKr� ∙ C2Kr dC1Krdt = αKr,1 ∙ C2Kr + βKr,2 ∙ OKr + μKr ∙ InKr − �2 ∙ αKr,2 + βKr,1� ∙ C1Kr dOKrdt = αKr,i ∙ InKr + αKr,2 ∙ C1Kr + kDof,off ∙ BKr − �βKr,i + βKr,2 + kDof,on� ∙ OKr dIndt = αKr,2 ∙ C1Kr + βKr,i ∙ OKr + kDof,off,i ∙ InBKr − �μKr + αKr,i + kDof,on,i� ∙ InKr dC3BKrdt = βKr ∙ C2BKr − αKr ∙ C3BKr dC2BKrdt = βKr,1 ∙ C1BKr + αKr ∙ C3BKr − �αKr,1 + βKr� ∙ C2BKr 
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dC1BKrdt = αKr,1 ∙ C2BKr + βKr,2 ∙ BKr + μKr,Dof ∙ InBKr − �2 ∙ αKr,2 + βKr,1� ∙ C1BKr dBKrdt = αKr,i,Dof ∙ InBKr + αKr,2 ∙ C1BKr + kDof,on ∙ OKr − �βKr,i + βKr,2 + kDof,off� ∙ BKr dInBdt = αKr,2 ∙ C1BKr + βKr,i ∙ BKr + kDof,on,i ∙ InKr − �μKr,Dof + αKr,i,Dof + kDof,off,i� ∙ InBKr  GKr = 5.2530 ∙ 10−3 ∙ ([K+]o)0.59 IKr = GKr ∙ OKr ∙ (Vm − EK) 
 
1.16 Slowly activating delayed rectifier K+ current (IKs) 
1.16.1 HRd2009 version (Chapter 2) 
The Hodgkin-Huxley based formulation for IKs used in a previous model of the canine epicardial 
myocyte4 was replaced with the 17 state Markov model proposed by Silva and Rudy34. The structure 
of the IKs model is shown in Figure 11 of Chapter 2. The original Silva-Rudy model accurately 
reproduces the kinetics of IKs in guinea pig and human based on underlying voltage sensor transitions 
and has provided insight into the role of IKs in APD adaptation in these species.
34 Transition rate 
parameters were adjusted to fit the following data from canine epicardial and midmyocardial 
myocytes: i) tail current amplitudes at holding potentials from -20 to +70 mV after 300 ms and 3000 
ms of activation38 ; ii) tail currents at holding potentials from -10 to 60 mV after 5000 ms of 
activation35, 39; iii) activation half-time on depolarization to + 20 mV35, 39; iv) deactivation half-times 
for tail currents to -25, -50 and -80 mV35, 39 and v) accumulation characteristics for inter-pulse 
intervals between 20 and 150 ms after 200 ms depolarizing steps39. Current density was scaled to 
that of canine epicardial myocytes.35, 39 
αKs = 1.4864 ∙ 10−2 ∙ exp(2.9877 ∙ 10−2 ∙ Vm ∙ FR ∙ T) 
βKs = 8.3986 ∙ 10−2 ∙ exp(−5.5461 ∙ 10−2 ∙ Vm ∙ FR ∙ T) 
γKs = 1.4601 ∙ 10−2 ∙ exp(2.4465 ∙ 10−1 ∙ Vm ∙ FR ∙ T) 
δKs = 3.1173 ∙ 10−3 ∙ exp(−4.2625 ∙ 10−1 ∙ Vm ∙ FR ∙ T) 
ηKs = 7.7320 ∙ 10−2 ∙ exp(−6.4726 ∙ 10−2 ∙ Vm ∙ FR ∙ T) 
θKs = 8.9538 ∙ 10−2 
ωKs = 7.9405 ∙ 10−1 ∙ exp(−8.0174 ∙ 10−2 ∙ Vm ∙ FR ∙ T) 
ψKs = 5.8638 ∙ 10−1 ∙ exp(2.8206 ∙ 10−1 ∙ Vm ∙ FR ∙ T) 
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dC1Ksdt = −(4 ∙ αKs) ∙ C1Ks + βKS ∙ C2Ks dC2Ksdt = −(3 ∙ αKs + βKs + γKs) ∙ C2Ks + 4 ∙ αKs ∙ C1Ks + 2 ∙ βKs ∙ C3Ks + δKs ∙ C6Ks dC3Ksdt = −(2 ∙ αKs + 2 ∙ βKs + 2 ∙ γKs) ∙ C3Ks + 3 ∙ αKs ∙ C2Ks + 3 ∙ βKs ∙ C4Ks + δKs ∙ C7Ks dC4Ksdt = −(αKs + 3 ∙ βKs + 3 ∙ γKs) ∙ C4Ks + 2 ∙ αKs ∙ C3Ks + 4 ∙ βKs ∙ C5Ks + δKs ∙ C8KsNP dC5Ksdt = −(4 ∙ βKs + 4 ∙ γKs) ∙ C5Ks + αKs ∙ C4Ks + δKs ∙ C9Ks dC6Ksdt = −(3 ∙ αKs + δKs) ∙ C6Ks + βKs ∙ C7Ks + γKs ∙ C2Ks dC7Ksdt = −(2 ∙ αKs + βKs + γKs + δKs) ∙ C7Ks + 3 ∙ αKs ∙ C6Ks + 2 ∙ βKs ∙ C8Ks + 2 ∙ γKs ∙ C3Ks + 2
∙ δKs ∙ C10Ks dC8Ksdt = −(αKs + 2 ∙ βKs + 2 ∙ γKs + δKs) ∙ C8Ks + 2 ∙ αKs ∙ C7Ks + 3 ∙ βKs ∙ C9Ks + 3 ∙ γKs ∙ C4Ks+ 2 ∙ δKs ∙ C11Ks dC9Ksdt = −(3 ∙ βKs + 3 ∙ γKs + δKs) ∙ C9Ks + αKs ∙ C8Ks + 4 ∙ γKs ∙ C5Ks + 2 ∙ δKs ∙ C12Ks dC10Ksdt = −(2 ∙ αKs + 2 ∙ δKs) ∙ C10Ks + βKs ∙ C11Ks + γKs ∙ C7Ks dC11Ksdt = −(αKs + βKs + γKs + 2 ∙ δKs) ∙ C11Ks + 2 ∙ αKs ∙ C10Ks + 2 ∙ βKs ∙ C12Ks + 2 ∙ γKs
∙ C8Ks + 3 ∙ δKs ∙ C13Ks dC12Ksdt = −(2 ∙ βKs + 2 ∙ γKs + 2 ∙ δKs) ∙ C12Ks + αKs ∙ C11Ks + 3 ∙ γKs ∙ C9Ks + 3 ∙ δKs ∙ C14Ks dC13Ksdt = −(αKs + 3 ∙ δKs) ∙ C13Ks + βKs ∙ C14Ks + γKs ∙ C11Ks dC14Ksdt = −(βKs + γKs + 3 ∙ δKs) ∙ C14Ks + αKs ∙ C13Ks + 2 ∙ γKs ∙ C12Ks + 4 ∙ δKs ∙ C15Ks dC15Ksdt = −(4 ∙ δKs + θKs) ∙ C15Ks + γKs ∙ C14Ks + ηKs ∙ O1Ks dO1Ksdt = −(ηKs + ψKs) ∙ O1Ks + θKs ∙ C15Ks + ωKs ∙ O2Ks dO2Ksdt = −(ωKs) ∙ O2Ks + ψKs ∙ O1Ks 
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G�Ks = 0.19561 ∙
⎝
⎜
⎛1 + 0.61 + �3.8 ∙ 10−5[Ca2+]i�1.4⎠⎟
⎞
 
IKs = G�Ks ∙ �O1Ks + O2Ks� ∙ (Vm − EKs) 
 
1.16.2 HRdβARS and HRdβARS Stoch version (Chapters 3,5-7) 
IKs kinetics, current amplitude and adrenergic modulation are species and age dependent.
40 In large 
mammals (dog, human), IKs is small under baseline conditions with slow activation kinetics and fast 
deactivation kinetics.39 Phosphorylation by PKA significantly increases IKs in most environments, 
including guinea pig ventricular myocytes,41 human IKs expressed in HEK cells
42 and (adult) canine 
ventricular myocytes38. In the dog a 3-fold increase in current amplitude, left-ward shift in tail 
current amplitude I-V curve, increased activation kinetics and decreased deactivation kinetics are 
observed in the presence of isoproterenol.38, 39 The 17-state Markov model (Figure 11 of Chapter 2), 
which represent 2 transitions of the voltage sensor for each of the 4 subunits34 is used here. Both its 
baseline and βAR versions reproduce experimental data from canine ventricular myocytes in the 
absence or presence of isoproterenol.38, 39 The increased IKs observed during adrenergic stimulation 
can result from increased channel density, increased single channel conductance and/or increased 
channel open probability.  Recently, Severi et al. used the same Markov model structure to simulate 
IKs and its modulation by adrenergic stimulation in guinea pig ventricular myocytes.
41 They showed 
that an increase in total conductance is not required to simulate all IKs properties during adrenergic 
stimulation. Similarly, we are able to reproduce both baseline and adrenergic stimulated 
characteristics of canine IKs without altering the total conductance. 
 
Nonphosphorylated Channels: 
αKs
NP = 7.3990 ∙ 10−31 + exp(−Vm − 3.1196 ∙ 10−28.0019 ∙ 10−1 ∙ FR ∙ T) 
βKs
NP = 5.6992 ∙ 10−31 + exp(Vm −  4.1520 ∙ 10−21.3489 ∙ FR ∙ T) 
γKs
NP = 3.8839 ∙ 10−11 + exp(−Vm + 1.5019 ∙ 10−16.0693 ∙ 10−1 ∙ FR ∙ T) 
δKs
NP = 9.0654 ∙ 10−2 ∙ exp(−1.1157 ∙ 10−1 ∙ Vm ∙ FR ∙ T ) 
ηKs
NP = 3.1124 ∙ 10−3 + 2.8330 ∙ 10−2 − 3.1124 ∙ 10−31 + exp(Vm + 5.1660 ∙ 10−21.5522 ∙ FR ∙ T) 
θKs
NP = 2.7304 ∙ 10−3 
ωKs
NP = 4.4198 ∙ 10−4 ∙ exp(−1.2022 ∙ Vm ∙ FR ∙ T ) 
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ψKs
NP = 4.0173 ∙ 10−4 ∙ exp(2.0873 ∙ 10−4 ∙ Vm ∙ FR ∙ T ) 
 dC1KsNPdt = −�4 ∙ αKsNP� ∙ C1KsNP + βKsNP ∙ C2KsNP dC2KsNPdt = −�3 ∙ αKsNP + βKsNP + γKsNP� ∙ C2KsNP + 4 ∙ αKsNP ∙ C1KsNP + 2 ∙ βKsNP ∙ C3KsNP + δKsNP ∙ C6KsNP dC3KsNPdt = −�2 ∙ αKsNP + 2 ∙ βKsNP + 2 ∙ γKsNP� ∙ C3KsNP + 3 ∙ αKsNP ∙ C2KsNP + 3 ∙ βKsNP ∙ C4KsNP + δKsNP ∙ C7KsNP dC4KsNPdt = −�αKsNP + 3 ∙ βKsNP + 3 ∙ γKsNP� ∙ C4KsNP + 2 ∙ αKsNP ∙ C3KsNP + 4 ∙ βKsNP ∙ C5KsNP + δKsNP ∙ C8KsNP dC5KsNPdt = −�4 ∙ βKsNP + 4 ∙ γKsNP� ∙ C5KsNP + αKsNP ∙ C4KsNP + δKsNP ∙ C9KsNP dC6KsNPdt = −�3 ∙ αKsNP + δKsNP� ∙ C6KsNP + βKsNP ∙ C7KsNP + γKsNP ∙ C2KsNP dC7KsNPdt = −�2 ∙ αKsNP + βKsNP + γKsNP + δKsNP� ∙ C7KsNP + 3 ∙ αKsNP ∙ C6KsNP + 2 ∙ βKsNP ∙ C8KsNP + 2 ∙ γKsNP ∙ C3KsNP+ 2 ∙ δKsNP ∙ C10KsNP dC8KsNPdt = −�αKsNP + 2 ∙ βKsNP + 2 ∙ γKsNP + δKsNP� ∙ C8KsNP + 2 ∙ αKsNP ∙ C7KsNP + 3 ∙ βKsNP ∙ C9KsNP + 3 ∙ γKsNP
∙ C4KsNP + 2 ∙ δKsNP ∙ C11KsNP dC9KsNPdt = −�3 ∙ βKsNP + 3 ∙ γKsNP + δKsNP� ∙ C9KsNP + αKsNP ∙ C8KsNP + 4 ∙ γKsNP ∙ C5KsNP + 2 ∙ δKsNP ∙ C12KsNP dC10KsNPdt = −�2 ∙ αKsNP + 2 ∙ δKsNP� ∙ C10KsNP + βKsNP ∙ C11KsNP + γKsNP ∙ C7KsNP dC11KsNPdt = −�αKsNP + βKsNP + γKsNP + 2 ∙ δKsNP� ∙ C11KsNP + 2 ∙ αKsNP ∙ C10KsNP + 2 ∙ βKsNP ∙ C12KsNP + 2 ∙ γKsNP
∙ C8KsNP + 3 ∙ δKsNP ∙ C13KsNP dC12KsNPdt = −�2 ∙ βKsNP + 2 ∙ γKsNP + 2 ∙ δKsNP� ∙ C12KsNP + αKsNP ∙ C11KsNP + 3 ∙ γKsNP ∙ C9KsNP + 3 ∙ δKsNP
∙ C14KsNP dC13KsNPdt = −�αKsNP + 3 ∙ δKsNP� ∙ C13KsNP + βKsNP ∙ C14KsNP + γKsNP ∙ C11KsNP dC14KsNPdt = −�βKsNP + γKsNP + 3 ∙ δKsNP� ∙ C14KsNP + αKsNP ∙ C13KsNP + 2 ∙ γKsNP ∙ C12KsNP + 4 ∙ δKsNP ∙ C15KsNP dC15KsNPdt = −�4 ∙ δKsNP + θKsNP� ∙ C15KsNP + γKsNP ∙ C14KsNP + ηKsNP ∙ O1KsNP dO1KsNPdt = −�ηKsNP + ψKsNP� ∙ O1KsNP + θKsNP ∙ C15KsNP + ωKsNP ∙ O2KsNP dO2KsNPdt = −�ωKsNP� ∙ O2KsNP + ψKsNP ∙ O1KsNP 
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G�KsNP = 0.19561 ∙
⎝
⎜
⎛1 + 0.61 + �3.8 ∙ 10−5[Ca2+]i�1.4⎠⎟
⎞
 
PNa/K = 0.01833 EKs = R ∙ TF ∙ log�[K+]o + PNa/K ∙ [Na+]o[K+]i + PNa/K ∙ [Na+]i � IKsNP = G�KsNP ∙ �O1KsNP + O2KsNP� ∙ (Vm − EKs) 
 
 
 
Phosphorylated Channels: 
αKs
NP = 9.9415 ∙ 10−31 + exp(−Vm − 4.4809 ∙ 10−25.8172 ∙ 10−1 ∙ FR ∙ T) 
βKs
NP = 3.3201 ∙ 10−31 + exp(Vm −  9.4217 ∙ 10−20.9536 ∙ FR ∙ T) 
γKs
NP = 5.6356 ∙ 10−11 + exp(−Vm + 1.7986 ∙ 10−15.8381 ∙ 10−1 ∙ FR ∙ T) 
δKs
NP = 6.5700 ∙ 10−2 ∙ exp(−1.1899 ∙ 10−1 ∙ Vm ∙ FR ∙ T ) 
ηKs
NP = 3.8525 ∙ 10−4 + 1.2406 ∙ 10−2 − 3.8525 ∙ 10−41 + exp(Vm + 6.4118 ∙ 10−27.7992 ∙ 10−1 ∙ FR ∙ T) 
θKs
NP = 4.6171 ∙ 10−3 
ωKs
NP = 2.3730 ∙ 10−4 ∙ exp(−1.9742 ∙ Vm ∙ FR ∙ T ) 
ψKs
NP = 2.2652 ∙ 10−4 ∙ exp(2.4689 ∙ 10−4 ∙ Vm ∙ FR ∙ T ) 
 dC1KsPdt = −�4 ∙ αKsP � ∙ C1KsP + βKsP ∙ C2KsP  dC2KsPdt = −�3 ∙ αKsP + βKsP + γKsP � ∙ C2KsP + 4 ∙ αKsP ∙ C1KsP + 2 ∙ βKsP ∙ C3KsP + δKsP ∙ C6KsP  dC3KsPdt = −�2 ∙ αKsP + 2 ∙ βKsP + 2 ∙ γKsP � ∙ C3KsP + 3 ∙ αKsP ∙ C2KsP + 3 ∙ βKsP ∙ C4KsP + δKsP ∙ C7KsP  dC4KsPdt = −�1 ∙ αKsP + 3 ∙ βKsP + 3 ∙ γKsP � ∙ C4KsP + 2 ∙ αKsP ∙ C3KsP + 4 ∙ βKsP ∙ C5KsP + δKsP ∙ C8KsP  
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dC5KsPdt = −�4 ∙ βKsP + 4 ∙ γKsP � ∙ C5KsP + αKsP ∙ C4KsP + δKsP ∙ C9KsP  dC6KsPdt = −�3 ∙ αKsP + δKsP � ∙ C6KsP + βKsP ∙ C7KsP + γKsP ∙ C2KsP  dC7KsPdt = −�2 ∙ αKsP + βKsP + γKsP + δKsP � ∙ C7KsP + 3 ∙ αKsP ∙ C6KsP + 2 ∙ βKsP ∙ C8KsP + 2 ∙ γKsP ∙ C3KsP + 2
∙ δKs
P ∙ C10KsP  dC8KsPdt = −�αKsP + 2 ∙ βKsP + 2 ∙ γKsP + δKsP � ∙ C8KsP + 2 ∙ αKsP ∙ C7KsP + 3 ∙ βKsP ∙ C9KsP + 3 ∙ γKsP ∙ C4KsP+ 2 ∙ δKsP ∙ C11KsP  dC9KsPdt = −�3 ∙ βKsP + 3 ∙ γKsP + δKsP � ∙ C9KsP + αKsP ∙ C8KsP + 4 ∙ γKsP ∙ C5KsP + 2 ∙ δKsP ∙ C12KsP  dC10KsPdt = −�2 ∙ αKsP + 2 ∙ δKsP � ∙ C10KsP + βKsP ∙ C11KsP + γKsP ∙ C7KsP  dC11KsPdt = −�αKsP + βKsP + γKsP + 2 ∙ δKsP � ∙ C11KsP + 2 ∙ αKsP ∙ C10KsP + 2 ∙ βKsP ∙ C12KsP + 2 ∙ γKsP
∙ C8KsP + 3 ∙ δKsP ∙ C13KsP  dC12KsPdt = −�2 ∙ βKsP + 2 ∙ γKsP + 2 ∙ δKsP � ∙ C12KsP + αKsP ∙ C11KsP + 3 ∙ γKsP ∙ C9KsP + 3 ∙ δKsP ∙ C14KsP  dC13KsPdt = −�αKsP + 3 ∙ δKsP � ∙ C13KsP + βKsP ∙ C14KsP + γKsP ∙ C11KsP  dC14KsPdt = −�βKsP + γKsP + 3 ∙ δKsP � ∙ C14KsP + αKsP ∙ C13KsP + 2 ∙ γKsP ∙ C12KsP + 4 ∙ δKsP ∙ C15KsP  dC15KsPdt = −�4 ∙ δKsP + θKsP � ∙ C15KsP + γKsP ∙ C14KsP + ηKsP ∙ O1KsP  dO1KsPdt = −�ηKsP + ψKsP � ∙ O1KsP + θKsP ∙ C15KsP + ωKsP ∙ O2KsP  dO2KsPdt = −�ωKsP � ∙ O2KsP + ψKsP ∙ O1KsP  
 
G�KsP = 0.19561 ∙
⎝
⎜
⎛1 + 0.61 + �3.8 ∙ 10−5[Ca2+]i�1.4⎠⎟
⎞
 
IKsP = G�KsP ∙ �O1KsP + O2KsP � ∙ (Vm − EKs) 
 
Combined current: 
f̂KsP = fIKsP −  �0.0306 + [IKs]ARN[IKs]tot �0.7850 −  �0.0306 + [IKs]ARN[IKs]tot � 
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IKs = f̂KsP ∙ IKsP + (1 − f̂KsP ) ∙ IKsNP 
 
1.16.3 HRdβARS A341V version (Chapter 4) 
Model structure, differential equations and calculation of IKs are identical to that in section 1.16.2. 
Model parameters were adjusted based on data obtained in CHO cells expressing WT or mutant IKs 
channels in the absence or presence of cAMP/OA (Chapter 4): 
WT IKs parameters: 
αKs
NP = 8.7313 ∙ 10−31 + exp(−Vm − 3.3032 ∙ 1011.1946 ∙ FR ∙ T) 
βKs
NP = 1.1068 ∙ 10−21 + exp(Vm −  1.9519 ∙ 10−21.4447 ∙ FR ∙ T) 
γKs
NP = 1.5226 ∙ 10−11 + exp(−Vm + 5.3866 ∙ 10−25.3191 ∙ 10−1 ∙ FR ∙ T) 
δKs
NP = 1.0372 ∙ 10−2 ∙ exp(4.7872 ∙ 10−3 ∙ Vm ∙ FR ∙ T ) 
ηKs
NP = 1.5447 ∙ 10−2 + 6.9977 ∙ 10−2 − 1.5447 ∙ 10−21 + exp(Vm + 1.0318 ∙ 1025.2369 ∙ 10−1 ∙ FR ∙ T) 
θKs
NP = 1.7695 ∙ 10−3 
ωKs
NP = 5.6517 ∙ 10−4 ∙ exp(−1.5643 ∙ Vm ∙ FR ∙ T ) 
ψKs
NP = 2.8148 ∙ 10−5 ∙ exp(1.9762 ∙ 10−4 ∙ Vm ∙ F
R ∙ T
) 
αKs
P = 6.9994 ∙ 10−31 + exp(−Vm − 5.6717 ∙ 10−15.7717 ∙ 10−1 ∙ FR ∙ T) 
βKs
P = 1.3731 ∙ 10−21 + exp(Vm −  3.8608 ∙ 10−31.7486 ∙ FR ∙ T) 
γKs
P = 1.6490 ∙ 10−11 + exp(−Vm − 2.0329 ∙ 10−24.8136 ∙ 10−1 ∙ FR ∙ T) 
δKs
P = 4.7241 ∙ 10−3 ∙ exp(1.6283 ∙ 10−2 ∙ Vm ∙ FR ∙ T ) 
ηKs
P = 9.6896 ∙ 10−3 + 1.4242 ∙ 10−1 − 9.6896 ∙ 10−31 + exp(Vm + 1.1338 ∙ 1025.5965 ∙ 10−1 ∙ FR ∙ T) 
θKs
P = 3.2528 ∙ 10−3 
ωKs
P = 2.3813 ∙ 10−3 ∙ exp(−1.9602 ∙ Vm ∙ FR ∙ T ) 
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ψKs
P = 4.4670 ∙ 10−5 ∙ exp(8.9068 ∙ 10−5 ∙ Vm ∙ FR ∙ T ) 
 
A341VHet IKs parameters: 
αKs
NP = 7.8749 ∙ 10−31 + exp(−Vm − 5.1876 ∙ 1011.0212 ∙ FR ∙ T) 
βKs
NP = 4.5532 ∙ 10−31 + exp(Vm −  1.4922 ∙ 10−24.2919 ∙ FR ∙ T) 
γKs
NP = 1.0993 ∙ 10−11 + exp(−Vm + 1.1599 ∙ 10−36.2763 ∙ 10−1 ∙ FR ∙ T) 
δKs
NP = 2.6854 ∙ 10−2 ∙ exp(2.3346 ∙ 10−3 ∙ Vm ∙ FR ∙ T ) 
ηKs
NP = 9.0527 ∙ 10−3 + 6.5743 ∙ 10−2 − 9.0527 ∙ 10−31 + exp(Vm + 3.0409 ∙ 1010.7658 ∙ FR ∙ T) 
θKs
NP = 1.2691 ∙ 10−3 
ωKs
NP = 5.6517 ∙ 10−4 ∙ exp(−1.5643 ∙ Vm ∙ FR ∙ T ) 
ψKs
NP = 2.8148 ∙ 10−5 ∙ exp(1.9762 ∙ 10−4 ∙ Vm ∙ FR ∙ T ) 
αKs
P = 1.1355 ∙ 10−21 + exp(−Vm − 6.8892 ∙ 1011.4039 ∙ FR ∙ T) 
βKs
P = 3.8524 ∙ 10−31 + exp(Vm −  1.0399 ∙ 10−23.3478 ∙ FR ∙ T) 
γKs
P = 1.2805 ∙ 10−11 + exp(−Vm + 1.1741 ∙ 10−30.4837 ∙ FR ∙ T) 
δKs
P = 2.1670 ∙ 10−2 ∙ exp(2.4782 ∙ 10−3 ∙ Vm ∙ FR ∙ T ) 
ηKs
P = 5.8191 ∙ 10−3 + 4.4396 ∙ 10−2 − 5.8191 ∙ 10−31 + exp(Vm + 4.2618 ∙ 1011.1263 ∙ FR ∙ T) 
θKs
P = 6.2849 ∙ 10−4 
ωKs
P = 5.6517 ∙ 10−4 ∙ exp(−1.5643 ∙ Vm ∙ FR ∙ T ) 
ψKs
P = 2.8148 ∙ 10−5 ∙ exp(1.9762 ∙ 10−4 ∙ Vm ∙ F
R ∙ T
) 
 
A341VHom IKs parameters: 
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αKs
NP = 6.4929 ∙ 10−31 + exp(−Vm − 8.4272 ∙ 1011.1093 ∙ FR ∙ T) 
βKs
NP = 2.6793 ∙ 10−31 + exp(Vm −  1.4346 ∙ 10−23.1158 ∙ FR ∙ T) 
γKs
NP = 6.6132 ∙ 10−21 + exp(−Vm + 1.5849 ∙ 10−30.2105 ∙ FR ∙ T) 
δKs
NP = 3.0593 ∙ 10−2 ∙ exp(3.8659 ∙ 10−3 ∙ Vm ∙ FR ∙ T ) 
ηKs
NP = 7.7273 ∙ 10−3 + 8.7107 ∙ 10−2 − 7.7273 ∙ 10−31 + exp(Vm + 1.3602 ∙ 1010.8158 ∙ FR ∙ T) 
θKs
NP = 3.3856 ∙ 10−4 
ωKs
NP = 5.6517 ∙ 10−4 ∙ exp(−1.5643 ∙ Vm ∙ FR ∙ T ) 
ψKs
NP = 2.8148 ∙ 10−5 ∙ exp(1.9762 ∙ 10−4 ∙ Vm ∙ F
R ∙ T
) 
αKs
P = 7.2469 ∙ 10−31 + exp(−Vm − 8.0876 ∙ 1010.9005 ∙ FR ∙ T) 
βKs
P = 3.3092 ∙ 10−31 + exp(Vm −  1.4431 ∙ 10−23.4604 ∙ FR ∙ T) 
γKs
P = 6.6278 ∙ 10−21 + exp(−Vm + 1.4175 ∙ 10−30.1937 ∙ FR ∙ T) 
δKs
P = 3.0039 ∙ 10−2 ∙ exp(3.6233 ∙ 10−3 ∙ Vm ∙ FR ∙ T ) 
ηKs
P = 7.7647 ∙ 10−3 + 7.7303 ∙ 10−2 − 7.7647 ∙ 10−31 + exp(Vm + 1.3807 ∙ 1010.9041 ∙ FR ∙ T) 
θKs
P = 3.4785 ∙ 10−4 
ωKs
P = 5.6517 ∙ 10−4 ∙ exp(−1.5643 ∙ Vm ∙ FR ∙ T ) 
ψKs
P = 2.8148 ∙ 10−5 ∙ exp(1.9762 ∙ 10−4 ∙ Vm ∙ F
R ∙ T
) 
 
And  G�Ks = 0.6603 ∙ �1 + 0.6
1+�3.8∙ 10−5
�Ca2+�i
�
1.4� for all conditions. 
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1.17 Ultrarapid plateau K+ current (IKur / IKp) 
1.17.1 HRd2009 version (Chapter 2) 
The formulation for the plateau potassium current is equivalent to that in the original HRd model.4 G�Kur = 2.760 ∙ 10−3  IKur = G�Kur ∙ 11 + exp�(7.488 − Vm)/5.980� ∙ (Vm − EK) 
 
1.17.2 HRdβARS and HRdβARS  Stoch version (Chapters 3-7) 
In many species and cell types, there exists an ultrarapid delayed rectifier potassium current 
activating at plateau membrane potentials (IKur).
43 Although IKur was originally thought to be 
functionally absent in ventricular myocytes from larger mammals including the dog, recent reports 
describe a plateau activated potassium current sensitive to micromolar concentrations of 4-
aminopyridine.44, 45 This current is increased in the presence of isoproterenol. In addition, the non-
stimulated I-V relationship of this current is consistent with the plateau potassium current that is 
present in the baseline model.21 Therefore, adrenergic stimulation-dependent changes in I-V of IKur 
are included in the model and replace the original formulation of IKp. 
 
Nonphosphorylated Channels: GKurNP = 3.48 ∙ 10−3  IKurNP = GKurNP ∙ 11 + exp�(15.0 − Vm)/17� ∙ (Vm − EK) 
 
Phosphorylated Channels: GKurP = 3.62 ∙ 3.48 ∙ 10−3  IKurP = GKurP ∙ 11 + exp�(36.0 − Vm)/17� ∙ (Vm − EK) 
 
Combined IKur current: f̂KurP = fIKurP −  0.39370.5894 –  0.3937 IKur = f̂KurP ∙ IKurP + (1 − f̂KurP ) ∙ IKurNP  
 
1.18 Na+ current (INa) 
1.18.1 HRd2009 version (Chapter 2) 
Fast Na+ current density (INa) was adjusted to achieve conduction velocity,
46 maximum upstroke 
velocity47 and maximum upstroke voltage47 consistent with data in canine epicardial tissue. Na+ 
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current recovery from inactivation was adjusted to fit data on recovery of upstroke velocity in canine 
epicardial myocytes48: 
αm = 0.32 ∙ (Vm + 47.13)1 − exp�−0.1 ∙ (Vm + 47.13)� 
βm = 0.08 ∙ exp �−Vm11� 
If Vm > -40.0 mV       αh = 0.0, αj = 0.0      βh = 10.13 ∙ �1 + exp �Vm + 10.66−11.1 ��      βj = 0.3 ∙ exp(−2.535 ∙ 10−7 ∙ Vm)1 + exp�−0.1 ∙ (Vm + 32)�  
Else      αh = 0.135 ∙ exp �80 + Vm−6.8 � 
    αj = �−1.2714 ∙ 105 ∙ exp(0.2444 ∙ Vm) − 6.948 ∙ 10−5 ∙ exp(−0.04391 ∙ Vm)� ∙ (Vm + 37.78)1 + exp�0.311 ∙ (Vm + 79.23)�       βh = 3.56 ∙ exp(0.079 ∙ Vm) + 3.1 ∙ 105 ∙ exp(0.35 ∙ Vm)      βj = 0.1212 ∙ exp(−0.01052 ∙ Vm)1 + exp�−0.1378 ∙ (Vm + 40.14)� 
 dmdt = αm ∙ (1 − m) − βm ∙  m dhdt = αh ∙ (1 − h) − βh ∙ h djdt = αj ∙ (1 − j) − βj ∙ j 
 
G�Na = 9.075 mSμF  INa = G�Na ∙ m3 ∙ h ∙ j ∙ (Vm − ENa) 
 
1.18.2 HRdβARS version (Chapters 3-6) 
βAR stimulation alters INa through both increase channel trafficking as well as phosphorylation of a 
number of consensus phosphorylation sites. This results in increased current amplitude and a 
hyperpolarizing shift of the activation and inactivation I-V relationships.49, 50 The model reproduces 
the 3.7 mV and 4.9 mV shifts in respectively the activation and inactivation curves measured in 5 
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mmol/L extracullar Na+ in canine ventricular myocytes in the presence of a PKA activator ‘cocktail’ 
(8-cpt-cAMP, IBMX and forskolin).50 A similar modulation of INa by CaMKII has been reported in 
rabbit myocytes overexpressing CaMKIIδ51 and was incorporated in a previous model24. We 
incorporate four populations of INa (non-phosphorylated, phosphorylated by PKA, phosphorylated by 
CaMKII or phosphorylated by both kinases). 
 
Nonphosphorylated Channels: 
αm
NP = 0.32 ∙ (Vm + 58.5029)1 − exp�−0.1 ∙ (Vm + 58.5029)� 
βm
NP = 0.08 ∙ exp �−Vm − 13.729911 � 
If Vm > -40.0 mV       αhNP = 0.0, αjNP = 0.0      βhNP = 10.13 ∙ �1 + exp �Vm + 27.4034−11.1 ��      βjNP = 0.3 ∙ exp(−2.535 ∙ 10−7 ∙ Vm)1 + exp�−0.1 ∙ (Vm + 32)�  
Else      αhNP = 0.135 ∙ exp �87 + Vm−6.8 �      αjNP
= �−1.2714 ∙ 105 ∙ exp(0.2444 ∙ Vm) − 6.948 ∙ 10−5 ∙ exp(−0.04391 ∙ Vm)� ∙ (Vm + 37.78)1 + exp�0.311 ∙ (Vm + 79.23)�       βhNP = 3.56 ∙ exp�0.079 ∙ (Vm + 7)� + 3.1 ∙ 105 ∙ exp�0.35 ∙ (Vm + 7)�      βjNP = 0.1212 ∙ exp(−0.01052 ∙ Vm)1 + exp�−0.1378 ∙ (Vm + 40.14)� 
 dmNPdt = αmNP ∙ �1 − mNP� − βmNP ∙ mNP dhNPdt = αhNP ∙ �1 − hNP� − βhNP ∙ hNP djNPdt = αjNP ∙ �1 − jNP� − βjNP ∙ jNP 
 G�NaNP = 19.5112 mSμF  INaNP = G�NaNP ∙ �mNP�3 ∙ hNP ∙ jNP ∙ (Vm − ENa) 
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PKA Phosphorylated Channels: 
∆VNa,Act = 3.7 mV, ∆VNa,InactPKA = 4.9 mV 
αm
P,PKA = 0.32 ∙ �Vm + 58.5029 + ∆VNa,Act�1 − exp �−0.1 ∙ �Vm + 58.5029 + ∆VNa,Act�� 
βm
P,PKA = 0.08 ∙ exp �−Vm − 13.7299 + ∆VNa,Act11 � 
If Vm > -40.0 mV       αhP,PKA = 0.0, αjP,PKA = 0.0      βhP,PKA = 10.13 ∙ �1 + exp�Vm + ∆VNa,InactPKA + 27.4034−11.1 �� 
     βjP,PKA = 0.3 ∙ exp �−2.535 ∙ 10−7 ∙ �Vm + ∆VNa,InactPKA ��1 + exp �−0.1 ∙ �Vm + ∆VNa,InactPKA + 32��  
Else      αhP,PKA = 0.135 ∙ exp�87 + Vm + ∆VNa,InactPKA−6.8 �      αjP,PKA = 11 + exp �0.311 ∙ �Vm + ∆VNa,InactPKA + 79.23��
∙ �−1.2714 ∙ 105 ∙ exp �0.2444 ∙ �Vm + ∆VNa,InactPKA �� − 6.948 ∙ 10−5
∙ exp �−0.04391 ∙ �Vm + ∆VNa,InactPKA ��� ∙ �Vm + ∆VNa,InactPKA + 37.78�      βhP,PKA = 3.56 ∙ exp �0.079 ∙ �Vm + ∆VNa,InactPKA + 7�� + 3.1 ∙ 105
∙ exp �0.35 ∙ �Vm + ∆VNa,InactPKA + 7�� 
     βjP,PKA = 0.1212 ∙ exp �−0.01052 ∙ �Vm + ∆VNa,InactPKA ��1 + exp �−0.1378 ∙ �Vm + ∆VNa,InactPKA + 40.14�� 
 dmP,PKAdt = αmP,PKA ∙ �1 − mP,PKA� − βmP,PKA ∙ mP,PKA dhP,PKAdt = αhP,PKA ∙ �1 − hP,PKA� − βhP,PKA ∙ hP,PKA djP,PKAdt = αjP,PKA ∙ �1 − jP,PKA� − βjP,PKA ∙ jP,PKA 
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G�NaP = 1.25 ∙ 19.5112 mSμF  INaP,PKA = G�NaP ∙ �mP,PKA�3 ∙ hP,PKA ∙ jP,PKA ∙ (Vm − ENa) 
 
CaMKII Phosphorylated Channels: 
∆VNa,InactCaMK = 3.25 mV 
αm
P,CaMK = αmNP,   βmP,CaMK = βmNP 
If Vm + ∆VNa,InactCaMK > -40.0 mV       αhP,CaMK = 0.0, αjP,CaMK = 0.0      βhP,CaMK = 10.13 ∙ �1 + exp�Vm + ∆VNa,InactCaMK + 27.4034−11.1 �� 
     βjP,CaMK = 0.3 ∙ exp �−2.535 ∙ 10−7 ∙ �Vm + ∆VNa,InactCaMK ��1 + exp �−0.1 ∙ �Vm + ∆VNa,InactCaMK + 32��  
Else      αhP,CaMK = 0.135 ∙ exp�87 + Vm + ∆VNa,InactCaMK−6.8 �      αjP,CaMK = 0.82 ∙ 11 + exp �0.311 ∙ �Vm + ∆VNa,InactCaMK + 79.23��
∙ �−1.2714 ∙ 105 ∙ exp �0.2444 ∙ �Vm + ∆VNa,InactCaMK �� − 6.948 ∙ 10−5
∙ exp �−0.04391 ∙ �Vm + ∆VNa,InactCaMK ��� ∙ �Vm + ∆VNa,InactCaMK + 37.78�      βhP,CaMK = 3.56 ∙ exp �0.079 ∙ �Vm + ∆VNa,InactCaMK + 7�� + 3.1 ∙ 105
∙ exp �0.35 ∙ �Vm + ∆VNa,InactCaMK + 7�� 
     βjP,CaMK = 0.1212 ∙ exp �−0.01052 ∙ �Vm + ∆VNa,InactCaMK ��1 + exp �−0.1378 ∙ �Vm + ∆VNa,InactCaMK + 40.14�� 
 dmP,CaMKIIdt = αmP,CAMK ∙ �1 − mP,CAMK� − βmP,CaMK ∙ mP,CaMK dhP,CaMKIIdt = αhP,CaMK ∙ �1 − hP,CaMK� − βhP,CaMK ∙ hP,CaMK djP,CaMKIIdt = αjP,CaMK ∙ �1 − jP,CaMK� − βjP,CaMK ∙ jP,CaMK 
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INaP,CaMK = G�NaNP ∙ �mP,CaMK�3 ∙ hP,CaMK ∙ jP,CaMK ∙ (Vm − ENa) 
 
PKA and CaMKII Phosphorylated Channels: G�NaP = 19.5112 mSμF  INaP,Both = G�NaP ∙ �mP,PKA�3 ∙ hP,CaMK ∙ jP,CaMK ∙ (Vm − ENa) 
 
Combined INa current: f̂INaPKA = fINaP −  0.23950.9501 –  0.2395 fINaBoth = f̂INaPKA ∙ fINaP,CaMKII fINaPKA,only = f̂INaPKA − fINaBoth fINaCaMKII,only = fINaP,CaMKII − fINaBoth INa = �1 − fINaPKA,only − fINaCaMKII,only − fINaBoth� ∙ INaNP + fINaPKA,only ∙ INaP,PKA + fINaCaMKII,only
∙ INaP,CaMK + fINaBoth ∙ INaP,Both 
 
1.18.3 HRdβARS Stoch version (Chapter 7) 
The Markov model structure of Clancy and Rudy52 was employed for both normal inactivation and 
slow inactivation populations (Figure 2 of Chapter 7). Model parameters were adjusted to reproduce 
characteristics of INa and INaL from the original Hodgkin-Huxley-based formulation, including PKA- and 
CaMKII-dependent alterations (section 1.18.2). Model INa peak I-V relationship and steady-state 
inactivation are consistent with those measured in isolated canine ventricular myocytes.50 
αNa,11NP = 4.51706.6161 ∙ 10−2 ∙ exp �− Vm18.033� + 2.1276 ∙ 10−1 ∙ exp �− Vm167.77� 
αNa,12NP = 4.51706.6161 ∙ 10−2 ∙ exp �− Vm24.237� + 1.7127 ∙ 10−1 ∙ exp �− Vm167.77� 
αNa,13NP = 4.51706.6161 ∙ 10−2 ∙ exp �− Vm13.038� + 2.7731 ∙ 10−1 ∙ exp �− Vm167.77� 
βNa,11NP = 1.7687 ∙ 10−1 ∙ exp �− Vm15.905� 
βNa,12NP = 2.2240 ∙ 10−1 ∙ exp �−Vm − 6.196715.905 � 
βNa,13NP = 2.9500 ∙ 10−1 ∙ exp �−Vm − 10.89115.905 � 
αNa,2NP = 6.3736 ∙ exp �Vm + 3.3271 ∙ fINaP,CaMKII109.64 � , αNa,2lNP = αNa,2NP ∙ 1.8366 ∙ 10−4 
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βNa,iNP = 8.0991 ∙ 10−8 ∙ exp�−Vm + 3.3271 ∙ fINaP,CaMKII5.6611 � , βNa,ilNP = βNa,iNP ∙ 1.1014 ∙ 10−2 
αNa,4NP = βNa,iNP9.2183 , αNa,4lNP = αNa,4NP ∙ 1.1014 ∙ 10−2 
αNa,iNP = 3.1367 ∙ 10−2 + 1.6356 ∙ 10−5 ∙ �Vm + 3.3271 ∙ fINaP,CaMKII�,
αNa,ilNP = αNa,iNP ∙ 1.1014 ∙ 10−2 
βNa,2NP = αNa,13NP ∙ αNa,2NP ∙ βNa,iNPβNa,13NP ∙ αNa,iNP , βNa,2lNP = αNa,13NP ∙ αNa,2lNP ∙ βNa,ilNPβNa,13NP ∙ αNa,ilNP  
γNa
NP = 1.3053 ∙ 10−7 + 2.4015 ∙ 10−7 ∙ fINaP,CaMKII + 2.90 ∙ 10−71 + � 4.0[ATXII]�2 
δNa
NP = 4.8365 ∙ 10−4 fNa,slowNP = γNaNPγNaNP + δNaNP  
αNa,11P = 8.32416.6161 ∙ 10−2 ∙ exp �− Vm18.033� + 2.1276 ∙ 10−1 ∙ exp �− Vm167.77� 
αNa,12P = 8.32416.6161 ∙ 10−2 ∙ exp �− Vm24.237� + 1.7127 ∙ 10−1 ∙ exp �− Vm167.77� 
αNa,13P = 8.32416.6161 ∙ 10−2 ∙ exp �− Vm13.038� + 2.7731 ∙ 10−1 ∙ exp �− Vm167.77� 
βNa,11P = 1.0336 ∙ 10−1 ∙ exp �− Vm15.905� 
βNa,12P = 2.2972 ∙ 10−1 ∙ exp �−Vm − 6.196715.905 � 
βNa,13P = 2.6387 ∙ 10−1 ∙ exp �−Vm − 10.89115.905 � 
αNa,2P = 5.3095 ∙ exp �Vm + 0.5625 ∙ fINaP,CaMKII109.64 � , αNa,2lP = αNa,2P ∙ 1.4827 ∙ 10−4 
βNa,iP = 2.9162 ∙ 10−8 ∙ exp�−Vm + 0.5625 ∙ fINaP,CaMKII5.6779 � , βNa,ilNP = βNa,iNP ∙ 2.6707 ∙ 10−2 
αNa,4P = βNa,iP6.0179 , αNa,4lP = αNa,4P ∙ 2.6707 ∙ 10−2 
αNa,iP = 3.1367 ∙ 10−2 + 7.9063 ∙ 10−6 ∙ �Vm + 0.5625 ∙ fINaP,CaMKII�,
αNa,ilP = αNa,iP ∙ 2.6707 ∙ 10−2 
βNa,2P = αNa,13P ∙ αNa,2P ∙ βNa,iPβNa,13P ∙ αNa,iP , βNa,2lNP = αNa,13P ∙ αNa,2lP ∙ βNa,ilPβNa,13P ∙ αNa,ilP  
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γNa
P = 1.4099 ∙ 10−7 + 2.1616 ∙ 10−7 ∙ fINaP,CaMKII + 2.90 ∙ 10−71 + � 4.0[ATXII]�2 
δNa
P = 4.6975 ∙ 10−4 fNa,slowP = γNaPγNaP + δNaP   For x ∈ {NP, P} : dLC3Naxdt = βNa,11x ∙ LC2Nax + βNa,ilx ∙ LIC3Nax − �αNa,11x + αNa,ilx � ∙ LC3Nax  dLC2Naxdt = αNa,11x ∙ LC3Nax + βNa,12x ∙ LC1Nax + βNa,ilx ∙ LIC2Nax − �αNa,12x + βNa,11x + αNa,ilx � ∙ LC2Nax  dLC1Naxdt = αNa,12x ∙ LC2Nax + βNa,13x ∙ LONax + βNa,ilx ∙ LIC1Nax − �αNa,13x + βNa,12x + αNa,ilx � ∙ LC1Nax  dLONaxdt = αNa,13x ∙ LC1Nax + βNa,2lx ∙ LIFNax − �βNa,13x + αNa,2lx � ∙ LONax  dUC3Naxdt = βNa,11x ∙ LC2Nax + βNa,ix ∙ LIC3Nax − �αNa,11x + αNa,ix � ∙ UC3Nax  dUC2Naxdt = αNa,11x ∙ LC3Nax + βNa,12x ∙ LC1Nax + βNa,ix ∙ LIC2Nax − �αNa,12x + βNa,11x + αNa,ix � ∙ UC2Nax  dUC1Naxdt = αNa,12x ∙ LC2Nax + βNa,13x ∙ LONax + βNa,ix ∙ LIFNax − �αNa,13x + βNa,12x + αNa,ix � ∙ UC1Nax  dUONaxdt = αNa,13x ∙ LC1Nax + βNa,2x ∙ LIFNax − �βNa,13x + αNa,2x � ∙ UONax        dLIC3Naxdt = βNa,11x ∙ LIC2Nax + αNa,ilx ∙ LC3Nax − �αNa,11x + βNa,ilx � ∙ LIC3Nax  dLIC2Naxdt = αNa,11x ∙ LIC3Nax + βNa,12x ∙ LIFNax + αNa,ilx ∙ LC2Nax − �αNa,12x + βNa,11x + βNa,ilx � ∙ LIC2Nax  dLIFNaxdt = αNa,12x ∙ LIC2Nax + βNa,ilx ∙ LIMNax + αNa,ilx ∙ LC1Nax + αNa,2x ∙ LONax
− �αNa,4lx + βNa,12x + βNa,2lx + βNa,ilx � ∙ LIFNax  dLIMNaxdt = αNa,4lx ∙ LIFNax − βNa,ilx ∙ LIMNax       dUIC3Naxdt = βNa,11x ∙ UIC2Nax + αNa,ix ∙ UC3Nax − �αNa,11x + βNa,ix � ∙ UIC3Nax  dUIC2Naxdt = αNa,11x ∙ UIC3Nax + βNa,12x ∙ UIFNax + αNa,ix ∙ UC2Nax − �αNa,12x + βNa,11x + βNa,ix � ∙ UIC2Nax  
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dUIFNaxdt = αNa,12x ∙ UIC2Nax + βNa,ix ∙ UIMNax + αNa,ix ∙ UC1Nax + αNa,2x ∙ UONax
− �αNa,4x + βNa,12x + βNa,2x + βNa,ix � ∙ UIFNax  dUIMNaxdt = αNa,4x ∙ UIFNax − βNa,ix ∙ UIMNax   INaNP = 11.188 ∙ ��1 − fNa,slowNP � ∙ UONaNP + fNa,slowNP ∙ LONaNP� ∙ (Vm − ENa) INaP = 11.188 ∙ ��1 − fNa,slowP � ∙ UONaP + fNa,slowP ∙ LONaP � ∙ (Vm − ENa) INa = �1 − f̂INaPKA� ∙ INaNP + f̂INaPKA ∙ INaP  
 
1.19 Background Na+ current (INab) 
1.19.1 HRd2009, HRdβARS and HRdβARSStoch version (Chapters 2-7) 
Background Na+ current (INab) and co-transporter fluxes were required to maintain a resting [Na
+]i 
concentration consistent with measurements in canine epicardial myocytes.3 Na+ permeability for 
the background Na+ current was given by the constant field equation, following the formulation used 
by Gao et al.3: PNab = 0.32 ∙ 10−8 cm/s 
INab = PNab ∙ F2 ∙ VmR ∙ T ∙ [Na+]i ∙ exp �Vm ∙ FR ∙ T� − [Na+]oexp �Vm ∙ FR ∙ T� − 1   
1.20 Na+-Ca2+ exchange current (INaCa) 
1.20.1 HRd2009 and HRdβARS version (Chapters 2-6) 
The Na+-Ca2+ exchanger formulation was adopted from Bers and Weber.53 20% of exchangers were 
located in the restricted space, consistent with experimental results and previous work from our 
lab.54 vmax,NaCa  = 4.50 pA/pF, η = 0.27, KmCa,act = 1.24 ∙ 10−4 mmol/L KmCa,o  = 1.30 mmol/L, KmCa,i = 3.60 ∙ 10−3 mmol/L, KmNa,o = 87.5 mmol/L KmNa,i  = 12.3 mmol/L, ksat = 0.32  ANaCa,ss = KmCa,o ∙ [Na+]ss3 + KmNa,o3 ∙ [Ca2+]ss + KmNa,i3 ∙ [Ca2+]o ∙ �1 + [Ca2+]ssKmCa,i � + KmCa,i
∙ [Na+]o3 ∙ �1 + [Na+]ss3KmNa,i3 � + [Na+]ss3 ∙ [Ca2+]o + [Na+]o3 ∙ [Ca2+]ss 
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DNaCa,ss = [Na+]ss3 ∙ [Ca2+]o ∙ exp �η ∙ Vm ∙ FR ∙ T� − [Na+]o3 ∙ [Ca2+]ss ∙ exp�(η − 1) ∙ Vm ∙ FR ∙ T� INaCa,ss = 0.2 ∙ vmax,NaCa ∙ DNaCa,ss
�1 + �KmCa,act[Ca2+]ss�2� ∙ �1 + ksat ∙ exp�(η − 1) ∙ Vm ∙ FR ∙ T�� ∙ ANaCa,ss 
 ANaCa,i = KmCa,o ∙ [Na+]i3 + KmNa,o3 ∙ [Ca2+]i + KmNa,i3 ∙ [Ca2+]o ∙ �1 + [Ca2+]iKmCa,i � + KmCa,i ∙ [Na+]o3
∙ �1 + [Na+]i3KmNa,i3 � + [Na+]i3 ∙ [Ca2+]o + [Na+]o3 ∙ [Ca2+]i DNaCa,i = [Na+]i3 ∙ [Ca2+]o ∙ exp �η ∙ Vm ∙ FR ∙ T� − [Na+]o3 ∙ [Ca2+]i ∙ exp�(η − 1) ∙ Vm ∙ FR ∙ T� INaCa,i = 0.8 ∙ vmax,NaCa ∙ DNaCa,i
�1 + �KmCa,act[Ca2+]i �2� ∙ �1 + ksat ∙ exp�(η − 1) ∙ Vm ∙ FR ∙ T�� ∙ ANaCa,i 
 
1.21 Na+-K+ pump current (INaK) 
1.21.1 HRd2009 version (Chapter 2) 
A recently developed INaK formulation based on data from canine left ventricular epicardial 
myocytes3, 55 was incorporated into the model. Pump density was adjusted to 37°C using Q10 = 2.1.
56 
 KNaK,Ko = 1.5 mmol/L, KNaK,Nai = 2.6 mmol/L, IN̅aK = 1.4 mS/μF 
φNaK = 11 + exp �−(Vm + 92) ∙ FR ∙ T� PKNaK = [K+]o[K+]o + KNaK,KoNP  PNaNaK = � [Na+]i[Na+]i + KNaK,NaiNP �3 INaK = IN̅aK ∙ φNaK ∙ PKNaK ∙ PNaNaK 
 
1.21.2 HRdβARS version (Chapters 3-6) 
Complex results regarding the regulation of the Na+-K+-ATPase current (INaK) by PKA-dependent 
phosphorylation have been reported in various species including rat,57 guinea pig58 and dog,59 
showing either an increase or decrease in pump current depending on intracellular Ca2+ 
concentrations. More recently, it has been shown that the PKA dependent stimulation of INaK is 
isoform specific and mediated by the associated protein phospholemman (PLM).60, 61 PLM has long 
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been recognized as a major PKA and PKC substrate in the heart and is proposed to have a similar role 
as PLB for SERCA (i.e., inhibition relieved by phosphorylation). In the model we assume that the PKA-
dependent increase in INaK results from an increased Na
+ affinity mediated through PLM 
phosphorylation. The 30% increase in Na+ affinity (as found in mouse ventricular myocytes61) results 
in a 17%-33% increase in pump current for intracellular Na+ levels in the physiological range, 
consistent with the increase in INaK measured experimentally.
60-62 We assume that under normal 
physiological conditions the Ca2+ concentrations are such that only stimulation of INaK occurs and 
hence do not incorporate the Ca2+ dependence explicitly in our model. Other groups have reported 
that PLM also affects Na+-Ca2+ exchange,63 but disparate results exist.64 Because we do not 
incorporate direct effects of βAR stimulation on Na+-Ca2+ exchange,65 we also do not consider 
interactions between PLM and Na+-Ca2+ exchanger. 
 
Nonphosphorylated Channels: KNaK,KoNP = 1.5 mmol/L, KNaK,NaiNP = 2.6 mmol/L, IN̅aKNP = 1.4 mS/μF 
φNaK
NP = 11 + exp �−(Vm + 92) ∙ FR ∙ T� PKNaK,NP = [K+]o[K+]o + KNaK,KoNP  PNaNaK,NP = � [Na+]i[Na+]i + KNaK,NaiNP �3 INaKNP = IN̅aKNP ∙ φNaKNP ∙ PKNaK,NP ∙ PNaNaK,NP 
 
Phosphorylated Channels: KNaK,KoP = 1.5 mmol/L, KNaK,NaiP = 1.846 mmol/L, IN̅aKP = 1.4 mS/μF 
φNaK
P = 11 + exp �−(Vm + 92) ∙ FR ∙ T� PKNaK,P = [K+]o[K+]o + KNaK,KoP  PNaNaK,P = � [Na+]i[Na+]i + KNaK,NaiP �3 INaKP = IN̅aKP ∙ φNaKP ∙ PKNaK,P ∙ PNaNaK,P 
 
Combined current: f̂NaKP = fINaKP −  0.12630.9980 –  0.1263 INaK = f̂NaKP ∙ INaKP + (1 − f̂NaKP ) ∙ INaKNP  
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1.21.3 HRdβARS Stoch version (Chapter 7) 
Smith and Crampin have previously described a detailed model of the Na+-K+-ATPase based on a 
consecutive (“ping-pong”) model for Na+ and K+ binding.66 In their model, ‘slippage’ of ions is 
negligible due to a tight coupling between conformational changes of the pump and ion binding, 
thereby ensuring a strict 3 Na+ : 2 K+ stoichiometry. Based on these assumptions and since both 
pumps belong to the family of P-type cation transporters,66 we employed a similar two-state model 
structure as that used for SERCA. We set the ‘backward’ (counter-clockwise) rates to zero to ensure 
the strict stoichiometry. Forward rates were fitted to reproduce Na+, K+ and Vm dependence of the 
original INaK formulation for both the non-phosphorylated and phosphorylated populations. 
φNaK = 11 + exp �−(Vm + 92) ∙ FR ∙ T� kNaK,1+NP = 1.1893 ∙ φNaK ∙ � [Na+]i11.5767 + [Na+]i�1.5298 ∙ 2.00 ∙ 106N�NaK , kNaK,1−NP = 0 kNaK,2+NP = 1.6425 ∙ φNaK ∙ � [K+]o2.3694 + [K+]o�1.5298 ∙ 2.00 ∙ 106N�NaK , kNaK,2−NP = 0 nNaKNP = kNaK,2+NP + kNaK,2−NPkNaK,1+NP + kNaK,1−NP + kNaK,2+NP + kNaK,2−NP ∙ �1 − fINaKP � ∙ N�NaK FNaKNP = 3 ∙ B�nNaKNP , kNaK,1+NP ∙ ∆t� − 2 ∙ B ��1 − fINaKP � ∙ N�NaK − nNaKNP , kNaK,2+NP ∙ ∆t� 
 
kNaK,1+P = 1.1112 ∙ φNaK ∙ � [Na+]i7.6962 + [Na+]i�1.5206 ∙ 2.00 ∙ 106N�NaK , kNaK,1−P = 0 kNaK,2+P = 1.7324 ∙ φNaK ∙ � [K+]o2.3694 + [K+]o�1.5206 ∙ 2.00 ∙ 106N�NaK , kNaK,2−P = 0 nNaKP = kNaK,2+P + kNaK,2−PkNaK,1+P + kNaK,1−P + kNaK,2+P + kNaK,2−P ∙ fINaKP ∙ N�NaK FNaKP = 3 ∙ B�nNaKP , kNaK,1+P ∙ ∆t� − 2 ∙ B�fINaKP ∙ N�NaK − nNaKP , kNaK,2+P ∙ ∆t� INaK = �FNaKNP + FNaKP � ∙ 109 ∙ F∆t ∙ NA ∙ Cm ∙ Acap  
 
1.22 Late component of Na+ current (INaL) 
1.22.1 HRd2009 version (Chapter 2) 
The formulation for the late Na+ current is equivalent to that in the original HRd model.4 
αmL = 0.32 ∙ (Vm + 47.13)1 − exp�−0.1 ∙ (Vm + 47.13)� 
βmL = 0.08 ∙ exp �−Vm11� 
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hL,∞ = 11 + exp �Vm + 916.1 � 
τhL = 600 ms  dmLdt = αmL ∙ (1 − mL) − βmL ∙ mL dhLdt = hL,∞ − hLτhL   INaL = 6.500 ∙ 10−3 ∙ (mL)3 ∙ hL ∙ (Vm − ENa)  
1.22.2 HRdβARS version (Chapters 3-5) 
A small number of Na+ channels fail to inactivate rapidly and enter a “burst-mode” which in the 
model is represented by the late Na+ current (INaL). It has been shown that PKA does not affect the 
sustained component of wild-type INa channels
67 and hence INaL is not modulated by PKA in our 
model. CaMKII, on the other hand, increases the fraction of channels gating in this burst mode,24 
which is represented by an increase in maximal conductance in the model. 
αmL = 0.32 ∙ (Vm + 47.13)1 − exp�−0.1 ∙ (Vm + 47.13)� 
βmL = 0.08 ∙ exp �−Vm11� hL,∞ = 11 + exp �Vm + 916.1 � 
τhL = 600 ms  dmLdt = αmL ∙ (1 − mL) − βmL ∙ mL dhLdt = hL,∞ − hLτhL   INaLNP = 6.500 ∙ 10−3 ∙ (mL)3 ∙ hL ∙ (Vm − ENa) INaLP,CaMK = 1.600 ∙ 10−2 ∙ (mL)3 ∙ hL ∙ (Vm − ENa) INaL = �1 − fNaP,CaMKII� ∙  INaLNP + fNaP,CaMKII ∙ INaLP,CaMK 
 
1.22.3 HRdβARS SCR version (Chapter 6) 
The maximal conductance of INaL was increased to represent the midmyocardial origin of the 
myocytes68 and to match experimental APD rate dependence (Figure 2 in Chapter 6). 
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INaLNP = 1.6 ∙ 6.500 ∙ 10−3 ∙ (mL)3 ∙ hL ∙ (Vm − ENa) INaLP,CaMK = 1.6 ∙ 1.600 ∙ 10−2 ∙ (mL)3 ∙ hL ∙ (Vm − ENa)  
1.22.4 HRdβARS Stoch version (Chapter 7) 
In the stochastic model, the sustained (or late) component of INa, including its CaMKII-dependent 
regulation, is included in the Markov model of the Na+ channel. As such the INaL current is set to zero. INaL = 0 
 
1.23 Transient outward K+ current (ITo) 
1.23.1 HRd2009 version (Chapter 2) 
Model ITo is derived from a previous formulation.
69 Modifications were made to better fit 
experimental measurements from the canine (Figure 5 of Chapter 2). Model ITo density is consistent 
with multiple experiments from canine left ventricular epicardial cells.48, 70, 71 Activation and 
inactivation kinetics were adjusted to reproduce experimentally measured time to peak48, 72, 73 and 
onset of inactivation48, 71, 72. Model time to peak falls in the middle range of published data from 
canine epicardial cells and is a significant improvement on other published Hodgkin- Huxley 
formulations71, 74, in which time to peak is much faster (<1 ms) than that observed experimentally. A 
slow inactivation gate was included to reproduce the slow recovery from inactivation observed in 
canine70. 
 
RTo = exp � Vm550� , G�To = 0.4975 mS/μF 
τTo,a =
⎝
⎜
⎛ 11.2089 ∙ �1 + exp �Vm − 18.4099−29.3814 �� + 3.51 + exp �Vm + 10029.3814 �⎠⎟
⎞
−1
 
Toa,∞ = 11 + exp((Vm + 9.437)/−7.133) 
αTo,if = 0.0251 + exp((Vm + 58)/5) 
βTo,if = 19.7953 ∙ �1 + exp((Vm + 19)/−9)� 
αTo,is = 1250 ∙ �1 + exp((Vm + 60)/5)� 
βTo,is = βTo,if 
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dToadt = Toa,∞ − ToaτTo,a  dToifdt = αTo,if ∙ (1 − Toif) − βTo,if ∙ Toif dToisdt = αTo,is ∙ (1 − Tois) − βTo,is ∙ Tois ITo = G�To ∙ Toa3 ∙ Toif ∙ Tois ∙ RTo ∙ (Vm − EK) 
 
1.23.2 HRdβARS and HRdβARSStoch version (Chapters 3-7) 
Currently there is no clear evidence for PKA-dependent modulation of the 4-AP sensitive transient 
outward K+ current (ITo; see 
75 for a recent review). Recently, however, Wagner et al. found that both 
chronic (transgenic) and acute (adenovirus-mediated) CaMKII overexpression altered ITo.
33 Both 
acute and chronic CaMKII overexpression increased the slow component of ITo via increased Kv1.4 
expression, and chronic (but not acute) CaMKII overexpression caused downregulation of Kv4.2 and 
KChIP2. However, these changes were not sensitive to CaMKII-inhibtion by AIP, implicating 
mechanisms other than direct phosphorylation of channel subunits. In contrast, both acute and 
chronic CaMKII overexpression accelerated ITo recovery from inactivation and this effect was 
reversible by AIP. Consistent with these data,33 we increased the fast and slow rates of ITo recovery 
from inactivation by 1.9 and 2.9 fold, respectively for CaMKII-phosphorylated channels. The Hodgkin-
Huxley formulation with two independent inactivation gates was adapted to a combined 
biexponential formulation to match the biexponential time course of recovery from inactivation 
observed in canine ventricular myocytes.70 
 
Nonphosphorylated Channels: RTo = exp � Vm550� , G�To = 0.4975 mS/μF 
τTo,a =
⎝
⎜
⎛ 11.2089 ∙ �1 + exp �Vm − 18.4099−29.3814 �� + 3.51 + exp �Vm + 10029.3814 �⎠⎟
⎞
−1
 
Toa,∞ = 11 + exp((Vm + 9.437)/−7.133) 
αTo,if = 0.021441 + exp((Vm + 58)/5) 
βTo,if = 10.5 ∙ 9.7953 ∙ �1 + exp((Vm + 19)/−9)� 
αTo,is = 0.56034250 ∙ �1 + exp((Vm + 60)/5)� 
βTo,is = βTo,if 
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dToadt = Toa,∞ − ToaτTo,a  dToifdt = αTo,if ∙ (1 − Toif) − βTo,if ∙ Toif dToisdt = αTo,is ∙ (1 − Tois) − βTo,is ∙ Tois IToNP = G�To ∙ Toa3 ∙ (0.7356 ∙ Toif + 0.2644 ∙ Tois) ∙ (Vm − EK) 
 
CaMKII phosphorylated Channels: 
αTo,ifP,CaMK = 0.047961 + exp((Vm + 58)/5) 
βTo,ifP,CaMK = βTo,if 
αTo,isP,CaMK = 2.4600250 ∙ �1 + exp((Vm + 60)/5)� 
βTo,isP,CaMK = βTo,ifP,CaMK  dToifP,CaMKIIdt = αTo,ifP,CaMK ∙ �1 − ToifP,CaMKII� − βTo,ifP,CaMK ∙ ToifP,CaMKII dToisP,CaMKIIdt = αTo,isP,CaMK ∙ �1 − ToisP,CaMKII� − βTo,isP,CaMK ∙ ToisP,CaMKII IToP,CaMKII = G�To ∙ Toa3 ∙ �0.7356 ∙ ToifP,CaMKII + 0.2644 ∙ ToisP,CaMKII� ∙ (Vm − EK)  
Combined ITo current: ITo = �1 − fIToP,CaMKII� ∙ IToNP + fIToP,CaMKII ∙ IToP,CaMKII 
 
1.24 SR Ca2+ release (IRel) 
1.24.1 HRd2009 version (Chapter 2) 
Model SR release formulation is equivalent to that in Livshitz et al.76 
∆β0 = 1.000 mmol/L, Kβ = 0.2800 mmol/L, hβ = 10 
κ = 0.1125 pA/pF, KRel,∞ = 1.000 mmol/L, hRel = 8 KRel,τ = 0.0123 mmol/L, β0 = 4.7500 ms 
∆βτ,CaMK = ∆β01 + � KβCaMKactive�hβ 
βτ = β0 ∙ �1 + ∆βτ,CaMK� 
αRel = κ ∙ βτ 
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IRel,τ = βτ1 + KRel,τ[Ca2+]JSR IRel,∞ = αRel ∙ ICa,L1 + � KRel,∞[Ca2+]JSR�hR 
 dIReldt = − IRel,∞ +  IRelIRel,τ   
1.24.2 HRdβARS version (Chapters 3-5) 
The exact mechanisms and functional effects of ryanodine receptor (RyR) phosphorylation are still 
actively debated.77 Marks and colleagues showed increased RyR open probability after PKA-
dependent phosphorylation of Ser 2809 (Ser 2808 in mice) and dissociation of the regulatory protein 
FKBP12.6.78 Furthermore, they argued that the RyR may become hyperphosphorylated during heart 
failure, leading to increased sensitivity to Ca2+-induced RyR activation. Other groups have questioned 
these results, showing no differences in adrenergic response of S2808A knock-in mice79 and no 
differences between RyR phosphorylation levels in normal and failing canine hearts.80 The 
mechanisms of RyR phosphorylation are further complicated by the fact that there are multiple 
consensus phosphorylation sites for multiple kinases. Xiao and others provided evidence that not 
S2809 but S2030 is the major phosphorylation site activated by βAR stimulation and that 
phosphorylation increased the sensitivity of the RyR to luminal Ca2+.81 Other confounding effects 
include the effects of adrenergic stimulation on PLB and ICaL, which change the trigger strength and 
Ca2+ load that affect RyR properties indirectly. Ginsburg and Bers analyzed the effects of 
isoproterenol on SR-Ca2+ release in rabbit and mouse ventricular myocytes with controlled Ca2+ load 
and trigger strength and found no difference in the total amount of Ca2+ released compared to 
control conditions. However, this amount of Ca2+ was released faster during isoproterenol.82 Similar 
findings were reported recently by Ogrodnik and Niggli in guinea pig ventricular myocytes.83 
 
Because the model does not distinguish individual phosphorylation sites on a substrate, we are only 
interested in the overall functional response of RyRs to βAR stimulation. Here, we adopt the results 
from Ginsburg and Bers.82 The phosphorylated channels release approximately the same total 
amount of Ca2+ when the ICaL trigger and Ca
2+ load are matched to baseline conditions (same initial 
Ca2+ concentration in the JSR and ICaL clamped) but the maximum release is approximately 1.8 fold 
higher in phosphorylated channels than in non-phosphorylated channels. In addition, the RyR can be 
phosphorylated by CaMKII. Formulations for the changes caused by CaMKII phosphorylation were 
included in our baseline model and remained unchanged.21, 76  
 
Besides effects on the triggered, Ca2+ induced Ca2+ release, βAR stimulation also increases the leak of 
Ca2+ from the SR.83, 84 This effect is independent of cAMP but sensitive to CaMKII inhibition and 
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results in a much steeper dependence of leak amplitude on SR Ca2+ load.84 We incorporate an 
explicit JSR Ca2+ leak formulation with phosphorylation as a direct function of ISO, because of the 
cAMP independence and as yet unclear mechanism resulting in cAMP-independent increases in 
CaMKII phosphorylation of RyR. 
 
Nonphosphorylated Channels: 
∆β0
NP = 2.0mmol/L, β0 = 3.167 ms, κ = 0.1125 μA/uF KRel,τ = 0.0123 mmol/L, KRel,∞ = 1.0 mmol/L, hR = 8.0 
∆βτ,CaMK = ∆β0NP ∙ fRyRP,CaMKII 
βτ = β0 ∙ �1 + ∆βτ,CaMK� 
αRel = κ ∙ βτ IRel,τNP = βτ1 + KRel,τ[Ca2+]JSR IRel,∞NP = αRel ∙ ICa,L1 + � KRel,∞[Ca2+]JSR�hR 
 dIRelNPdt = − IRel,∞NP +  IRelNPIRel,τNP  IRyR,leakNP = 1.75 ∙ 10−4 ∙ exp �[Ca2+]JSR20 � ∙ �[Ca2+] JSR − [Ca2+]SS� 
 
Phosphorylated Channels: 
∆β0
P = 0.0 mmol/L 
∆βτ,CaMK = ∆β0P ∙ fRyRP,CaMKII 
βτ = β0 ∙ �1 + ∆βτ,CaMK� IRel,τP = 0.4 ∙ βτ1 + KRel,τ[Ca2+]JSR IRel,∞P = 1.8 ∙ αRel ∙ ICa,L1 + � KRel,∞[Ca2+]JSR�hR 
 dIRelPdt = − IRel,∞P +  IRelPIRel,τP  
Appendix 
| 309 
IRyR,leakP = 5.0 ∙ 10−4 ∙ exp�[Ca2+]JSR1.1 � ∙ �[Ca2+] JSR − [Ca2+]SS� 
 
Combined current: 
f̂RyRP = fRyRp −  �0.0329 + [RyR]ARN[RyR]tot �0.9586 – �0.0329 + [RyR]ARN[RyR]tot � df̂RyR,leakPdt = � [ISO][ISO] + 0.05 − f̂RyR,leakP �τRyR,leak , τRyR,leak = 100 s IRel = �1 − f̂RyRP � ∙ IRelNP + f̂RyRP ∙ IRelP + �1 − f̂RyR,leakP � ∙ IRyR,leakNP + f̂RyR,leakP ∙ IRyR,leakP  
 
Store-overload induced Ca2+ release: 
αSOICR = 0.00781 + exp�− [Ca2+]JSR − 2.38141.0 ∙ 10−4 � 
βSOICR = 7.7525 ∙ 10−4 + 7.6084 ∙ 10−21 + exp �[Ca2+]JSR − 0.74101.0 ∙ 10−4 � dSwitchOndt = αSOICR ∙ (1 − SwitchOn) − βSOICR ∙ SwitchOn IRelSpon,∞ = GRelSpon1 + exp �− SwitchOn − 0.750.0001 � , GRelSpon = 0.6655 
τRelSpon = 7.01531 + KRel,τ[Ca2+]JSR dIRel,SOICRdt = IRelSpon,∞ − IRel,SOICRτRelSpon   IRel = �1 − f̂RyRP � ∙ IRelNP + f̂RyRP ∙ IRelP + �1 − f̂RyR,leakP � ∙ IRyR,leakNP + f̂RyR,leakP ∙ IRyR,leakP + IRel,SOICR 
 
1.24.3 HRdβARS SCR version (Chapter 6) 
To initiate diastolic Ca2+ release, steady-state RyR activation was set to a constant value in one of the 
two domains (indicated with superscript x) for the interval of diastolic SR Ca2+ release. In addition, 
the steepness of the dependence on SR Ca2+ load and ICaL trigger strength were adjusted to reduce 
the incidence of secondary activation of RyR during repolarization. hR = 10 
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IRel,∞NP = αRel1 + � KRel,∞[Ca2+]JSRx �hR ∙
IICaLx1 + exp �(IICaLx + 1.5)0.0001 � − SCRlevel 
IRel,∞P = 1.9925 ∙ αRel1 + � KRel,∞[Ca2+]JSRx �hR ∙
IICaLx1 + exp �(IICaLx + 1.5)0.0001 � − SCRlevel 
 
1.24.4 HRdβARS Stoch version (Chapter 7) 
The original phosphorylated and non-phosphorylation CICR formulations were replaced by two 4-
state Markov Models proposed by Restrepo et al. in their local control model of Ca2+ handling in the 
rabbit ventricular myocyte.85 Model parameters were adjusted to reproduce rate-dependent Ca2+ 
transient (CaT) properties (amplitude, time to peak, and time constant of decay) of the original 
HRdβAR model in the absence or presence of β-adrenergic stimulation (βARS). 
 
Nonphosphorylated Channels: M�RyRNP = 11 + �[Ca2+]JSR0.4163 �15.24 
AcRyR,∞NP = 3.9665 ∙ 10−5 ∙ �exp�[Ca2+]JSR2.4898 � − 1� + 0.0321 + �1.1960 ∙ 10−3 ∙ �1 + 2.0 ∙ fRYRP,CaMKII�[Ca2+]ss,CaL �8 AclRyR,∞NP = 3.9665 ∙ 10−5 ∙ �exp�[Ca2+]JSR2.4898 � − 1� + 0.00051 + �0.003 ∙ �1 + 2.0 ∙ fRYRP,CaMKII�[Ca2+]ss,CaL �8 
τRyR,AcNP = 0.2 + 0.5000 ∙ M�RyRNP  kRyR,12NP = AcRyR,∞NPτRyR,AcNP , kRyR,21NP = 1 − AcRyR,∞NPτRyR,AcNP  kRyR,43NP = AclRyR,∞NPτRyR,AcNP , kRyR,34NP = 1 − AclRyR,∞NPτRyR,AcNP  kRyR,14,23NP = M�RyRNP0.5250 , kRyR,41NP = 1395.19 kRyR,32NP = kRyR,41NP ∙ kRyR,12NP ∙ kRyR,34NPkRyR,43NP ∙ kRyR,21NP   dCBRyRNPdt = kRyR,21NP ∙ OBRyRNP + kRyR,41NP ∙ CURyRNP − �kRyR,12NP + kRyR,14,23NP � ∙ CBRyRNP  
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dOBRyRNPdt = kRyR,12NP ∙ CBRyRNP + kRyR,32NP ∙ OURyRNP − �kRyR,21NP + kRyR,14,23NP � ∙ OBRyRNP  dOURyRNPdt = kRyR,14,23NP ∙ OBRyRNP + kRyR,43NP ∙ CURyRNP − �kRyR,32NP + kRyR,34NP � ∙ OURyRNP  dCURyRNPdt = kRyR,14,23NP ∙ CBRyRNP + kRyR,34NP ∙ OURyRNP − �kRyR,41NP + kRyR,43NP � ∙ CURyRNP  
 
IRelNP = 3.5289 ∙ 10−5Vss ∙ �OBRyRNP + OURyRNP � ∙ �[Ca2+]JSR − [Ca2+]ss,CaL� 
 
Phosphorylated Channels: M�RyRP = 11 + �[Ca2+]JSR0.4240 �15.24 
AcRyR,∞P = 1.8891 ∙ 10−5 ∙ �exp�[Ca2+]JSR1.4257 � − 1� + 0.071 + �0.003 ∙ �1 + 2.0 ∙ fRYRP,CaMKII�[Ca2+]ss,CaL �8 AclRyR,∞P = 1.8891 ∙ 10−5 ∙ �exp�[Ca2+]JSR1.4257 � − 1� + 0.00051 + �0.006 ∙ �1 + 2.0 ∙ fRYRP,CaMKII�[Ca2+]ss,CaL �8 
τRyR,AcP = 0.3026 + 3.0000 ∙ M�RyRP  kRyR,12P = AcRyR,∞PτRyR,AcP , kRyR,21P = 1 − AcRyR,∞PτRyR,AcP  kRyR,43P = AclRyR,∞PτRyR,AcP , kRyR,34P = 1 − AclRyR,∞PτRyR,AcP  kRyR,14,23P = M�RyRP0.6000 , kRyR,41P = 1409.16 kRyR,32P = kRyR,41P ∙ kRyR,12P ∙ kRyR,34PkRyR,43P ∙ kRyR,21P   dCBRyRPdt = kRyR,21P ∙ OBRyRP + kRyR,41P ∙ CURyRP − �kRyR,12P + kRyR,14,23P � ∙ CBRyRP  dOBRyRPdt = kRyR,12P ∙ CBRyRP + kRyR,32P ∙ OURyRP − �kRyR,21P + kRyR,14,23P � ∙ OBRyRP  dOURyRPdt = kRyR,14,23P ∙ OBRyRP + kRyR,43P ∙ CURyRP − �kRyR,32P + kRyR,34P � ∙ OURyRP  dCURyRPdt = kRyR,14,23P ∙ CBRyRP + kRyR,34P ∙ OURyRP − �kRyR,41P + kRyR,43P � ∙ CURyRP  
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IRelP = 3.5289 ∙ 10−5Vss ∙ �OBRyRP + OURyRP � ∙ �[Ca2+]JSR − [Ca2+]ss,CaL� 
 
Combined current: 
f̂RyRP = fRyRp −  �0.0329 + [RyR]ARN[RyR]tot �0.9586 – �0.0329 + [RyR]ARN[RyR]tot � IRel = �1 − f̂RyRP � ∙ IRelNP + f̂RyRP ∙ IRelP  
 
1.25 SR Ca2+ uptake (Iup) 
1.25.1 HRd2009 version (Chapter 2) 
Model SR uptake formulation is equivalent to that in Livshitz et al.76 
∆�Km,PLB = 1.700 ∙ 10−4 mmol/L, Km,CaMK = 0.15, NSR������ = 15 mmol/L  
∆�Iup,CaMK = 0.75, Km,up = 9.200 ∙ 10−4 mmol/L, Iu̅p = 4.3750 ∙ 10−3 mmol/L/ms 
 
∆Km,PLB = ∆�Km,PLB ∙ CaMKactiveKm,CaMK + CaMKactive 
∆Iup,CaMK = ∆�Iup,CaMK ∙ CaMKactiveKm,CaMK + CaMKactive Iup = Iu̅p ∙ �1 + ∆Iup,CaMK� ∙ [Ca2+]i[Ca2+]i + Km,up − ∆Km,PLB − Iu̅pNSR������ ∙ [Ca2+]NSR 
 
1.25.2 HRdβARS version (Chapters 3-6) 
Phospholamban (PLB), the inhibitor protein of the SR-Ca2+ uptake pump (SERCA2a) can be 
phosphorylated at Ser 10 by PKC, Ser 16 by PKA and at Thr 17 by CaMKII. Ser 10 phosphorylation is 
physiologically not relevant, but phosphorylation of Ser 16 and Thr 17 relieves PLB inhibition of 
SERCA2a, 86 thereby increasing the affinity of SERCA2a to Ca2+ 87 and increasing the Ca2+ uptake into 
the SR and contributing to the lusitropic effect of βAR stimulation. Phosphorylation of PLB by CaMKII 
was already incorporated in our baseline model,4, 21 and we use the formulation presented there. We 
assume that phosphorylation of PLB by PKA and CaMKII occurs independently, as suggested by 
Hagemann et al.88 Other studies have claimed that Ser 16 phosphorylation by PKA is required for Thr 
17 phosphorylation by CaMKII in situ.86 However, this could be because βAR stimulation indirectly 
enhances the CaMKII signaling pathway through increased Ca2+-cycling, thereby making the extent of 
Thr 17 phosphorylation strongly influenced by Ser 16 phosphorylation. This is also suggested by the 
rightward shift in Thr 17 isoproterenol dose-response curve in comparison with Ser 16.89 The two 
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separate phosphorylation processes result in 4 populations of channels: non-phosphorylated, 
phosphorylated by PKA only, phosphorylated by CaMKII only and phosphorylated by both kinases.  
 
In addition, we have adapted the modulation of SERCA2a by CaMKII that was present in the baseline 
model21 to enhance the frequency dependent increase in CaT decay. DeSantiago et al. showed that 
frequency dependent acceleration of relaxation (FDAR) and CaT decay are mediated by CaMKII but 
are independent of PLB.90 In the model, time constants of CaT decay are 188 ms and 239 ms at CL = 
1000 ms and CL = 6000 ms, respectively, consistent with experimental observations in canine 
ventricular myocytes (147±22 ms and 237±55 ms).91 FDAR, as quantified by the ratio of CaT decay 
time-constants at CLs of 500 and 5000 ms, is 0.56 in the model. This is qualitatively similar to the 
value of 0.36±0.03 observed by DeSantiago et al. in rat ventricular myocytes, considering the well 
known differences in Ca2+ handling between rodents and large mammals. Consistent with the data of 
DeSantiago et al., FDAR is significantly reduced (ratio of 0.95) when CaMKII is inhibited. As in 
previous modeling studies,92 we combined the NSR leak flux Ileak, which represents reverse mode 
SERCA2a, in the formulation of Iup,. 
 
fupPKA = fPLBP − 0.65910.9945 − 0.6591 fupBoth = fupPKA ∙ fPLBP,CaMKII fupPKA,only = fupPKA − fupBoth fupCaMKII,only = fPLBP,CaMKII − fupBoth 
 Km,upBaseline = 9.2 ∙ 10−4 mmol/L, Km,upPKA = 4.97 ∙ 10−4 mmol/L,  Km,upCaMKII = 7.5 ∙ 10−4 mmol/L, Km,upBoth = 4.97 ∙ 10−4 mmol/L Iu̅p = 4.375 ∙ 10−3 mmol/Lms ,   [Ca2+]NSR,Max = 15 mmol/L Km,up = �1 − fupPKA,only − fupCaMKII,only − fupBoth� ∙ Km,upBaseline + fupPKA,only ∙ Km,upPKA + fupCaMKII,only
∙ Km,upCaMKII + fupBoth ∙ Km,upBoth  fSERCA2aCaMKII = 11 + � 0.03CaMKactive�2 Iup = �1 + 2.25 ∙ fSERCA2aCaMKII � ∙ Iu̅p ∙ � [Ca2+]iKm,up + [Ca2+]i − [Ca2+]NSR[Ca2+]NSR,Max� 
 
1.25.3 HRdβARS Stoch version (Chapter 7) 
The SR and sarcolemmal Ca2+-ATPases (underlying Iup and IpCa, respectively) were simulated using the 
two-state, four-transition model structure of Tran et al.31 Parameters of the models were adjusted to 
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reproduce the Ca2+ dependence of the deterministic formulations (section 1.25.2). We assumed that 
the state distribution changes more rapidly than the changes in ionic concentrations on both sides of 
the pump, resulting in a quasi-equilibrium situation in which individual rates are decoupled. The 
number of ions transported via each transition was derived from a Binomial distribution and the net 
ion flux (or current) in the interval ∆t was determined. N�SERCA = 2.20 ∙ 106 pumps fupNP = 1 − fupPKA,only − fupCaMKII,only − fupBoth kSERCA,1+NP = 4.6571 ∙ 103 ∙ [Ca2+]i ∙ 2.00 ∙ 106N�SERCA , kSERCA,1−NP = 1.1618 ∙ 2.00 ∙ 106N�SERCA  kSERCA,2+NP = 0.7514 ∙ [Ca2+]NSR ∙ 2.00 ∙ 106N�SERCA , kSERCA,2−NP = 2.5205 ∙ 2.00 ∙ 106N�SERCA  nSERCANP = kSERCA,2+NP + kSERCA,2−NPkSERCA,1+NP + kSERCA,1−NP + kSERCA,2+NP + kSERCA,2−NP ∙ fupNP ∙ N�SERCA JupNP = B�nSERCANP , kSERCA,1+NP ∙ ∆t� − B�fupNP ∙ N�SERCA − nSERCANP , kSERCA,2+NP ∙ ∆t� 
 
kSERCA,1+P = 7.5269 ∙ 103 ∙ [Ca2+]i ∙ 2.00 ∙ 106N�SERCA , kSERCA,1−P = 0.7188 ∙ 2.00 ∙ 106N�SERCA  kSERCA,2+P = 0.8456 ∙ [Ca2+]NSR ∙ 2.00 ∙ 106N�SERCA , kSERCA,2−P = 2.6131 ∙ 2.00 ∙ 106N�SERCA  nSERCAP = kSERCA,2+P + kSERCA,2−PkSERCA,1+P + kSERCA,1−P + kSERCA,2+P + kSERCA,2−P ∙ �fupPKA,only + fupBoth� ∙ N�SERCA JupPKA = B�nSERCAP , kSERCA,1+P ∙ ∆t� − B ��fupPKA,only + fupBoth� ∙ N�SERCA − nSERCAP , kSERCA,2+P ∙ ∆t� 
 
kSERCA,1+CaMKIIP = 5.6542 ∙ 103 ∙ [Ca2+]i ∙ 2.00 ∙ 106N�SERCA , kSERCA,1−CaMKIIP = 0.7009 ∙ 2.00 ∙ 106N�SERCA  kSERCA,2+CaMKIIP = 1.1779 ∙ [Ca2+]NSR ∙ 2.00 ∙ 106N�SERCA , kSERCA,2−CaMKIIP = 2.6034 ∙ 2.00 ∙ 106N�SERCA  nSERCACaMKIIP = kSERCA,2+CaMKIIP + kSERCA,2−CaMKIIPkSERCA,1+CaMKIIP + kSERCA,1−CaMKIIP + kSERCA,2+CaMKIIP + kSERCA,2−CaMKIIP ∙ fupCaMKII,only ∙ N�SERCA JupCaMKII = B�nSERCACaMKIIP, kSERCA,1+CaMKIIP ∙ ∆t� − B �fupCaMKII,only ∙ N�SERCA − nSERCACaMKIIP, kSERCA,2+CaMKIIP ∙ ∆t� 
 
Iup = �1 + 2.25 ∙ fSERCA2aCaMKII � ∙ �JupNP + JupPKA + JupCaMKII� ∙ 109∆t ∙ NA ∙ VNSR  
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1.26 Membrane potential 
A detailed description of computational methods for strand simulations has been described 
previously.93 Briefly, propagation in a strand of serially connected HRd model cells was simulated via 
a finite difference approximation of the cable equation and no-flux boundary conditions were 
employed. Iion = ICaL + ICab +  IpCa + ICl,b + ICl(Ca) + IK1 + IKr + IKs + IKur +  INaCa + INaCa,ss + INa + INaK+ INab + INaL + ITo 
 
For single cell simulations: dVmdt = − 1Cm ∙ (Iion + Istim) 
 
For 1-dimensional strand simulations with spatial step-size ∆x: 
dVmdt = 1Cm ∙ ��Vmi−1 − Vmi � − �Vmi+1 − Vmi �∆x2 ∙ 1000 ∙ r2 ∙ RCG ∙ Ri − (Iion + Istim)� 
Ri = Rmyo + Rg∆x , Rmyo = 150 Ω ∙ cm, Rg = 1.5 Ω ∙ cm2 
 
2. β-ADRENERGIC SIGNALING MODEL 
 
2.1 General constants 
The tables in this section provide an overview of the parameters used in the βAR signaling model. 
Parameters are taken directly from the cited literature (indicated by #), converted from the cited 
literature (indicated by &), result from a direct fit from the data in the cited literature (@) or result 
from a global fit to more macroscopic data (%). Species specificity is indicated by (C) for dog, (R) for 
rat, (A) for Rabbit, (M) for mouse, (N) for expressions in Chinese hamster ovary cells, (E) for 
expressions in insect cells, (G) for guinea pig and (H) for human.  
 
It should be noted that all rate constants and derivatives in the adrenergic signaling component of 
the model are given in s-1, whereas the electrophysiological model operates in ms-1. As such, 
derivatives of the signaling component have to be scaled by a factor 1000 when both components 
are implemented.  
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Parameter Value Description Ref [L] 0…1 μmol/L Concentration of isoproterenol  [IBMX] 0…100 μmol/L Concentration of IBMX  VCELL 3.801E-5 μL Cell volume 21, 94# VCAV 0.02∙ VCELL Caveolar volume 21# VECAV 0.04∙ VCELL Extracaveolar volume 94& VCYT 0.678∙ VCELL Cytosolic volume 21# 
 
2.2 State vector 
# Variable Description Initial 
1 [Gs]α,GTPCAV  Concentration of active Gsα subunit in caveolar compartment (μmol/L) 6.8504E-03 
2 [Gs]α,GTPECAV  Concentration of active Gsα subunit in extracaveolar compartment (μmol/L) 1.8463E-02 
3 [Gs]α,GTPCYT  Concentration of active Gsα subunit in cytoplasmic compartment (μmol/L) 7.3142E-04 
4 [Gs]βγCAV Concentration of Gsβγ subunit in caveolar compartment (μmol/L) 7.4577E-03 
5 [Gs]βγECAV Concentration of Gsβγ subunit in extracaveolar compartment (μmol/L) 1.9102E-02 
6 [Gs]βγCYT Concentration of Gsβγ subunit in cytoplasmic compartment (μmol/L) 1.1514E-03 
7 [Gs]α,GDPCAV  Concentration of inactive Gsα subunit in caveolar compartment (μmol/L) 6.0732E-04 
8 [Gs]α,GDPECAV  Concentration of inactive Gsα subunit in extracaveolar compartment (μmol/L) 6.3904E-04 
9 [Gs]α,GDPCYT  Concentration of inactive Gsα subunit in cytoplasmic compartment (μmol/L) 4.1999E-04 
10 [Gi]α,GTPCAV  Concentration of active Giα subunit in caveolar compartment (μmol/L) 1.5963E-03 
11 [Gi]α,GTPECAV  Concentration of active Giα subunit in extracaveolar compartment (μmol/L) 3.6432E-04 
12 [Gi]βγCAV Concentration of active Giβγ subunit in caveolar compartment (μmol/L) 2.0991E-03 
13 [Gi]βγECAV Concentration of active Giβγ subunit in extracaveolar compartment (μmol/L) 7.0566E-04 
14 [Gi]α,GDPCAV  Concentration of inactive Giα subunit in caveolar compartment (μmol/L) 5.0279E-04 
15 [Gi]α,GDPECAV  Concentration of inactive Giα subunit in extracaveolar compartment (μmol/L) 3.4134E-04 
16 [cAMP]CAV Concentration of cAMP in caveolar compartment (μmol/L) 3.4710E-01 
17 [cAMP]ECAV Concentration of cAMP in extracaveolar compartment (μmol/L) 9.6236E+00 
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18 [cAMP]CYT Concentration of cAMP in cytosolic compartment (μmol/L) 4.7408E-01 
19 �Rβ1�PKA,totCAV  Concentration of total PKA-phosphorylated β1 receptors (caveolar; μmol/L) 1.4904E-02 
20 �Rβ1�PKA,totECAV  Concentration of total PKA-phosphorylated β1 receptors (extracaveolar; μmol/L) 2.0302E-02 
21 �Rβ1�PKA,totCYT  Concentration of total PKA-phosphorylated receptors (cytoplasmic; μmol/L) 9.4446E-03 
22 �Rβ1�GRK,totCAV  Concentration of total GRK-phosphorylated receptors (caveolar; μmol/L) 0.0000E+00 
23 �Rβ1�GRK,totECAV  Concentration of total GRK-phosphorylated receptors (extracaveolar; μmol/L) 0.0000E+00 
24 �Rβ1�GRK,totCYT  Concentration of total GRK-phosphorylated receptors (cytoplasmic; μmol/L) 0.0000E+00 
25 �Rβ2�PKA,totCAV  Concentration of total PKA-phosphorylated β2 receptors (caveolar; μmol/L) 2.7546E-02 
26 �Rβ2�PKA,totECAV  Concentration of total PKA-phosphorylated β2 receptors (extracaveolar; μmol/L) 1.1025E-02 
27 �Rβ2�GRK,totCAV  Concentration of total GRK-phosphorylated β2 receptors (caveolar; μmol/L) 0.0000E+00 
28 �Rβ2�GRK,totECAV  Concentration of total GRK-phosphorylated β2 receptors (extracaveolar; μmol/L) 0.0000E+00 
29 [ARC]CAV Concentration of PKA RC dimer with 1 cAMP molecule bound (caveolar; μmol/L) 9.0480E-02 
30 [A2RC]CAV Concentration of PKA RC dimer with 2 cAMP molecules bound (caveolar; μmol/L) 2.7649E-03 
31 [A2R]CAV Concentration of PKA R subunit with 2 cAMP molecules bound (caveolar; μmol/L) 2.2548E-01 
32 [C]CAV Concentration of free PKA catalytic subunit (caveolar; μmol/L) 3.2657E-02 
33 [PKIC]CAV Concentration of PKI inactivated PKA C subunit (caveolar; μmol/L) 1.9282E-01 
34 [ARC]ECAV Concentration of PKA RC dimer with 1 cAMP molecule bound (extracaveolar; μmol/L) 2.0544E-01 
35 [A2RC]ECAV Concentration of PKA RC dimer with 2 cAMP molecules bound (extracaveolar; μmol/L) 1.7406E-01 
36 [A2R]ECAV Concentration of PKA R subunit with 2 cAMP molecules bound (extracaveolar; μmol/L) 8.1716E-01 
37 [C]ECAV Concentration of free PKA catalytic subunit (extracaveolar; μmol/L) 5.6725E-01 
38 [PKIC]ECAV Concentration of PKI inactivated PKA C subunit (extracaveolar) 2.4991E-01 
39 [ARC]CYT Concentration of PKA RC dimer with 1 cAMP molecule 
bound (cytoplasmic; μmol/L) 
6.4693E-02 
40 [A2RC]CYT Concentration of PKA RC dimer with 2 cAMP molecules bound (cytoplasmic; μmol/L) 6.6500E-02 
41 [A2R]CYT Concentration of PKA R subunit with 2 cAMP molecules bound (cytoplasmic; μmol/L) 4.8906E-01 
42 [C]CYT Concentration of free PKA catalytic subunit (cytoplasmic; μmol/L) 3.6211E-01 
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43 [PKIC]CYT Concentration of PKI inactivated PKA C subunit (cytoplasmic; μmol/L) 1.2695E-01 
44 [PDE3]PCAV Concentration of phosphorylated PDE3 (caveolar; μmol/L) 2.3692E-02 
45 [PDE3]PCYT Concentration of phosphorylated PDE3 (cytoplasmic; μmol/L) 1.2840E-02 
46 [PDE4]PCAV Concentration of phosphorylated PDE4 (caveolar; μmol/L) 6.3736E-03 
47 [PDE4]PECAV Concentration of phosphorylated PDE4 (extracaveolar; μmol/L) 4.2917E-05 
48 [PDE4]PCYT Concentration of phosphorylated PDE4 (cytoplasmic; μmol/L) 9.1704E-03 
49 [Inhib1]PCYT Concentration of phosphorylated PP1 Inhibitor 1 (cytoplasmic; μmol/L) 2.8266E-02 
50 [ICaL]P Concentration of phosphorylated L-type Ca2+ channels 6.7371E-04 
51 [IKs]P Concentration of phosphorylated IKs channels 7.6599E-04 
52 fPLBp  Fraction of phosphorylated PLB 5.9217E-01 
53 fTnIp  Fraction of phosphorylated TnI 6.7351E-01 
54 fINap  Fraction of phosphorylated INa channels 2.3948E-01 
55 fINaKp  Fraction of phosphorylated INaK 1.2635E-01 
56 [RyR]P Concentration of phosphorylated RyR 4.1069E-03 
57 fIKurp  Fraction of phosphorylated IKur 5.8938E-02 
58 fICaLP,CaMKII Fraction of CaMKII-phosphorylated ICaL 0.0000E+00 
59 fPLBP,CaMKII Fraction of CaMKII-phosphorylated PLB 0.0000E+00 
60 fINaP,CaMKII Fraction of CaMKII-phosphorylated INa 0.0000E+00 
61 fRyRP,CaMKII Fraction of CaMKII-phosphorylated RyR 0.0000E+00 
62 fIToP,CaMKII Fraction of CaMKII-phosphorylated ITo 0.0000E+00 
63 fIK1P,CaMKII Fraction of CaMKII-phosphorylated IK1 0.0000E+00 
 
2.3 Adrenergic receptor and G protein activation 
Both β1 and β2 adrenergic receptor isoforms are incorporated in the model. The former make up 
80% of the βAR in healthy ventricular myocytes and are distributed throughout the whole cell.95, 96 In 
contrast, β2AR are highly localized in the CAV domain.97 β2AR in the model have higher affinity for 
isoproterenol, consistent with experimental observations.98 Upon phosphorylation by PKA, β2AR 
switch from predominantly Gs-coupled to Gi-coupled, thereby providing an attenuating signal during 
intense βAR stimulation.99 The exact mechanism by which the Gi pathway localizes the effects of 
β2AR stimulation is not known. Jo et al.100 have shown that the Gβγ subunits of Gi and 
phosphatidylinositol 3 kinase play a major role in limiting the effect of β2AR stimulation on PLB 
phosphorylation in adult rat ventricular myocytes. The exact link between phosphatidylinositol 3 
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kinase and PLB phosphorylation, however is unknown. On the other hand the main adenylyl cyclase 
(AC) isoform in the heart is known to be inhibited by Gi. In line with the adenylyl cyclase mediated 
mechanism, Zama et al.99  have shown that pertussis toxin (PTX) mediated inhibition of Gi results in 
enhanced AC activity in pseudo- phosphorylated β2AR. Because of the incomplete understanding of 
the phosphatidylinositol 3 kinase pathway, we have currently only modeled the effect of β2AR-
mediated Gi activation on AC. 
 
The complex formation between receptor, G-protein (Gs for β1AR, either Gs or Gi for β2AR) and 
ligand is assumed to be very fast94, 101 and hence is given by algebraic, steady-state equations. This 
requires finding the unique nonnegative real root of a second order (for CYT and Gi binding to β2AR 
in CAV and ECAV) or third order (β1AR/β2AR/Gs/Ligand binding in CAV and ECAV) polynomial to 
determine the distribution of free and complexed proteins. For both receptor isoforms, 
desensitization due to PKA phosphorylation is independent of ligand and/or G-protein binding, 
whereas desensitization through GRK only affects the ligand bound states.101, 102 G-proteins are 
activated through a slow process by the RG complex and a fast process by the LRG complex. 
Inhibition of either β1AR or β2AR is simulated by reducing the active fraction of the LRG complex of 
each respective receptor isoform. 
 
For 𝑥 ∈ {𝐶𝐴𝑉,𝐸𝐶𝐴𝑉}: 
�Rβ1�tot𝑥 = fR,β1x ∙ �Rβ1�tot ∙ VCELLVx  [Rβ2]tot𝑥 = fR,β2x ∙ [Rβ2]tot ∙ VCELLVx  [Gs]αβγx = fGsx ∙ [Gs]tot ∙ VCELLVx − [Gs]α,GTPx − [Gs]α,GDPx  [Gi]αβγx = fGix ∙ [Gi]tot ∙ VCELLVx − [Gi]α,GTPx − [Gi]α,GDPx  [Rβ1]np,totx = [Rβ1]totx − [Rβ1]PKA,totx − [Rβ1]GRK,totx  [Rβ2]np,totx = [Rβ2]totx − [Rβ2]PKA,totx − [Rβ2]GRK,totx   aLRGi = 1Kβ2,N ∙ �Kβ2,F + [L]� ∙ �Kβ2,N + [L]� bLRGi = [Gi]αβγx ∙ �L + Kβ2,F� − �Kβ2,F + [L]� ∙ �Rβ2�PKA,totx + Kβ2,A ∙ Kβ2,F + Kβ2,A ∙ Kβ2,F ∙ [L]Kβ2,N  cLRGi =  −�Rβ2�PKA,totx ∙ Kβ2,A ∙ Kβ2,F 
�Rβ2�PKA,fx = −bLRGi + �bLRGi2 − 4 ∙ aLRGi ∙ cLRGi2 ∙ aLRGi  
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[Gi]fx = [Gi]αβγx1 + �Rβ2�PKA,fxKβ2,A + [L] ∙ �Rβ2�PKA,fxKβ2,A ∙ Kβ2,F  [Rβ2Gi]PKAx = [Rβ2]PKA,fx ∙ [Gi]fxKβ2,A  [LRβ2Gi]PKAx = [L] ∙ [Rβ2]PKA,fx ∙ [Gi]fxKβ2,A ∙ Kβ2,F   bLRG = �Rβ1�np,totx + �Kβ1,C ∙ Kβ1,H ∙ Kβ2,L ∙ [L]2 − [Gs]αβγx
∙ �Kβ1,L ∙ Kβ2,L ∙ [L]2 + Kβ1,H ∙ Kβ2,H ∙ Kβ1,L ∙ Kβ2,L + Kβ1,H ∙ Kβ1,L ∙ Kβ2,L ∙ [L]+ Kβ2,H ∙ Kβ1,L ∙ Kβ2,L ∙ [L]� +  Kβ2,C ∙ Kβ2,H ∙ Kβ1,L ∙ [L]2 + Kβ1,L ∙ Kβ2,L ∙ [L]2
∙ �Rβ2�np,totx + Kβ1,C ∙ Kβ1,H ∙ Kβ1,L ∙ Kβ2,H ∙ Kβ2,L + Kβ1,H ∙ Kβ1,L ∙ Kβ2,C ∙ Kβ2,H
∙ Kβ2,L + Kβ1,C ∙ Kβ1,H ∙ Kβ2,H ∙ Kβ2,L ∙ [L] + Kβ1,H ∙ Kβ1,L ∙ Kβ2,C ∙ Kβ2,H ∙ [L]+  Kβ1,C ∙ Kβ1,L ∙ Kβ2,H ∙ Kβ2,L ∙ [L] + Kβ1,L ∙ Kβ2,C ∙ Kβ2,H ∙ Kβ2,L ∙ [L] + �Rβ2�np,totx
∙ �Kβ1,H ∙ Kβ1,L ∙ Kβ2,H ∙ Kβ2,L + Kβ1,H ∙ Kβ1,L ∙ Kβ2,L ∙ [L] + Kβ1,L ∙ Kβ2,H ∙ Kβ2,L
∙ [L])�/�Kβ1,L ∙ Kβ2,L ∙ [L]2 + Kβ1,H ∙ Kβ1,L ∙ Kβ2,H ∙ Kβ2,L + Kβ1,H ∙ Kβ1,L ∙ Kβ2,L ∙ [L]+ Kβ1,L ∙ Kβ2,H ∙ Kβ2,L ∙ [L]� cLRG =  ���Rβ2�np,totx − [Gs]αβγx �
∙ �Kβ2,L ∙ Kβ1,C ∙ Kβ1,H ∙ [L]2 + Kβ1,C ∙ Kβ1,H ∙ Kβ1,L ∙ Kβ2,L ∙ Kβ2,H + Kβ1,H ∙ Kβ1,C
∙ Kβ2,H ∙ Kβ2,L ∙ [L] + Kβ1,H ∙ Kβ1,L ∙ Kβ1,C ∙ Kβ2,L ∙ [L]� + ��Rβ1�np,totx − [Gs]αβγx �
∙ �Kβ1,H ∙ Kβ1,L ∙ Kβ2,H ∙ Kβ2,L ∙ Kβ2,C + Kβ2,H ∙ Kβ1,L ∙ Kβ2,C ∙ Kβ2,L ∙ [L] + Kβ2,C
∙ Kβ2,H ∙ Kβ1,L ∙ [L]2 + Kβ1,L ∙ Kβ1,H ∙ Kβ2,H ∙ Kβ2,C ∙ [L]� + Kβ1,C ∙ Kβ1,H ∙ Kβ1,L
∙ Kβ2,H ∙ Kβ2,L ∙ Kβ2,C + Kβ1,H ∙ Kβ1,C ∙ Kβ2,C ∙ Kβ2,H ∙ Kβ2,L ∙ [L] + Kβ1,H ∙ Kβ1,C
∙ Kβ2,C ∙ Kβ2,H ∙ Kβ1,L ∙ [L] + Kβ1,C ∙ Kβ1,H ∙ Kβ2,C ∙ Kβ2,H ∙ [L]2�/ �Kβ1,L ∙ Kβ2,L ∙ �Kβ2,H + [L]� ∙ �Kβ1,H + [L]�� 
dLRG = �[Gs]αβγx ∙ Kβ1,H ∙ Kβ1,C ∙ Kβ2,H ∙ Kβ2,C ∙ �Kβ2,L + [L]� ∙ �Kβ1,L + [L]��
�Kβ1,L ∙ Kβ2,L ∙ �Kβ2,H + [L]� ∙ �Kβ1,H + [L]��  
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φLRG = �12 ∙ dLRG + 16 ∙ bLRG ∙ cLRG − 127 ∙ (bLRG)3
+ �− 127 ∙ (bLRG)3 ∙ dLRG − 1108 ∙ (bLRG)2 ∙ (cLRG)2 + 16 ∙ bLRG ∙ cLRG ∙ dLRG + 127
∙ (cLRG)3 + 14 ∙ (dLRG)2�12�
1
3 
[Gs]fx =  φLRG − 1φLRG ∙ �cLRG3 − (bLRG)29 � − bLRG3  
�Rβ1�np,fx = �Rβ1�np,totx1 + [L]Kβ1,L + [Gs]fx ∙ � 1Kβ1,C + [L]Kβ1,C ∙ Kβ1,H� 
�Rβ2�np,fx = �Rβ2�np,totx1 + [L]Kβ2,L + [Gs]fx ∙ � 1Kβ2,C + [L]Kβ2,C ∙ Kβ2,H�  [LRβ1]npx = [L] ∙ [Rβ1]np,fxKβ1,L  [Rβ1Gs]npx = [Rβ1]np,fx ∙ [Gs]fxKβ1,C  [LRβ1Gs]npx = [L] ∙ [Rβ1]np,fx ∙ [Gs]fxKβ1,C ∙ Kβ1,H   [LRβ2]npx = [L] ∙ [Rβ2]np,fxKβ2,L  [Rβ2Gs]npx = [Rβ2]np,fx ∙ [Gs]fxKβ2,C  [LRβ2Gs]npx = [L] ∙ [Rβ2]np,fx ∙ [Gs]fxKβ2,C ∙ Kβ2,H    d[Rβ1]PKA,totxdt = kPKAp ∙ [C]x ∙ [Rβ1]np,totx − kPKAdp ∙ [Rβ1]PKA,totx  d�Rβ1�GRK,totxdt = kGRKp ∙ [GRK] ∙ ��LRβ1�npx + �LRβ1Gs�npx � − kGRKdp ∙ �Rβ1�GRK,totx  d�Rβ2�PKA,totxdt = kPKAp ∙ [C]x ∙ �Rβ2�np,totx − kPKAdp ∙ �Rβ2�PKA,totx  
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d�Rβ2�GRK,totxdt = kGRKp ∙ [GRK] ∙ ��LRβ2�npx + �LRβ2Gs�npx � − kGRKdp ∙ �Rβ2�GRK,totx  d[Gs]α,GTPxdt = kact2,Gs ∙ ��Rβ1Gs�npx + �Rβ2Gs�npx � + kact1,Gs ∙ ��LRβ1Gs�npx + �LRβ2Gs�npx �
− khydr,Gs ∙ [Gs]α,GTPx  d[Gs]βγxdt = kact2,Gs ∙ ��Rβ1Gs�npx + �Rβ2Gs�npx � + kact1,Gs ∙ ��LRβ1Gs�npx + �LRβ2Gs�npx �
− kreas,Gs ∙ [Gs]βγx ∙ [Gs]α,GDPx  d[Gs]α,GDPxdt = khydr,Gs ∙ [Gs]α,GTPx − kreas,Gs ∙ [Gs]βγx ∙ [Gs]α,GDPx  d[Gi]α,GTPxdt = kact2,Gi ∙ �Rβ2Gi�PKAx + kact1,Gi ∙ �LRβ2Gi�PKAx − khydr,Gi ∙ [Gi]α,GTPx  d[Gi]βγxdt = kact2,Gi ∙ �Rβ2Gi�PKAx + kact1,Gi ∙ �LRβ2Gi�PKAx − kreas,Gi ∙ [Gi]βγx ∙ [Gi]α,GDPx  d[Gi]α,GDPxdt = khydr,Gi ∙ [Gi]α,GTPx − kreas,Gi ∙ [Gi]βγx ∙ [Gi]α,GDPx  
 
For 𝑥 ∈ {𝐶𝑌𝑇}: [Rβ1]totx = fR,β1x ∙ [Rβ1]tot ∙ VCELLVx  [Gs]αβγx = fGsx ∙ [Gs]tot ∙ VCELLVx − [Gs]α,GTPx − [Gs]α,GDPx  [Rβ1]np,totx = [Rβ1]totx − [Rβ1]PKA,totx − [Rβ1]GRK,totx  aLRG = 1Kβ1,L ∙ �Kβ1,H + [L]� ∙ �Kβ1,L + [L]� bLRG = [Gs]αβγx ∙ �L + Kβ1,H� − �Kβ2,H + [L]� ∙ �Rβ1�np,totx + Kβ1,C ∙ Kβ1,H+ Kβ1,C ∙ Kβ1,H ∙ [L]Kβ1,L  cLRG =  −�Rβ1�np,totx ∙ Kβ1,H ∙ Kβ1,C 
�Rβ1�np,fx = −bLRG + �bLRG2 − 4 ∙ aLRG ∙ cLRG2 ∙ aLRG  [Gs]fx = [Gs]αβγx1 + �Rβ1�np,fxKβ1,C + [L] ∙ �Rβ1�np,fxKβ1,H ∙ Kβ1,C  [LRβ1]npx = [L] ∙ [Rβ1]np,fxKβ1,L  
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[Rβ1Gs]npx = [Rβ1]np,fx ∙ [Gs]fxKβ1,C  [LRβ1Gs]npx = [L] ∙ [Rβ1]np,fx ∙ [Gs]fxKβ1,C ∙ Kβ1,H   d[Rβ1]PKA,totxdt = kβ1,PKAp ∙ [C]x ∙ [Rβ1]np,totx − kβ1,PKAdp ∙ [Rβ1]PKA,totx  d�Rβ1�GRK,totxdt = kβ1,GRKp ∙ [GRK] ∙ ��LRβ1�npx + �LRβ1Gs�npx � − kβ1,GRKdp ∙ �Rβ1�GRK,totx  d[Gs]α,GTPxdt = kact2,Gs ∙ �Rβ1Gs�npx + kact1,Gs ∙ �LRβ1Gs�npx − khydr,Gs ∙ [Gs]α,GTPx  d[Gs]βγxdt = kact2,Gs ∙ �Rβ1Gs�npx + kact1,Gs ∙ �LRβ1Gs�npx − kreas,Gs ∙ [Gs]βγx ∙ [Gs]α,GDPx  d[Gs]α,GDPxdt = khydr,Gs ∙ [Gs]α,GTPx − kreas,Gs ∙ [Gs]βγx ∙ [Gs]α,GDPx   
Parameter Value Description Ref [Rβ1]tot 0.85*0.025 μmol/L Total cellular β1AR concentration 95, 103#,(C) [Rβ2]tot 0.15*0.025 μmol/L Total cellular β2AR concentration 103#,(C) fR,β1CAV 0.0812 Fraction of receptors located in CAV % fR,β1ECAV 0.4874 Fraction of receptors located in ECAV % fR,β1CYT 1 − fR,β1CAV − fR,β1ECAV Fraction of receptors located in CYT  fR,β2CAV 0.850 Fraction of β2AR located in CAV 97, 104&,(R) fR,β2ECAV 1 − fR,β2CAV Fraction of β2AR located in ECAV  [Gs]tot 224∙ [Rβ1]tot Total Gs protein concentration 105#,(R) [Gi]tot 0.500 μmol/L Total Gi protein concentration 94& fGsCAV 1.1071E-3 Fraction of G-proteins located in CAV % fGsECAV 0.5664 Fraction of G-proteins located in ECAV % fGsCYT 1 − fGsCAV − fGsECAV Fraction of G-proteins located in CYT  fGiCAV 0.850 Fraction of Gi located in CAV 97, 104&,(R) fGiECAV 1 − fGiCAV Fraction of Gi located in ECAV  Kβ1,L 0.567 μmol/L β1 Receptor / ligand low affinity constant 98#,(N) Kβ1,H 0.062 μmol/L β1 Receptor / ligand high affinity constant 98#,(N) 
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Kβ1,C 2.4490 μmol/L β1 Receptor / G-protein affinity constant % Kβ2,L 1.053 μmol/L β2 Receptor / ligand low affinity constant 98#,(N) Kβ2,H 0.012 μmol/L β2 Receptor / ligand high affinity constant 98#,(N) Kβ2,C 1.8463 μmol/L β2 Receptor / G-protein affinity constant % Kβ2,N Kβ2,L Phosph. β2 receptor/ligand low affinity constant  Kβ2,F 0.100 μmol/L Phosph. β2 receptor/ligand high affinity constant % Kβ2,A 1.6655 μmol/L Phosph. β2 Receptor/Gi-protein affinity constant % kGRKp
∙ [GRK] 4.655E-4 s-1 Rate for GRK dependent receptor desensitization % kGRKdp 3.442E-4 s-1 Rate for GRK dephosphorylation % kPKAp 2.275E-3 μmol/L-1s-1 Rate for PKA dependent receptor desensitization % kPKAdp 3.5556E-4 s-1 Rate for PKA dephosphorylation % kact1,Gs 4.9054 s-1 Activation rate for Gs by high affinity complex % kact2,Gs 0.2595 s-1 Activation rate for Gs by low affinity complex % khydr,Gs 0.800 s-1 Gs GTP to GDP hydrolysis constant 94, 102, 106# kreas,Gs 1.210E3 μmol/L-1s-1 Reassociation rate for Gs subunits 94, 102, 106# kact1,Gi 4.000 s-1 Activation rate for Gi by high affinity complex 94& kact2,Gi 0.050 s-1 Activation rate for Gi by low affinity complex 94& khydr,Gi khydr,Gs Gi GTP to GDP hydrolysis constant  kreas,Gi kreas,Gs Reassociation rate for Gi subunits  
 
2.4 Adenylyl Cyclase 
Two distinct groups of adenylyl cyclases (ACs) are distinguished in the model. AC types 5 and 6 are 
the most common ACs In the mammalian heart.107 Both are stimulated by Gsα with similar affinities 
and show significant sequence similarity. AC types 4 and 7 make up approximately 25% of the ACs in 
the ventricle and have a higher affinity for Gs than types 5 and 6.94, 108 Furthermore, there is a 
difference in the regulation by Gi of types 5/6 versus 4/7 with the former being inhibited by the Giα 
subunit and the latter being stimulated by the Giβγ subunits.
94 Because of the pronounced caveolar 
localization of Gi-coupled β2-receptors and the absence of AC4/7 from this domain, we only 
modeled Gi regulation of AC 5/6. All types are modeled with a Hill equation and fixed affinity for 
ATP. AC activity is scaled by a constant factor to produce the desired intracellular cAMP 
concentration during maximal βAR stimulation (2.5 – 3.0 μmol/L in canine ventricular myocytes,109 
also consistent with 20.5 pmol / 2 * 105 rat ventricular myocytes = 20.5 pmol / 7.6 μL = 2.7μmol/L as 
in Post et al. 105). Parameters for types 5 and 6 were derived from human AC expressed in Sf9 cells.110 
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It should be noted, however, that significant species differences have been reported for these types. 
Other parameters were determined by fitting experimental AC activity dose response curves.111-113 
 
In neurons it is known that overall AC activity is modulated by free intracellular Ca2+, but this effect is 
much less pronounced in the heart.114 Some influence of local Ca2+ entrance through L-type Ca2+ 
channels has been reported in chick embryonic ventricular myocytes,115 but to the best of our 
knowledge no detailed characterization of the physiological importance of this regulation has been 
performed in adult mammalian ventricular myocytes. Disparate results also exist about the 
functional effect of phosphorylation of AC types 5 and 6 by PKA. Several reports show an inhibitory 
effect of PKA-dependent phosphorylation on AC activity in expression systems.107, 114 However, 
experiments in crude membrane preparations of rat myocardium showed an increased AC activity 
when PKA catalytic subunits were added in the presence of isoproterenol.116 Both Ca2+ and PKA-
dependent inhibition of AC were proposed as negative feedback mechanisms limiting cAMP 
accumulation during intense adrenergic stimulation. However, other negative feedback loops exist, 
and are incorporated into the model. Because of the lack of clear experimental evidence about the 
functional relevance of AC inhibition by Ca2+ and PKA, these mechanisms are not included in this 
model.  
 
[AC56]CAV = fAC56CAV ∙ fAC56,AC47 ∙ [AC]tot ∙ VCELLVCAV  [AC56]CYT = (1 − fAC56CAV ) ∙ fAC56,AC47 ∙ [AC]tot ∙ VCELLVCYT  [AC47]ECAV = fAC47ECAV ∙ (1 − fAC56,AC47) ∙ [AC]tot ∙ VCELLVECAV [AC47]CYT = �1 − fAC47ECAV� ∙ (1 − fAC56,AC47) ∙ [AC]tot ∙ VCELLVCYT  [Gi]α,GTPCYT =0.0 
 
For 𝑥 ∈ {𝐶𝐴𝑉,𝐶𝑌𝑇}: kAC56x = AF56 ∙ �AC56basal + �[Gs]α,GTPx �hAC56,GsKm,GsAC56 + �[Gs]α,GTPx �hAC56,Gs�
∙ �1 − �1 − VGsGiAC56 ∙ �[Gs]α,GTPx �hAC56,GsGiKm,GsGiAC56 + �[Gs]α,GTPx �hAC56,GsGi� ∙ [Gi]α,GTPxKm,GiAC56 + [Gi]α,GTPx � dcAMPAC56xdt = kAC56x ∙ [AC56]x ∙ [ATP]Km,ATP + [ATP]  
 
For 𝑥 ∈ {𝐸𝐶𝐴𝑉,𝐶𝑌𝑇}: 
Model definition and equations 
326 | 
kAC47x = AF47 ∙ �AC47basal + �[Gs]α,GTPx �hAC47Km,AC47 + �[Gs]α,GTPx �hAC47� dcAMPAC47xdt = kAC47x ∙ [AC47]x ∙ [ATP]Km,ATP + [ATP]   
Parameter Value Description Ref Km,ATP 315 μmol/L AC affinity for ATP 117# [ATP] 5.00E3 μmol/L Concentration of ATP 117# [AC]tot 3∙ [Rβ1]tot Total cellular AC concentration 105#,(R) fAC56,AC47 0.740 Fraction of AC that is of type 5/6 108&,(H) fAC56CAV  0.0875 Fraction of AC56 located in caveolae % fAC47ECAV 0.1648 Fraction of AC47 in extracaveolar space % Km,GsAC56 0.0852 μmol/L AC56 affinity for Gs 110@,(E) hAC56,Gs 1.357 Hill coefficient for AC56 activation 110@,(E) Km,GsGiAC56  0.482 μmol/L Gs-dependence of inactivation by Gi for AC56 110@,(E) hAC56,GsGi 0.662 Hill coefficient for Gs/Gi interaction of AC56 110@,(E) VGsGiAC56 0.857 Maximum reduction in Gi inhibition by Gs 110@,(E) Km,GiAC56 0.0465 μmol/L AC56 affinity for inhibition by Gi 110@,(E) AC56basal 0.0377 μmol/L Basal AC56 activity % AF56 41.320 s-1 Amplification factor for AC56 % Km,AC47 0.0314 μmol/L AC47 affinity for Gs 94#, (E) hAC47 1.004 Hill coefficient for AC47 activation 94#, (E) AC47basal 0.0315 Basal AC47 activity 94# AF47 3.3757 s-1 Amplification factor for AC47 % 
 
2.5 Phosphodiesterases 
Four phosphodiesterase isoforms (PDE1-4) have been identified in the mammalian heart. PDE1 is 
mostly found in non-myocyte cardiac cells118, 119 and is therefore not included in our model. 
Considerable information is available about the relative distribution and activity of PDE2-4 in the 
canine ventricle.119 80-90% of the PDE cAMP-hydrolizing activity in the dog is present in the cytosol. 
In the particulate fraction, PDE3 and PDE4 are present in a 78% to 22% ratio, whereby PDE3 is mostly 
associated with T-tubule and sarcoplasmic reticulum and PDE4 is associated with the sarcolemmal 
membrane. In the cytosol, PDE3 is responsible for 30-40% of the hydrolyzing activity. Furthermore, 
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in dog myocardium PDE4 levels are 7-fold higher in cytosolic compared to particulate fractions. 
These relative activities are used to determine the subcellular distribution of PDEs in the model. 
IBMX is a non-specific pharmacological PDE inhibitor with different affinities for PDE2-4.120 We 
assume that IBMX inhibits PDEs equivalently in each compartment. The relative activities of the 
different PDE isoforms under basal conditions are similar to those reported by Rochais et al. in adult 
rat ventricular myocytes.121 However, opposite to the experimental data from the rat, the model 
shows a slightly larger contribution of PDE3 versus PDE4. This is consistent with experimental 
observations highlighting species differences between PDE isoforms in rodents (PDE4 dominant in 
mouse, similar PDE3/PDE4 in rat) and larger mammals (PDE3 dominant).119 Finally, the rate of cAMP 
hydrolysis by long isoforms of PDE3 and PDE4 is stimulated between 2 and 3-fold after 
phosphorylation by PKA.118 This results in an approximately 50% increase in whole-cell PDE activity in 
the presence of ISO.122 
 
rPDE3,CYT = fPDE3,CYT1 − fPDE3,CYT fPDE2,PART = fPDE2CAV + fPDE2ECAV 
αPDE3 = rPDE3,CYT
∙ �fPDE4,PART ∙ �1 + rPDE3.PDE4 −  rPDE3.PDE4 ∙ fPDE2,PART − fPART,PDE�+ fPDE2,PART ∙ �fPART,PDE − 1�� + rPDE3.PDE4 ∙ fPDE4,PART
∙ �fPART,PDE − fPDE2,PART� 
βPDE3 = fPDE4,PART ∙ �1 + rPDE3.PDE4 + fPART,PDE ∙ �rPDE3,CYT − rPDE3.PDE4�� − fPART,PDE
∙ �1 + rPDE3,CYT� [PDE3]tot = αPDE3βPDE3 ∙ [PDE2]tot [PDE4]tot = �fPART,PDE − fPDE2,PART� ∙ [PDE2]tot + fPART,PDE ∙ [PDE3]tot(1 + rPDE3.PDE4) ∙ fPDE4,PART − fPART,PDE  fPDE4ECAV = fPDE4,PART − fPDE4CAV  fPDE3CAV = rPDE3.PDE4 ∙ fPDE4,PART ∙ [PDE4]tot[PDE3]tot  fPDE3CYT = 1 − fPDE3CAV  
 
For 𝑥 ∈ {𝐶𝐴𝑉,𝐸𝐶𝐴𝑉,𝐶𝑌𝑇}: [PDE2]x = �1 − [IBMX]ℎ𝐼𝐵𝑀𝑋,𝑃𝐷𝐸2Km,PDE2IBMX + [IBMX]ℎ𝐼𝐵𝑀𝑋,𝑃𝐷𝐸2� ∙ fPDE2x ∙ [PDE2]tot ∙ VCELLVx  [PDE4]totx = �1 − [IBMX]ℎ𝐼𝐵𝑀𝑋,𝑃𝐷𝐸4Km,PDE4IBMX + [IBMX]ℎ𝐼𝐵𝑀𝑋,𝑃𝐷𝐸4� ∙ fPDE4x ∙ [PDE4]tot ∙ VCELLVx  d[PDE4]pxdt = kf,PDEp ∙ [C]x ∙ �[PDE4]totx − [PDE4]px� −  kb,PDEp ∙ [PDE4]px  
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dcAMPPDE2xdt = kPDE2 ∙ [PDE2]x ∙ [cAMP]xKm,PDE2 + [cAMP]x  dcAMPPDE4xdt = kPDE4 ∙ ([PDE4]totx − [PDE4]px) ∙ [cAMP]x + ∆k,PDE3/4 ∙ kPDE4 ∙ [PDE4]px ∙ [cAMP]xKm,PDE4 + [cAMP]x  
 
For 𝑥 ∈ {𝐶𝐴𝑉,𝐶𝑌𝑇}: [PDE3]totx = �1 − [IBMX]ℎ𝐼𝐵𝑀𝑋,𝑃𝐷𝐸3Km,PDE3IBMX + [IBMX]ℎ𝐼𝐵𝑀𝑋,𝑃𝐷𝐸3� ∙ fPDE3x ∙ [PDE3]tot ∙ VCELLVx  d[PDE3]pxdt = kf,PDEp ∙ [C]x ∙ �[PDE3]totx − [PDE3]px� −  kb,PDEp ∙ [PDE3]px  dcAMPPDE3xdt = kPDE3 ∙ ([PDE3]totx − [PDE3]px) ∙ [cAMP]x + ∆k,PDE3/4 ∙ kPDE3 ∙ [PDE3]px ∙ [cAMP]xKm,PDE3 + [cAMP]x   
Parameter Value Description Ref [PDE2]tot 2.9268E-2 μmol/L Total cellular concentration of PDE2 % fPDE2CAV  0.1696 Fraction of PDE2 located in caveolar compartment % fPDE2ECAV 2.1257E-4 Fraction of PDE2 located in extracaveolar compartment % fPDE2CYT  1 − fPDE2CAV− fPDE2ECAV Fraction of PDE2 located in cytosolic compartment  fPDE3,CYT 0.35 Fraction of PDE in cytosol that is of type 3 119#,(C) fPDE4,PART 0.125 Fraction of PDE4 located in the particulate fraction 119#,(C) fPART,PDE 0.2 Fraction of total PDE located in the particulate fraction 119#,(C) rPDE3,PDE4 3.71 Ratio of PDE3 to PDE4 in the particulate fraction 119#,(C) fPDE4CAV  0.1248 Fraction of PDE4 located in caveolar compartment % fPDE4CYT  1 − fPDE4,part Fraction of PDE4 located in cytosolic compartment  [IBMX] 0…100 μmol/L Concentration of IBMX  hIBMX,PDE2 1.167 Hill coefficient for inhibition of PDE2 by IBMX 120@,(G) KPDE2IBMX 21.58 μmol/L Affinity of IBMX for PDE2 120@,(G) hIBMX,PDE3 0.7629 Hill coefficient for inhibition of PDE3 by IBMX 120@,(G) KPDE3IBMX 2.642 μmol/L Affinity of IBMX for PDE3 120@,(G) hIBMX,PDE4 0.9024 Hill coefficient for inhibition of PDE4 by IBMX 120@,(G) KPDE4IBMX 11.89 μmol/L Affinity of IBMX for PDE4 120@,(G) kf,PDEp 0.0196 μmol/L-1 s-1 Rate of phosphorylation by PKA of PDE3 and PDE4 123& 
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kb,PDEp 0.0102 s-1 Rate of dephosphorylation of PDE3 and PDE4 123& 
∆k,PDE3/4 3.0 Increase in PDE3 / PDE4 activity after phosphorylation 118# kPDE2 20 s-1 Rate of cAMP hydrolysis by PDE2 106& Km,PDE2 50 μmol/L Affinity of PDE2 for cAMP 119#,(C) kPDE3 2.5 s-1 Rate of cAMP hydrolysis by PDE3 106, 124& Km,PDE3 0.8 μmol/L Affinity of PDE3 for cAMP 119#,(C) kPDE4 4.0 s-1 Rate of cAMP hydrolysis by PDE4 106, 124& Km,PDE4 1.4 μmol/L Affinity of PDE4 for cAMP 119#,(C)  
2.6 PKA 
A concentration of protein kinase A (PKA) is located in each compartment. We assume that a cAMP 
molecule can only bind to the first binding site of a regulatory subunit, which causes a 
conformational change that makes it possible for a second cAMP molecule to bind to the second 
binding site. Once both binding sites are occupied, the C subunit can dissociate.125 Furthermore, we 
assume that both R subunits are identical and operate independently.102, 126 Therefore, only R-C 
dimer states are modeled. Inhibition of PKA catalytic subunit by PKI is included with an apparent 
affinity of 0.2 nM.127 The total amount of PKI in the cell is sufficient to inhibit at most 20% of the 
PKA127 and is assumed to have the same distribution as PKA. 
 
In the heart, PKA is made up of two different isoforms which differ in their regulatory subunits (RI 
and RII). Distribution of the isoforms is species-dependent, but in general PKA type I is assumed to 
be mainly cytosolic whereas PKA type II is mainly found in the particulate fraction.128, 129 Accordingly, 
we define the PKA in the caveolar and extracaveolar compartments to be of type II, and the PKA in 
the cytosolic compartment to be of type I. The different isoforms have similar affinities for the 
binding between R and C subunits (although rate constants for type II are approximately six times 
faster than type I),130 but differ in their affinities for activation by cAMP.131 Therefore, the affinities 
for the two cAMP binding reactions are significantly higher in the cytosolic compartment in order to 
reproduce the cAMP dose-response curve for PKA type I. In contrast to the RI subunit, the RII subunit 
can be phosphorylated by the catalytic subunit on Ser-96, which affects RII-C binding affinity, affinity 
of binding between PKA and A-kinase anchoring proteins (AKAPs) and substrate phosphorylation.132 
However, under normal physiological conditions, RII is almost completely phosphorylated both in 
the absence and presence of βAR stimulation by isoproterenol132, 133 and therefore 
(de)phosphorylation of RII is not explicitly incorporated in our model.    
 
For 𝑥 ∈ {𝐶𝐴𝑉,𝐸𝐶𝐴𝑉}: [PKA]x = fPKAx ∙ [PKA]tot ∙ VCELLVx  
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[RC]fx = 2 ∙ [PKA]x − [ARC]x − [A2RC]x − [A2R]x [PKI]fx = fPKIx ∙ [PKI]tot ∙ VCELLVx − [PKIC]x kPKAII,b1 = kPKAII,f1 ∙ KPKAII,1 kPKAII,b2 = kPKAII,f2 ∙ KPKAII,2 kPKAII,b3 = kPKAII,f3 ∙ KPKAII,3 kPKI,b = kPKI,f ∙ KPKI d[cAMP]PKAxdt = −kPKAII,f1 ∙ [RC]fx ∙ [cAMP]x + kPKAII,b1 ∙ [ARC]x − kPKAII,f2 ∙ [ARC]x ∙ [cAMP]x+ kPKAII,b2 ∙ [A2RC]x d[ARC]xdt = kPKAII,f1 ∙ [RC]fx ∙ [cAMP]x − kPKAII,b1 ∙ [ARC]x − kPKAII,f2 ∙ [ARC]x ∙ [cAMP]x+ kPKAII,b2 ∙ [A2RC]x d[A2RC]xdt = kPKAII,f2 ∙ [ARC]x ∙ [cAMP]x − �kPKAII,b2 + kPKAII,f3� ∙ [A2RC]x + kPKAII,b3 ∙ [A2R]x
∙ [C]x d[A2R]xdt = kPKAII,f3 ∙ [A2RC]x − kPKAII,b3 ∙ [A2R]x ∙ [C]x d[C]xdt = kPKAII,f3 ∙ [A2RC]x − kPKAII,b3 ∙ [A2R]x ∙ [C]x + kPKI,b ∙ [PKIC]x − kPKI,f ∙ [PKI]fx ∙ [C]x d[PKIC]xdt = −kPKI,b ∙ [PKIC]x + kPKI,f ∙ [PKI]fx ∙ [C]x  
For 𝑥 = 𝐶𝑌𝑇: [PKA]x = fPKAx ∙ [PKA]tot ∙ VCELLVx  [RC]fx = 2 ∙ [PKA]x − [ARC]x − [A2RC]x − [A2R]x [PKI]fx = fPKIx ∙ [PKI]tot ∙ VCELLVx − [PKIC]x kPKAI,b1 = kPKAI,f1 ∙ KPKAI,1 kPKAI,b2 = kPKAI,f2 ∙ KPKAI,2 kPKAI,b3 = kPKAI,f3 ∙ KPKAI,3 kPKI,b = kPKI,f ∙ KPKI d[cAMP]PKAxdt = −kPKAI,f1 ∙ [RC]fx ∙ [cAMP]x + kPKAI,b1 ∙ [ARC]x − kPKAI,f2 ∙ [ARC]x ∙ [cAMP]x+ kPKAI,b2 ∙ [A2RC]x d[ARC]xdt = kPKAI,f1 ∙ [RC]fx ∙ [cAMP]x − kPKAI,b1 ∙ [ARC]x − kPKAI,f2 ∙ [ARC]x ∙ [cAMP]x+ kPKAI,b2 ∙ [A2RC]x 
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d[A2RC]xdt = kPKAI,f2 ∙ [ARC]x ∙ [cAMP]x − �kPKAI,b2 + kPKAI,f3� ∙ [A2RC]x + kPKAI,b3 ∙ [A2R]x
∙ [C]x d[A2R]xdt = kPKAI,f3 ∙ [A2RC]x − kPKAI,b3 ∙ [A2R]x ∙ [C]x d[C]xdt = kPKAI,f3 ∙ [A2RC]x − kPKAI,b3 ∙ [A2R]x ∙ [C]x + kPKI,b ∙ [PKIC]x − kPKI,f ∙ [PKI]fx
∙ [C]x d[PKIC]xdt = −kPKI,b ∙ [PKIC]x + kPKI,f ∙ [PKI]fx ∙ [C]x  
Parameter Value Description Ref [PKA]tot 0.25 μmol/L Total cellular concentration of PKA holoenzyme 134, 135#,(A) fPKACAV 3.880E-2 Fraction of PKA located in caveolar compartment % fPKAECAV 0.100 Fraction of PKA located in extracaveolar compartment % fPKACYT 1 − fPKACAV− fPKAECAV Fraction of PKA located in cytosolic compartment  [PKI]tot 2 ∙ 0.2∙ [PKA]tot Total cellular concentration of PKA inhibitor 135# fPKICAV fPKACAV Fraction of PKI located in caveolar compartment  fPKIECAV fPKAECAV Fraction of PKI located in extracaveolar compartment  fPKICYT fPKACYT Fraction of PKI located in cytosolic compartment  kPKAII,f1 100 μmol/L-1 s-1 Forward rate for binding of the first cAMP to PKA 136& KPKAII,1 2.4984 μmol/L Equilibrium value for the binding of the first cAMP to PKA 135@ kPKAII,f2 kPKAII,f1 Forward rate for binding of the second cAMP to PKA 136& KPKAII,2 11.359 μmol/L Equilibrium value for binding of the second cAMP to PKA 135@ kPKAII,f3 100 s-1 Forward rate for dissociation of C subunit 136& KPKAII,3 0.3755 μmol/L-1 Equilibrium value for dissociation of C subunit 135@ kPKAI,f1 kPKAII,f1 Forward rate for binding of the first cAMP to PKA 136& KPKAI,1 0.1088 μmol/L Equilibrium value for the binding of the first cAMP to PKA 131@ kPKAI,f2 kPKAII,f1 Forward rate for binding of the second cAMP to PKA 136& KPKAI,2 0.4612 μmol/L Equilibrium value for binding of the second cAMP to PKA 131@ kPKAI,f3 6 ∙ kPKAII,f3 Forward rate for dissociation of C subunit 130# 
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KPKAI,3 KPKAII,3 Equilibrium value for dissociation of C subunit 130# kPKI,f 50 μmol/L-1 s-1 Forward rate for inhibition of C subunit by PKI 136& KPKI 2.0E-4 μmol/L Equilibrium value for inhibition of C subunit by PKI 127#  
2.7 cAMP 
As in Iancu et al.,94 cAMP can diffuse between the three compartments. The rate of change in free 
cAMP concentration in each compartment depends on the production of cAMP by ACs, its 
breakdown by PDEs, buffering by PKA and transfer between compartments. 
 d[cAMP]CAVdt = dcAMPPKACAVdt + dcAMPAC56CAVdt − dcAMPPDE2CAVdt − dcAMPPDE3CAVdt − dcAMPPDE4CAVdt − JCAV/ECAV
∙
[cAMP]CAV − [cAMP]ECAVVCAV − JCAV/CYT ∙ [cAMP]CAV − [cAMP]CYTVCAV  d[cAMP]ECAVdt = dcAMPPKAECAVdt + dcAMPAC47ECAVdt − dcAMPPDE2ECAVdt − dcAMPPDE4ECAVdt + JCAV/ECAV
∙
[cAMP]CAV − [cAMP]ECAVVECAV − JECAV/CYT ∙ [cAMP]ECAV − [cAMP]CYTVECAV  d[cAMP]CYTdt = dcAMPPKACYTdt + dcAMPAC56CYTdt + dcAMPAC47CYTdt − dcAMPPDE2CYTdt − dcAMPPDE3CYTdt − dcAMPPDE4CYTdt+ JCAV/CYT ∙ [cAMP]CAV − [cAMP]CYTVCYT − JECAV/CYT ∙ [cAMP]ECAV − [cAMP]CYTVCYT   
Parameter Value Description Ref JCAV/CYT 7.500E-8 µL s-1 Rate of cAMP diffusion between caveolar and cytosolic compartments 106# JCAV/ECAV 5.000E-9 µL s-1 Rate of cAMP diffusion between caveolar and extracaveolar compartments 106# JECAV/CYT 0.900E-8 µL s-1 Rate of cAMP diffusion between extracaveolar and cytosolic compartments 106# 
 
2.8 Protein phosphatase inhibitor 
PP1 is inhibited by the phosphorylated form of inhibitor protein 1, 137 thereby providing a positive 
feedback loop for PKA-dependent substrate phosphorylation. Inhibitor protein 1 is only found in the 
cytosolic compartment and has a very high affinity for PP1 (1 nM). 137 As such, PP1-Inhibitor binding 
is assumed to be instantaneous and modeled by an algebraic equation. Knockout of inhibitor protein 
1 resulted in a 23% increase in PP1 activity in the isoproterenol-stimulated mouse heart. 138 In the 
model, total concentration of inhibitor 1 is chosen to produce a similar effect. Inhibitor protein 1 
does not alter ICaL or TnI phosphorylation. 
138 In the model, the absence of ICaL effects results from the 
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different subcellular localization whereas the absence of TnI effects can be explained by the fact that 
PP2A (which is not inhibited by inhibitor protein 1) is the major phosphatase dephosphorylating TnI. 
139 
  
[Inhib1]totCYT = fPP1,Inh11 − fPP1,Inh1 ∙ KInh1 + fPP1,Inh1 ∙ [PP1]totCYT d[Inhib1]pCYTdt = kInh1p ∙ [C]CYT ∙ ([Inhib1]totCYT − [Inhib1]pCYT)KInh1p + ([Inhib1]totCYT − [Inhib1]pCYT) − kInh1dp ∙ [PP2A]CYT ∙ [Inhib1]pCYTKInh1dp + [Inhib1]pCYT  [PP1]CYT = 12 ∙ ��KInh1 − [PP1]totCYT + [Inhib1]pCYT�2 + 4 ∙ KInh1 ∙ [PP1]totCYT − 12
∙ �KInh1 − [PP1]totCYT + [Inhib1]pCYT�  
Parameter Value Description Ref fPP1,Inh1 0.3 Fractional increase in PP1 after Inh1 knockout 138#, (M) kInh1,p 1.0145E-2 s-1 Rate of phosphorylation of inhibitor 1 by PKA 140@,(G) kInh1,dp
∙ [PP2A]CYT 3.5731E-3 μmol/L s-1 Rate of dephosphorylation of inhibitor 1 140@,(G) KInh1,p 1.4690E-3 μmol/L Affinity of inhibitor 1 for PKA catalytic subunit 140@,(G) KInh1,dp 1.9526E-5 μmol/L Affinity of inhibitor 1 for PP2A 140@,(G) [PP1]totCYT 0.2 μmol/L Total concentration of PP1 in the cytosolic compartment % KInh1 1.0E-3 μmol/L Affinity for PP1 – Inhibitor 1 binding 137#  
2.9 Substrate phosphorylation 
The substrates are divided into those with and without AKAPs. For the substrates without AKAPs, a 
standard Michaelis-Menten formalism for phosphorylation is implemented. For substrates with 
AKAPs, a steady-state distribution is calculated for AKAP / Channel complexes, AKAP / Channel / PKA 
complexes, AKAP / Channel / phosphatase complexes and AKAP / Channel / PKA / phosphatase 
complexes. Although some AKAPs also bind PDEs, 141 we do not incorporate this explicitly in our 
model and only consider the effects of an AKAP on its associated channel. Different AKAPs bind PKA 
with different affinities in the range of 2 – 90 nM. 142 We use an intermediate affinity of 10 nM for all 
AKAPs and assume this affinity is similar for the binding of PP1. AKAPs and channels are assumed to 
have a 1:1 stoichiometry and high affinity (0.1 nM) under normal physiological conditions124 
(although mutations in both channel 143 and AKAP 144 have been described that greatly reduce this 
affinity). 
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AKAPs are critical for reliable (de)phosphorylation of their associated channels. Moreover, it is 
known for the IKs channel that the AKAP yotiao also has an active role in mediating the 
phosphorylation effect on channel gating and phosphomimetic mutations in the IKs channel do not 
result in gating changes in the absence of yotiao. 143, 145 Based on this data, the model assumes that, 
for substrates with AKAPs (IKs, ICaL, RyR), phosphorylation and dephosphorylation only occur in 
channels with AKAP. Channels with AKAP and PKA are constitutively phosphorylated whereas 
channels with AKAP and phosphatase are always dephosphorylated. Channels with AKAP, PKA and 
phosphatase follow a standard Michaelis-Menten formalism. 
 
Affinities and rate constants for phosphorylation are derived by fitting the model to the 
isoproterenol dose-response curves and the time course of phosphorylation obtained 
experimentally in ventricular myocytes. All substrates have half-maximal isproterenol concentrations 
in the nanomolar range and reach maximum phosphorylation levels in 2-4 minutes. 
 dfIKurPdt = kIKur,PKA ∙ [C]ECAV ∙ (1 − fIKurP )KIKur,PKA + (1 − fIKurP ) − kIKur,PP ∙ [PP1]ECAV ∙ fIKurPKIKur,PP + fIKurP  dfINaPdt = kINa,PKA ∙ [C]CAV ∙ (1 − fINaP )KINa,PKA + (1 − fINaP ) − kINa,PP ∙ [PP]CAV ∙ fINaPKINa,PP + fINaP  dfINaKPdt = kINaK,PKA ∙ [C]CAV ∙ (1 − fINaKP )KINaK,PKA + (1 − fINaKP ) − kINaK,PP ∙ [PP]CAV ∙ fINaKPKINaK,PP + fINaKP  dfPLBPdt = kPLB,PKA ∙ [C]CYT ∙ (1 − fPLBP )KPLB,PKA + (1 − fPLBP ) − kPLB,PP ∙ [PP1]CYT ∙ fPLBPKPLB,PP + fPLBP  dfTnIPdt = kTnI,PKA ∙ [C]CYT ∙ (1 − fTnIP )KTnI,PKA + (1 − fTnIP ) − kTnI,PP ∙ [PP2A]CYT ∙ fTnIPKTnI,PP + fTnIP  
 
For 𝐼𝐾𝑠: K = KPP1,Yotiao, L = KIKs,Yotiao, M = KPKA,Yotiao [PP1]f = 12 ∙ K−1
∙ �− �1 + K−1 ∙ �[Yotiao]tot − [PP1]ECAV��
+ ��1 + K−1 ∙ ([Yotiao]tot − [PP1]ECAV)�2 + 4 ∙ K−1 ∙ [PP1]ECAV� 
[IKs]NNN = 12 ∙ L−1
∙ �−�1 + L−1 ∙ ([Yotiao]tot − [IKs]tot)�
+ ��1 + L−1 ∙ ([Yotiao]tot − [IKs]tot)�2 + 4 ∙ L−1 ∙ [IKs]tot� 
Appendix 
| 335 
[R]f = 12 ∙ M−1 ∙ �− �1 + M−1 ∙ �[Yotiao]tot − [PKA]ECAV��+ ��1 + M−1 ∙ ([Yotiao]tot − [PKA]ECAV)�2 + 4 ∙ M−1 ∙ [PKA]ECAV� 
[Yotiao]f = [Yotiao]tot − [IKs]tot + [IKs]NNNK−1 ∙ [PP1]f + M−1 ∙ (K−1 ∙ [PP1]f + 1) ∙ [R]f + 1 [IKs]ARN = L−1 ∙ M−1 ∙ [IKs]NNN ∙ [Yotiao]f ∙ [R]f [IKs]ARP = [IKs]ARN ∙ K−1 ∙ [PP1]f  d[IKs]Pdt = kIKs,PKA ∙ [C]ECAV ∙ ([IKs]ARP − [IKs]P)KIKs,PKA + ([IKs]ARP − [IKs]P) − kIKs,PP ∙ [PP1]ECAV ∙ [IKs]PKIKs,PP + [IKs]P  fIKsP = [IKs]P + [IKs]ARN[IKs]tot  
 
For 𝑦 ∈ {𝐼𝐶𝑎𝐿,𝑅𝑦𝑅}: Ky = KPP1,AKAP,y, Ly = Ky,AKAP, My = KPKA,AKAP,y bPP =  [AKAP]totICaL + [AKAP]totRyR + KICaL + KRyR − [PP]CAV cPP =  [AKAP]totICaL ∙ KRyR + [AKAP]totRyR ∙ KICaL + KICaL ∙ KRyR − [PP]CAV ∙ �KICaL + KRyR� dPP =  [PP]CAV ∙ KICaL ∙ KRyR 
φPP = �12 ∙ dPP + 16 ∙ bPP ∙ cPP − 127 ∙ (bPP)3
+ �− 127 ∙ (bPP)3 ∙ dPP − 1108 ∙ (bPP)2 ∙ (cPP)2 + 16 ∙ bPP ∙ cPP ∙ dPP + 127 ∙ (cPP)3
+ 14 ∙ (dPP)2�12�
1
3 
[PP]f =  φPP − 1φPP ∙ �cPP3 − (bPP)29 �− bPP3   bR =  [AKAP]totICaL + [AKAP]totRyR + MICaL + MRyR − [PKA]CAV cR =  [AKAP]totICaL ∙ MRyR + [AKAP]totRyR ∙ MICaL + MICaL ∙ MRyR − [PKA]CAV ∙ �MICaL + MRyR� dR =  [PKA]CAV ∙ MICaL ∙ MRyR 
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φR = �12 ∙ dR + 16 ∙ bR ∙ cR − 127 ∙ (bR)3
+ �− 127 ∙ (bR)3 ∙ dR − 1108 ∙ (bR)2 ∙ (cR)2 + 16 ∙ bR ∙ cR ∙ dR + 127 ∙ (cR)3 + 14
∙ (dR)2�12�13 
[R]f =  φR − 1φR ∙ �cR3 − (bR)29 � − bR3  
 [y]NNN = 12 ∙ �Ly�−1
∙ �− ��Ly�−1 ∙ �[AKAP]toty − [y]tot� + 1�
+ ���Ly�−1 ∙ �[AKAP]toty − [y]tot� + 1�2 + 4 ∙ �Ly�−1 ∙ [y]tot� 
[AKAP]fy = [AKAP]toty − [y]tot + [y]NNN
�Ky�−1 ∙ [PP]f + �My�−1 ∙ ��Ky�−1 ∙ [PP]f + 1� ∙ [R]f + 1 [y]ARN = �Ly�−1 ∙ �My�−1 ∙ [y]NNN ∙ [AKAP]fy ∙ [R]f [y]ARP = [y]ARN ∙ �Ky�−1 ∙ [PP]f  d[y]pdt = ky,PKA ∙ [C]CAV ∙ ([y]ARP − [y]P)Ky,PKA + ([y]tot − [y]P) − ky,PP ∙ [PP]CAV ∙ [y]pKy,PP + [y]P  fyP = [y]P + [y]ARN[y]tot  
 
Parameter Value Description Ref kICaL,PKA 5.1009E-4 s-1 Rate of ICaL phosphorylation 20, 146@, (C) KICaL,PKA 1.2702E-6 μmol/L Affinity of ICaL for phosphorylation by PKA 20, 146@, (C) kICaL,PP 6.9030E-4 s-1 Rate of ICaL dephosphorylation 20, 146@, (C) KICaL,PP 6.3064E-3 μmol/L Affinity of ICaL for dephosphorylation by phosphatases 20, 146@, (C) kIKs,PKA 1.6305E-1 s-1 Rate of IKs phosphorylation 147@, (C) KIKs,PKA 9.9794E-05 μmol/L Affinity of IKs for phosphorylation by PKA 147@, (C) 
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kIKs,PP 1.0542 s-1 Rate of IKs dephosphorylation 147@, (C) KIKs,PP 1.1147E-4 μmol/L Affinity of IKs for dephosphorylation by phosphatases 147@, (C) kIKur,PKA 6.9537E-2 s-1 (μmol/L)-1 Rate of IKur phosphorylation 43@, (C) KIKur,PKA 2.7623E-1 Affinity of IKur for phosphorylation by PKA 43@, (C) kIKur,PP 3.1700E-1 s-1 (μmol/L)-1 Rate of IKur dephosphorylation 43@, (C) KIKur,PP 2.3310E-3 Affinity of IKur for dephosphorylation by phosphatases 43@, (C) kINa,PKA 1.3680E-2 s-1 (μmol/L)-1 Rate of INa phosphorylation 148@, (R) KINa,PKA 1.09883E-1 Affinity of INa for phosphorylation by PKA 148@, (R) kINa,PP 5.2811E-2 s-1 (μmol/L)-1 Rate of INa dephosphorylation 148@, (R) KINa,PP 7.8605 Affinity of INa for dephosphorylation by phosphatases 148@, (R) kINaK,PKA 1.5265E-2 s-1 (μmol/L)-1 Rate of INaK phosphorylation 62@, (G) KINaK,PKA 1.1001E-3 Affinity of INaK for phosphorylation by PKA 62@, (G) kINaK,PP 9.2455E-2 s-1 (μmol/L)-1 Rate of INaK dephosphorylation 62@, (G) KINaK,PP 5.7392 Affinity of INaK for dephosphorylation by phosphatases 62@, (G) kPLB,PKA 1.1316E-1 s-1 (μmol/L)-1 Rate of PLB phosphorylation 1, 89, 149@, (R)/(G) 
KPLB,PKA 4.9097E-4 Affinity of PLB for phosphorylation by PKA 1, 89, 149@, 
(R)/(G) 
kPLB,PP 2.5755E-1 s-1 (μmol/L)-1 Rate of PLB dephosphorylation 1, 89, 149@, (R)/(G) 
KPLB,PP 4.8393E-2 Affinity of PLB for dephosphorylation by phosphatases 1, 89, 149@, (R)/(G) kRyR,PKA 2.5548E-3 s-1 Rate of RyR phosphorylation 81@, (R) KRyR,PKA 6.6298E-5 μmol/L Affinity of RyR for phosphorylation by PKA 81@, (R) kRyR,PP 3.8257E-3 s-1 Rate of RyR dephosphorylation 81@, (R) KRyR,PP 4.3003E-2 μmol/L Affinity of RyR for dephosphorylation by phosphatases 81@, (R) kTnI,PKA 1.0408E-1 s-1 (μmol/L)-1 Rate of TnI phosphorylation 1, 150@, (R) KTnI,PKA 2.7143E-5 Affinity of TnI for phosphorylation by PKA 1, 150@, (R) 
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kTnI,PP
∙ [PP2A]CYT 5.2633E-2 s-1 (μmol/L)-1 Rate of TnI dephosphorylation 1, 150@, (R) KTnI,PP 2.6714E-1 Affinity of TnI for dephosphorylation by phosphatases 1, 150@, (R) KPKA,Yotiao 0.01 μmol/L Binding affinity between PKA and yotiao 133& KIKs,Yotiao 1E-4 μmol/L Binding affinity between IKs channel andyYotiao 124# KPP1,Yotiao KPKA,Yotiao Binding affinity between PP1 and yotiao  [Yotiao]tot 0.025 μmol/L Total concentration of yotiao 124# [IKs]tot 0.025 μmol/L Total concentration of IKs channels 124# KPKA,AKAP,ICaL KPKA,Yotiao Binding affinity between PKA and ICaL AKAP  KPP1,AKAP.ICaL KPKA,Yotiao Binding affinity between PP1 and ICaL AKAP  KICaL,AKAP KIKs,Yotiao Binding affinity between ICaL channel and AKAP  KPKA,AKAP,RyR KPKA,Yotiao Binding affinity between PKA and RyR AKAP  KPP1,AKAP.RyR KPKA,Yotiao Binding affinity between PP1 and RyR AKAP  KRyR,AKAP KIKs,Yotiao Binding affinity between RyR channel and AKAP  [ICaL]tot 0.025 μmol/L Total concentration of ICaL channels 124# [AKAP]totICaL 0.025 μmol/L Total concentration of ICaL AKAP  [RyR]tot 0.125 μmol/L Total concentration of RyRs 124# [AKAP]totRyR 0.125 μmol/L Total concentration of RyR AKAP  [PP]CAV 0.25 μmol/L PP concentration in caveolar compartment % [PP1]ECAV 0.1 μmol/L PP1 concentration in extracaveolar compartment % 
 
3. CAMKII MODELS 
3.1.1 HRd2009 version (Chapter 2) 
Model CaMKII formulation is equivalent to that in the original HRd model.4 
CaMKbound = CaMK0 ∙ �1 − CaMKtrap� ∙ 11 + Km,CaM[Ca2+]ss dCaMKtrapdt = αCaMK ∙ CaMKbound ∙ �CaMKbound + CaMKtrap� − βCaMK ∙ CaMKtrap CaMKactive = CaMKbound + CaMKtrap 
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Parameter Value Description Ref CaMK0 0.05 Equilibrium fraction of active CaMKII binding sites 4# Km,CaM 0.0015 mmol/L CaMKII affinity for Ca2+/CaM activation 4# 
αCaMK 50 s
-1 Rate of phosphorylation of CaMKII 4# 
βCaMK 0.68 s
-1 Rate of dephosphorylation of CaMKII 4#  
3.1.2 HRdβARS and HRdβARS Stoch version (Chapters 3-7) 
In the model, activation of CaMKII is localized to the Ca2+ subspace, where Ca2+ levels are sufficiently 
high for activation of CaMKII, consistent with previous modeling studies.4, 151, 152 In contrast to cAMP 
compartmentation, where different FRET sensors (PKA or EPAC based) and cyclic-nucleotide-gated 
channels can be used to measure cAMP concentrations in different parts of the cell, there are 
currently no experimental techniques to measure localized CaMKII activity. Therefore, we did not 
include detailed localization of CaMKII, other than its dependence on subspace Ca2+. Nonetheless, a 
distinction is made between the substrates localized in or near the T-tubules and those further away 
with respect to the time constant of phosphorylation. Time constants for phosphorylation of RyR 
and ICaL phosphorylation are based on the time-course of CaMKII-dependent RyR phosphorylation at 
S2815 by Huke et al, whereas time constants for the other substrates (IK1, ITo, INa, PLB) are based on 
the time-course of PLB T17 phosphorylation reported by the same group.153 Steady-state CaMKII 
phosphorylation levels are based on those previously published.4, 24 Based on experimental data, we 
have included an additional interaction between the cAMP/PKA signaling pathway via PP1-
dependent dephosphorylation of CaMKII activity. Huke et al. found that CaMKII activity is strongly 
regulated by PP1.153 Consistent with their observations, we made the deactivation rate of 
autonomous CaMKII dependent on whole cell PP1 activity. This PP1 activity can subsequently be 
modulated by βARS via PKA-dependent activation of Inh1 and inhibition of PP1. 
 
CaMKbound = CaMK0 ∙ �1 − CaMKtrap� ∙ 11 + Km,CaM[Ca2+]ss dCaMKtrapdt = αCaMK ∙ CaMKbound ∙ �CaMKbound + CaMKtrap� − CaMKtrap
∙ �0.1 ∙ βCaMK + 0.9 ∙ βCaMK
∙
VCAV ∙ [PP]CAV + VECAV ∙ [PP1]ECAV + VCYT ∙ [PP1]CYTVCELL ∙ 0.1371 � CaMKactive = CaMKbound + CaMKtrap  dfICaLP,CaMKIIdt = � CaMKactiveCaMKactive + KICaL,CaMKII − fICaLP,CaMKII� /τICaL,CaMKII 
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dfPLBP,CaMKIIdt = � CaMKactiveCaMKactive + KPLB,CaMKII − fPLBP,CaMKII� /τPLB,CaMKII dfINaP,CaMKIIdt = � CaMKactiveCaMKactive + KINa,CaMKII − fINaP,CaMKII� /τINa,CaMKII dfRyRP,CaMKIIdt = � CaMKactive2CaMKactive2 + KRyR,CaMKII2 − fRyRP,CaMKII� /τRyR,CaMKII dfIToP,CaMKIIdt = � CaMKactiveCaMKactive + KITo,CaMKII − fIToP,CaMKII� /τITo,CaMKII dfIK1P,CaMKIIdt = � CaMKactiveCaMKactive + KIK1,CaMKII − fIK1P,CaMKII� /τIK1,CaMKII  
Parameter Value Description Ref CaMK0 0.05 Equilibrium fraction of active CaMKII binding sites 21# Km,CaM 0.0015 mmol/L CaMKII affinity for Ca2+/CaM activation 21# 
αCaMK 50 s
-1 Rate of phosphorylation of CaMKII 21# 
βCaMK 0.68 s
-1 Rate of dephosphorylation of CaMKII 21# KICaL,CaMKII KPLB,CaMKII Affinity of ICaL for CaMKII  
τICaL,CaMKII τRyR,CaMKII Time constant of CaMKII ICaL phosphorylation  KPLB,CaMKII 0.15 Affinity of PLB for CaMKII 21# 
τPLB,CaMKII 100 s Time constant of CaMKII PLB phosphorylation 153@,(R) KINa,CaMKII KPLB,CaMKII Affinity of INa for CaMKII  
τINa,CaMKII τPLB,CaMKII Time constant of CaMKII INa phosphorylation  KRyR,CaMKII KPLB,CaMKII Affinity of RyR for CaMKII  
τRyR,CaMKII 50 s Time constant of CaMKII RyR phosphorylation 153@,(R) KITo,CaMKII KPLB,CaMKII Affinity of ITo for CaMKII  
τITo,CaMKII τPLB,CaMKII Time constant of CaMKII ITo phosphorylation  KIK1,CaMKII KPLB,CaMKII Affinity of IK1 for CaMKII  
τIK1,CaMKII τPLB,CaMKII Time constant of CaMKII IK1 phosphorylation  
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